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Interleukin	   (IL)-­‐6-­‐type	   cytokines	   signal	   through	   glycoprotein	   (gp)	   130,	   which	   is	   a	   key	  
component	  of	   their	   receptor	  complex.	  Upon	  stimulation,	  gp130	  mediates	   the	  activation	  of	  
Janus	   kinases	   (JAKs)	   and	   signal	   transducers	   and	   activators	   of	   transcription	   (STATs),	  
extracellular	  signal-­‐regulated	  kinase	   (ERK)	  1	  and	  ERK2,	  phosphoinositol-­‐3	  kinase	   (PI3K)	  and	  
AKTs.	  Here,	  it	  is	  demonstrated	  that	  ERK2,	  but	  not	  ERK1,	  controls	  the	  expression	  and	  function	  
of	  gp130.	  Silencing	  ERK2	  in	  human	  osteosarcoma	  U2OS	  cells	  with	  short	  interfering	  (si)	  RNAs	  
nearly	  obliterated	  gp130	  expression,	  and	  this	  effect	  could	  be	  seen	  in	  cancer	  cell	   lines	  from	  
different	   origins	   (e.g.	   breast,	   prostate,	   lung	   and	   cervix)	   that	   possess	   different	   mutational	  
backgrounds,	   as	   well	   as	   in	   non-­‐cancer	   cell	   lines	   (prostate	   and	   kidney).	   Interestingly,	   this	  
regulation	  was	  not	  observed	  to	  the	  same	  extent	  in	  two	  mouse	  cell	   lines	  (MEF	  and	  NIH3T3)	  
tested.	   Chemical	   inhibition	   of	   ERK1/2	   did	   not	   have	   an	   impact	   on	   the	   receptor	   expression	  
suggesting	   that	   the	   regulation	   of	   gp130	   by	   ERK2	   is	   independent	   of	   its	   canonical	   kinase	  
activity.	   Importantly,	   ERK2	   binds	   to	   the	   GP130	   promoter,	   thereby	   decreasing	   gp130	  
expression,	  possibly	  by	  interacting	  with	  the	  transcriptional	  machinery.	  RNAi	  against	  ERK2	  led	  
to	   a	   reduction	   in	   RNA	   polymerase	   II	   activation,	   and	   luciferase	   reporter	   assays	   containing	  
GP130	  promoter	  and	  messenger	  RNA	  stability	  experiments	  also	  suggested	  that	  ERK2	  has	  a	  
transcriptional	  role	  important	  for	  the	  regulation	  of	  gp130	  protein	  expression.	  Together,	  the	  
data	  identity	  a	  new	  role	  for	  ERK2,	  not	  shared	  by	  ERK1,	   in	  the	  regulation	  of	  gp130	  and	  that	  
may	  be	  involved	  in	  cancer	  progression	  and	  inflammation.	  
Additionally,	  genetic	  ablation	  of	  AKT2	  and	  AKT3,	  two	  key	  components	  of	  the	  PI3K	  pathway	  
that,	   under	   certain	   cellular	   backgrounds,	   are	   also	   activated	   downstream	   of	   the	   gp130	  
receptor,	  also	  impacts	  on	  gp130	  expression.	  In	  this	  case,	  however,	  AKT	  enzymatic	  activation	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1.1	   Cancer	  
Worldwide,	  cancer	  is	  the	  leading	  cause	  of	  death	  with	  a	  mortality	  rate	  of	  7.6	  millions	  deaths	  
in	  2008.	   It	   is	  predicted	  that	   the	  estimated	  12.7	  millions	  cases	   in	  2008	  will	   increase	  to	  22.2	  
million	  by	  2030.	  Lung	  cancer	   is	   the	  most	  common	  cause	  of	  cancer	  mortality	   (18.2%	  of	   the	  
total)	   followed	  by	   stomach	   (9.7%)	  and	   liver	   (9.2%)	   (Figure	   1.1)	   (Bray	  et	   al.,	   2012;	   Ferlay	   J,	  
2010).	  There	  are	  several	  factors	  that	  can	  affect	  the	  predisposition	  to	  cancer:	  gender,	  lifestyle	  
(nutrition,	  exercise	  and	  smoking/drinking),	  genetics	  (ethnicity	  and	  family	  history)	  and	  social	  
background	  (Sambamoorthi	  and	  McAlpine,	  2003;	  Truong	  et	  al.,	  2010).	  Statistical	  differences	  
between	  developed	  and	  developing	  countries	  also	  occur:	  cancer	  causes	  4%	  of	  all	  deaths	   in	  
Africa	  and	  23%	  in	  North	  America.	  These	  differences,	  however,	  might	  be	  due	  to	  a	  differences	  
in	  diagnosing	  and	  keeping	  records	  in	  developing	  countries	  (Valsecchi	  and	  Steliarova-­‐Foucher,	  
2008).	  
	  
In	  the	  United	  Kingdom,	  cancer	  was	  responsible	  for	  a	  quarter	  of	  all	  deaths	  in	  2004	  (29.2%	  in	  
males	  and	  24.7%	  in	  females),	  being	  the	  third	  biggest	  killer	  after	  cardiovascular	  and	  chronic	  
diseases	  (Mathers,	  2004).	  Sadly,	  the	  projections	  for	  2030	  do	  not	  show	  any	  improvement	  on	  
this	  situation	  (Mistry	  et	  al.,	  2011).	  
A.	  Male	   	   	   	   	   	   B.	  Female	  
	  
Figure	  1.1	  -­‐	  Estimated	  relative	  mortality	  during	  2004	  in	  the	  UK.	  A.	  Male,	  B.	  Female	  population.	  After	  
cardiovascular	   disease	   (almost	   40%	  of	   all	   deaths)	   and	  other	   chronic	   conditions,	   cancer	   is	   the	   third	  
main	   cause	   of	   death	   responsible	   for	   about	   25%	   of	   all	   deaths	   in	   UK	   [Taken	   from	   (Mathers,	   2004)	  
https://apps.who.int/infobase/Mortality.aspx].	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1.1.1.	   Lung	  cancer	  
Lung	   cancer	   causes	  more	   deaths	  per	   year	   than	   any	   other	   type	   of	   cancer	   in	  males	   (Lopes	  
Pegna	   and	   Picozzi,	   2009;	   Spiro	   and	   Silvestri,	   2005)	   and	   it	   is	   the	   second	   cause	   of	   death	   in	  
women	  after	   breast	   cancer	   (Jemal	   et	   al.,	   2010).	   Smoking	   is	   the	  major	   causative	   factor	   for	  
lung	  cancer	  by	  far	  (Shivapurkar	  et	  al.,	  2003).	   In	  2008	  about	  1.52	  million	  people	  around	  the	  
world	  were	  diagnosed	  with	  lung	  cancer	  and	  approximately	  1.31	  million	  of	  people	  died	  from	  
the	  disease	  (Lopes	  Pegna	  and	  Picozzi,	  2009).	  Lung	  cancer	  symptoms	  are	  detected	  very	  late	  in	  
most	  patients	  (Lopes	  Pegna	  and	  Picozzi,	  2009;	  Spiro	  and	  Silvestri,	  2005),	  which	  together	  with	  
lack	   of	   effective	   treatments	   contribute	   to	   a	   poor	   prognosis	   for	   most	   patients.	   Indeed,	  
regional	  or	  distant	  metastases	  are	  found	  in	  more	  than	  two-­‐thirds	  of	  patients	  (Lopes	  Pegna	  
and	  Picozzi,	  2009).	  Surgery,	  radiotherapy	  and	  chemotherapy	  are	  used	  to	  treat	  patients	  but	  
better	  therapies	  and,	  undoubtedly,	  early	  disease	  markers	  are	  seriously	  needed	  (Lopes	  Pegna	  
and	  Picozzi,	  2009).	  	  
	  
The	   classification	   of	   human	   lung	   cancer	   includes	   two	  major	   types:	   small	   cell	   lung	   cancer	  
(SCLC)	   and	   non-­‐small	   cell	   lung	   cancer	   (NSCLC).	  NSCLC	   includes	   several	   sub-­‐types	   of	  which	  
adenocarcinoma	  is	  the	  most	  common	  (Shivapurkar	  et	  al.,	  2003).	  
	  
1.1.2.	   Interleukin-­‐6	  and	  lung	  cancer	  
Interleukin	   (IL)-­‐6	  secretion	   is	  often	   increased	   in	  cancer	  patients	  and	  many	  cancer	  cell	   lines	  
(Gao	  et	  al.,	  2007).	  This	  cytokine	  is	  considered	  a	  pro-­‐tumourigenic	  agent	  in	  many	  cancer	  types	  
such	  as	  breast,	   lung,	  colon,	  prostate	  and	  ovarian,	  as	  well	  as	   in	  haematological	  cancers	  and	  
melanomas	  (Hodge	  et	  al.,	  2005).	  Signal	  transducers	  and	  activators	  of	  transcription	  (STAT)	  3	  is	  
constitutively	   activated	   in	   around	   50%	   of	   primary	   NSCLC	   tumours	   and	   cancer	   cells	   lines	  
derived	  from	  them	  (Gao	  et	  al.,	  2007;	  Haura	  et	  al.,	  2005;	  Mukohara	  et	  al.,	  2003;	  Seki	  et	  al.,	  
2004).	  It	  has	  been	  shown	  that	  IL-­‐6	  induces	  transcription	  of	  the	  IL-­‐6	  gene	  via	  JAK2	  and	  STAT3	  
leading	   to	   an	   increase	   in	   the	   production	   of	   this	   cytokine	   in	  many	   cancer	   cell	   lines.	   Thus,	  
regulating	  JAK2	  and/or	  STAT3	  could	  potentially	  reduce	  IL-­‐6	  production,	  thereby	  reducing	  cell	  
growth	  and	  maybe	  making	  cells	  more	  susceptible	  to	  other	  treatments	  (Huang	  et	  al.,	  2010).	  
Indeed,	  blockade	  of	   IL-­‐6	  signalling	   in	   lung	  cancer-­‐derived	  cell	   lines	   is	  enough	  to	   inhibit	  cell	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growth	  (Bihl	  et	  al.,	  1998;	  Gao	  et	  al.,	  2007).	  Some	  tumours	  in	  mice	  are	  induced	  by	  Ras,	  which	  
can	  also	  stimulate	  secretion	  of	   IL-­‐6	   in	  different	  cell	  types.	  Accordingly,	  knockdown,	  genetic	  
ablation	  or	  antibody	  neutralization	  of	   IL-­‐6	   limits	  tumour	  growth	   induced	  by	  Ras	   (Ancrile	  et	  
al.,	  2007).	  Interestingly,	  some	  human	  lung	  adenocarcinomas	  also	  have	  RAS	  mutated	  (Schafer	  
and	   Brugge,	   2007).	   The	   role	   of	   RAS	   in	   tumourigenesis	   is	   well	   described	   [reviewed	   in	  
(Fernandez-­‐Medarde	   and	   Santos,	   2011)].	   RAS	   signalling	   is	   involved	   in	   proliferation,	  
differentiation	  and	  survival.	  Mutations	  in	  the	  RAS	  gene,	  or	  in	  signalling	  molecules	  upstream	  
and	  downstream	  of	  RAS	  can	  alter	  the	  balance	  between	  these	  processes	  and	  lead	  to	  cancer	  
(Fernandez-­‐Medarde	  and	  Santos,	  2011).	  Indeed,	  when	  activated,	  RAS	  leads	  to	  the	  activation	  
of	  MAPK	  and	  PI3K	  pathways,	  both	  of	  which	  have	  also	  been	  greatly	  implicated	  in	  carcinogenic	  
processes.	   Several	   approaches	   can	   be	   used	   to	   reduce	   RAS-­‐mediated	   signalling	   and	   these	  
include	   direct	   inhibition	   of	   RAS	   and	   inhibition	   of	   its	   downstream	   targets	   [reviewed	   in	  
(Takashima	  and	  Faller,	  2013)].	  	  
 
Paradoxically,	   IL-­‐6	  can,	  under	  certain	  circumstances,	  decrease	  cell	  growth	  in	  some	  types	  of	  
lung	   cancer	   cells	   (Hong	   et	   al.,	   2007).	   For	   example,	   the	   growth	   of	   Lewis	   lung	   cancer	  
carcinoma	  cells	  decreases	  after	  inducing	  IL-­‐6	  expression.	  Treating	  these	  cells	  with	  an	  anti-­‐IL-­‐
6	  antibody	  has	  no	  effect	  on	  proliferation,	  indicating	  that	  growth	  inhibition	  is	  not	  related	  to	  a	  
direct	  autocrine	  effect	  of	  IL-­‐6	  (Porgador	  et	  al.,	  1992).	  In	  contrast,	  in	  other	  NSCLC	  cell	  lines,	  IL-­‐
6	   causes	   an	   increase	   in	   growth	   (A549,	   Calu3,	   Calu6,	   and	   H23).	   In	   the	   presence	   of	   IL-­‐6	  
antisense	   phosphorothioated	   oligonucleotides,	   cell	   proliferation	   is	   notably	   reduced.	  
However,	   neither	   the	   presence	   of	   monoclonal	   neutralizing	   anti-­‐IL-­‐6	   antibodies,	   nor	  
exogenous	  IL-­‐6,	  seems	  to	  interfere	  with	  cell	  proliferation,	  or	  IL-­‐6	  synthesis	  (Bihl	  et	  al.,	  1998).	  
In	   addition,	   circulating	   levels	   of	   IL-­‐6	   especially	   after	   chemotherapy	   are	   correlated	   with	  
survival	   in	  NSCLC,	   indicating	  that	   IL-­‐6	   is	   implicated	  in	  drug	  resistance	  of	  tumours	  (Chang	  et	  
al.,	  2012).	  
	  
Oncogenic	   mutations	   in	   epidermal	   growth	   factor	   receptor	   (EGFR)	   have	   been	   shown	   to	  
constitutively	   activate	   STAT3	   in	   lung	   cancer	   (Gao	   et	   al.,	   2007).	   Although	   EGFR	   has	   been	  
reported	   to	   directly,	   or	   indirectly	   (via	   SRC)	   activate	   STAT3	   (Quesnelle	   et	   al.,	   2007),	   this	  
activation	  has	  been	  shown	  to	  be	  due,	  at	  least	  under	  certain	  circumstances,	  to	  an	  increase	  in	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IL-­‐6	  production	  (Colomiere	  et	  al.,	  2009)	  	  
	  
1.1.3.	   Physiological	  and	  pathological	  role	  of	  Interleukin-­‐6	  	  
IL-­‐6	  has	  vast	  biological	   and	  pathological	   roles	   [Reviewed	   in	   (Mihara	  et	  al.,	   2012)].	   IL-­‐6	   is	   a	  
pleiotropic	  cytokine	   that	  plays	   important	   roles	   in	  cell	  proliferation,	  differentiation,	   survival	  
and	   apoptosis	   (Kamimura	   et	   al.,	   2003).	   IL-­‐6	   also	   takes	   part	   in	   immune	   responses,	  
haematopoiesis	   and	   inflammation	   [reviewed	   in	   (Costa-­‐Pereira	   et	   al.,	   2011;	  Heinrich	   et	   al.,	  
2003;	  Heinrich	  et	  al.,	  1998)].	  In	  addition,	  IL-­‐6	  can	  control	  a	  variety	  of	  responses	  in	  many	  cell	  
types	   and	   is	   a	   crucial	   regulator	   of	  many	   systems	   including	   the	   nervous	   system,	   endocrine	  
system	  and	  bone	  metabolism	  (Sehgal	  et	  al.,	  1995).	  Furthermore,	  IL-­‐6-­‐deficient	  mice	  present	  
with	  liver	  failure	  and	  deficient	  regeneration	  of	  hepatocytes,	  which	  can	  be	  restored,	  at	  least	  
in	  part,	  by	  IL-­‐6	  administration.	  This	  demonstrates	  the	  crucial	  role	  of	  IL-­‐6	  in	  the	  homeostasis	  
of	   the	   liver	   (Cressman	   et	   al.,	   1996).	   The	   involvement	   of	   IL-­‐6/IL-­‐6R	   in	   angiogenesis	   is	  
described	   through	   VEGF	   production	   (Hashizume	   et	   al.,	   2009).	   IL-­‐6	   also	   plays	   roles	   in	  
neutrophil	   trafficking,	   B-­‐cell	   differentiation,	   antibody	   production,	   proliferation	   and	  
differentiation	  of	   helper	   T-­‐cells,	   and	   in	   lipids	   and	   cartilage	  metabolism.	   The	   role	  of	   IL-­‐6	   in	  
bone	  metabolism	   is	   still	   controversial	   [reviewed	   in	   (Mihara	  et	  al.,	   2012)]	  even	   though	   IL-­‐6	  
deficient	  mice	  revealed	  that	  IL-­‐6	  is	  not	  critical	  to	  osteoclastogenesis	  and	  osteoclastic	  bone-­‐
resorbing	  activity	  (Poli	  et	  al.,	  1994).	  	  
	  
Several	   pathologies	   have	   been	   associated	   with	   elevated	   production	   of	   IL-­‐6.	   For	   example,	  
reducing	   IL-­‐6	   levels	   using	   an	   antibody	   such	   as	   Tocilizumab	   is	   efficient	   against	   rheumatoid	  
arthritis,	   systemic	   onset	   juvenile	   idiopathic	   arthritis,	   adult-­‐onset	   Still’s	   disease,	   Crohn’s	  
disease,	  Castleman’s	  disease,	  lupus	  erythematosus,	  Takayasu	  arthritis,	  polyarterutus	  nodosa,	  
systemic	  sclerosis,	  reactive	  arthritis	  dermatomyosis	  and	  polymyositis	  [reviewed	  in	  (Mihara	  et	  
al.,	  2005;	  Murakami	  and	  Nishimoto,	  2011)].	  	  
	  
In	  cancer,	  IL-­‐6	  was	  shown	  to	  promote	  proliferation,	  metastasis	  and	  cachexia	  symptoms.	  The	  
relevance	   of	   IL-­‐6	   in	   breast	   cancer	   and	   other	   cancers	   is	   widely	   described	   [reviewed	   in	  
(Knupfer	  and	  Preiss,	  2007;	  Mihara	  et	  al.,	  2012)].	  In	  breast	  cancer,	  in	  vitro	  studies	  show	  that	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IL-­‐6	   can	   either	   promote	   or	   reduce	   tumour	   formation.	   IL-­‐6	   seems	   to	   inhibit	   apoptosis	   by	  
inducing	  specific	  proteins	  such	  as	  BCL-­‐2,	  BCL-­‐XL	  and	  MCL-­‐1	  (Knupfer	  and	  Preiss,	  2007).	  IL-­‐6	  
role	  as	  an	  anti-­‐apoptotic	  molecule	  has	  been	  suggested	  in	  prostate	  cancer	  (Cavarretta	  et	  al.,	  
2007).	  IL-­‐6	  serum	  levels	  are	  increased	  in	  cancer	  patients.	  These	  levels	  can	  be	  correlated	  with	  
severity	   of	   the	   disease	   in	   ovarian	   cancer,	   renal	   carcinoma,	   melanoma,	   lymphoma	   and	  
prostate	  cancer	  (Mihara	  et	  al.,	  2012).	  
	  
1.2.	   Interleukin-­‐6	  signalling	  pathways	  
The	   IL-­‐6-­‐type	   cytokine	   family	   includes	   molecules	   such	   as	   IL-­‐6,	   IL-­‐11,	   leukaemia	   inhibitor	  
factor	  (LIF),	  oncostatin	  M	  (OSM),	  ciliary	  neurotrophic	  factor	  (CNTF),	  cardiotrophin	  (CT)-­‐1,	  CT-­‐
like	   cytokine	   (CLC)	   (Heinrich	   et	   al.,	   2003;	   Kamimura	   et	   al.,	   2003)	   and,	   more	   recently,	  
neuropoietin	   (NPN),	   IL-­‐27	  and	   IL-­‐31	   (Derouet	  et	  al.,	  2004;	  Dillon	  et	  al.,	  2004;	  Hodge	  et	  al.,	  
2005;	  Pflanz	  et	   al.,	   2004).	   These	  molecules	  bind	   to	   receptor	   complexes	   involving	  different	  
heterodimeric	  molecules	  and	  a	  common	  signal	  transducing	  unit,	  glycoprotein	  (gp)	  130,	  also	  
known	  as	  IL-­‐6	  signal	  transducer	  (IL-­‐6ST),	  IL-­‐6Rβ,	  or	  CD130	  (Heinrich	  et	  al.,	  2003;	  Kamimura	  et	  
al.,	  2003;	  Rose-­‐John	  et	  al.,	  2006).	  	  
	  
Signalling	   downstream	   of	   gp130	   activates	   transcription	   factors	   that	   belong	   to	   the	   STAT	  
family	   through	   Janus	   kinase	   (JAK)	   activation.	   This	   signalling	   also	   involves	   activation	   of	  
mitogen-­‐activated	   protein	   kinases	   (MAPKs)	   and	   phosphatidyl-­‐inositol-­‐3-­‐kinase	   (PI3K),	   as	  
illustrated	  in	  Figure	  1.2.	  Although	  gp130	  expression	  in	  cells	  is	  ubiquitous,	  only	  a	  few	  respond	  
to	   IL-­‐6	   since	   the	   expression	   of	   other	   subunits	   is	   limited	   and	   strictly	   regulated.	   With	   the	  
exception	  of	  OSMR	  (Mosley	  et	  al.,	  1996),	   the	  α	   receptors	   (e.g.	  LIFR,	   IL-­‐6Rα)	  are	  the	   ligand	  
binding	  molecules,	   thus	   providing	  most	   of	   the	   specificity	   to	   the	   response	   (Heinrich	   et	   al.,	  
2003;	  Kamimura	  et	  al.,	  2003).	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Figure	   1.2	   -­‐	   Pathways	   activated	   by	   IL-­‐6.	   STAT3	   and	   STAT1	   are	   activated	   through	   four	  
phosphotyrosine	  motifs	   (Y767,	   Y814,	   Y905	   and	   Y915)	   on	   gp130’s	   cytoplasmic	   tail.	  MAPK	   and	   PI3K	  
pathways	  are	  activated	  through	  binding	  of	  SHP2	  to	  the	  Y759	  phosphotyrosine	  motif.	  [Adapted	  from	  
(Costa-­‐Pereira	  et	  al.,	  2011)]	  
	  
The	  IL-­‐6	  receptor	  complex	  is	  composed	  of	  two	  α	  chains	  (IL-­‐6Rα)	  that	  interact	  with	  IL-­‐6	  and	  
two	  β	   chains	   (gp130)	   that	   transduce	   the	   signal	   by	   virtue	   of	   having	   STAT	   docking	   sites.	   In	  
contrast,	  OSM	  only	  requires	  one	  gp130	  molecule	  and	  one	  OSMR	  to	  signal.	  The	  80	  kDa	  IL-­‐6R	  
(also	  named	  gp80,	   IL-­‐6α	  or	  CD126)	  can	  be	  found	  associated	  with	  the	  membrane,	  mainly	   in	  
hepatocytes,	   neutrophils,	  monocytes	   and	  macrophages,	   or,	   as	   a	   soluble	  molecule	   (sIL-­‐6R).	  
Many	   cells	   do	   not	   express	   IL-­‐6R	   but	   they	   respond	   to	   IL-­‐6	   in	   the	   presence	   of	   the	   soluble	  
receptor,	  sIL-­‐6R,	  inducing	  what	  is	  known	  by	  trans-­‐signalling	  (Johnson	  et	  al.,	  2012;	  Kishimoto	  
et	  al.,	  1992;	  Scheller	  et	  al.,	  2011).	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1.2.1.	   Glycoprotein	  130	  
Only	  a	  single	  transcript	  has	  been	  identified	  for	  human	  gp130	  (Hibi	  et	  al.,	  1990).	  Amino	  acid	  
sequence	  analysis	  of	  human	  gp130	  reveals	  twelve	  potential	  N-­‐linked	  glycosylation	  sites	  in	  its	  
extracellular	  domain	   (Wang	  et	  al.,	  1992).	  Like	  some	  other	   transmembrane	  proteins,	  gp130	  
matures	   in	   the	   endoplasmic	   reticulum	   (ER)	   and	   Golgi	   complex,	   resulting	   in	   a	   150	   kDa	  
polypeptide	   by	   the	   addition	   of	   oligosaccharides	   linked	   to	   its	   N-­‐terminus	   (Gerhartz	   et	   al.,	  
1994).	   Two	   forms	   can	   be	   found	   by	   sodium	   dodecyl	   sulphate	   polyacrylamide	   gel	  
electrophoresis	  (SDS-­‐PAGE)/Western	  blotting	  analysis:	  the	  mature	  form	  (150	  kDa),	  which	  is	  
more	  abundant,	   and	   its	  precursor	   (130	  kDa)	  precursor	   (Wang	  and	  Fuller,	   1995).	  N-­‐glycans	  
are	   important	   for	  signalling	   initiation	  but	  not	   for	   the	  transport	  of	  gp130	  to	   the	  membrane	  
(Yanagisawa	  and	  Yu,	  2009).	  	  
	  
Since	  IL-­‐6R	  has	  a	  short	  cytoplasm	  tail	  of	  around	  80	  amino	  acids,	  it	  is	  unlikely	  that	  it	  has	  a	  key	  
role	   in	   transducing	   the	   signal	   (Taga	   et	   al.,	   1989).	   gp130	   cannot	   bind	   IL-­‐6	   directly	   but	   is	  
essential	  to	  promote	  the	  tight	  binding	  of	  the	  receptor	  complex	  with	  IL-­‐6	  and	  is	  essential	  to	  
IL-­‐6	   responses.	   It	   has	   several	   motifs	   in	   its	   C-­‐terminus	   (the	   cytoplasmic	   portion)	   that	   are	  
essential	   for	  the	  association	  of	  the	  JAKs	  to	  the	  receptor	  complex	  (Box1/2	  motif),	   to	  recruit	  
the	  STATs	  (tyrosine	  motifs)	  and	  to	  couple	  to	  MAPK	  and	  PI3K	  pathways	  Receptors	  activated	  
by	   IL-­‐6	   type	  cytokines	  have	   fibronectin	   type	   III	   (FNIII)-­‐like	  and	   Ig-­‐like	  domains	   (Figure	   1.3).	  
Two	  FNIII	  domains	  form	  a	  cytokine-­‐binding	  module	  (CBM)	  that	  is	  characteristic	  of	  this	  type	  
of	   receptor.	  A	  CBM	   is	   located	  near	   the	  N-­‐terminal	   after	   an	   Ig-­‐like	  domain	   (Heinrich	  et	   al.,	  
2003;	  Heinrich	  et	  al.,	  1998).	  
	  
After	   IL-­‐6	   binds	   to	   the	   receptor,	   both	   are	   internalised	   and	   IL-­‐6	   is	   degraded.	   This	   leads	   to	  
down-­‐regulation	  of	  the	  signal	  (Zohlnhofer	  et	  al.,	  1992).	  For	  this	  internalisation	  to	  occur	  two	  
leucines	  present	  in	  the	  cytoplasmic	  tail	  of	  gp130	  are	  essential:	  the	  so-­‐called	  ‘di-­‐leucine’	  motif	  
(Figure	   1.3),	   which	   is	   located	   on	   positions	   145	   and	   146	   (Dittrich	   et	   al.,	   1996).	   Studies	   by	  
Sugamura	   and	   colleagues	   (Tanaka	   et	   al.,	   2008)	   showed	   that	   in	   unstimulated	   cells	   gp130	  
degradation	   is	   inhibited	   by	   a	   proteasome	   inhibitor	   (epoxomicin)	   but	   not	   by	   lysosomal	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inhibitors	   (E-­‐64-­‐d	  and	  PEP).	   In	   contrast,	   in	   IL-­‐6	   stimulated	  cells	   lysosomal	  degradation	  was	  
induced	   in	   parallel	   with	   an	   increase	   in	   lysine	   69	   polyubiquitination	   of	   gp130.	   This	   occurs	  
even	  though	  gp130	  lacks	  ubiquitin	  binding	  sites	  in	  its	  structure.	  Linkage	  is	  made	  via	  SHP2,	  in	  
a	   tyrosine	   phosphorylation-­‐dependent	  manner.	   This	   can	   interact	  with	   c-­‐CBL,	   an	   E3	   ligase,	  
thereby	  mediating	  ubiquitination.	  After	  IL-­‐6	  stimulus,	  gp130	  molecules	  quickly	  translocate	  to	  
endosomal	   compartments,	   where	   the	   ubiquitinated	   form	   is	   recognised	   and	   sorted	   for	  
lysosomal	   degradation.	   Absence	   of	   hepatocyte	   growth	   factor	   (HGF)	   regulated	   tyrosine	  
kinase	   substrate	   (HRS)	   or	   c-­‐CBL	   results	   in	   deficient	   degradation	   of	   gp130	   and	   generates	  
amplification	  of	  the	  signal	  (Tanaka	  et	  al.,	  2008).	  
	  
Fas	  (also	  known	  as	  CD95)	  is	  a	  death	  receptor	  capable	  of	  inducing	  apoptosis	  after	  stimulation	  
by	   the	   Fas	   ligand.	   It	   is	   also	   known	   to	  be	   able	   to	  block	   gp130-­‐mediated	   signalling.	  A	   study	  
using	   liver	   cells	   has	   shown	   that	   cross-­‐linking	   of	   Fas	   leads	   to	   caspase	   activation	   and	  
degradation	  of	  gp130	  (Graf	  et	  al.,	  2008).	  This,	  in	  turn,	  inhibits	  IL-­‐6	  signalling.	  Interestingly,	  it	  
turns	  out	  that	  gp130	  has	  a	  caspase	  binding	  domain	  in	  its	  cytoplasmic	  tail	  (Graf	  et	  al.,	  2008).	  
During	   stress	   induction,	   or	   pro-­‐inflammatory	   cytokine	   stimulation	   (IL-­‐1β,	   TNFα),	   signalling	  
through	   gp130	   is	   also	   limited	   by	   receptor	   internalisation	   and	   degradation.	   Hermanns	   and	  
colleagues	   (Radtke	  et	  al.,	  2010)	  have	  shown	  that	   this	   is	  mediated	  by	  the	  stress	  kinase	  p38	  
and	   its	   substrate,	  MAPK-­‐activated	  protein	  kinase	  2	   (MK2),	  which	  can	  phosphorylate	  serine	  
782	  on	  gp130.	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Figure	  1.3	  -­‐	  Structural	  representation	  of	  the	  IL-­‐6	  receptor	  complex.	  On	  the	  extracellular	  side,	  two	  IL-­‐
6	   (red)	   bind	   to	   two	   IL-­‐6R	   (green),	  which	   are	   associated	  with	   two	   gp130	  molecules	   (homodimer	   in	  
blue	   and	   cyan).	   On	   the	   C-­‐terminus,	   gp130	   has	   six	   key	   tyrosine	   residues	   (YXPQ	   motif).	   Molecular	  
structures	  of	  JAKs,	  STATs,	  and	  the	  two	  key	  negative	  regulators	  of	  the	  pathway,	  SHP2	  and	  SOCS3,	  are	  

















































































































	   33	  
	  
1.3.	   JAK/STAT	  signalling	  
The	   non-­‐receptor	   tyrosine	   kinases	   JAKs,	  
associate	   with	   box	   1/2	   motifs	   on	   the	  
membrane	  proximal	  part	  gp130.	  Binding	  of	  
IL-­‐6	  to	  the	  receptor	  is	  thought	  to	  lead	  to	  a	  
conformational	   change	   that	   brings	   the	  
JAKs	   (JAK1,	   JAK2	   and	   TYK2)	   into	   close	  
proximity	   (Murakami	  et	  al.,	  1993).	  This,	   in	  
turn,	   leads	   to	   transactivation	   of	   the	   JAKs	  
and	   phosphorylation	   of	   specific	   tyrosine	  
residues	  on	  gp130.	   The	  human	  gp130	  has	  
six	   important	   tyrosine	   residues.	   Tyrosine	  
759	   (Y757	   in	   mice)	   is	   required	   for	   the	  
recruitment	   of	   SH2-­‐domain	   containing	  
phosphatase	   2	   (SHP2,	   also	   known	   as	  
PTPN11	   and	   PTP1D)	   and	   for	   a	   feedback	  
inhibitor	   known	  as	   suppressor	  of	   cytokine	  
signalling	   3	   (SOCS3)	   (and,	   indirectly,	   the	  
ERKs)	   (Nicholson	   et	   al.,	   2000;	   Schmitz	   et	  
al.,	  2000b).	  In	  contrast,	  tyrosines	  767,	  814,	  
905	   and	   915	   (all	   YXPQ	  motifs)	   have	   been	  
shown	  to	  recruit	  STAT3	  preferentially	  over	  STAT1,	  while	  phosphotyrosines	  905	  and	  915	  were	  
thought	  to	  display	  a	  preference	  for	  STAT1	  recruitment	  (Gerhartz	  et	  al.,	  1996;	  Heinrich	  et	  al.,	  
2003;	  Kamimura	  et	  al.,	  2003;	  Schmitz	  et	  al.,	  2000a;	  Stahl	  et	  al.,	  1995).	   In	  reality,	   it	   is	   likely	  
that	   all	   these	   residues	   recruit	   STAT3	   and	   STAT1	   indiscriminately.	   To	   the	   best	   of	   our	  
knowledge,	  no	  function	  has	  as	  yet	  been	  ascribed	  to	  tyrosine	  683.	  Phosphorylation	  of	  STATs	  
on	   specific	   tyrosine	   residues	   (tyrosine	   705	   for	   STAT3	   and	   701	   for	   STAT1)	   induces	   their	  
dimerization.	   Activated	   dimers	   translocate	   into	   the	   nucleus	   and	   bind	   to	   STAT	   responsive	  
elements	  on	  target	  gene	  promoters,	  thereby	  initiating	  transcription	  (Stahl	  et	  al.,	  1995).	  
Figure	  1.4	  -­‐	  JAK/STAT	  signalling	  in	  response	  
to	   IL-­‐6.	   Ligand	   binding	   induces	   auto-­‐	   and	  
trans-­‐phosphorylation	   of	   receptor	   pre-­‐
associated	  JAKs,	  phosphorylation	  of	  tyrosine	  
motifs	   in	   the	   receptor	   signalling	   subunit,	  
recruitment	  and	  reassortment	  of	  associated	  
STATs	  which,	  upon	  tyrosine	  phosphorylation	  
by	   the	   JAKs,	   are	   released,	   migrate	   to	   the	  
nucleus	  and	  activate	  transcription.	  [Adapted	  
from	  (Costa-­‐Pereira	  et	  al.,	  2011)].	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1.3.1.	  Janus	  kinases	  (JAKs)	  
Four	  members	  of	   the	  JAK	  family	  exist	   in	  mammals:	   JAK1,	   JAK2,	   JAK3	  and	  tyrosine	  kinase	  2	  
(TYK2)	   [reviewed	   in	   (Laurence	   et	   al.,	   2012)].	   JAK3	   is	   mainly	   expressed	   in	   haematopoietic	  
system;	  all	  the	  others	  are	  ubiquitously	  expressed.	  All	  JAKs	  have	  over	  1000	  amino	  acids	  with	  a	  
molecular	  weight	   ranging	   from	  120-­‐130	  kDa.	   JAKs	  are	  bound	  to	   receptors	   in	  a	  proline-­‐rich	  
domain	  generally	  called	  box1/box2	  region.	  Stimulated	  receptors	  change	  their	  conformation,	  
bringing	   JAKs	   close	   to	   each	   other	   and,	   consequently,	   allowing	   their	   activation	   by	   trans-­‐
phosphorylation	   (Kisseleva	   et	   al.,	   2002).	   The	   common	   structure	   of	   JAK	   molecules	   is	  
represented	   in	   Figure	   1.3.	   Briefly,	   these	   molecules	   have	   seven	   JAK	   homology	   (JH1-­‐7)	  
domains,	  which	  include:	  the	  4.1,	  ezrin,	  radixin,	  moesin	  (FERM)	  domain,	  which	  is	  responsible	  
for	   the	   interaction	  of	   JAKs	  with	  the	  receptor	  at	   the	  plasma	  membrane;	  SH2;	  pseudokinase	  
and	  kinase	  domains.	  JAKs	  contain	  an	  “activation	  loop”	  containing	  several	  tyrosine	  residues,	  
which	   are	   responsible	   for	   controlling	   their	   kinase	   activity	   (Laurence	   et	   al.,	   2012).	   TYK2	   is	  
associated	  with	   signalling	   downstream	  of	   different	   receptors	   such	   as	   the	   Interferon	   (IFN)-­‐
α/β	   receptor	   (IFNAR),	   gp130,	   and	   IL-­‐10,	   IL-­‐12,	   IL-­‐23	   and	   IL-­‐27	   receptors.	   The	   biological	  
effects	  associated	  with	  the	   lack	  of	  TYK2	  varies	  between	  humans	  and	  mice,	  possibly	  due	  to	  
the	  high	  number	  of	  receptors	  that	  depend	  to	  a	  lesser	  or	  greater	  extent	  on	  TYK2	  (Minegishi	  et	  
al.,	   2006).	   JAK1	   associates	   with	   receptors	   such	   as	   gp130	   and	   both	   type	   I	   and	   type	   II	   IFN	  
receptors.	  Mice	  lacking	  JAK1	  present	  defects	  in	  nerves’	  development	  and	  lymphopoiesis	  and	  
die	  perinatally.	  In	  humans,	  mutations	  in	  this	  protein	  have	  been	  related	  with	  acute	  leukaemia	  
(Laurence	  et	  al.,	  2012).	  Likewise,	  JAK2-­‐deficient	  mice	  die	  due	  to	  defective	  erythropoiesis.	  In	  
humans,	  mutations	  are	   found	   linked	   to	  acute	   leukaemia,	  myeloproliferative	  diseases,	   such	  
as	   polycythaemia	   vera.	   JAK2	   is	   associated	   with	   erythropoietin	   (EPO)	   and	   thymic	   stromal	  
lymphopoietin	   (TSLP)	   receptors	   thus	   promoting	   B	   cells	   and	   erythoid	   development	   and	  
proliferation.	  JAK3	  only	  associates	  with	  IL-­‐2	  common	  γ	  chain,	  which	  associate	  with	  different	  
ligand-­‐specific	   subunits	   that	   form	   the	   receptor	   for	   IL-­‐2,IL-­‐4,	   IL-­‐7,	   IL-­‐9,	   IL-­‐16	   and	   IL-­‐21.	   IL-­‐2	  
common	   γ	   chain	   is	   widely	   expressed	   in	   the	   hematopoietic	   system.	   Lack	   of	   JAK3	   in	   mice	  
results	   in	   severe	   immunodeficiency	   as	   a	   result	   of	   defects	   in	   T,	   B	   and	   NK	   cell	   function.	  
Similarly	   in	   humans,	   severe	   immunodeficiency	   is	   associated	   with	   lack	   of	   T	   and	   NK	  
lymphocytes	  and	  mutations	  inducing	  gain	  of	  function	  have	  been	  related	  to	  acute	  leukaemia	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(Laurence	  et	  al.,	  2012).	  	  
	  
1.3.2.	  Signal	  transducers	  and	  activators	  of	  transcription	  (STATs)	  
Seven	  mammalian	  STATs	  have	  been	  identified,	  some	  of	  which	  have	  different	  splicing	  variants	  
(STAT1,	  STAT3	  and	  STAT4).	  These	  are	  found	  in	  three	  chromosomal	  clusters	  and	  can	  also	  arise	  
post-­‐translationally	   after,	   for	   example,	   proteolytic	   processing	   (STAT5A	   and	   STAT5B)	  
[reviewed	  in	  (Pellegrini	  and	  Dusanter-­‐Fourt,	  1997)].	  STATs	  are	  750-­‐850	  amino	  acids	  long	  and	  
are	  ubiquitously	  expressed	  except	  for	  STAT4,	  which	  is	  mainly	  expressed	  in	  myeloid	  cells	  and	  
testis	  (Zhong	  et	  al.,	  1994).	  Their	  activity	  is	  regulated	  not	  only	  through	  tyrosine	  but	  also	  serine	  
phosphorylation	  (Shuai	  et	  al.,	  1993;	  Zhang	  et	  al.,	  1995).	  The	  structure	  of	  these	  molecules	  is	  
depicted	   in	   Figure	   1.3.	   It	   is	   note	   worthy	   that	   their	   SH2	   domains	   are	   responsible	   for	   the	  
association	  of	  STAT	  with	  tyrosine-­‐phosphorylated	  motifs	   in	  the	  receptor	  (Stahl	  et	  al.,	  1995)	  
and	  dimerisation	  with	  other	  tyrosine	  phosphorylated	  STATs	  (Heim	  et	  al.,	  1995;	  Shuai	  et	  al.,	  
1994).	   STAT1	   and	   STAT3	   are	   able	   to	   form	   homo-­‐	   and	   heterodimers,	   as	  well	   as	   tetramers	  
(Santos	  and	  Costa-­‐Pereira,	  2011)	  Near	   the	  C-­‐terminus	   is	   the	   transactivation	  domain	   (TAD).	  
This	  domain	  has	  a	  serine	  residue	  (amino	  acids	  727	  in	  STAT1	  and	  STAT3)	  that	  is	  necessary	  for	  
maximal	   transcriptional	   activation	   of	   some	   genes	   (Bhattacharya	   et	   al.,	   1996;	   Zhang	   et	   al.,	  
1996).	   After	   a	   few	   minutes	   of	   IL-­‐6	   treatment,	   STAT1	   and	   STAT3	   become	   tyrosine	  
phosphorylated	   in	  the	  cytoplasm	  and	  accumulate	  almost	  exclusively	   in	  the	  nucleus	  (Santos	  
and	   Costa-­‐Pereira,	   2011).	   Negative	   regulation	   occurs	   and	   nuclear	   STAT	   concentration	  
decreases	  within	  two	  hours	  (Zhang	  et	  al.,	  1995).	  	  	  
	  
Mutation	  of	  gp130	  on	  Y759	  to	  a	  phenylalanine	  impedes	  its	  phosphorylation	  and	  leads	  to	  an	  
increase	  the	  IL-­‐6	  signalling	  (Anhuf	  et	  al.,	  2000;	  Kim	  et	  al.,	  1998;	  Schaper	  et	  al.,	  1998;	  Symes	  
et	  al.,	  1997).	   Indeed,	  SOCS3,	  and	  the	  phosphatase	  SHP2,	  can	  bind	  gp130	  to	  phosphorylate	  
Y759	   thus	   triggering	   a	  wave	   of	   classical	   negative	   feedback	   events	   [(Lehmann	   et	   al.,	   2003;	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1.3.3.	  SOCSs,	  PIAS	  and	  other	  inhibitory	  pathways	  
SOCS	   proteins	   (also	   named	   JAK-­‐binding	   proteins,	   JABs,	   and	   STAT-­‐induced	   STAT	   inhibitors,	  
SSI)	  are	  known	  inhibitors	  of	  JAK/STAT	  pathways	  (Santos	  and	  Costa-­‐Pereira,	  2011).	  The	  SOCS	  
family	   has	   eight	   members:	   SOCS1-­‐7	   and	   Cytokine-­‐inducible	   SH2	   protein	   (CIS).	   These	  
molecules	  are	  characterized	  by	  an	  SH2	  central	  domain	  and	  by	  a	  SOCS	  box	   (represented	   in	  
Figure	   1.3).	   They	   also	   have	   an	   extended	   SH2	   subdomain	   (ESS)	   important	   for	   tyrosine	  
peptides	  binding	  and	  a	  kinase	   inhibitor	  region	  (KIR)	   (Yasukawa	  et	  al.,	  1999).	  They	  can	  thus	  
act	  by	  distinct	  mechanisms:	  (i)	  by	  binding	  phosphorylated	  tyrosine	  residues	  on	  the	  receptor	  
chain	   or	   to	   the	   JAKs,	   or	   (ii)	   by	   binding	   to	   STATs	   and	   blocking	   their	   recruitment	   to	   the	  
receptor.	   In	   addition,	   (iii)	   the	   SOCS	   box	   can	   target	   STATs	   to	   degradation,	   as	   it	   has	   E3	  
ubiquitin	  ligase	  activity	  (Croker	  et	  al.,	  2008).	  STATs	  can	  also	  be	  inactivated	  directly	  by	  protein	  
inhibitors	  of	  activated	  STAT	  proteins	  (PIAS)	  (Chung	  et	  al.,	  1997;	  Liu	  et	  al.,	  1998).	  PIAS	  can	  act	  
on	   different	   levels:	   (i)	   they	   can	   bind	   directly	   to	   STATs,	   thereby	   blocking	   protein-­‐DNA	  
interactions,	  (ii)	  they	  can	  induce	  degradation	  of	  the	  STATs	  or	  (iii)	  alter	  their	  localisation	  (Lee	  
et	  al.,	  1997).	  These	  negative	  regulatory	  mechanisms	  controlling	  STATs,	  together	  with	  those	  
involving	  phosphatases,	  ensure	  that	  STAT	  activation	  is	  cyclic	  and	  transient.	  SHP2	  has	  a	  role	  
not	  only	  as	  an	  enzyme	  but	  also	  as	  a	  protein	  adapter	   (Hof	  et	  al.,	  1998).	  gp130-­‐bound	  SHP2	  
can	  bind	  GRB2	  via	  two	  tyrosine	  residues	  in	  the	  C-­‐terminal	  (Y542	  and	  Y580)	  that	  are	  believed	  
to	  establish	   interactions	  with	   the	  GRB2-­‐SOS	  complex	   (Fukada	  et	  al.,	  1996;	  Lu	  et	  al.,	  2001).	  
This	   complex	   is	   a	   GDP/GTP	   exchanger	   for	   RAS.	   The	   GTP	   form	   results	   in	   MAPK	   cascade	  
activation.	   Activation	   of	  MAPK	   signalling	   through	   gp130	   thus	   requires	   phosphorylation	   of	  
Y759	   (Kamimura	   et	   al.,	   2003).	   This	   also	   involves	   GAB1,	   a	   scaffold	   protein.	   This	   further	  
increases	  the	  complexity	  of	  the	  response	  by	  allowing	  the	  recruitment	  of	  additional	  signalling	  
pathways,	  such	  as	  phospholipase	  C	  (PLC)-­‐γ	  and	  the	  p85	  subunit	  of	  PI3K	  (Costa-­‐Pereira	  et	  al.,	  
2011;	  Lee	  et	  al.,	  2000;	  Schaeper	  et	  al.,	  2000).	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1.4	   MAPK	  signalling	  
As	   previously	   mentioned,	   when	  
stimulated,	   the	   gp130	   receptor	  
activates	   not	   only	   JAK/STAT	   but,	   in	  
some	  cases,	  also	  MAPK	  and/or	  PI3K	  
cascades.	   	   ERK1/2	   activation	   is	  
dependent	   on	   phosphotyrosine	   759	  
within	   gp130’s	   cytoplasmic	   tail,	  
which	   recruits	   SHP2	   (Fukada	   et	   al.,	  
1996;	  Lai	  et	  al.,	  1999).	  The	  latter	   is	  
a	   tyrosine	   phosphatase	   that	   is	  
ubiquitously	   expressed.	   It	   is	   585	  
amino	   acids	   long	  with	   a	  molecular	  
weight	   of	   65	   kDa.	   Upon	   JAK1	  
phosphorylation	   of	   gp130,	   SHP2	  
binds	   to	   Y759	   (Schaper	   et	   al.,	  
1998).	   Phosphorylated	   SHP2	   then	  
binds	  to	  the	  GRB2-­‐SOS	  complex	  linking	  SOS	  to	  the	  gp130	  receptor.	  This	  recruitment,	  at	  the	  
plasma	  membrane	   level,	   enables	   RAS	   activation	   to	   occur	   and,	   consequently,	   leads	   to	   the	  
engagement	   of	   the	   MAPK	   pathway.	   MAPK	   activation	   can	   also	   be	   triggered	   by	   another	  
molecule,	  such	  as	  GRB2-­‐associating	  binder	  1	  (GAB1)	  (Itoh	  et	  al.,	  2000).	  Phosphorylated	  GAB1	  
interacts	  with	  SHP2	  and	  PI3K	  through	  its	  subunit	  p85	  and	  the	  complex	  SHP2/GAB1/PI3K	  then	  
initiates	  the	  MAPK	  pathway	  (Gu	  et	  al.,	  1998;	  Holgado-­‐Madruga	  et	  al.,	  1996).	  These	  initiating	  
mechanisms	   for	   the	   MAPK	   pathway	   culminate	   in	   the	   activation	   of	   RAS	   or	   RAP1	   small	  
GTPases	  followed	  by	  the	  recruitment	  of	  RAF	  kinases	  to	  the	  plasma	  membrane	  (Wellbrock	  et	  
al.,	  2004).	  To	  date,	  three	  members	  of	  the	  RAF	  kinase	  family	  have	  been	  described:	  A-­‐RAF,	  B-­‐
RAF	  and	  C-­‐RAF.	  These	  3	  molecules	  encompass	  three	  conserved	  regions:	  CR1,	  CR2	  and	  CR3	  
(Morrison	  and	  Cutler,	  1997).	  CR3	   is	  the	  catalytic	  domain	  that	   is	  regulated	  by	  CR1	  and	  CR2.	  
RAF	   activation	   is	   a	   complex	   process	   which	   requires	   (i)	   protein-­‐protein	   interactions,	   (ii)	  
dimerization	   and	   (iii)	   phospho-­‐	   and	   dephosphorylation	   events	   (Kolch,	   2005;	  Morrison	   and	  
Figure	   1.5	   -­‐	   MAPK	   pathway.	   After	   gp130	   stimulation,	  
the	  MAPK	  pathway	   is	   activated	   through	   the	  binding	   of	  
SHP2	   to	   the	   phosphotyrosine	   motif	   (Y759)	   on	   gp130	  
receptor.	   RAS	   activates	   RAF	   that	   subsequently	   activate	  
MEK.	   The	   latter	   phosphorylate	   and	   activate	   ERK1	   and	  
ERK2	   that	   can	   then	   move	   to	   the	   nucleus	   and	   activate	  
several	   transcription	   factors.	   [Adapted	   from	   (Costa-­‐
Pereira	  et	  al.,	  2011)]	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Cutler,	  1997).	  
	  
RAF	  phosphorylation	   leads	   to	   the	   phosphorylation	  of	  MEK1/2	  on	   two	   serines	   located	   in	   a	  
conserved	  sequence	  common	  to	  all	  MAPKKs	  –	  S-­‐X-­‐A-­‐X-­‐S/T	   (Alessi	  et	  al.,	  1994).	  Due	   to	   the	  
fact	   that	   the	  MEK	  molecule	   is	  more	  abundant	   than	   the	  RAFs,	   this	   step	   is	   critical	   for	   signal	  
amplification.	   MEK1/2	   have	   85%	   homology	   and	   are	   responsible	   for	   phosphorylating	  
downstream	  ERKs	  (Ohren	  et	  al.,	  2004).	  ERK1/2	  are	  phosphorylated	  on	  the	  conserved	  motif	  
T-­‐E-­‐Y	   (hERK1:	   aa:	   202-­‐204;	   hERK2:	   aa:	   185-­‐187).	   The	   molecule	   can	   be	   single	   or	   doubly	  
phosphorylated,	   but	   these	   phosphorylations	   occur	   through	   two	   independent	   processes.	  
Despite	   the	   fact	   that	   the	   tyrosine	   residue	   modification	   is	   the	   most	   predominant,	   single	  
threonine	  phosphorylation	  is	  also	  possible	  (Ferrell	  and	  Bhatt,	  1997).	  
	  
Tyrosine	   phosphorylation	   per	   se	   bestows	   very	   little	   kinase	   activity;	   instead,	   it	   allows	   the	  
accumulation	   of	   ERK	   phosphorylated	   on	   tyrosine	   so	   that	   threonine	   phosphorylation	   can	  
occur,	  thus	  promoting	  signal	  propagation	  only	  if	  MEKs	  are	  activated	  for	  long	  enough	  periods.	  
When	  fully	  active,	  ERK1/2	  phosphorylate	  multiple	  substrates	  including	  transcription	  factors,	  
membrane	  proteins,	   cytoskeletal	   elements,	   phosphatases	   and	   kinases.	   To	  date	  more	   then	  
200	   substrates	   have	   been	   identified,	   but	   it	   is	   believed	   the	   number	   will	   increase	   (von	  
Kriegsheim	  et	  al.,	  2009;	  Wortzel	  and	  Seger,	  2011;	  Yoon	  and	  Seger,	  2006).	  As	  proline-­‐directed	  
kinases,	  ERKs	  phosphorylate	  substrates	  in	  the	  consensus	  site	  P-­‐X-­‐S/T-­‐P	  or	  S/T-­‐P.	  The	  latter	  is	  
a	  shorter	  version	  but	  still	  long	  enough	  for	  ERK	  phosphorylation	  (Gonzalez	  et	  al.,	  1991).	  When	  
activated,	   ERK1/2	   translocate	   to	   different	   places	   in	   the	   cell	   where	   they	   phosphorylate	  
substrates	  related	  to	  transcription	  (Cruzalegui	  et	  al.,	  1999),	  nuclear	  transport	  (Vomastek	  et	  
al.,	  2008)	  and	  chromatin	  dynamics	  (Cohen-­‐Armon	  et	  al.,	  2007;	  Kosako	  et	  al.,	  2009).	  ERK1/2	  
can	  also	  regulate	  eukaryotic	  translation	   initiation	  factors	  (eIFs)	  (Shveygert	  et	  al.,	  2010)	  and	  
biogenesis	   of	   ribosomes	   (Mariappan	   et	   al.,	   2011).	   When	   stimulated,	   gp130-­‐containing	  
receptor	   complexes	   can	   also	   activate	   stress-­‐induced	   MAPKs,	   such	   as	   p38	   and	   c-­‐JUN	   N-­‐
terminal	  kinase	  (JNK)	  (Bode	  et	  al.,	  2001;	  Wang	  et	  al.,	  2000).	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1.4.1	   Mitogen-­‐activated	  protein	  kinases	  (MAPK)	  
ERK1	  was	  discovered	  in	  1990	  (Boulton	  et	  al.,	  1990).	  This	  protein	  was	  found	  to	  be	  around	  50%	  
homologous	   to	   the	   yeast	   proteins	   Kss1	   and	   Fus3,	   which	   had	   been	   previous	   reported	   to	  
control	   the	  cell	  cycle	  when	  stimulated	  with	  pheromones	   (Courchesne	  et	  al.,	  1989;	  Elion	  et	  
al.,	  1990).	  With	  the	  identification	  of	  ERK2	  and	  ERK3,	  a	  new	  protein	  kinase	  family	  was	  defined	  
and	  aptly	  named	  MAPK	  (Boulton	  et	  al.,	  1991).	  To	  date,	  the	  family	  comprises	  20	  members.	  
	  
MAPKs	   are	   often	   involved	   in	   oncogenesis	   and	   neurodegenerative	   diseases.	   They	   are	   key	  
molecules	   that	   regulate	   intracellular	   signalling	   involved	   in	   the	   responses	   to	   a	   variety	   of	  
cellular	  stresses,	  cell	  proliferation,	  differentiation,	  survival	  and	  death	  (Kim	  and	  Choi,	  2010).	  
They	   are	   ubiquitously	   expressed,	   functioning	   in	   different	   subcellular	   locations.	   These	  
serine/threonine	   kinases	   have	   different,	   specific,	   roles	   in	   cells	   and	   are	   activated	   by	  
cytokines,	   growth	   factors,	   antigens,	   toxins,	   pharmacological	   drugs	   and	   by	   different	   stress	  
signals	  (e.g.	  irradiation	  and	  temperature	  alterations)	  (Dhanasekaran	  and	  Johnson,	  2007).	  	  
	  
The	  mammalian	  MAPK	  family	   includes	  extracellular	  signal-­‐regulated	  kinase	  (ERK1	  to	  ERK8),	  
p38	   (α,	  β,	   γ	   and	  δ),	   and	   c-­‐JUN	  N-­‐terminal	   kinase	   (JNK1	   to	   JNK3).	   Core	   signalling	   involving	  
these	  molecules	   comprises	   three	  main	  components:	  MAPK	  kinase	  kinases	   (MAP3K),	  MAPK	  
kinases	  (MAP2K,	  or	  MEK)	  and	  MAPKs.	  GTP-­‐binding	  proteins	  of	  the	  RAS/RHO	  family	  activate	  
MAP3K	  by	  phosphorylation	  and/or	  by	  direct	   interaction.	  MAP3K	  phosphorylation	  activates	  
MEK,	   which	   also	   becomes	   phosphorylated	   and	   subsequently	   phosphorylates	   MAPK.	   This	  
eventually	  leads	  to	  the	  activation	  of	  several	  transcription	  factors,	  such	  as	  E	  twenty-­‐six	  (ETS)-­‐
like	   transcription	   factor	   1	   (ELK1),	   c-­‐JUN,	   ATF-­‐2	   and	   p53.	   Several	   cytoskeletal	   proteins	   and	  
enzymes	   (e.g.	   MAPK	   activated	   protein	   kinases	   ,MKs)	   are	   also	   substrates	   of	   MAPKs	   and	  
several	  specific	  phosphatases,	  such	  as	  the	  MAPK	  phosphatases	  (MKPs)	  downregulate	  MAPK	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1.4.1.1	   Six	  distinct	  mammalian	  MAPK	  pathways	  	  
Table	   1.1	   shows	   twenty	   mammalian	   MAPK	   identified	   to	   the	   date.	   They	   are	   grouped	  
differently	   according	   to	   the	   similarity	   on	   the	   sequences	   that	   are	   responsible	   for	   their	  
functions.	  MAPKs	   are	   part	   of	   the	   CMGC	   family	   of	   protein	   kinases,	   which	   includes:	   cyclin-­‐
dependent	   kinase	   (CDKs),	   MAPKs,	   glycogen	   synthase	   kinases	   (GSKs)	   and	   CDK-­‐like	   kinases	  
(CLK)	   (Manning	   et	   al.,	   2002).	   As	   shown	   in	   Table	   1.1,	   MAPKs	   are	   classified	   as	   either	  
conventional	  or	  atypical	  kinases.	  The	  former	  (ERK1/2,	  ERK5,	  p38s	  and	  JNKs)	  are	  activated	  by	  
MEK	  and	  all	  have	  a	  T-­‐X-­‐Y	  motif	  in	  their	  activation	  loop,	  whereas	  the	  latter	  (ERK3/4,	  ERK7/8)	  
either	  share	  a	  MEK-­‐independent	  mechanism	  of	  activation,	  or	  the	  activation	  loop	  has	  only	  a	  
single	  phosphoracceptor	  (Coulombe	  and	  Meloche,	  2007).	  
	  
Table	  1.1	  –	  Six	  distinct	  mammalian	  MAPK	  pathways.	  [Adapted	  from	  (Cargnello	  and	  Roux,	  2011)].	  	  
	  
Conventional	  MAPKs	   Atypical	  MAPKs	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1.4.1.1.1.	   Extracellular	  signal-­‐regulated	  kinases	  1	  and	  2	  (ERK1/2)	  
ERK1	  and	  ERK2	   (also	   known	  as	  MAPK3	  and	  MAPK1)	  have	  molecular	  weights	  of	   44	  and	  42	  
kDa,	  respectively,	  and	  share	  nearly	  85%	  of	  their	  sequences	  (Figure	  1.6)	  (Lefloch	  et	  al.,	  2008;	  
Marchi	   et	   al.,	   2008;	   Mebratu	   and	   Tesfaigzi,	   2009).	   These	   two	   isoforms	   are	   ubiquitously	  
expressed.	   In	   almost	   all	  mammalian	   tissues,	   it	   has	   been	   shown	   that	   ERK2	   is	   expressed	   at	  
higher	   levels	   than	  ERK1	   (Lefloch	  et	   al.,	   2008;	  Pages	  et	   al.,	   1999).	   Tumour	   growth	   is	   highly	  
related	  to	  ERK	  signalling	  as	  demonstrated	  by	  the	  high	   incidence	  of	  oncogenic	  mutations	   in	  
this	  pathway	   (Marchi	  et	   al.,	   2008).	   In	   the	  MAPK	  pathway,	  ERKs	   can	  phosphorylate	   several	  
substrates	   on	   serine	   and	   threonine	   residues	   [reviewed	   in	   (Yoon	   and	   Seger,	   2006)].	   Their	  
activity	  depends	  on	  phosphorylation	  on	  both	  threonine	  and	  tyrosine	  residues	  (human	  ERK1:	  
Thr202/Tyr204;	   human	   ERK2:	   T185/Y187)	   (Ferrell	   and	   Bhatt,	   1997).	   They	   are	   spatio-­‐
temporally	   regulated	   and	   their	   different	   biological	   functions	   thus	   depend	   on	   their	  
localisation	   (membrane,	   cytosol	   or	   nucleus)	   and	   on	   when	   phosphorylation	   occurs	  
(Pouyssegur	   et	   al.,	   2002).	   These	   kinases	   prefer	   P-­‐X-­‐S/T-­‐P	   sites	   as	   substrates.	   Specificity	   is	  
given	  by	  the	  docking	  domain	  and	  groove	  that	  are	  distant	  from	  the	  active	  centre	  (Tanoue	  et	  
al.,	  2000;	  Tanoue	  et	  al.,	  2001).	  Activation	  of	  this	  pathway	  can	  be	  achieved	  through	  different	  
membrane	  receptors,	  including	  growth	  factor	  receptors	  (e.g.	  FGFR,	  EGFR),	  insulin	  receptors,	  
cytokine	  receptors	  and	  integrins	  (Rodriguez	  and	  Crespo,	  2011).	  In	  the	  cytoplasm,	  ERK1/2	  can	  
form	  homodimers	  though	  interaction	  with	  scaffold	  proteins	  that	  act	  as	  assembly	  platforms	  
and	   facilitate	  contact	  with	   substrates	   (Casar	  et	  al.,	  2008).	  Within	  MAPK	  signalling,	   scaffold	  
proteins	   are	   also	   important	   in	   the	   regulation	   of	   signal	   intensity	   and	   amplitude,	   as	  well	   as	  
spatial	  specificity	  (Rodriguez	  and	  Crespo).	  However,	  it	  is	  thought	  that	  ERK1/2	  translocate	  to	  
the	  nucleus	  as	  monomers	  (Burack	  and	  Shaw,	  2005;	  Casar	  et	  al.,	  2008;	  Lidke	  et	  al.,	  2010;	  Wolf	  
et	   al.,	   2001).	   Downregulation	   of	   ERK	   signalling	   involves	   dephosphorylation	   by	   a	   family	   of	  
dual	   specific	   phosphatases	   (DUSPs)	   responsible	   for	   removing	   the	   phosphates	   from	   both	  
serine/threonine	  or	  tyrosine-­‐phosphorylated	  peptides	  [reviewed	  in	  (Caunt	  and	  Keyse,	  2013;	  
Shi,	  2009;	  Tonks,	  2006)].	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Figure	  1.6	  –	  ERK1	  and	  ERK2	  amino	  acid	  sequence	  comparison.	  The	  differences	  in	  the	  sequences	  are	  
represented	   in	   red.	  The	  different	  domains	  are	  highlighted	   in	  different	  colours.	   Initiator	  methionine	  
(lime),	   kinase	   domain	   (orange),	   nucleotide	   and	   ATP	   binding	   regions	   (burgundy),	   inhibitor	   binding	  
regions	  (green),	  TEY	  motif	  (brown),	  DNA	  binding	  site	  (purple),	  cytoplasmic	  retention	  motif	  (sky	  blue)	  
and	   nuclear	   translocation	   motif	   (blue).	   [Adapted	   from	   (Roskoski,	   2012)	   and	  
(http://www.uniprot.org/)]	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ERK2  1 MAAAAAAGAG P--------- --------
ERK1   1 MAAAAAQGGG GGEPRRTEGV GPGVPGEV
        
ERK2     12 EMVRGQVFDV GPRYTNLSYI GEGAYGMVCS AYDNVNKVRV AIKKISPFEH QTYCQRTLRE
ERK1     29 EMVKGQPFDV GPRYTQLQYI GEGAYGMVSS AYDHVRKTRV AIKKISPFEH QTYCQRTLRE
ERK2     72 IKILLRFRHE NIIGINDIIR APTIEQMKDV YIVQDLMETD LYKLLKTQHL SNDHICYFLY 
ERK1     89 IQILLRFRHE NVIGIRDILR ASTLEAMRDV YIVQDLMETD LYKLLKSQQL SNDHICYFLY
ERK2    132 QILRGLKYIH SANVLHRDLK PSNLLLNTTC DLKICDFGLA RVADPDHDHT GFLTEYVATR
ERK1    149 QILRGLKYIH SANVLHRDLK PSNLLINTTC DLKICDFGLA RIADPEHDHT GFLTEYVATR
ERK2    192 WYRAPEIMLN SKGYTKSIDI WSVGCILAEM LSNRPIFPGK HYLDQLNHIL GILGSPSQED
ERK1    209 WYRAPEIMLN SKGYTKSIDI WSVGCILAEM LSNRPIFPGK HYLDQLNHIL GILGSPSQED
ERK2    252 LNCIINLKAR NYLLSLPHKN KVPWNRLFPN ADSKALDLLD KMLTFNPHKR IEVEQALAHP
ERK1    269 LNCIINMKAR NYLQSLPSKT KVAWAKLFPK SDSKALDLLD RMLTFNPNKR ITVEEALAHP
ERK2    312 YLEQYYDPSD EPIAEAPFKF DMELDDLPKE KLKELIFEET ARFQPG
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Mice	  which	   lack	  erk2	  develop	  placental	  defects	  and	  die	  due	  to	  an	  deficiency	   in	  trophobast	  
function,	  mesoderm	  formation	  or	  placental	  development	  (Hatano	  et	  al.,	  2003;	  Saba-­‐El-­‐Leil	  et	  
al.,	  2003;	  Yao	  et	  al.,	  2003).	  In	  contrast,	  while	  erk1	  knockout	  mice	  are	  deficient	  in	  thymocyte	  
maturation	   and	   have	   some	   modifications	   in	   synaptic	   plasticity	   and	   behaviour,	   they	   can	  
procreate	  and	  are	  normal	  in	  size	  (Mazzucchelli	  et	  al.,	  2002;	  Pages	  et	  al.,	  1999).	  This	  suggests	  
that	   ERK2	   can	   compensate	   for	   the	   loss	   of	   ERK1,	   or	   that	   these	   two	   kinases	   have	   different	  
functions,	  a	  possibility	  that	  until	  recently	  had	  been	  overlooked.	  	  
	  
The	   two	   isoforms	   have	   been	   extensively	   studied	   and	   different	   hypotheses	   have	   been	  
proposed	   to	   explain	   their	   differing	   biological	   functions.	   It	   is	   possible	   that	   ERK1	   and	   ERK2	  
interact	   differently	   with	   MEK,	   with	   ERK1	   having	   a	   lower	   binding	   affinity	   than	   ERK2.	  	  
Alternatively,	  there	  maybe	  differences	  in	  how	  ERK1/2	  interact	  with	  substrates	  in	  the	  nucleus	  
(Marchi	   et	   al.,	   2008).	   Costa	   and	   colleagues	   (Marchi	   et	   al.,	   2008)	   have	   shown	   that	   ERK1/2	  
translocation	  between	   the	  nucleus	  and	   the	  cytoplasm	  can	  contribute	   to	   the	  differences	   in	  
roles	  of	  these	   isoforms.	   Indeed,	  translocation	  of	  ERK1	  to	  the	  nucleus	  appears	  to	  be	  slower	  
than	  ERK2.	  This	  is	  caused	  by	  the	  N-­‐terminal	  domain	  in	  ERK1	  (residues	  8	  and	  39),	  as	  removal	  
of	   this	   sequence	  makes	   it	   behave	   like	  ERK2.	  Expression	  of	   ERK2	   fused	  with	   this	   additional	  
sequence	  induced	  an	  ERK1-­‐like	  phenotype.	  Mouse	  embryonic	  fibroblasts	  (MEFs)	  deficient	  in	  
Erk1	  have	  an	   increased	  Erk2	  activity	  and	   increased	  proliferation.	  This	  observation	  suggests	  
that	  ERK1	  may	  play	  a	  role	  as	  an	  ERK2	  antagonist	  or	  partial	  agonist	  to	  balance	  ERK2	  signalling	  
(Indrigo	  et	  al.,	  2010;	  Vantaggiato	  et	  al.,	  2006).	  Our	  own	  data	  seems	  to	  suggest	  this,	  as	  after	  
ERK2	   knockdown	   we	   observe	   a	   decrease	   of	   gp130	   expression,	   which	   contributes	   to	   cell	  
proliferation	   and	   development	  while	   ERK1	   knockdown	  has	   no	   effect	   on	   the	   expression	   of	  
this	   receptor	   (Bonito	   et	   al.,	   2013).	   In	   NIH	   3T3	   cells	   knockdown	   of	   Erk2	   decreased	   the	  
activation	  of	  MAPK	  pathway	  while	  Erk1	  knockdown	  increased	  it.	  	  
	   	  
1.	  Introduction	  
	   44	  
	  
1.4.1.1.1.1	   Roles	  of	  ERK1/2	  which	  are	  independent	  of	  their	  kinase	  activity	  	  
ERK1/2	  also	  have	  roles	  that	  do	  not	  depend	  on	  their	  kinase	  activity	  [reviewed	  in	  (Rodriguez	  
and	  Crespo,	  2011)].	  For	   instance,	  ERK1/2	  can	  regulate	  their	  own	  kinase	  activity	  when	  they	  
interact	   with	   their	   substrates,	   as	   this	   changes	   their	   conformations	   and,	   consequently,	  
increases	  considerably	  their	  affinity	  for	  the	  DUSPs	  (Rodriguez	  and	  Crespo,	  2011).	  
	  
After	   their	   translocation	   to	   the	  nucleus,	  ERKs	  have	  a	  number	  of	   roles,	   including	  chromatin	  
remodelling	  and	  gene	  expression	  regulation	  [Reviewed	  by	  (Yoon	  and	  Seger,	  2006)].	  One	  such	  
example	   is	   the	   interaction	   of	   ERK2	   with	   poly(ADP-­‐ribose)	   polymerases	   (PARPs).	   These	  
proteins	  induce	  an	  important	  post-­‐translational	  modification,	  poly(ADP)-­‐ribosylation,	  which	  
occurs	   at	   the	   chromatin	   level	   on	   proteins	   that	   bind	   to	   DNA.	   PARP-­‐1	   is	   commonly	  
phosphorylated	   as	   a	   result	   of	   DNA	   damage	   (Schreiber	   et	   al.,	   2006).	   In	   absence	   of	   such	  
damage,	   however,	   PARP-­‐1	   can	   bind	   to	   ERK2	   and	   be	   activated	   by	   it	   (Cohen-­‐Armon	   et	   al.,	  
2007).	   This	   activation	   is	   independent	   of	   ERK2	   kinase	   activity	   but	   it	   still	   requires	   ERK2	  
phosphorylation.	   The	   common	  docking	   (CD)	   domain	  of	   the	   ERK2	  molecule	   establishes	   the	  
binding	  of	   ERK	   to	  PARP-­‐1.	   This	   complex	   then	  associates	  with	  ELK1,	   thereby	   increasing	   the	  
expression	  of	   ELK1-­‐target	   gene	   c-­‐FOS.	   This	   leads	   to	  activation	  of	  PARP-­‐1	   independently	  of	  
DNA	   binding.	   Furthermore,	   when	   activated	   by	   ERK2,	   the	   biological	   roles	   of	   PARP-­‐1	   are	  
different	  from	  those	  it	  fulfils	  when	  activated	  by	  DNA	  damage	  (Cohen-­‐Armon	  et	  al.,	  2007).	  
	  
DNA	   topoisomerase	   II	   is	   another	   example	   of	   a	   protein	   that	   can	   be	   activated	   by	   ERK1/2	  
independently	   of	   its	   kinase	   activity,	   although,	   as	   for	   PARP,	   ERK	   phosphorylation	   is	   also	  
involved	   (Heisig,	  2009;	   Shapiro	  et	  al.,	   1999).	  DNA	   topoisomerase	   is	   involved	   in	   chromatin-­‐
related	  events,	  catalysing	  double-­‐stranded	  DNA	  breaks	  that	  precede	  re-­‐ligation	  of	  the	  DNA	  
(Heisig,	  2009).	  
	  
In	  yeast,	  the	  ERK1/2	  homologous	  protein,	  Kss1,	  can	  bind	  to	  the	  transcription	  complexes	  that	  
interact	  with	  gene	  promoters	  and	  contribute	  to	  gene	  expression	  (Pokholok	  et	  al.,	  2006).	   In	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pancreatic	   β	  cells,	   depending	   on	   the	   glucose	   concentration,	   ERK2	   can	   either	   bind	   to	   the	  
insulin	   gene	  promoter,	   or	   to	  other	   glucose	  dependent	   genes	  as	  part	  of	   a	  multiple	  protein	  
complex.	   This	   complex	   contributes	   to	   enhance	   gene	   expression,	   or	   enhanced	   association	  
with	   the	   repressor	   C/EBP-­‐β	   thus	   inhibiting	   its	   transcription.	   There	   are	   six	   C/EBPs	  
transcription	  factors.	  These	  proteins	  have	  a	  highly	  conserved	  leucine	  zipper	  motif	  motif	  that	  
binds	  to	  DNA.	  The	  ERK	  substrate	  C/EBP-­‐β	  is	  ubiquitously	  expressed	  in	  many	  tissues	  and	  has	  a	  
crucial	  role	  in	  differentiation	  and	  proliferation.	  It	  is	  activated	  by	  mitogenic	  agents,	  cytokines,	  
hormones	  and	  inflammatory	  substances	  (Huber	  et	  al.,	  2012).	  The	  C/EBP-­‐β	  gene	  is	  expressed	  
as	   a	   single	   mRNA	   molecule	   that	   can	   form	   3	   different	   isoforms	   by	   alternative	   translation	  
initiation:	  C/EBP-­‐β1,	  C/EBP-­‐β2	   (also	  know	  as	  LAP)	  and	   the	  smaller	   isoform,	  C/EBP-­‐β3	   (LIP).	  
The	   latter	   has	   the	   DNA	   binding	   domain	   but	   lacks	   the	   transactivation	   domain	   and	   it	   thus	  
often	   works	   as	   a	   gene	   repressor	   (Abreu	   and	   Sealy,	   2012).	   Indirect	   ERK2	   binding	   to	   gene	  
promoters	   is	   also	   seen	   following	   NGF	   but,	   in	   this	   case,	   the	   kinase	   activity	   seems	   to	   be	  
important	  for	  this	  process	  (Lawrence	  et	  al.,	  2008).	  
	  
Controversially,	  ERK2	  can	  also	  bind	  gene	  promoters,	  most	  likely	  independently	  of	  its	  kinase	  
activity	   as	   shown	   by	   Hu	   and	   colleagues	   (Hu	   et	   al.,	   2009).	   This	   research	   group	   has	  
demonstrated	   that	   ERK2	   represses	   interferon	   (IFN)-­‐γ	   stimulated	   genes	   (γISGs).	  Upon	  ERK2	  
knockdown,	  82	  ISGs	  increased	  their	  expression.	  Interestingly,	  they	  identified	  a	  DNA	  binding	  
sequence	   for	   ERK2,	   G/CAAAG/C,	   which	   is	   usually	   localised	   near	   -­‐90	   base	   pairs	   from	   the	  
transcription	  starting	  site	  (TSS)	  within	  IFN-­‐γ	  activated	  transcriptional	  elements	  (GATEs)	  (Roy	  
et	  al.,	  2000).	  K259	  and	  Y261	  on	  the	  ERK2	  molecule	  were	  identified	  as	  being	  responsible	  for	  
the	  binding	  of	  the	  ERK2	  to	  the	  DNA	  (Hu	  et	  al.,	  2009)	  (Figure	  1.6).	  	  
	  
More	  recently,	  Goke	  and	  colleagues	  (Goke	  et	  al.,	  2013)	  have	  shown	  that	  ERK2	  is	  required	  for	  
the	  self-­‐renewal	  of	  human	  embryonic	  stem	  cells	  (hESCs).	  They	  have	  mapped	  the	  interactions	  
between	  ERK2	  and	   chromatin,	   and	   found	   that	   ERK2	  binds	   to	  non-­‐coding	   genes	   and	  genes	  
related	   to	   cell	   cycle,	   metabolism	   and	   pluripotency.	   Interestingly,	   the	   ERK2	   binding	   places	  
identified	  match	  those	  previously	  identified	  for	  ELK1,	  a	  well-­‐known	  target	  gene	  of	  the	  ERKs.	  
When	   ELK1	   is	   bound	   to	   gene	   promoters	   without	   ERK2	   molecules,	   it	   recruits	   polycomb	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proteins,	  which	   repress	  gene	  expression.	  This	   repression	   is,	  however,	   released	  when	  ERK2	  
binds	  to	  ELK1.	  It	  is	  still	  not	  known	  whether	  ERK2	  activity	  in	  required	  for	  this	  regulation,	  but	  




Figure	  1.7	  –	  Schematic	  representation	  of	  the	  model	  proposed	  by	  Goke	  and	  colleagues	  (Goke	  et	  al.,	  
2013).	   In	   the	  absence	  of	   ERK2,	  ELK1	  binds	   to	  promoters	   recruiting	  polycombs	  proteins	   that	   inhibit	  
gene	   expression.	   When	   ERK2	   binds	   to	   the	   promoters	   it	   releases	   the	   repression	   induced	   by	   ELK	  
promoting	   gene	  expression.	   In	   this	  model,	  MEK	   inhibition	   leads	   to	   the	  displacement	  of	   both	   ERK2	  
and	  ELK1	  from	  the	  promoter	  thus	  reliving	  the	  repression.	  
	  
1.4.1.1.1.2.	  Signal	  orchestration	  model	  
Hirano	  and	  colleagues	   (Kamimura	  et	  al.,	  2003)	  have	  described	  several	  experiments	  carried	  
out	  with	   gp130	   receptor	  mutants	   in	   order	   to	   understand	   its	   regulation	   and	   the	   impact	   of	  
downstream	   pathways	   activated	   upon	   IL-­‐6	   signalling.	   They	   noted	   that	   there	   was	   a	  
compensatory	   balance	   between	   the	   JAK/STAT	   and	  MAPK	   pathways	   when	   either	   pathway	  
was	   disturbed.	   In	   fact,	   it	   appears	   that	   inputs	   transduced	   by	   gp130	   can	   activate	   opposite	  
signalling	  cues.	  This	  may	  explain	  why	  and	  how	  IL-­‐6	  can	  have	  multiple	  functions	  in	  different	  
types	  of	  cells	  (Kamimura	  et	  al.,	  2003).	  Other	  reports	  concur	  that	  STAT3	  and	  ERK1/2	  signalling	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activation	   increased	   the	   proliferation	   of	   liver	   progenitor	   cells,	   while	   ERK1/2	   activity	  
decreased	  it	  (Yeoh	  et	  al.,	  2007).	  The	  present	  Thesis	  also	  provides	  evidence	  that	  favours	  the	  
notion	  that	  ERK1	  and	  ERK2	  have	  some	  non-­‐redundant	  functions.	  
	  
Figure	  1.8	  –	  Schematic	  illustration	  of	  the	  molecular	  organization	  of	  different	  MAPKs.	  They	  all	  share	  
a	   serine/threonine	   kinase	   domain	   bordered	   by	   regions	   of	   different	   sizes.	   Some	   MAPKs	   have	  
additional	   recognizable	   domains,	   such	   as	   the	   transactivation	   domain	   (TAD)	   in	   ERK5,	   nuclear	  
localization	  sequences	  (NLS)	  in	  ERK5,	  ERK7	  and	  ERK8,	  a	  conserved	  region	  present	  in	  ERK3	  and	  ERK4	  
denoted	  C34	  and	  a	  alanine-­‐	  and	  histidine-­‐	  rich	  domain	  (AHQr)	  in	  NLK.	  ERK7	  molecule	  has	  two	  proline	  
rich	   regions	   (PXXXP),	  which	  are	  suggested	   to	   interact	  with	  SH3	  domains	   [adapted	   from	  (Abe	  et	  al.,	  
1999;	  Cargnello	  and	  Roux,	  2011)].	  	  
	  
1.4.1.1.2.	   JNKs	  
Three	  genes	   (JNK1,	   JNK2	  and	   JNK3)	  with	  13	   splice	   variants	   comprise	   this	   family.	   JNK1	  and	  
JNK2	  are	  ubiquitously	  expressed	   in	   cells,	  while	   JNK3	  expression	   is	  usually	   limited	   to	   testis,	  
brain	  and	  heart.	  These	  molecules	  are	  activated	  mostly	  by	  stress	  stimuli	  such	  as	  cytokines,	  UV	  
radiation,	  DNA	  damaging	  agents,	  oxidative	  stress	  and	  growth	  factor	  deprivation	  (Kyriakis	  et	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motif	  by	  MEK4/7.	  After	  activation,	  JNK	  shift	  to	  the	  nucleus,	  where	  they	  activate	  and	  regulate	  
transcription	  factors.	  	  
	  
JNK	   biological	   studies	   are	   reviewed	   in	   (Aouadi	   et	   al.,	   2006;	   Bogoyevitch	   et	   al.,	   2010).	  
Combined	   Jnk1	   and	   Jnk2	   deletion	   in	   mice	   is	   lethal	   and	   the	   individual	   knockout	   animals	  
suggest	   the	   involvement	   of	   JNK1	   and	   JNK2	   in	   diabetes.	   The	   absence	   of	   Jnk2	   aggravates	  
albuminuria	   while	   that	   of	   Jnk1	   increases	   insulin	   sensitivity.	   Further	   studies	   demonstrated	  
that	  even	   though	   these	  proteins	  are	   similar,	   they	  have	  non-­‐redundant	   roles.	   Jnk3	   -­‐/-­‐	  mice	  
revealed	   that	   this	  molecule	   is	   involved	   in	   neuronal	   reaction	   to	   excitotoxic	   stress	   inducing	  
apoptosis.	  Most	   literature	  suggests	  that	  JNKs	  are	   involved	   in	  carcinogenesis,	   inflammation,	  
hepatocellular	   injury	   and	   liver	   regeneration,	   perhaps	   reflecting	   their	  multiple	   roles	   in	   cell	  
proliferation,	  growth	  and	  apoptosis.	  
	  
IL-­‐6	   can	   activate	   JNK	   proteins	   that	   translocate	   to	   the	   nucleus	   and	   activate	   different	  
transcription	  factors	  including	  c-­‐Jun.	  This	  molecule	  can	  increase	  the	  levels	  of	  AP-­‐1.	  JNK	  and	  
AP-­‐1	  have	  important	  roles	  in	  cell	  apoptosis,	  proliferation	  and	  different	  physiological	  as	  well	  
as	  pathological	  events	  (Johnson	  et	  al.,	  2012).	  	  
	  
1.4.1.1.3.	   p38	  kinases	  
Similarly	   to	   JNK,	   this	   family	   is	  also	  activated	  by	  stress	   factors.	  When	  a	  p38	   family	  member	  
gets	   activated	   it	   will	   induce	   a	   transcription	   factors.	   The	   four	   proteins	   [p38α,	   p38β,	   p38γ	  
(ERK6)	  and	  p38δ]	  are	  encoded	  by	  four	  genes	  (Raman	  et	  al.,	  2007).	  JNK	  and	  p38	  kinases	  share	  
their	  upstream	  MAP3Ks:	  MEKK1-­‐4,	  TAO1/2	  and	  ASK1/2.	  These	  molecules	  can	  phosphorylate	  
and	  activate	  MEK3	  and	  MEK6	  and	  as	  a	  consequence	  activate	  p38	  kinases.	  In	  vivo,	  MEK4	  has	  
also	  been	  shown	  to	  phosphorylate	  p38s	  upon	  UV	  radiation	  (Brancho	  et	  al.,	  2003).	  Disruption	  
of	   p38	   signalling	   has	   been	   related	   to	   defects	   in	   growth	   arrest	   and	   thus	   tumourigenesis	  
(Brancho	   et	   al.,	   2003).	   In	   addition,	   hepatocellular	   carcinoma	   cells	   display	   reduced	   p38	  
activity	  when	  compared	  to	  cells	  in	  adjacent	  normal	  tissues	  (Iyoda	  et	  al.,	  2003).	  Overall,	  the	  
p38	   pathway	   plays	   roles	   in	   cancer,	   being	   involved	   in	   cell	   cycle	   arrest,	   senescence	   and	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apoptosis	   (Bulavin	   et	   al.,	   2003)	  
and	  also	  inflammation	  (Radtke	  et	  
al.,	   2010).	  With	   the	   exception	   of	  
p38α,	   the	   knockouts	   of	   p38β,	  
p38γ	   and	   p38δ	   or	   double	  
knockout	   of	   γ	   and	   δ	   are	   viable,	  
fertile	   and	   the	   isoforms	   do	   not	  
have	   an	   impact	   the	  
expression/activity	   of	   the	   others	  
[reviewed	   in	   (Aouadi	   et	   al.,	  
2006)].	   This	   indicates	   that	   p38α	  
has	   crucial	   roles	   that	   cannot	   be	  
compensated	  by	  any	  of	  the	  other	  
isoforms.	   In	   fact,	   p38α	   knockout	  
mice	  die	  during	  embryogenesis	  at	  
day	   10.5-­‐11.5	   with	   placenta	  
development	   defects	   and,	  
potentially,	  abnormal	  angiogenesis.	  
When	   the	   embryonic	   defects	   are	  
rescued,	   the	   animals	   develop	   to	  
term	   suggesting	   that	   p38α	   is	   not	  
essential	   for	   embryogenic	  
development	  other	   than	   its	   role	   in	  
the	  placenta.	  Some	  knockout	  animals	   can	  get	  pass	  day	  11.5	  but	   those	   that	  do	  are	  anemic	  
due	   to	   reduced	   Epo	   gene	   expression	   (Aouadi	   et	   al.,	   2006).	   Overall,	   studies	   using	   p38α	  
knockout	  mice	  suggest	  that	  it	  plays	  an	  important	  role	  in	  cell	  differentiation.	  
	  
Evidences	   suggest	   an	   important	   role	   of	   p38	   signalling	   mediated	   by	   IL6	   during	   tumour	  
formation.	   IL6	   can	   activate	   p38	   in	   malignant	   cholangiocytes	   but	   not	   in	   normal	  
cholangiocytes.	   Importantly,	   the	   inhibition	  of	  p38	   in	   the	  malignant	   cholangiocytes	   reduces	  
their	  proliferation	  (Johnson	  et	  al.,	  2012).	   	  
Figure	   1.9	   –	   Activation	   of	   JNK	   and	   p38	   pathways	  
downstream	   of	   various	   cellular	   stresses.	   Factors	  
such	   as	   environmental	   stress,	   growth	   factors	   and	  
inflammatory	  cytokines	   (including	   IL-­‐6)	  can	  activate	  
these	   pathways.	   Different	   biological	   processes	   are	  
influenced	   by	   JNK	   and	   p38	   pathways,	   namely	   cell	  
proliferation,	  survival,	  differentiation	  and	  migration.	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1.4.1.1.4.	   ERK5	  
At	  98	  kDa,	  ERK5	  is	  the	  largest	  MAPK,	  the	  reason	  why	  it	  is	  also	  known	  as	  big	  MAPK1	  (BMK1).	  
Its	  kinase	  domain	  is	  similar	  to	  that	  of	  ERK1/2	  in	  the	  N-­‐terminal	  (sharing	  66%	  similarity),	  while	  
the	  C-­‐terminus	  has	  a	  transactivation	  domain	  (TAD)	  that	  is	  unique	  to	  this	  molecule	  (Cargnello	  
and	  Roux,	  2011).	  The	  C-­‐terminal	  of	  ERK5	  contains	  a	  bipartite	  nuclear	  localisation	  signal	  (NLS)	  
that	   is	   essential	   for	   its	   nuclear	   import	   (Kondoh	   et	   al.,	   2006).	   Unsurprisingly,	   ERK5	   shows	  
transcriptional	  activity	  [(Cargnello	  and	  Roux,	  2011;	  Nithianandarajah-­‐Jones	  et	  al.,	  2012)].	  
	  
After	   being	   activated	   by	   MEKK2	   and	   MEKK3,	   MEK5	   phosphorylates	   and	   activates	   ERK5,	  
which	   then	   is	   able	   to	   phosphorylate	   its	   own	   substrates,	   some	   of	   which	   are	   also	   ERK1/2	  
targets.	  ERK5	  can	  be	  activated	  by	  stress	  stimuli	  (oxidative	  stress	  and	  hyperosmolarity)	  and,	  
to	   a	   lesser	   extent,	   by	   serum	   or	   nerve	   growth	   factor	   (NGF).	   MEK5	   can	   be	   inhibited	   with	  
MEK1/2	  ‘specific’	  inhibitors,	  such	  as	  PD98059,	  U0126	  and	  PD184352,	  albeit	  the	  latter	  is	  not	  
as	  effective	  as	  the	  former	  inhibitors.	  Erk5-­‐deficient	  mice	  die	  at	  the	  embryonic	  stage	  due	  to	  
cardiovascular	  defects	  and	  angiogenic	  failure	  (Nishimoto	  and	  Nishida,	  2006).	  ERK5	  has	  been	  
reported	   to	   also	   play	   in	   cell	   proliferation	   and	  migration	   (Arnoux	   et	   al.,	   2008;	   Kato	   et	   al.,	  
1997).	  	  
ERK	   signalling	   can	   be	   triggered	   through	   engagement	   of	   numerous	   receptors,	   such	   as	   G-­‐
protein	   coupled	   receptors	   (GPCRs),	   receptor	   tyrosine	   kinases	   (RTKs),	   cytokine	   receptors,	  
integrins	  and	  ion	  channels.	  The	  signal	  transducers	  involved	  in	  these	  cascades	  vary	  but	  their	  
activation	   mechanisms	   share	   similarities	   with	   those	   described	   for	   gp130	   [reviewed	   in	  
(Bardwell,	  2006;	  Cargnello	  and	  Roux,	  2011)].	  	  
	  
1.4.1.1.5.	   ERK3/4	  
ERK3	   (MAPK6,	   97	   kDa)	   and	   ERK4	   (MAPK4,	   67	   kDa)	   are	   very	   similar	   to	   each	   other.	   These	  
proteins	  have	   a	   single	  phosphoracceptor	   site	   (S-­‐E-­‐G)	   and	  have	   a	   S-­‐P-­‐R	  motif	   in	   the	   kinase	  
activation	   loop,	   replacing	   A-­‐P-­‐E	   found	   in	   most	   protein	   kinases	   (Bogoyevitch	   and	   Court,	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2004).	  ERK4	  is	  mainly	  found	  in	  the	  cytoplasm	  while	  ERK3	  is	  present	  in	  the	  nucleus	  (Deleris	  et	  
al.,	   2008).	  Many	   different	   types	   of	   stimuli	   tested,	   such	   as	   phorbol	   ester	   and	   serum,	   have	  
failed	  to	  change	  ERK3	  localisation	  (Cheng	  et	  al.,	  1996;	  Deleris	  et	  al.,	  2008;	  Julien	  et	  al.,	  2003).	  
ERK3/ERK4	   are	   detected	   phosphorylated	   in	   the	   absence	   of	   common	  mitogenic	   factors	   or	  
stress	  stimuli	  (Deleris	  et	  al.,	  2008).	  To	  date,	  their	  corresponding	  MAP3K	  and	  MEK	  have	  not	  
been	  identified	  but	  ERK3	  is	  phosphorylated	  in	  vivo	  and	  this	  molecule	  can	  autophosphorylate	  
in	  vitro.	  p21-­‐activated	  kinases	  (PAKs)	  have	  been	  shown	  to	  phosphorylate	  ERK3/ERK4	  which	  
then	  leads	  to	  the	  consequent	  activation	  of	  MAPK-­‐activated	  protein	  kinase-­‐5	  (MK5)	  (Deleris	  
et	  al.,	  2011).	  MK5	  is	  the	  only	  identified	  ERK3/4	  substrate.	  The	  role	  of	  the	  C-­‐terminal	  domain	  
found	   in	   these	   molecules	   is	   not	   known,	   but	   it	   is	   thought	   to	   be	   involved	   in	   subcellular	  
targeting.	  The	  biological	  role	  of	  ERK4	  is	  unknown	  but	  ERK3	  has	  been	  shown	  to	  be	  important	  
in	   several	   processes	   including	   cell	   proliferation,	   differentiation	   and	   cell	   cycle	   progression	  
(Cargnello	  and	  Roux,	  2011).	  	  
	  
1.4.1.1.6.	   ERK7	  
ERK7	   is	   45%	   similar	   to	   ERK1	   in	   the	   N-­‐terminal	   domain.	   Its	   C-­‐terminal	   domain	   is	   unique,	  
containing	   a	   putative	   NLS	   and	   two	   proline-­‐rich	   domains,	   which	   are	   alleged	   SH3	   binding	  
domains	  (Coulombe	  and	  Meloche,	  2007).	  It	  is	  widely	  expressed,	  with	  a	  size	  of	  60	  kDa	  (Abe	  et	  
al.,	   1999).	   ERK7	   has	   a	   T-­‐E-­‐Y	  motif	   within	   the	   activation	   loop	   and	   its	   enzymatic	   activation	  
involves	  autophosphorylation,	  and,	  thus,	  does	  not	  depend	  on	  other	  MEK	  (Abe	  et	  al.,	  1999).	  
Because	   of	   this	   auto-­‐regulation,	   it	   is	   thought	   that	   ERK7	   is	   tightly	   regulated	   by	   protein	  
turnover	   (Kuo	  et	  al.,	  2004).	  ERK7	  demonstrates	  different	  substrate	  specificity	   from	  ERK1/2	  
(Abe	  et	  al.,	  1999).	  It	  has	  been	  suggested	  that	  it	  has	  roles	  in	  proliferation	  (Abe	  et	  al.,	  1999),	  
chloride	   transport	   (Qian	   et	   al.,	   1999)	   and	   signalling	   of	   nuclear	   receptors	   (Henrich	   et	   al.,	  
2003).	  More	   recently,	   it	   has	  been	   implicated	   in	   the	   responses	   to	  nutrient	   starvation	   in	   fly	  
and	  human	  cells	   (Zacharogianni	  et	  al.,	  2011).	  ERK7	  phosphorylation	  has	  been	  shown	  to	  be	  
activated	   by	   certain	   stimuli	   such	   as	   serum	   and	   H2O2	   suggesting	   the	   existence	   of	   a	   MEK	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1.4.1.1.7.	   Nemo-­‐like	  kinase	  (NLK)	  
With	   45%	   similarity	   to	   ERK2,	   NLK	   is	   considered	   atypical	   because	   it	   has	   a	   single	  
phosphorylation	  residue.	  Unlike	  the	  other	  MAPKs,	  this	  molecule	  contains	  an	  uncharacterised	  
N-­‐terminal	   extension	   and	   a	   conserved	   C-­‐terminal,	  which	   possibly	   contributes	   to	   substrate	  
interaction.	  Wnt	  signalling	  and	  several	  cytokines,	  such	  as	  IL-­‐6,	  G-­‐CSF	  and	  TGF-­‐β,	  are	  thought	  
to	  activate	  NLK.	  The	  activation	  is	  not	  fully	  understood,	  however	  TAK-­‐1,	  a	  MAP3K,	  is	  reported	  
to	  activate	  NLK.	  The	  activation	  loop	  of	  this	  molecule	  is	  composed	  by	  a	  T-­‐Q-­‐E	  motif	  (Cargnello	  
and	  Roux,	  2011).	  NLK	  is	  associated	  with	  proliferation	  suppression	  and	  apoptosis	  induction	  in	  
breast	  and	  lung	  cancer	  cells	  by	  Wnt	  signalling	  via	  c-­‐Myb	  regulation	  (Huang	  et	  al.,	  2013).	  	  
	  
	  
	   	  
1.	  Introduction	  
	   53	  
	  
1.5.	   PI3K	  signalling	  
The	   PI3K	   pathway	   was	   initially	   identified	   whilst	   researching	   insulin	   receptor	   signalling	  
[reviewed	   in	   (Alessi,	   2001;	   Brazil	   and	   Hemmings,	   2001;	   Shanware	   et	   al.,	   2013)].	   Insulin	  
receptor	   substrate	   (IRS)	   proteins	   activate	   PI3K,	   which	   activate	   AKT	   via	   phosphoinositide-­‐
dependent	  protein	  kinase	  1	  (PDK1)	  (Hemmings	  and	  Restuccia,	  2012).	  	  
	  
The	   PI3K/AKT	   pathway	   is	   tightly	   conserved	   and	   controlled.	   AKT	   can	   be	   activated	   by	   RTKs,	  
which	  directly	  stimulate	  class	  IA	  PI3Ks.	  These	  PI3K	  molecules	  are	  either	  bound	  directly	  to	  the	  
receptor	   by	   their	   regulatory	   subunits	   or	   via	   adapter	   molecules	   such	   as	   IRS.	   When	   PI3K	  
activation	  is	  triggered,	  its	  catalytic	  domain	  converts	  phosphatidylinositol	  (3,4)-­‐bisphosphate	  
(PIP2)	   lipids	   to	   phosphatidylinositol	   (3,4,5)-­‐trisphosphate	   (PIP3)	   at	   the	   plasma	   membrane	  
(Bellacosa	  et	  al.,	  2005;	  Hemmings	  and	  Restuccia,	  2012).	  PIP3	  binds	  to	  the	  PH	  domain	  of	  AKTs	  
allowing	   PDK1	   to	   access	   and	   phosphorylate	   T308	   in	   AKT1	   (309	   in	   AKT2	   and	   305	   in	   AKT3)	  
located	  in	  the	  “activation	  loop”	  (T-­‐loop),	  leading	  to	  partial	  AKT	  activation	  (Alessi	  et	  al.,	  1997).	  
This	  modification	  is	  enough	  to	  activate	  the	  mammalian	  target	  of	  rapamycin	  (mTOR)	  complex	  
1	  (mTORC1)	  through	  direct	  phosphorylation	  and	  inactivation	  of	  proline-­‐rich	  AKT	  substrate	  of	  
40	  kDa	  (PRAS40)	  and	  tuberous	  sclerosis	  protein	  2	  (TSC2)	  (Vander	  Haar	  et	  al.,	  2007).	  	  
	  
In	   order	   to	   become	   fully	   active,	   AKT	   requires	   not	   only	   the	   previously	   described	  
phosphorylation	  on	  the	  “activation	  loop”,	  but	  also	  the	  phosphorylation	  of	  the	  S473	  residue	  
for	  AKT1	  (474	  in	  AKT2	  and	  472	  in	  AKT3)	  located	  in	  the	  hydrophobic	  motif	  of	  the	  C-­‐terminal	  
tail.	  This	  phosphorylation	  can	  be	  done	  by	  mTOR	  (Sarbassov	  et	  al.,	  2005)	  or	  by	  DNA-­‐PK	  (Feng	  
et	   al.,	   2004).	   The	   hydrophobic	   motifs	   of	   AKT	   can	   associate	   with	   mTORC2,	   and	   DNA-­‐
dependent	  protein	  kinase	  (DNA-­‐PK).	  Recently,	  it	  has	  been	  shown	  that	  RAS	  can	  also	  crosstalk	  
with	   the	   PI3K/AKT	   pathway	   (Aksamitiene	   et	   al.,	   2012;	   Mendoza	   et	   al.,	   2011).	   PI3K/AKT	  
signalling	   is	   involved	   in	   many	   cellular	   functions,	   such	   as	   angiogenesis,	   growth,	   survival,	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AKT	  inactivation	  mechanisms	  have	  been	  investigated	  because	  PI3K/AKT	  pathway	  activation	  
contributes	   to	   tumourigenesis.	   The	  phosphatase	  and	   tensin	  homolog	   (PTEN)	  molecule	   is	   a	  
tumour	   suppressor	   that	   converts	   PIP3	   to	   PIP2	   (Di	   Cristofano	   et	   al.,	   1998;	   Stambolic	   et	   al.,	  
1998).	   In	   addition,	   SH2	   domain-­‐containing	   inositol	   5’-­‐phosphateses	   (SHIP1/SHIP2)	  
dephosphorylate	  PIP3	  on	  5’-­‐OH	  producing	  a	  different	  form	  of	  the	  molecule	  (Vanhaesebroeck	  
et	   al.,	   2005).	   Many	   other	   serine-­‐threonine	   phosphatases	   are	   also	   involved	   in	   AKT	  
inactivation,	   including	   phosphatase	   2A	   (PP2A),	   which	   is	   responsible	   for	   T308	  
dephosphorylation	   (Andjelkovic	  et	  al.,	  1996)	  and	  PH-­‐domain	   leucine-­‐rich-­‐repeat-­‐containing	  
protein	  (PHLPP1/2),	  which	  dephosphorylates	  S473	  (Alessi	  et	  al.,	  1997;	  Brognard	  et	  al.,	  2007;	  
Hemmings	  and	  Restuccia,	  2012).	  	  
	  
	  
Figure	   1.10	   –	   PI3K/AKT	   pathway.	   After	   RTK	   stimulation,	   PI3K	   is	   activated	   and	   promotes	   PIP2	  
phosphorylation.	   Active	   PIP3	   binds	   to	   PH	   regions	   of	   the	   AKT	   molecule,	   allowing	   PDK1	   to	  
phosphorylate	  the	  T308	  residue.	  For	  full	  activation,	  AKT	  needs	  to	  be	  phosphorylated	  both	  on	  specific	  
Thr	  and	  Ser	  residues.	  DNA-­‐PK	  and	  mTOR	  can	  phosphorylate	  AKT	  on	  serine	  residues.	  Active	  AKT	  can	  
promote	   the	   activation	   of	   mTORC1	   by	   direct	   inhibition	   of	   PRAS40,	   an	   mTORC1	   inhibitor,	   and	   by	  
inhibition	  of	  TSC2.	  AKT	  dephosphorylation	  is	  promoted	  by	  PTEN,	  which	  converts	  PIP3	  into	  PIP2,	  and	  
phosphatases	  PP2A	  and	  PHLPP,	  which	  dephosphorylate	  Thr	  and	  Ser	  residues,	  respectively.	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Depending	  on	   cell	   type,	   it	   is	   possible	   to	   observe	  PI3K	   activation	   following	   IL-­‐6	   stimulation	  
(Heinrich	  et	  al.,	  2003;	  Kortylewski	  et	  al.,	  2003),	  although	  the	  molecular	  mechanisms	  involved	  
are	  still	  not	  fully	  known.	  After	  IL-­‐6	  treatment,	  GAB1	  becomes	  activated	  and	  can,	  as	  a	  result,	  
activate	  PI3K	  (Takahashi-­‐Tezuka	  et	  al.,	  1998).	  Similarly,	  following	  treatment	  with	  OSM,	   in	  a	  
JAK-­‐dependent	   fashion,	   IRS-­‐1	  becomes	  active,	   associating	  with	  PI3K	   (Burfoot	   et	   al.,	   1997).	  
These	   observations	   suggest	   the	   involvement	   of	   GAB1	   and/or	   IRS-­‐1	   in	   PI3K	   activation	  
downstream	  of	  gp130.	  However,	  direct	  interaction	  between	  gp130	  and	  p85	  subunit	  of	  PI3K	  
has	  also	  been	  reported	  in	  prostate	  cancer	  cells	  (Chung	  et	  al.,	  2000).	  This	  indicates	  that	  gp130	  
can	  activate	  PI3K	  directly.	  
	  
1.5.1.	  PI3K	  	  
PI3Ks	   are	   enzymes	   that	   phosphorylate	   the	   third	   position	   of	   the	   inositol	   ring	   in	  
phosphoinositides	  substrates	  [reviewed	  in	  (Hawkins	  et	  al.,	  2006)].	  PI3K	  family	  are	  classified	  
into	   four	   classes	   (IA,	   IB,	   II	   and	   III),	   according	   to	   their	   structural	   and	   functional	  homologies	  
[reviewed	  (Fruman	  et	  al.,	  1998;	  Hawkins	  et	  al.,	  2006)].	  PI3Ks	  that	  generate	  PIP3	  from	  PIP2	  are	  
classified	  as	  Class	  IA,	  or	  Class	  IB.	  Class	  I	  molecules	  are	  often	  involved	  in	  signal	  transduction	  
pathways	   in	   response	   to	   receptor	   stimulation	  at	   the	  cell	   surface.	  Class	   III	  PI3Ks	  are	  mainly	  
responsible	   for	   the	   synthesis	   of	   phosphatidylinositol-­‐3phosphate	   (PI3P),	   a	   molecule	   that	  
regulates	  endocytosis,	  vesicle	  transport	  and	  the	  formation	  of	  the	  lysosomes.	  Class	  II,	  on	  the	  
other	  hand,	  are	  thought	  to	  provide	  an	  alternative	  to	  the	  way	  PI3P	  phosphorylation	  that	  can	  
occur	  downstream	  of	  receptors	  activation	  and	  endocytosis	  process	  (Hawkins	  et	  al.,	  2006).	  
	  
Class	   IA	   are	   characterized	   by	   two	   subunits:	   a	   catalytic	   (p110α,	   p110β	   or	   p110δ)	   and	   a	  
regulatory	   (p85α,	   p85β,	   p55α,	   p50α	   or	   p55γ)	   [reviewed	   in	   (Mellor	   et	   al.,	   2012;	  
Vanhaesebroeck	  et	  al.,	  2005)].	  With	  the	  exception	  of	  p55γ	  expression,	  which	  is	  restricted	  to	  
brain	   and	   testis,	   all	   the	   regulatory	   subunits	   are	   widely	   distributed	   in	   tissues.	   They	   are	  
important	  in	  the	  recruitment	  of	  p110	  to	  the	  plasma	  membrane,	  where	  their	  substrates	  are	  
located.	  In	  addition,	  p85	  controls	  p110	  kinase	  activity	  by	  interacting	  with	  different	  regulatory	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molecules	   containing	   phosphor-­‐tyrosines.	   As	   represented	   in	   Figure	   1.11,	   structurally,	   p85	  
has	  a	  SH3	  domain	  in	  its	  N-­‐terminal,	  followed	  by	  a	  B-­‐cell	  receptor	  homology	  (BH)	  domain	  with	  
proline-­‐rich	  sequences,	  p110	  binding	  domain	  and	  two	  SH2	  domains	   (nSH2:	  N-­‐terminal	  SH2	  
domain	  and	  cSH2:	  C-­‐terminal	  domain).	  On	   the	  other	  hand,	   class	   IA	  p110α	   is	   composed	  of	  
five	   domains:	   p85	   binding,	   RAS	   binding,	   C2,	   phosphoinositol	   kinase	   homology	   (PIK)	   and	   a	  
catalytic	  domain.	  The	  p85	  binding	  domain	  is	  responsible	  for	  the	  interactions	  between	  p110α	  
and	   p110	   binding	   domain	   of	   the	   p85	   molecule.	   The	   C2	   domain	   present	   on	   p110α	   also	  
interacts	  with	   p110	   binding	   domain.	   The	   PIK	   domain	   of	   the	   p110	  molecule	   interacts	  with	  
nSH2	  domain	  of	  the	  p85	  inhibiting	  p110α	  catalytic	  activity	  [reviewed	  in	  (Mellor	  et	  al.,	  2012)].	  
PIK	  and	  catalytic	  domains	  are	  homologous	   to	  domains	  belonging	   to	  other	  protein	  kinases,	  
such	  as	  mTOR,	  ATM,	  ATR	  and	  DNA-­‐PK	  (Bellacosa	  et	  al.,	  2005;	  Engelman	  et	  al.,	  2006).	  
	  
1.5.2.	  AKT	  
When	   PIP3	   is	   formed,	   it	   recruits	   proteins	   containing	   pleckstrin	   homology	   (PH)	   domains	  
(Hawkins	  et	  al.,	  2006;	  Hers	  et	  al.,	  2011).	  Nearly	  20	  proteins	  have	  been	  identified	  containing	  
PH	  domains.	  They	  participate	  in	  a	  number	  of	  different	  signalling	  cascades	  (Krugmann	  et	  al.,	  
2002).	   Of	   all	   these	   proteins,	   AKTs	   are	   the	   most	   widely	   studied,	   and	   perhaps	   the	   most	  
important.	   They	   are	   ubiquitously	   expressed	   in	   cells	   [reviewed	   in	   (Manning	   and	   Cantley,	  
2007)].	   The	   stimulation	   of	   PI3K/AKT	   pathway	   is	   likely	   to	   spread	   beyond	  AKT	   signalling,	   as	  
both	   PI3K	   and	   AKT	   interact	   with	   effectors	   of	  many	   other	   pathways.	   As	   it	   is	   observed	   for	  
other	  kinases,	  activation	  of	  AKT	  and	  consequent	  activation	  of	   the	  downstream	  targets	  can	  
vary	   depending	   on	   cell	   type,	   space	   and	   time	   (Hawkins	   et	   al.,	   2006;	  Manning	   and	  Cantley,	  
2007).	  	  
	  
To	  date,	  three	  AKT	  isoforms	  have	  been	  identified	  (Manning	  and	  Cantley,	  2007)	  and	  these	  are	  
represented	   in	   Figure	   1.11	   The	   two	   phosphorylation	   sites,	   threonine	   and	   serine,	   are	  
phosphorylated	  when	   the	  molecule	   is	  activated.	  To	  date,	  around	  100	  AKT	   substrates	  have	  
been	   identified,	   each	   with	   different	   roles	   in	   the	   cell,	   including	   cell	   survival,	   growth	   and	  
proliferation	  [reviewed	  in	  (Hers	  et	  al.,	  2011;	  Manning	  and	  Cantley,	  2007)].	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Figure	   1.11	   –	   Structural	   representation	   of	   PI3K	   and	   AKT	   molecules.	   Class	   IA	   PI3K	  molecules	   are	  
heterodimeric	  complexes	  that	  comprise	  a	  regulatory	  domain	  (p85)	  and	  a	  catalytic	  domain	  (p110).	  As	  
represented	   in	   the	   figure,	   p85	   isoforms	   share	   the	   same	   core	   structure:	   two	  SH2	  domains	   and	  one	  
p110	  binding	  domain.	  The	  domains	  surrounded	  by	  dashed	  lines	  [SH3,	  BH	  flanked	  by	  two	  proline-­‐rich	  
(PR)	   regions]	   belong	   to	   the	   longer	   isoforms	   (p85α,	   p85β).	   The	  p110	  domains	   are	  homologous	   and	  
consist	  of	  a	  p85	  binding	  domain	  near	  the	  N-­‐terminal,	  Ras	  binding	  domain	  (mediates	  the	  activation	  by	  
Ras),	  C2,	  PIK	  and	  the	  catalytic	  domain.	  AKT1,	  AKT2	  and	  AKT3	  are	  isoforms	  sharing	  similar	  structures.	  
At	   the	  N-­‐terminal	   they	   have	   a	   PH	   domain,	   followed	   by	   a	   kinase	   domain	   and	   a	   hydrophobic	  motif	  
(HM).	   The	   phosphorylation	   domains	   represented	   are	   responsible	   for	   the	   full	   activation	   of	   AKT	  
molecules	  [adapted	  from	  (Bellacosa	  et	  al.,	  2005;	  Engelman	  et	  al.,	  2006)].	  	  
	  
It	  is	  the	  integration	  of	  all	  these	  molecules	  and	  their	  signal	  transduction	  pathways	  that	  leads	  
to	  the	  appropriate	  messages	  reaching	  the	  nucleus	  to	  elicit	  meaningful	  biological	  responses.	  
Such	   responses,	   usually	   involve	   transcription	  and	  de	  novo	   protein	   synthesis	   and	   these	  are	  
also	  highly	  regulated	  processes.	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1.6.	   Gene	  regulation	  
In	   a	   differentiated	   organism,	   tight	   regulation	   of	   gene	   expression	   is	   necessary	   in	   order	   to	  
obtain	  distinct	  lineage	  pathways	  and	  achieve	  different	  developmental	  stages.	  Elucidation	  of	  
how	   these	   programs	   are	   controlled	   is	   crucial	   for	   an	   understanding	   of	   development,	  
differentiation	  and	  growth.	  This	  genomic	  regulation	  can	  occur	  at	  different	  levels:	  positioning	  
of	  loci	  within	  the	  three-­‐dimensional	  space	  on	  the	  nucleus,	  DNA	  packing	  into	  chromatin	  and	  
recruitment	  of	  transcription	  factors,	  all	  of	  which	  have	  a	  role	  in	  the	  transcription	  of	  the	  DNA.	  
Genome	   messages	   are	   transcribed	   into	   RNA	   molecules	   by	   RNA	   polymerases.	   These	   RNA	  
molecules	   are	   then	   modified	   by	   post-­‐transcriptional	   processing.	   They	   can	   either	   be	  
translated	  into	  proteins	  or	  they	  can	  act	  on	  their	  own,	   in	  different	  structural	  and	  functional	  
roles.	   Gene	   regulation	   involves,	   therefore,	   a	   number	   of	   different	   levels	   of	   interactions	  
resulting	  in	  complex	  transcriptional	  states.	  
	  
1.6.1.	   Genomic	  context	  
Genomic	  DNA	  contains	  not	  only	  the	  genetic	  information	  necessary	  for	  the	  development	  and	  
function	   of	   the	   organism	   but	   also	   regulatory	   sequences	   responsible	   for	   their	   first	   level	   of	  
activation	   control.	   Promoter	   and	  enhancer	   regions	   are	   located	   around	   specific	   genes,	   and	  
can	   recruit	   activators	   and	   repressor	   factors	   (De	   and	  Babu,	   2010).	  Despite	  much	   is	   already	  
known,	  the	  total	  understanding	  of	  the	  mechanisms	  involved	  in	  such	  regulation	  has	  yet	  to	  be	  
achieved.	   Gene	   expression	   varies	   depending	   on	   gene	   density,	   base	   composition,	   repeat	  
elements	  and	  intron	  length.	  It	  can	  also	  be	  influenced	  by	  epigenetic	  modification	  of	  the	  DNA,	  
or	   surrounding	   proteins.	   Taken	   all	   together,	   these	   factors	   constitute	   the	   “genomic	  
environment”	   that	   is	   vastly	   responsible	   for	   different	   protein	   expression	   levels	   in	   different	  
cell	   types	   and,	   therefore,	   the	   phenotypic	   differences	   between	   them	   (Festenstein	   et	   al.,	  
1996).	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1.6.1.1.	   Transcriptional	  machinery	  
Transcription	   factors	   (TFs)	   usually	   bind	   to	   DNA	   facilitating	   the	   recruitment	   of	   RNA	  
polymerases	  (RNAPs)	  and	  controlling	  many	  of	  the	  other	  stages	  in	  transcription.	  Although	  in	  
vitro	  TFs	  have	  a	  reduced	  influence	  in	  transcription,	  in	  vivo	  they	  can	  interfere	  with	  repressive	  
and	   chromatin	   compaction	   factors.	   The	   transcriptional	   machinery	   can	   be	   regulated	   by	  
different	   sequence-­‐specific	   TFs	   and	   regulatory	   co-­‐factors	   (Kadonaga,	   2004;	   Roeder,	   2005;	  
Sikorski	   and	   Buratowski,	   2009).	   Sequence-­‐specific	   TFs	   establish	   the	   link	   between	  
transcription	  machinery	  and	  genetic	  sequence	  by	  facilitating	  RNAP	  function	  or	  by	  recruiting	  
co-­‐factors	  (Kadonaga,	  2004).	  
	  
Regulatory	   co-­‐factors	   often	   do	   not	   bind	   to	   the	   DNA.	   However,	   they	   can	   influence	  
transcription	   by	   interaction	   with	   TFs,	   RNAP,	   or	   by	   remodelling	   the	   chromatin.	   The	   latter	  
facilitates	  access	  to	  regulatory	  regions	  (Roeder,	  2005).	  When	  the	  mediator	  complex,	  which	  is	  
a	   multi-­‐subunit	   protein	   complex,	   is	   formed	   it	   establishes	   the	   link	   between	   the	   basal	  
transcription	  machinery	   and	   regulatory	   co-­‐factors,	   or	   sequence-­‐specific	   TFs.	   This	   complex	  
can	  influence	  transcription	  positive-­‐	  or	  negatively.	  It	  acts	  as	  a	  positive	  mediator	  by	  increasing	  
the	  amount	  of	  general	  initiator	  factors	  at	  the	  promoter	  and	  RNAP	  II	  recruitment	  (Conaway	  et	  
al.,	  2005)	  or	  as	  a	  negative	  mediator	  by	  preventing	   the	  binding	  of	  general	   initiation	   factors	  
(Roeder,	  2005).	  	  
	  
The	  DNA	  sequence	  itself	  seems	  to	  contain	  some	  gene	  expression	  information.	  This	  is	  defined	  
by	   intron	   number	   and	   size,	   GC	   content	   and	   the	   presence	   of	   repeat	   elements	   (such	   as	  
mobile/	  transposable	  elements).	  Low	  expression	   is	   linked	  to	   low	  GC,	  extensive	   introns	  and	  
long	   interspersed	   nuclear	   elements	   (LINEs)	   (Versteeg	   et	   al.,	   2003).	   In	   contrast,	   high	   GC	  
content,	   smaller	   introns	   and	   short	   interspersed	   nuclear	   element	   (SINE)	   repeats	   is	  
characteristic	  of	  high	  gene	  expression.	  
	  
Low	   methylation	   status	   of	   promoter	   regions	   with	   a	   high	   number	   of	   GC	   di-­‐nucleotides	   is	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considered	  a	  marker	  of	  active	  transcription.	  Unmethylated	  CpG	  islands	  are	   indicative	  of	  an	  
active	   gene,	   as	   the	   chromatin	   is	   more	   permissive	   (Weber	   and	   Schubeler,	   2007)	   and	  
therefore,	   fewer	   chromatin	   remodelers	   are	   required	   in	   order	   to	   initiate	   transcription	  
(Ramirez-­‐Carrozzi	  et	  al.,	  2009).	  	  
	  
1.6.1.2.	   RNA	  polymerase	  (RNAP)	  II	  
RNAP	   II	   is	   a	   12-­‐subunit	   complex	   (RPB1-­‐12)	   that	   is	   responsible	   for	   mRNA	   and	   ncRNAs	  
production.	  It	  is	  also	  responsible	  for	  other	  nuclear	  processes	  such	  as	  chromatin	  modification,	  
RNA	  processing	  and	  DNA	  repair.	  The	  C-­‐terminal	  domain	  (CTD)	  located	  in	  RPB1,	  is	  subject	  to	  a	  
vast	   number	   of	  modifying	   activities	   that	   are	   responsible	   for	   RNAP	   II	   regulation	   in	   general	  
(Egloff	   and	   Murphy,	   2008).	   RPB1	   is	   the	   largest	   subunit	   of	   RNAP	   II.	   The	   CTD	   consists	   of	  
multiple	  repeats	  (52	  in	  mammalian	  cells)	  of	  a	  seven-­‐peptide	  sequence:	  Y1-­‐S2-­‐P3-­‐T4-­‐S5-­‐P6-­‐S7	  
(Brookes	  and	  Pombo,	  2009;	  Corden	  et	  al.,	  1985).	  The	  CTD	  is	  crucial	  for	  the	  transcription	  of	  
chromatin	   templates	   in	   vivo	   but	   is	   dispensable	   in	   the	   transcription	   of	   ‘naked’	   DNA	  
(Meininghaus	  et	  al.,	  2000).	  There	  are	  a	  large	  variety	  of	  proteins	  and	  factors	  that	  can	  bind	  to	  
the	  CTD	  of	  RNAP	  II.	  This	  includes	  proteins	  involved	  in	  a	  variety	  of	  gene	  expression	  regulatory	  
processes	   (histone	  modifications	   and	   RNA	   processing)	   and	   various	   associated	   factors	   that	  
are	   dependent	   on	   the	   CTD	   modification	   (e.g.	   phosphorylation,	   isomerisation	   and	  
glycosylation)	  (Phatnani	  and	  Greenleaf,	  2006).	  Such	  modification	  can	  alter	  the	  3D	  structure	  
of	  RNAP	  II,	  thus	  influencing	  the	  accessibility	  of	  the	  CTD.	  
	  
1.6.1.2.1.	   Phosphorylation	  of	  the	  CTD	  motif	  on	  RNAP	  II	  is	  crucial	  for	  the	  regulation	  of	  
the	  transcription	  cycle	  
The	   transcription	   cycle	   includes	   three	   main	   stages,	   namely	   initiation,	   elongation	   and	  
termination	   (Figure	   1.12).	   This	   cycle	   leads	   to	   the	   production	   of	   co-­‐transcriptionally	  
processed	   RNA,	   which	   is	   ready	   for	   export	   to	   the	   cytoplasm.	   Progress	   through	   the	  
transcription	   cycle	   is	   regulated	   by	   alterations	   in	   the	   RNAP	   II	   molecule,	   interactions	   with	  
inhibitors	  and	  repressors,	  chromatin	  remodelling	  and	  RNA	  processing,	  all	  of	  which	  ultimately	  
contribute	  to	  the	  tight	  control	  of	  gene	  expression	  (Buratowski,	  2003;	  Fuda	  et	  al.,	  2009).	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It	   has	   been	   suggested	   that	   phosphorylation	   is	   involved	   in	   transcription	   initiation,	   as	   it	   is	  
present	  in	  promoter	  regions	  of	  actively	  transcribing	  genes	  (Boehm	  et	  al.,	  2003;	  Komarnitsky	  
et	   al.,	   2000;	   Morris	   and	   Greenleaf,	   2000).	   RNAP	   II	   phosphorylated	   on	   S5	   influences	  
transcription	   positively,	   allowing	   it	   to	   clear	   from	   the	   promoter	   and	   pre-­‐initiation	   complex	  
(PIC),	   and	   for	   the	   recruitment	   of	   the	   necessary	   factors	   to	   initiate	   the	   transcription	  
(Komarnitsky	  et	  al.,	  2000),	  RNA	  capping	  (Ho	  and	  Shuman,	  1999)	  and	  methylation	  of	  histone	  
3	  on	  K4	  (H3K4)	  (Brookes	  and	  Pombo,	  2009;	  Ng	  et	  al.,	  2003).	  A	  mRNA	  capping	  enzyme	  adds	  a	  
7-­‐methyl	  guanosine	  (m7G)	  to	  the	  5’	  end	  of	  nascent	  RNAs	  increasing	  the	  stability	  of	  the	  RNA	  
molecule	  (Brookes	  and	  Pombo,	  2009).	  
	  
TFIIH	  mediates	  the	  phosphorylation	  of	  RNAP	  II	  on	  S5	  through	  the	  activity	  of	  CDK7	  (Rickert	  et	  
al.,	  1999).	  TFIIH	  can	  only	  phosphorylate	  the	  CTD	  when	  the	  RNAP	  II	  is	  bound	  to	  the	  DNA	  and	  a	  
PIC	   has	   been	   formed	   (Hengartner	   et	   al.,	   1998;	   Laybourn	   and	  Dahmus,	   1990).	   The	   binding	  
pattern	  of	  TFIIH	  along	  active	  genes	  correlates	  with	  pRNAP	  II-­‐S5	  (Komarnitsky	  et	  al.,	  2000).	  In	  
contrast,	  CDK8	  can	  phosphorylate	  S5	  within	  the	  CTD	  (Liao	  et	  al.,	  1995;	  Rickert	  et	  al.,	  1999)	  
only	  if	  the	  PIC	  has	  not	  yet	  been	  formed	  and,	  as	  such,	  has	  a	  negative	  effect	  on	  transcription	  
(Hengartner	  et	  al.,	  1998).	  Under	  stress	  conditions,	  ERKs	  can	  phosphorylate	  free	  RNAP	  II	  on	  
Ser5	  residue	  (Bonnet	  et	  al.,	  1999).	  
	  
An	   additional	   phosphorylation	   event,	   this	   one	   at	   S2	   (pRNAP	   II-­‐S2),	   which	   follows	   the	  
phosphorylation	  of	  RNAP	  II-­‐S5,	  is	  required	  for	  the	  elongation	  process	  (Kim	  et	  al.,	  2002;	  Lee	  
and	   Greenleaf,	   1997;	   Marshall	   et	   al.,	   1996),	   for	   the	   tri-­‐methylation	   of	   histone	   3	   on	   K36	  
(H3K36)	  (Li	  et	  al.,	  2005)	  and	  to	  recruit	  RNA	  processing	  factors	  (Proudfoot	  et	  al.,	  2002).	   It	   is	  
mainly	   found	   in	   the	   promoter	   region	   and	   increases	   after	   the	   TSS,	   which	   is	   thought	   to	  
contribute	   to	  RNAP	   II	   phosphorylation	   throughout	   the	   gene	   sequence.	  CDK9	   catalyses	   the	  
phosphorylation	   of	   S2	   and	   it	   is	   the	   kinase	   component	   of	   positive	   transcription	   elongation	  
factor	   b	   (P-­‐TEFb)	   (Cho	   et	   al.,	   2001;	   Marshall	   et	   al.,	   1996).	   In	   addition,	   pRNAP	   II-­‐S2	  
phosphorylation	   is	   also	   involved	   in	   co-­‐transcriptional	   RNA	  processing,	   participating	   on	   the	  
recruitment	  of	  splicing	  and	  polyadenylation	  factors.	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Figure	  1.12	  –	  RNAP	  II	  CTD	  phosphorylation	  varies	  at	  different	  stages	  of	  the	  transcription	  cycle.	  A.	  
RNAP	   II	   in	   its	   hypo-­‐phosphorylated	   state	   binds	   to	   the	   promoter.	   Here,	   the	   Ser5	   residue	   is	  
phosphorylated	  by	  TFIIH,	  which	  initiates	  transcription.	  If	  RNAP	  II	  is	  unstable,	  the	  transcription	  can	  be	  
aborted	   (top	   cycle).	   If	   it	   is	   able	   to	   progress,	   RNAP	   II	   can	   either	   be	   halted	   by	   negative	   elongation	  
factors	  at	  the	  pause	  site	  (represented	  by	  dashed	  line),	  or	  proceed	  to	  become	  phosphorylated	  on	  Ser2	  
by	  P-­‐TEF-­‐b,	  which	  enables	  elongation	  of	  the	  nascent	  mRNA	  molecule	  to	  occur.	  At	  the	  end	  of	  the	  gene	  
sequence	  (3’	  end),	  both	  RNAP	  II	  and	  the	  RNA	  template	  dissociate	  from	  the	  DNA	  template.	  RNAP	  II	  is	  
then	   dephosphorylated	   by	   phosphatases	   in	   mammals	   small	   CTD	   phosphatases	   (SCP1-­‐3)	   allowing	  
dissociation	   and	   the	   start	   of	   a	   new	   transcription	   round.	   B.	   Representation	   of	   chromatin	  
immunoprecipitation	  (ChIP)	  patterns	  of	  phosphorylated	  RNAP	  II	  throughout	  the	  gene	  (blue:	  pRNAP	  II-­‐
S5;	  purple:	  pRNA	  II-­‐S2).	  TSS	  and	  direction	  of	  transcription	  are	  indicated	  by	  the	  arrows;	  the	  distance	  
along	   gene	   is	   represented	   by	   the	   x-­‐axis	   and	   enrichment	   on	   the	   y-­‐axis.	   C.	   Co-­‐transcriptional	   RNA	  
processing.	  At	  the	  promoter	  of	  active	  genes	  pRNAP	  II-­‐S5	  is	  responsible	  for	  the	  recruitment	  of	  capping	  
machinery	  that	  adds	  m7G	  to	  immature	  RNA	  molecules.	  During	  elongation,	  pRNAP	  II-­‐S2	  is	  involved	  in	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1.7.	   Aims	  
Catarina	  Ramos	  do	  Carmo,	  a	  previous	  PhD	  student	  in	  our	  group,	  firstly	  observed	  that	  ERK1	  
and	  ERK2	  played	  different	  roles	  in	  the	  regulation	  of	  STAT3	  and	  gp130	  protein	  expression	  in	  
U2OS	  cells.	  She	  noted	  that	  upon	  knockdown	  of	  ERK2,	  but	  not	  ERK1,	  the	  levels	  of	  STAT3	  and	  
gp130	  were	  decreased.	  As	  a	  consequence,	  the	  signalling	  of	  IL-­‐6	  was	  also	  affected.	  She	  also	  
observed	  that	  transfecting	  U2OS	  cells	  with	  siRNA	  against	  ERK1	   led	  to	  an	   increase	   in	  gp130	  
precursor	   form	   and	   a	   decrease	   of	   the	   mature	   form,	   suggesting	   a	   role	   for	   ERK1	   in	   the	  
maturation	  of	  gp130.	  	  
	  
Figure	   1.13	   -­‐	   Silencing	   ERK1	   or	   ERK2	   has	   an	   impact	   on	   protein	   expression	   of	   gp130	   and	   STAT3.	  
U2OS	  cells	  were	  transfected	  with	  75	  nM	  siRNA	  against	  ERK2,	  STAT3	  or	  ERK1.	  After	  48	  h	  transfection,	  
proteins	  were	  extracted	  and	  separated	  on	  a	  7.5%	  SDS-­‐PAGE	  gel.	  A.	  Total	  cell	   lysates	  were	  Western	  
blotted	  as	  indicated.	  β-­‐actin	  was	  used	  as	  a	  loading	  control.	  These	  results	  are	  representative	  of	  three	  
independent	  experiments.	  U:	  untransfected	  cells,	  E2:	  ERK2,	  ST3:	  STAT3	  and	  E1:	  ERK1.	  The	  Western	  
blot	  bands	  were	  quantified	  using	  ImageJ	  and	  statistical	  analysis	  was	  performed	  comparing	  different	  
samples	  to	  untreated	  condition	  (taken	  from	  Catarina	  Ramos	  do	  Carmo	  PhD	  Thesis,	  ICL,	  2010).	  
	  
We,	  therefore,	  hypothesised	  that	  ERK1	  and	  ERK2	  played	  important	  roles	  in	  the	  regulation	  of	  
the	   expression	   of	   key	   effectors	   of	   IL-­‐6-­‐type	   signalling.	   These	   roles	   were	   likely	   to	   be	   in	  
addition	   to	   their	   previously	   recognised	   functions	   and	   probably	   extendable	   to	   additional	  
receptor	  molecules.	   Accordingly,	   we	   sought	   to	   understand	   the	  molecular	   mechanisms	   by	  
which	   ERKs	   impacted	   so	   profoundly	   on	   signalling	   through	   receptor	   complexes	   involving	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2.1.	  Materials	  	  
2.1.1.	  Equipment	  
Veriti®	  Thermal	  Cycler,	  7900	  HT	  Fast-­‐Real-­‐Time	  PCR	  system	  were	  from	  Applied	  Biosystems,	  
UK.	   FACS	   Canto	   flow	   cytometer	   was	   from	   BD	   biosciences	   (Oxford,	   UK).	   PHERAstar	  
luminescence	  microplate	  was	  from	  BMG	  Labtech,	  Germany.	  Eppendorf	  centrifuge	  5810	  was	  
from	  Eppendorf,	  Germany.	  iBlot®	  Dry	  Blotting	  system	  was	  from	  Invitrogen.	  Konica	  SRX-­‐101A	  
film	  processor	  was	  from	  Konica	  Minolta.	  SunriseTM	  microplate	  absorbance	  reader	  was	  from	  
Tecan	   Trading	   AG,	   Switzerland.	   Sorvall®	   Legend	   RT	   centrifuge	   was	   from	   Thermo	   Fisher	  
Scientific,	  UK.	  
	  
2.1.2.	  General	  reagents	  	  
Foetal	   calf	   serum	   (FCS)	   was	   purchased	   from	   FirstLink	   (Birmingham,	   UK).	   L-­‐glutamine,	  
Lipofectamine®	  RNAiMax	  transfection	  reagent,	  OneShot®	  TOP10	  Chemical	  competent	  cells,	  
Proteinase	  K,	  Protein	  G-­‐magnetic	  beads,	  Dynabeads®	  M-­‐280	  Streptavidin	  and	  polyvinylidene	  
difluoride	   (PVDF)	   iBlot®	  membranes	  were	   obtained	   from	   Invitrogen	   (UK).	   Acrylamide	  was	  
purchased	  from	  National	  Diagnostics	  (Hull,	  UK);	  phosphate	  buffered	  saline	  (PBS)	  from	  OXOID	  
(Hampshire,	   UK);	   glycine,	   nonidet-­‐P40	   (NP-­‐40)	   and	   para-­‐formaldehyde	   (p-­‐FA)	   from	   BDH	  
Chemicals	   (Poole,	   UK).	   Dithiothreitol	   (DTT)	   and	   milk	   were	   obtained	   from	   or	   AppliChem	  
GmbH,	  (Darmstadt,	  Germany).	  BioRad	  protein	  assay	  and	  bromophenol	  blue	  were	  obtained	  
from	   BioRad	   (Munich,	   Germany).	   Ethanol,	   glycerol,	   isopropyl	   alcohol,	   methanol,	  
ethylenediamine	   tetraacetic	   acid	   (EDTA),	   Tris-­‐(hydroxymethyl)	   aminomethane	   (Tris),	  
hydrochloric	  acid	  (HCl,	  37%	  v/v),	  glacial	  acetic	  acid,	  sodium	  chloride	  (NaCl),	  sodium	  dodecyl	  
sulphate	  (SDS),	  Fermentas	  PageRuler™	  prestained	  protein	  markers,	  and	  all	  siRNA	  sequences	  
were	  obtained	   from	  Fisher	  Thermo	  Scientific	   (Loughborough,	  UK)	  and	  qPCR	  reagents	  were	  
from	  Roche	   (Roche	  Applied	  Science,	  Mannheim,	  Germany).	  The	  ADG	  FIX	  &	  PERM®	  kit	  was	  
from	   Caltag	   Medsystems	   (Buckingham,	   UK)	   and	   enhanced	   chemiluminescence	   (ECL)	  
detection	   reagents	  were	  purchased	   from	  Amersham	   (Buckinghamshire,	  UK).	  Aprotinin	  and	  
leupeptin	  were	  purchased	  from	  Calbiochem	  (Darmstadt,	  Germany).	  RNeasy®	  kit	  was	  bought	  
from	   Qiagen	   (West	   Sussex,	   UK).	   Tris-­‐(hydroxymethyl)	   aminomethane	   was	   from	   VWR	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international	  (Leicestershire,UK).	  High	  contrast	  X-­‐ray	  film	  was	  from	  Photon	  Imaging	  Systems	  
Ltd	   (Wiltshire,	   UK).	   Ammonium	   persulphate	   (APS),	   bovine	   serum	   albumin	   (BSA),	  
bromophenol	  blue	  sodium	  salt,	  crystal	  violet,	  dimethyl	  sulfoxide	  (DMSO),	  glycine,	  Dulbecco’s	  
modified	   Eagle’s	  medium	   (DMEM),	   phenylmethanesulfonyl	   fluoride	   (PMSF),	   sodium	   azide,	  
sodium	   fluoride,	   sodium	   selenite,	   sodium	   orthovanadate,	   N,N,N’,N’-­‐tetramethylethylene	  
diamine	  (TEMED),	  trypsin,	  Tween	  20.	  Caspase-­‐Glo®	  3/7	  and	  Dual	  Glo	  ®	  Luciferase	  assay	  were	  
from	  Promega	  Corp,	  USA.	  All	  other	  reagents	  were	  bought	  from	  Sigma	  (Poole,	  Dorset,	  UK).	  
	  
2.1.3.	  Cell	  lines	  	  
U2OS,	   an	   osteosarcoma	   cell	   line	   derived	   from	   a	   15	   year-­‐old	   Caucasian	   female,	   was	  
predominantly	   used	   during	   the	   course	   of	   my	   studies,	   as	   was	   A549,	   a	   non-­‐small	   cell	   lung	  
cancer	  (NSCLC)	  cell	  line	  derived	  from	  a	  58-­‐year	  old	  Caucasian	  male.	  Additional	  cell	  lines	  used	  
include:	  H1299,	  a	  NSCLC	  cell	   line	  derived	  from	  43-­‐year	  old	  Caucasian	  male;	  H460,	  a	  NSCLC	  
cell	  line	  derived	  from	  a	  male	  patient;	  MCF-­‐7,	  an	  adenocarcinoma	  breast	  cancer	  cell	  line	  from	  
a	  69-­‐year	  old	  Caucasian	   female,	  HeLa	  Ohio,	  a	   cervical	  adenocarcinoma	   from	  a	  31-­‐year	  old	  
black	   female;	  HEK293,	   an	  embryonic	   kidney	   cell	   line	   from	  human	   foetus;	  wild-­‐type,	   ERK1-­‐
null	  and	  ERK2-­‐null	  mouse	  embryonic	  fibroblasts	  (MEFs)	  (Voisin	  et	  al.,	  2010);	  NIH3T3,	  which	  
are	   also	  mouse	   embryonic	   fibroblasts.	   All	   of	   these	   cell	   lines	  were	   grown	   in	  DMEM.	   Three	  
prostate	  cell	  lines	  were	  also	  used:	  DU145,	  a	  prostate	  carcinoma	  cell	  line	  derived	  from	  brain	  
tumour	  metastases	  in	  a	  69-­‐year	  old	  male;	  LNCaP	  C4-­‐2,	  prostate	  carcinoma	  cells	  derived	  from	  
a	   lymph	   node	   metastasis	   in	   a	   50-­‐year	   old	   Caucasian	   male	   and	   PTN1A	   “normal”,	  
immortalised,	  adult	  epithelial	  prostate	  cells.	  These	  prostate	  cell	  lines	  were	  grown	  in	  Roswell	  
Park	  Memorial	  Institute	  (RPMI)	  1640.	  Some	  characteristics	  of	  these	  cell	  lines	  are	  tabulated	  in	  
Table	  1.2.	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Table	  2.1	  –	  Cell	  lines	  used	  in	  this	  study	  and	  corresponding	  list	  of	  known	  mutations	  	  
Cell	  Line	   Type	  of	  Tumour	   Origin	   p53	  status	   Known	  mutations	  
U2OS	   Osteosarcoma	   Bone	   Wild-­‐type	   CDKN2A,	  FBXW7	  
A549	   Non-­‐small	  cell	  lung	  
cancer	  
Lung	   Wild-­‐type	   CDKN2A,	  KRAS,	  SMARCA4,	  
STK11	  




Null	   SMARCA4,	  NRAS	  
H460	   Non-­‐small	  cell	  lung	  
cancer	  
Lung	   Wild-­‐type	   STK11,	  KRAS,	  CDKN2A,	  
PIK3CA	  
DU145	   Prostate	  cancer	   Brain	   Mutant	  	  
(P223L/	  V274F)	  
CDKN2A,	  MLH1,	  RB1,	  
STK11,	  KRAS,	  NF1,	  PTEN,	  
SMARCA4,	  WT	  STAT3	  
constitutively	  activated	  
LNCaP	  C4-­‐2	   Prostate	  cancer	   Lymph	  
nodes	  
Wild-­‐type	   KRAS,	  PTEN,	  JAK1,	  AR+	  
(but	  AR	  independent)	  
PNT1A	   “Normal”	  prostate	   Prostate	   Wild-­‐type	   	  
HEK293	   “normal”	  liver	   liver	   Wild-­‐type	  	   	  
HeLa	   Cervical	  cancer	   Cervix	   Wild-­‐type	  but	  low	   CTNNB1,	  STK11	  




NIH3T3	   Mouse	  fibroblast	   	   Wild-­‐type	   	  
	  
2.1.4.	  Antibodies,	  cytokines	  and	  chemical	  inhibitors	  
Primary	  antibodies	  against	  pERK1-­‐T202/Y204	  pERK2-­‐T185/Y187,	  pSTAT1-­‐Y701,	  pSTAT3-­‐Y705,	  
pRSK1-­‐S380	  and	  STAT1	  were	  obtained	  from	  Cell	  Signalling	  Technology	  (Hitchin,	  UK).	  ERK1/2,	  
EGFR1,	   IFNGR1,	   STAT3,	   RNAP	   II	   (N-­‐20)	   were	   purchased	   from	   Santa	   Cruz	   Biotechnology	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(Heidelberg,	   Germany).	   The	   antibodies	   against	   β-­‐actin	   and	  α−tubulin	  were	   obtained	   from	  
Sigma-­‐Aldrich	   (Steinhelm,	   Germany);	   FGFR1	   was	   acquired	   from	   Epitomics;	   heat	   shock	  
protein	   90	   (HSP90)	   from	   Thermo	   Fischer	   Scientific	   (Cheshire,	   UK);	   Anti-­‐acetyl-­‐Histone	   H3	  
(cat#	   06-­‐599),	   anti-­‐ERK2	   (clone1B3B9)	   and	   mouse	   IgG	   (Milipore,	   Oxford,	   UK);	   rabbit	   IgG	  
(Abcam,	   Cambridge,	   UK);	   pRNA	   polymerase	   (RNAP)	   II-­‐S2	   (H5)	   and	   pRNAP	   II-­‐S5	   (CTD4H8)	  
were	   from	  Covance;	   gp130-­‐PE	   and	   ERK2-­‐APC	  were	   from	  BD	  Pharmingen	   (California,	  USA).	  
Human	  IL-­‐6,	  sIL-­‐6R	  and	  OSM	  were	  acquired	  from	  PeproTech	  (London,	  UK).	  LIF	  was	  from	  R&D	  
Systems	   (Abingdon,	   UK).	   MEK	   inhibitor	   PD0325901	   was	   provided	   by	   Pfizer	   (Connecticut,	  




2.2.1.	  Cell	  culture	  
Cells	  were	  grown	  in	  DMEM	  supplemented	  with	  10%	  (v/v)	  FCS,	  or	  RPMI	  supplemented	  with	  
5%	  (v/v)	  FCS	  and	  2mM	  L-­‐glutamine,	  50	  units/ml	  penicillin	  and	  50	  µg/ml	  streptomycin	  at	  37	  
˚C	  in	  a	  humidified	  atmosphere	  of	  10%,	  or	  5%	  CO2,	  respectively.	  All	  cell	  lines	  were	  passaged	  
twice	  a	  week.	  The	  passage	  consisted	  of	  washing	  cells	  twice	  using	  0.02%	  (w/v)	  EDTA	  followed	  
by	   incubation	  with	   trypsin	   [2.5	  mg/ml	   trypsin	   in	   0.02%	   (w/v)	   EDTA/	   0.09%	   (w/v)	   NaCl]	   at	  
37°C	  until	  cells	  detached	  from	  the	  culture	  plate.	  Trypsin	  activity	  was	  then	  inhibited	  by	  adding	  
culture	  media	  containing	  FCS.	  The	  cells	  were	  then	  plated	  in	  a	  new	  culture	  dish,	  usually	  at	  the	  
ratio	  of	  1:10.	  
	  
At	  least	  1x106	  cells/vial	  were	  resuspended	  drop	  wise	  in	  DMEM	  or	  RPMI	  media	  with	  30%	  FCS	  
(v/v)	  and	  2mM	  L-­‐glutamine,	  containing	  10%	  DMSO.	  Cells	  were	  placed	  on	  top	  of	  dry-­‐ice	  and	  
after	  a	   couple	  of	  hours	   transferred	   to	   -­‐80˚C.	  The	   following	  day	  vials	  were	   transferred	   into	  
liquid	  nitrogen.	  To	  thaw	  cells,	   frozen	  vials	  were	  placed	  on	  dry-­‐ice	   for	  15	  minutes	  and	  then	  
directly	   into	  a	  37	  ˚C	  water	  bath.	  After	  thawing,	  cells	  were	  transferred	  to	  25	  ml	  falcon	  tube	  
and	  room	  temperature	  medium	  was	  slowly	  added.	  Resuspended	  cells	  were	  then	  centrifuged	  
at	  178	  xg	  for	  2	  minutes	  and	  resuspended	  in	  their	  growth	  media	  before	  being	  placed	  onto	  a	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culture	  dish	  and	  incubated	  at	  37	  ˚C	  in	  a	  humidified	  atmosphere.	  
	  
2.2.2.	  RNA	  interference	  (RNAi)	  
RNA	   interference	   (RNAi)	   was	   performed	   using	   short-­‐interfering	   (si)	   RNA	   oligonucleotides.	  
Cells	  were	   transfected	  with	   siRNAs	   (at	   20	  nM)	  using	   Lipofectamine	  RNAiMax	   according	   to	  
the	   manufacturer’s	   instructions.	   The	   concentrations	   of	   RNAiMax	   and	   siRNAs	   (siGENOME	  
from	  Dharmacon)	  were	  optimized	  for	  A459	  and	  U2OS	  cells	  prior	  to	  the	  experiments.	  Protein	  
knockdown	   was	   assessed	   48	   h	   post-­‐transfection	   using	   Western	   blotting.	   All	   experiments	  
included	  untransfected	  cells	  and	  cells	   transfected	  with	  a	  non-­‐targeting	   siRNA	   (non-­‐specific	  
siRNA,	  siNS)	  as	  controls.	  Target	  molecules	  were	  silenced	  using	  siRNA	  pools	  containing	  four	  
individual	  sequences	  targeting	  different	  regions	  of	  the	  same	  mRNA.	  These	  were	  individually	  
characterised	   by	   Dharmacon	   using	   a	   genome-­‐wide	   microarray	   analysis,	   which	   identified	  
minimal	  off-­‐target	  signatures	  (Parsons	  et	  al.,	  2009)	  and	  further	  tested	  during	  these	  studies	  
using	  deconvolution.	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2.2.3.	  Protein	  extraction	  
Following	  treatments,	  cell	  culture	  plates	  were	  placed	  on	   ice,	  cells	  were	  washed	  twice	  with	  
cold	  PBS	  and	  then	  lysed	  with	  different	  buffers	  depending	  on	  the	  purpose	  of	  the	  experiment.	  
For	  the	  analysis	  of	  cytoplasmic	  proteins,	  Schindler	  buffer	  [50	  mM	  Tris	  pH	  8,	  150	  mM	  NaCl,	  
0.5%	  (v/v)	  NP-­‐40,	  2	  mM	  DTT,	  10%	  (v/v)	  glycerol,	  0.1	  mM	  EDTA	  pH	  8,	  50	  mM	  sodium	  fluoride	  
(NaF),	  0.1	  mM	  sodium	  orthovanadate	  (Na3VO4),	  100	  U/ml	  aprotinin,	  10	  μg/ml	  leupeptin	  and	  
1	  mM	  phenylmethylsulphonyl	   fluoride	   (PMSF)]	  was	  used.	  Radioimmunoprecipitation	   assay	  
(RIPA)	  lysis	  buffer	  was	  made	  up	  of	  50	  mM	  Tris	  pH	  8,	  150	  mM	  NaCl,	  0.5%	  (v/v)	  0.1%	  SDS,	  1%	  
Triton,	   0.5%	   sodium-­‐deoxycholate,	   2	   mM	   DTT,	   10%	   (v/v)	   glycerol,	   50	   mM	   NaF,	   0.1	   mM	  
Na3VO4,	  100	  U/ml	  aprotinin,	  10	  μg/ml	  leupeptin	  and	  1	  mM	  PMSF.	  Extracts	  were	  kept	  on	  ice	  
for	  30	  minutes,	  after	  which	  samples	  were	  cleared	  by	  centrifugation	  at	  16.2	  xg	  for	  15	  minutes	  
at	  4˚C.	  Total	  protein	  concentration	  was	  determined	  using	  a	  BioRad	  protein	  assay,	  according	  
to	   the	  manufacturer’s	   instructions.	   Proteins	  were	   resuspended	   in	   Laemmli	   buffer	   [0.25	  M	  
Tris	   HCl,	   pH	   6.8,	   8%	   (w/v)	   SDS,	   40%	   glycerol,	   0.042%	   (w/v)	   bromophenol	   blue,	   10%	   β-­‐
mercaptoethanol],	  boiled	  at	  99	  ˚C	  for	  5	  minutes	  and	  separated	  on	  a	  SDS-­‐	  polyacrylamide	  gel	  
electrophoresis	  (PAGE)	  gel.	  	  
	  
2.2.4.	  Sodium	  dodecyl	  sulphate	  polyacrylamide	  gel	  electrophoresis	  (SDS-­‐PAGE)	  and	  
Western	  blotting	  
Typically,	  proteins	  were	  separated	  using	  a	  5%	  acrylamide	  stacking	  gel	  [5%	  (v/v)	  acrylamide,	  
0.125	  M	  Tris,	  pH	  6.8,	  0.1%	  (w/v)	  SDS,	  0.075%	  (w/v)	  APS	  and	  0.083%	  (v/v)	  TEMED],	  and	  a	  7.5	  
or	   12.5%	   acrylamide	   resolving	   gel	   [7.5-­‐12.5%	   (v/v)	   acrylamide,	   0.375	  M	   Tris	   pH	   8.8,	   0.1%	  
(w/v)	   SDS,	   0.06%	   (w/v)	   APS,	   0.07%	   (v/v)	   TEMED]	   depending	   on	   the	   size	   of	   proteins	   being	  
analysed.	   Gels	  were	   run	   using	   a	   Tris-­‐glycine	   buffer	   [2.5	  mM	   Tris,	   0.2	  M	   glycine	   and	   0.1%	  
(w/v)	  SDS]	  at	  160	  V	  until	  the	  dye	  reached	  the	  bottom	  of	  the	  gel,	  or	  at	  25	  V	  overnight.	  Bio-­‐rad	  
precast	  gels	  were	  also	  used	  to	  separate	  proteins.	  Separated	  proteins	  were	  transferred	  onto	  
PVDF	  membrane	   using	   iBlot	   dry	   transfer	   for	   5	  minutes	   using	   programme	   P3.	   In	   order	   to	  
prevent	  non-­‐specific	  binding	  of	  antibody,	  membranes	  were	  blocked	   in	  5%	   (w/v)	  BSA/	  Tris-­‐
buffered	  saline/	  Tween	  (TBST)	  [0.01	  M	  Tris	  pH	  7.4,	  75	  mM	  NaCl,	  1.25	  mM	  EDTA	  pH	  8,	  0.1%	  
(v/v)	  Tween	  20]	  containing	  0.02%	  (w/v)	  of	  sodium	  azide	  for	  1	  to	  2	  h	  at	  room	  temperature	  or	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4	   ˚C	   overnight.	   Primary	   antibodies	   were	   diluted	   in	   5%	   (w/v)	   BSA/TBST	   containing	   sodium	  
azide	  and	  incubated	  overnight	  at	  4	  ˚C	  or	  for	  1	  h	  at	  room	  temperature	  (RT)	  depending	  on	  the	  
antibody.	   Membranes	   were	   washed	   three	   times	   for	   10	   minutes	   in	   TBST.	   Secondary	  
antibodies	  conjugated	  to	  horseradish	  peroxidase	  (HRP)	  were	  diluted	  in	  5%	  (w/v)	  milk/	  TBST	  
and	  incubated	  for	  1	  to	  2	  h	  at	  room	  temperature.	  Membranes	  were	  washed	  again	  at	  least	  six	  
times	   for	   5	   minutes	   before	   being	   exposed	   to	   ECL	   reagents.	   Membranes	   were	   re-­‐probed	  
when	  necessary.	  In	  this	  case,	  antibodies	  were	  removed	  overnight	  using	  stripping	  buffer	  [2	  M	  
glycine	   pH	   2.5,	   0.1%	   (w/v)	   SDS].	   Phosphorylated	   proteins	   were	   always	   probed	   for	   first,	  
followed	  by	  the	  total	  protein.	  β-­‐actin	  and/or	  Hsp90	  were	  used	  as	  loading	  controls.	  	  
	  
2.2.5.	  Flow	  Cytometry	  	  
2.2.5.1.	  Extracellular	  staining	  
For	  quantification	  purposes,	  gp130	  was	  also	  analysed	  by	   flow	  cytometry.	  Unpermeabilised	  
cells	   were	   incubated	   either	   with	   an	   anti-­‐gp130	   receptor	   antibody	   conjugated	   to	   PE	   or	  
blocking	  buffer	  (0.5%	  BSA	   in	  PBS)	  for	  1	  h	  at	  RT,	  washed	  five	  times	  with	  cold	  PBS	  and	  fixed	  
with	   1%	   p-­‐FA.	   To	   determine	   intracellular	   gp130	   levels,	   FIX	   &	   PERM®	   kit	   was	   used	   as	  
instructed	   by	   the	  manufacturer.	   Cells	   were	   analysed	   using	   a	   FACS	   Canto	   and	   data	  mined	  
using	   FlowJo	   (Tree	   Star	   Inc.,	   Ashland,	  USA).	   For	   the	   purpose	   of	  measuring	   changes	   in	   the	  
expression	   of	   gp130,	   geometric	   means	   were	   used	   for	   calculations.	   The	   geometric	   mean	  
estimates	  the	  quantity	  of	  molecules	  expressed	  per	  cell	  and	  is	  a	  more	  applicable	  metric	  for	  a	  
logarithmically	   normal	   distribution	   than	   cell	   population	   percentages	   (Imoukhuede	   and	  
Popel,	  2011).	  	  
	  
2.2.5.2.	  Intracellular	  staining	  
In	   order	   to	   concomitantly	   calculate	   the	   expression	   of	   ERK2	   and	   gp130	   in	   cells,	   cells	  were	  
dually	   stained	  with	  anti-­‐gp130–PE	  and	  anti-­‐ERK2-­‐APC	  antibodies.	  Cells	  were	  permeabilised	  
using	  the	  FIX	  &	  PERM®	  kit	  and	  analysed	  as	  above.	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2.2.5.3.	  Cell	  cycle	  analysis	  
Following	  siRNA	  transfection	  or	  starvation,	  cells	   in	  culture	  media	   (debris	  and	  floating	  dead	  
cells)	  were	  pooled	  together	  with	  trypsinased	  ones.	  Cells	  were	  then	  centrifuged	  at	  178	  xg	  for	  
5	  minutes.	  Cells	  were	  washed	  twice	  with	  PBS,	  after	  which	  they	  were	  fixed	  and	  permeabilised	  
by	  drop-­‐wise	  addition	  of	  ice-­‐cold	  methanol	  (1	  ml)	  while	  vortexing	  gently	  and	  incubated	  at	  4	  
°C	  overnight.	  Cells	  were	  then	  washed	  twice	  with	  PBS	  and	  resuspended	  in	  50	  µl	  of	  100	  µl/ml	  
RNase	  A	  and	  200	  µl	  of	  50	  µg/ml	  PI,	  and	  incubated	  for	  2	  h	  in	  the	  dark	  at	  room	  temperature.	  
Stained	  cells	  were	  analysed	  on	  a	  FACSCanto	  flow	  cytometer	  and	  data	  analysed	  as	  before.	  
	  
2.2.6.	  RNA	  extraction	  and	  quantitative	  polymerase	  chain	  reaction	  (qPCR)	  
2.2.6.1.	  RNA	  extraction	  
Total	   RNA	   was	   isolated	   using	   the	   RNeasy®	   Mini	   kit	   from	   Qiagen,	   as	   directed	   by	   the	  
manufacturer.	   Briefly,	   cells	   were	   collected	   with	   RLT	   buffer	   (350	   µl)	   and	   put	   through	   a	  
QIAshredder	   spin-­‐column.	  After	   spinning	   the	   column,	   350	  µl	   of	   ethanol	  was	   added	   to	   the	  
flow-­‐through.	   The	   mix	   was	   added	   to	   the	   RNeasy	   column	   and	   was	   spun	   at	   16.1	   xg.	   RNA	  
bound	  to	  the	  column	  was	  washed	  with	  RW1	  (750	  µl)	  and	  twice	  with	  RPE	  (500	  µl).	  The	  RNA	  
was	  then	  eluted	  with	  RNAase-­‐free	  water,	  usually	  30-­‐50	  µl.	  
	  
2.2.6.2.	  qPCR	  	  
Initial	   analyses	   of	   gene	   expression	   were	   done	   using	   a	   quantitative	   two-­‐step	   reverse	  
transcription	   (RT)-­‐PCR	   in	   collaboration	   with	   Dr	   Heike	   M.	   Hermanns	   and	   Mr	   Johannes	  
Drechsler	   (Rudolf	   Virchow	   Centre	   for	   Experimental	   Biomedicine,	   University	   of	   Würzburg,	  
Germany),	  as	  described	  in	  Bonito	  et	  al.	  (2013).	  Subsequent	  analyses	  were	  performed	  in	  our	  
laboratory,	  as	  follows:	  total	  RNA	  was	  isolated	  using	  the	  RNeasy	  kit,	  as	  above.	  Quantification	  
of	   RNA	   was	   performed	   using	   2	   µl	   of	   undiluted	   RNA	   with	   a	   Nanodrop	   ND-­‐1000	  
spectrophotometer	  (Labtech	  International,	  East	  Sussex,	  UK).	  Analysis	  of	  gene	  expression	  was	  
determined	  using	   a	   quantitative	   two-­‐step	  RT-­‐PCR.	   RT	  was	   performed	  using	   total	   RNA	  and	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the	   high	   capacity	   complementary	   DNA	   (cDNA)	   Reverse	   Transcription	   kit	   from	   Applied	  
Biosystems.	   The	   resulting	   cDNA	   was	   used	   to	   perform	   qPCR	   using	   the	   Fast	   SYBR®	   Green	  
Master	  Mix	   from	  Applied	   Biosystems,	   as	   instructed	   by	   the	  manufacturer.	   Specific	   primers	  
were	   designed	   using	   Primer3	   software	   (http://simgene.com/Primer3),	   or	   obtained	   from	  
Origene	   (http://www.origene.com/).	   In	   order	   to	   test	   the	   primer	   set	   efficiency,	   serial	  
dilutions	  with	  cDNA	  template	  were	  performed.	  For	  each	  target	  mRNA,	  10	  µl	  of	  Fast	  SYBR®,	  
300	  nM	  of	  each	  primer,	  deionised	  water	  and	  10	  µg	  of	  cDNA	  were	  mixed	  to	  a	  total	  volume	  of	  
20	  µl	  in	  96-­‐well	  plates	  in	  duplicates.	  PCR	  reactions	  were	  carried	  out	  in	  an	  ABI	  PRISM	  7900HT	  
using	  the	  following	  conditions:	  initial	  activation	  of	  20	  seconds	  at	  95	  ˚C,	  followed	  by	  40	  cycles	  
of	   1	   second	  denaturation	   at	   95	   ˚C,	   20	   seconds	   annealing/elongation	   at	   60	   ˚C,	  with	   a	   final	  
elongation	  at	  65	  ˚C	  for	  15	  seconds.	  The	  final	  melting	  curve	  consisted	  of	  15	  seconds	  at	  95	  ˚C	  
and	  15	  seconds	  at	  60	  ˚C	  (dissociation	  step)	  and	  was	  performed	  to	  confirm	  the	  specificity	  of	  
the	   primers	   used.	   Indeed,	   the	   primer	   set	   is	   specific	   only	   if	   a	   single	   and	   ‘clean’	   peak	   is	  
obtained.	   The	   high	   primer	   performance	   (independent	   of	   the	   target	   abundance)	   was	  
controlled	   by	   the	   serial	   dilution	   (1/4)	   of	   a	  mix	   of	   the	   different	   cDNA	   inputs	   to	   obtain	   the	  
slope	  that	  was	  calculated	  using	  SDS	  2.4	  software	  (Applied	  Biosystems).	  Only	  slopes	  between	  
-­‐3.1	   to	   -­‐3.6	   validated	   each	   primer	   set.	   Using	   the	   cycle	   threshold	   (Ct)	   values	   obtained,	  
quantification	   of	   target	   messages	   was	   performed	   and	   analysed	   using	   qBasePlus	   software	  
(Biogazelle,	  Zwijnaarde,	  Belgium).	  Target	  gene	  expression	  was	  normalised	  to	  house	  keeping	  
genes	  expression,	  such	  as	  HPRT,	  β-­‐actin	  and/or	  GAPDH.	  The	  data	  is	  presented	  in	  this	  thesis	  
as	  normalised	  relative	  quantity	  (NRQ).	  This	  represents	  the	  fold	  change	  of	  a	  reference,	  which	  
is	  normally	  either	  the	  untreated	  sample	  or	  cells	  transfected	  with	  a	  non-­‐specific	  RNA.	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h	  GP130	  for	   400	   AGGACCAAAGATGCCTCAAC	  
h	  GP130	  rev	   400	   GAATGAAGATCGGGTGGATG	  
h	  SOCS3	  for	   400	   AGACTTCGATTCGGGACCA	  
h	  SOCS3	  rev	   400	   AACTTGCTGTGGGTGACCA	  
h	  EGR1	  for	   400	   AGCCCTACGAGCACCTGAC	  
h	  EGR1	  rev	   400	   GGTTTGGCTGGGGTAACTG	  
h	  STAT3	  for	   400	   CCCTTGGATTGAGAGTCAAGA	  
h	  STAT3	  rev	   400	   AAGCGGCTATACTGCTGGTC	  
h	  HPRT	  for	   400	   TGACCTTGATTTATTTTGCATACC	  
h	  HPRT	  rev	   400	   CGAGCAAGACGTTCAGTCCT	  
h	  ERK1	  for	   400	   TGGCAAGCACTACCTGGATCAG	  
h	  ERK1	  rev	   400	   GCAGAGACTGTAGGTAGTTTCGG	  
h	  ERK2	  for	   400	   ACACCAACCTCTCGTACATCGG	  
h	  ERK2	  rev	   400	   TGGCAGTAGGTCTGGTGCTCAA	  
h	  AKT1	  for	   400	   TGGACTACCTGCACTCGGAGAA	  
h	  AKT1	  rev	   400	   GTGCCGCAAAAGGTCTTCATGG	  
h	  AKT2	  for	   400	   CAAGGATGAAGTCGCTCACACA	  
h	  AKT2	  rev	   400	   GAACGGGTGCCTGGTGTTC	  
h	  AKT3	  for	   400	   GTCGAGAGAGCGGGTGTTCT	  
h	  AKT3	  rev	   400	   TGTAGATAGTCCAAGGCAGAGACAA	  
h	  b-­‐actin	  for	   400	   ACCGAGCGCGGCTACAG	  
h	  b-­‐actin	  rev	   400	   CTTAATGTCACGCACGATTTCC	  
h	  GAPDH	  for	   300	   AGCCACATCGCTCAGACAC	  
h	  GAPDH	  rev	   300	   GCCCAATACGACCAAATCC	  
h	  OSMR	  for	   400	   TGTCTGGAGAATTGTGAGCTTG	  
h	  OSMR	  rev	   400	   CATGCAGTTTTGATAATGGCTTC	  
h	  LIFR	  for	   400	   GGCCCGGAGAAGAGTATGTA	  
h	  LIFR	  rev	   400	   TCACCACTCCAACAATGACAG	  
m	  GP130	  for	   400	   CTCTGAGTCCTTGAAGGCGTAC	  
m	  GP130	  rev	   400	   CCATTCTGGTCGTCCACAGGAA	  
m	  ERK2	  for	   400	   TCAAGCCTTCCAACCTCCTGCT	  
m	  ERK2	  rev	   400	   AGCTCTGTACCAACGTGTGGCT	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m	  ERK1	  for	   400	   GGCTTTCTGACGGAGTATGTGG	  
m	  ERK1	  rev	   400	   GTTGGAGAGCATCTCAGCCAGA	  
m	  β-­‐actin	  for	   400	   CATTGCTGACAGGATGCAGAAGG	  
m	  β-­‐actin	  rev	   400	   TGCTGGAAGGTGGACAGTGAGG	  
m	  STAT3	  for	   400	   AGGAGTCTAACAACGGCAGCCT	  
m	  STAT3	  rev	   400	   GTGGTACACCTCAGTCTCGAAG	  
h	  FGFR1	  for	   400	   CCTCTATGTGGGCATGGTTT	  
h	  FGFR1	  rev	   400	   TACAGGAAGGACGATCTGGG	  
h	  FGFR2	  for	   400	   CGCTGGTGAGGATAACAACACG	  
h	  FGFR2rev	   400	   TGGAAGTTCATACTCGGAGACCC	  
	  
	  
2.2.7.	  RNA	  stability	  	  
U2OS	  cells	  were	  transfected	  with	  siRNAs	  as	  described	  before	  (Section	  2.2.3)	  for	  48	  h.	  Cells	  
were	   then	   treated	  with	  5	  µg/ml	  of	   actinomycin	  D	   (Act	  D)	   for	  0.5,	   1,	   2	  or	  3	  h	  or	  were	   left	  
untreated.	   This	   was	   followed	   by	   RNA	   extraction	   (described	   in	   Section	   2.2.8.1).	   Gene	  
expression	   by	   qPCR	   was	   analysed	   as	   described	   before	   (Section	   2.2.8.3),	   using	   two	  
housekeeping	  genes	  (β-­‐actin	  and	  GAPDH).	  	  
	  
2.2.8.	  Chromatin	  Immunoprecipitation	  (ChIP)	  
Chromatin	  immunoprecipitation	  (ChIP)	  was	  performed	  as	  previously	  described	  by	  Nelson	  et	  
al.	   (2006)	  with	  some	  alterations	   (Nelson	  et	  al.,	  2006).	  We	  have	  used	  Protein	  G	  Dynabeads	  
blocked	   overnight	   with	   3%	   (w/v)	   BSA	   diluted	   in	   immunoprecipitation	   buffer	   without	  
inhibitors	  [50	  mM	  Tris-­‐HCl,	  pH7.5;	  0.5%	  (v/v)	  NP-­‐40;	  1%	  (v/v)	  Triton	  X-­‐100;	  150	  mM	  NaCl;	  5	  
mM	   EDTA;	   0.1%	   (w/v)	   sodium	   azide],	   together	   with	   40	   µg/ml	   sperm	   DNA.	   To	   avoid	  
discrepancies	  among	  the	  different	  conditions	  tested,	  protein	  concentration	  of	  each	  sample	  
was	  determined	  and	  the	  same	  amount	  (normally	  80-­‐150	  µg/	  per	  antibody)	  used	  across	  each	  
experiment.	  	  
	  
ChIP	  was	  done	  using	  10	  µg	  of	  anti-­‐ERK2,	  0.4	  µg	  of	  anti-­‐RNAP	  II	  (RNAP	  II	  total),	  10	  µg	  pRNAP	  
II-­‐Ser2,	  5	  µg	  pRNAP	  II-­‐Ser5,	  2	  µg	  of	  anti-­‐acetylated	  histones.	  Mouse	  and	  rabbit	  IgGs	  and/or	  
IgM	  were	  also	  used	  as	  controls.	  Primers	  were	  designed	  using	  Primer3	  for	  a	  product	  length	  of	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approximately	  100	  bp.	  Additionally,	  in	  silico	  PCR	  was	  performed	  to	  analyse	  the	  specificity	  of	  
the	  primer	  set	  obtained.	  Subsequently,	  dissociation	  steps	  were	  performed	  to	  ensure	  that	  the	  
primer	  pair	  sets	  chosen	  were	  specific.	  The	  primer	  pair	  sequences	  used	  are	  shown	   in	  Table	  
2.4.	  DNA	  quantification	  (samples	  and	  input)	  was	  done	  using	  a	  standard	  curve	  made	  from	  the	  
input.	  Samples	  were	  normalised	  to	  their	  corresponding	  input	  and	  presented	  as	  a	  percentage	  
of	  input.	  	  
	  
Table	  2.4	  –	  ChIP	  primer	  pairs	  used	  in	  this	  study	  
Primer	  Name	   Primer	  [nM]	   Sequence	  (5'-­‐>3')	  
GP130_p1	  for	   300	   CGGGTCAGCATACCAAAATC	  
GP130_p1	  rev	   300	   AATTCCTGGGCTCTAGCGAT	  
GP130_p2	  for	   300	   CTTTTACAGACACCCACGCA	  
GP130_p2	  rev	   300	   CCCTCAGAAAATGGACCTCA	  
GP130_p3	  for	   300	   GGTCGCGTAGCTGGAGTTAG	  
GP130_p3	  rev	   300	   CTGCGATAATCGAGGTGACA	  
GP130_g1	  for	   300	   TTGCACAATTCCAACCTTGA	  
GP130_g1	  rev	   300	   CAAGGTCTGGGAACCACTGT	  
GP130_g2	  for	   300	   GCTTTGGGTGGAATGGACTA	  
GP130_g2	  rev	   300	   TGCACGGTACCATCTTCTTG	  
GP130_g3	  for	   300	   ACACCAAGTTCCGTCAGTCC	  
GP130_g3	  rev	   300	   TACCATCACCGCCATCTACA	  
Chrm5_NS	  for	   300	   CTTTGGACACCAACACATGC	  
Chrm5_NS	  rev	   300	   ATGCCAGAATATGCTGAGGG	  
EGFR_p1	   300	   TGATCTTGAATTTCCCAGCC	  
EGFR_p1	   300	   CAGAAACCATGCAAGCAAGA	  
EGFR_p2	   300	   TAGCTCAAGTTCCTGCAGCC	  
EGFR_p2	   300	   GAGGCTAAGTGTCCCACTGC	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2.2.9.	  m7G	  RNA	  Immunoprecipitation	  (RNA	  IP)	  
Cells	  were	  transfected	  with	  siRNA	  (Section	  2.2.3)	  and	  RNA	  was	  as	  before	  (Section	  2.2.8.1)	  as	  
before.	   Ten μl	   of	   purified	   anti-­‐m7G	   antibody	   was	   pre-­‐bound	   to	   30 μl	   Protein	   G	  
Magnetic®Beads	   in	   RNA	   IP	   buffer	   [PBS	   supplemented	   with	   0.01%	   Triton,	   0.1 mg/ml	   BSA,	  
0.1 mg/ml	  polyU	  and	  1 mm	  DTT]	   for	   30 min	   at	  RT	   followed	  by	   two	  washes	  with	   the	   same	  
buffer.	   Immunoprecipitations	   were	   performed	   using	   2 μg	   RNA	   in	   10 μl	   of	   water	   that	   was	  
then	  mixed	  with	  10	  µl	  of	  2x	  RNA	  IP	  buffer	  plus	  40	  U	   μl	  RNase	  inhibitor	  (NEB)	  for	  1 h	  at	  RT	  
followed	  by	  three	  washes	  with	  buffer.	  One	  tenth	  input	  RNA	  was	  incubated	  under	  the	  same	  
conditions	  as	  the	  immunoprecipitations.	  RNA	  was	  purified	  from	  both	  immunoprecipitations	  
and	   inputs	  by	  phenol–chloroform	  extraction.	  For	   this	  purpose,	  beads	  were	  resuspended	   in	  
200	  µl	  of	  buffer,	  followed	  by	  the	  addition	  of	  250	  µl	  of	  phenol:	  chloroform:	   isoamyl	  alcohol	  
(25:24:1)	  and	  mixed	  by	  inverting	  12	  times.	  The	  mix	  was	  transferred	  to	  phase	  lock	  eppendorf	  
tubes	  and	   spun	   for	  1	  min	  at	  16.2	   xg	  at	  4	   °C.	   Supernatants	  were	   then	   transferred	   to	   clean	  
eppendorf	  tubes,	  and	  25	  µl	  3	  M	  sodium	  acetate,	  1.5	  µl	  glycogen	  and	  1	  ml	  96%	  (v/v)	  ethanol	  
were	   added.	   The	  mix	  was	   vortexed	   and	   incubated	   at	   -­‐20	   ˚C	   overnight.	   The	   following	   day,	  
samples	   were	   centrifuged	   for	   45	   minutes	   at	   16.2	   xg	   at	   4	   °C,	   after	   which	   the	   pellet	   was	  
washed	  with	  1	  ml	  70%	  (v/v)	  ethanol	  followed	  by	  centrifugation	  for	  30	  min	  at	  16.2	  xg	  at	  4	  °C.	  
The	  pellet	  was	   then	  air	  dried	  and	  resuspended	   in	  10	  µl	  RNase-­‐free	  water,	  which	  was	   then	  
used	  for	  RT.	  Two	  µl	  of	  each	  sample	  were	  used	  for	  qPCR.	  Samples	  were	  run	  in	  triplicate	  and	  
gp130	  and	  house	  keeping	  genes	  (β-­‐actin	  and	  GAPDH)	  amplified.	  
	  
2.2.10.	  Splicing	  analysis	  and	  RNA/mRNA	  ratio	  calculation	  
Cells	  were	  transfected	  with	  siRNA	  (Section	  2.2.3)	  and	  RNA	  was	  collected	  (Section	  2.2.8.1)	  as	  
described	   before.	   With	   the	   aim	   of	   comparing	   the	   levels	   of	   total	   RNA	   with	   the	   levels	   of	  
mRNA,	  two	  parallel	  qPCR	  reactions	  were	  performed	  using	  different	  primers.	  Total	  RNA	  cDNA	  
was	  amplified	  using	  random	  primers,	  while	  mRNA	  cDNA	  was	  amplified	  using	  OligodT	  primers	  
(Table	   2.5).	   qPCR	   was	   completed	   simultaneously	   for	   both	   sets	   of	   samples	   and	   the	   levels	  
were	   compared	   to	   cells	   transfected	   with	   a	   non-­‐targeting	   siRNA	   using	   different	   primers	  
targeting	   exons	   only.	   Our	   hypothesis	   was	   that	   a	   specific	   alteration	   within	   the	   cell	   that	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affected	  RNA	  splicing	  would	  lead	  to	  increased	  levels	  of	  immature	  RNA	  (i.e.	  total	  RNA	  level)	  
when	  compared	  to	  mRNA.	  
	  
Table	  2.5	  –	  qPCR	  primer	  pairs	  used	  to	  assess	  splicing	  
Primer	  Name	   Primer	  [nM]	   Sequence	  (5'-­‐>3')	  
A.	  GP130_p3	  for	   300	   GGTCGCGTAGCTGGAGTTAG	  
A.	  GP130_p3	  rev	   300	   CTGCGATAATCGAGGTGACA	  
B.	  GP130_I1.1	  for	   300	   TGAGGGAGGAGTCTGAGGAA	  
B.	  GP130_I1.1	  rev	   300	   AATTTTGGCTTTGATGTGCC	  
C.	  GP130_E1.1	  for	   300	   GCTTTGGGTGGAATGGACTA	  
C.	  GP130_E1.1	  rev	   300	   TGCACGGTACCATCTTCTTG	  
D.	  GP130_g2	  for	   300	   GCTTTGGGTGGAATGGACTA	  
D.	  GP130_g2	  rev	   300	   TGCACGGTACCATCTTCTTG	  
E.	  GP130_g3	  for	   300	   ACACCAAGTTCCGTCAGTCC	  
E.	  GP130_g3	  rev	   300	   TACCATCACCGCCATCTACA	  
F.	  h	  GP130	  for	   300	   AGGACCAAAGATGCCTCAAC	  
F.	  h	  GP130	  rev	   300	   GAATGAAGATCGGGTGGATG	  
	  
2.2.11.	  DNA	  plasmid	  manipulation	  
2.2.11.1.	  Heat-­‐shock	  transformation	  of	  competent	  bacteria	  
Each	   DNA	   plasmid	   was	   heat-­‐shock-­‐transformed	   into	   One	   Shot	   TOP10	   competent	   cells	   by	  
incubating	  2.5	  µl	  of	  plasmid	  and	  25	  µl	  of	  competent	  cells	  on	  ice	  for	  30	  minutes.	  The	  samples	  
were	  then	  kept	  for	  30	  secs	  at	  42	  ˚C	  and	  placed	  again	  on	  ice.	  The	  mix	  was	  added	  to	  250	  µl	  of	  
pre-­‐warmed	  Super	  Optimal	  broth	  with	  Catabolite	  (SOC)	  repression	  medium	  for	  1	  h	  at	  37	  ˚C	  
shaking	   at	   225	   rpm.	   The	   cell	   suspension	   was	   spread	   on	   Luria-­‐Bertani	   (LB)	   agar	   plates	  
supplemented	  with	  100	  µg/ml	   ampicillin	   and	  allowed	   to	   grow	  overnight	   at	   37	   ˚C.	   Positive	  
clones	  were	   selected	   and	   amplified	   by	   incubating	   bacteria	   in	   LB	   broth	  overnight	   at	   37	   ˚C.	  
DNA	  was	  isolated	  by	  perfoming	  DNA	  minipreps	  or	  maxipreps	  (Section	  2.2.13.2).	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2.2.11.2.	  Plasmid	  preparation	  	  
Selected	   colonies	   from	   transformation	   procedures	   describe	   above	   were	   allowed	   to	   grow	  
overnight	   and	   DNA	   plasmids	   were	   isolated	   using	   PureLink®	   Quick	   Plasmid	   miniprep	   Kit	  
according	  to	  the	  manufacturer’s	  instructions.	  Purified	  plasmids	  were	  checked	  for	  inserts	  by	  
restriction	   digestion	   following	   separation	   on	   agarose	   gels.	   Sequencing	   was	   performed	   to	  
detect	   potential	  mutations.	   For	   large	   scales,	   PureLink®	   HiPure	   Plasmid	   Filter	  Maxiprep	   kit	  
was	  used	  also	  according	  to	  manufacturer’s	  instructions.	  Briefly,	  200	  ml	  of	  E.	  coli	  culture	  was	  
grown	  overnight	  at	  37	  ˚C,	  shaking	  at	  200	  rpm.	  Bacteria	  were	  pelleted,	   lysed	  and	  their	  DNA	  
purified.	   Plasmid	  DNA	  was	   diluted	   in	  water	   and	   the	   concentration	  was	   quantified	   using	   a	  
NanoDrop.	  
	  
2.2.11.3.	  Agarose	  gel	  electrophoresis	  	  
Depending	  on	  the	  DNA	  fragment	  length,	  1-­‐2%	  (v/v)	  agarose	  gels,	  containing	  SYBER	  safe	  DNA	  
stain,	  were	  prepared.	  Samples	  were	  diluted	  with	  6x	   loading	  dye	  [2.5%	  Ficoll®-­‐400,	   	  11	  mM	  
EDTA,	   	  3.3	   mM	   Tris-­‐HCl,	   pH8,	   	  0.017%	   (w/v)	   SDS,	   	  0.015%	   (w/v)	   bromophenol	   blue]	   and	  
loaded	  onto	   the	   gel.	   The	   gel	  was	   run	   in	   Tris/Acetic	   acid/EDTA	   (TAE)	   [0.22M	  Tris,	   180	  mM	  
borate,	  5mM	  EDTA	  pH	  8.3]	   for	  45	  minutes	  at	  100	  V,	  and	  visualized	  using	  a	  UviDoc	  UV	  Gel	  
Documentation	  System.	  
	  
2.2.11.4.	  Site-­‐directed	  mutagenesis	  
Point	  mutations	  were	  done	  using	  a	  Quick	  Change®	  Lightning	  Site-­‐Directed	  Mutagenesis	  kit	  
according	  to	  the	  manufacturer’s	  instruction.	  The	  primers	  used	  were	  designed	  using	  a	  primer	  
design	   tool	   from	   Stratagene	   (http://www.genomics.agilent.com/primerDesignProgram.jsp)	  
and	   are	   listed	   in	   Table	   2.3.	   Briefly,	   plasmids	   sequences	   were	   amplified	   using	   mutated	  
primers	  by	  PCR.	  Original	  plasmids	  were	  then	  digested	  using	  Dpn	  I	  enzyme.	  Mutated	  plasmids	  
were	  propagated	  and	  isolated	  as	  described	  before.	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Table	  2.6	  –	  Point	  mutation	  primers	  used	  for	  site-­‐directed	  mutagenesis	  	  
Primer	  Name	  
[Primer]	  
	  (ng/µl)	   Sequence	  (5'-­‐>3')	  
(a-­‐c)	  GATE	  for	   2.5	   CCAATGCCTGGGCGCACAGGGTCTCTCAG	  
(a-­‐c)	  GATE	  rev	   2.5	   CTGAGAGACCCTGTGCGCCCAGGCATTGG	  
(a-­‐c)	  crt1	  for	   2.5	   GGGAGGTACAAACCGCACAGACACACTAGTCGCTTGG	  
(a-­‐c)	  crt1	  rev	   2.5	   CCAAGCGACTAGTGTGTCTGTGCGGTTTGTACCTCCC	  
(a-­‐c)	  crt2	  for	   2.5	   CTCATCTTCCTTTGGGGAGACACACACATCATGAGCCTTGAG	  
(a-­‐c)	  ctr2	  rev	   2.5	   CTCAAGGCTCATGATGTGTGTGTCTCCCCAAAGGAAGATGAG	  
(a-­‐c)	  ctr3	  for	   2.5	   AATAAACACCCCTCTAAATGGCACAGCTAGAACAGAATCTG	  
(a-­‐c)	  ctr3	  rev	   2.5	   CAGATTCTGTTCTAGCTGTGCCATTTAGAGGGGTGTTTATT	  
	  
	  
2.2.12.	  DNA	  plasmid	  transient	  transfection	  
Plasmids	  were	  transfected	  using	  Attractene	  Transfection	  Reagent	   from	  Qiagen,	  as	  directed	  
by	   the	  manufacturer.	  Briefly,	  24	  h	  after	  plating	  cells	  were	   transfected	  with	  plasmids	   (1	  µg	  
DNA/	  well	   in	  6	  well	  plates).	  Twenty-­‐four	  or	  48	  h	  after	  transfection	  cells	  were	  collected	  and	  
protein	   expression	   was	   analysed,	   as	   described	   before.	   The	   plasmids	   empty	   vector	   (EV),	  
strep-­‐tag	   II	   and	   flag-­‐tag	   (SF)-­‐ERK1,	   SF-­‐ERK2,	   SF-­‐ERK1>ERK2	   and	   SF-­‐ERK2>ERK1	  were	   a	   gift	  
from	  Professor	  Jim	  Norman	  (Beatson	  Institute	  for	  Cancer	  Research,	  Glasgow,	  Scotland)	  (von	  
Thun	  et	  al.,	  2012)	  (Figure	  2.1).	  
Figure	  2.1	  –	  ERK	  plasmids	  and	  chimeras	  representation.	  Schematic	  representation	  of	  ERK1	  (green)	  
and	  ERK2	  (red)	  plasmids	  constructs	  and	  chimeras.	  The	  N-­‐terminal	  tag,	  SF	  (yellow)	  is	  also	  represented.	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2.2.13.	  Luciferase	  assays	  	  
U2OS	   cells	   were	   plated	   in	   24-­‐well	   plates	   (4x104)	   and	   allowed	   to	   adhere	   overnight.	   The	  
following	  day,	   cells	  were	   transfected	  with	   siRNA	  as	  described	  before.	   Twenty-­‐four	  h	   later,	  
100	   ng	   of	   pGL3-­‐Basic,	   p2433–WT	   or	   p2433	  mutated	   vectors	   (Firefly	   luciferase	   expression	  
vectors)	   were	   transfected	   together	   with	   10	   ng	   of	   pRL-­‐CMV	   (Renilla	   luciferase)	   using	  
Attractene	  Transfection	  Reagent.	  Firefly	  and	  Renilla	  luciferase	  activities	  were	  measured	  24	  h	  
hours	  later	  using	  Dual-­‐Glo®	  Luciferase	  Assay	  System.	  The	  growth	  media	  was	  removed	  and	  50	  
µl	  of	  OptiMEM®	  and	  50	  µl	  of	  Dual-­‐Glo®	   Luciferase	  Reagent	  were	  added	   to	  each	  well.	   The	  
plate	  was	   incubated	  at	  RT	   in	  the	  dark	  for	  15	  minutes.	  After	  this	  period,	  the	  contents	  were	  
transferred	  to	  a	  96-­‐well	  Opti-­‐plate	  and	  Firefly	   luminescence	  activity	  was	  measured	  using	  a	  
PHERAstar	   luminescence	  microplate	   reader.	  Then,	   the	  Dual-­‐Glo®	  Stop	  &	  Glo®	   reagent	  was	  
prepared	   and	   50	   µl	   added	   to	   each	   well.	   The	   plate	   was	   incubated	   shaking	   at	   room	  
temperature	   in	  the	  dark	   for	  15	  minutes.	  Renilla	   luciferase	  activity	  was	  then	  measured.	  For	  
the	  data	  analysis,	  the	  Firefly	  luciferase	  activity	  was	  normalised	  to	  Renilla	  luciferase	  activity.	  	  
	  
2.2.14.	  Caspase	  3/7	  activity	  assay	  
U2OS	  cells	  were	  transfected	  with	  siRNAs	  against	  different	  molecules	  in	  96-­‐well	  plates.	  Forty-­‐
eight	   hours	   after	   transfection,	   cell	   viability	   was	   analysed	   by	   monitoring	   caspase	   3	   and	  
caspase	  7	  activity.	  This	  was	  performed	  using	  a	  Caspase-­‐Glo®	  3/7	  assay	  kit	  according	  to	  the	  
manufacturer’s	  instructions.	  In	  brief,	  100	  µl	  of	  Caspase-­‐Glo	  3/7®	  reagent	  was	  added	  per	  well	  
to	   100	   µl	   medium.	   This	   reagent	   lyses	   the	   cells	   and	   enables	   the	   luminogenic	   caspase3/7	  
substrate	   to	   be	   cleaved	   by	   any	   active	   caspase	   3	   and/or	   caspases	   7.	   The	   resulting	  
luminescence	   is	   thus	   proportional	   to	   the	   amount	   of	   active	   caspase	   in	   the	   sample.	   The	  
luminescence	   was	   measured	   1	   h	   after	   incubation	   in	   the	   dark	   at	   RT	   using	   a	   PHERAstar	  
luminescence	  microplate	   reader.	   Each	   sample	   was	   performed	   in	   duplicate.	   The	   data	   was	  
recorded	  and	  analysed	  in	  Microsoft	  Office	  Excel.	  
	  
	  
2.	  Materials	  and	  Methods	  
	   83	  
	  
2.2.15.	  Crystal	  violet	  staining	  
Crystal	  violet	   is	  used	  to	  stain	  cells	  adhered	  to	  a	  plate,	  and	  thus	  presumably	  alive.	  This	  dye	  
binds	  to	  DNA	  and	  glycoproteins.	  After	  siRNA	  transfection,	  cells	  were	  washed	  twice	  with	  ice-­‐
cold	  PBS	  and	  incubated	  with	  0.5%	  (w/v)	  crystal	  violet	  dissolved	  in	  25%	  (v/v)	  methanol	  for	  1	  
h.	   After	   staining,	   the	   plates	   were	   washed,	   after	   carefully	   removing	   the	   excess	   of	   dye,	   by	  
rinsing	  them	  with	  copious	  amounts	  of	  water.	  Plates	  were	  left	  to	  dry	  overnight.	  The	  dye	  was	  
dissolved	  in	  100	  µl/	  per	  well	  of	  10%	  (v/v)	  acetic	  acid,	  which	  was	   incubated	  for	  30	  minutes.	  
The	  absorbance	  was	  then	  read	  at	  595	  nm	  using	  a	  Tecan	  SunriseTM	  Absorbance	  Reader.	  The	  
absorbance	  obtained	  directly	  correlated	  with	  the	  number	  of	  cells	  stained.	  Data	  points	  were	  
normalised	  to	  the	  non-­‐specific	  transfection	  control,	  which	  was	  set	  to	  1.	  Each	  condition	  was	  
performed	  in	  triplicate.	  
	  
2.3.	  Statistical	  analysis	  
Statistical	   significance	   was	   determined	   using	   the	   t-­‐test.	   As	   the	   results	   followed	   a	   normal	  
distribution	   unpaired,	   two-­‐tailed	   student’s	   t-­‐tests	   were	   used.	   Samples	   were	   considered	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3.1.	  Introduction	  
Constitutive	  activation	  of	   the	  gp130	   receptor	  as	  a	   result	  of	  different	  mutations	   in	   its	  gene	  
has	   been	   reported	   in	   hepatocellular	   adenomas	   (Rebouissou	   et	   al.,	   2009).	   As	   described	   in	  
more	  detail	  in	  the	  Introduction	  (Chapter	  1),	  when	  engaged,	  this	  receptor	  leads	  to	  activation	  
of	   STAT3	   (Section	   1.2.2),	   MAPK	   (Section	   1.2.3)	   and	   PI3K	   (Section	   1.2.4)	   pathways,	   all	   of	  
which	  are	  implicated	  in	  cell	  proliferation,	  development	  and	  survival.	  Inflammatory	  cytokines,	  
such	  as	  IL-­‐6	  and	  OSM,	  are	  often	  elevated	  in	  cancer	  contributing	  to	  the	  development	  of	  the	  
disease	  (Grivennikov	  et	  al.,	  2009;	  Kujawski	  et	  al.,	  2008;	  Neurath	  and	  Finotto,	  2011).	  	  
	  
Increased	   IL-­‐6	   causes	   prolonged	   activation	   of	   STAT3,	   which	   is	   a	   recognised	   oncogene	  
(Bromberg	   and	   Wang,	   2009;	   Bromberg	   et	   al.,	   1999)	   and	   the	   main	   transcription	   factor	  
downstream	   of	   IL-­‐6-­‐type	   cytokines	   signalling	   (Bromberg	   et	   al.,	   1999;	   Costa-­‐Pereira	   et	   al.,	  
2011;	  Heinrich	  et	  al.,	  2003;	  Santos	  and	  Costa-­‐Pereira,	  2011;	  Yu	  et	  al.,	  2009).	  This	  activation,	  
however,	  is	  under	  strict	  regulation	  that	  ensures	  that	  it	  only	  lasts	  for	  the	  appropriate	  time.	  In	  
contrast,	   constitutive	   activation	   of	   STAT3	   is	   frequently	   observed	   in	   tumours	   (Rosell	   et	   al.,	  
2009;	  Song	  et	  al.,	  2003;	  Yu	  and	   Jove,	  2004).	   Somewhat	   surprisingly,	  with	   the	  exception	  of	  
large	  granular	  lymphocytic	  leukaemia,	  STAT3	  mutations	  are	  not	  common	  in	  cancers	  (Koskela	  
et	   al.,	   2012),	   perhaps	   because	   it	   is	   the	   activation	   of	   STAT3	   that	   is	   important	   for	   tumour	  
development	  and	  that	  is	  often	  seen	  downstream	  of	  mutated	  RTKs.	  
	  
The	  role	  of	  MAPK	  and	  PI3K	  pathways	  in	  cancer	  has	  also	  been	  widely	  studied	  [reviewed	  in	  (De	  
Luca	  et	  al.,	  2012)].	  Mutations	  of	  proteins	  that	  are	  part	  of	  MAPK	  pathway,	  such	  as	  RAS	  family	  
members,	  BRAF	  and,	  less	  frequently,	  CRAF	  and	  MEK,	  generally	  lead	  to	  overactivation	  of	  the	  
pathway	   that	   culminates	   in	   intensification	   of	   ERK1/2	   activity.	   Likewise,	   PI3K	   signalling	   can	  
also	  be	  amplified	  in	  cancer	  cells	  as	  a	  result	  of	  mutations	  such	  as	  AKT	  mutations,	  amplification	  
of	  catalytic	  PI3K	  subunit,	  or	  loss	  of	  the	  tumour	  suppressor	  PTEN	  (De	  Luca	  et	  al.,	  2012).	  Both	  
pathways	   can	   also	   be	   amplified	   due	   to	   mutations	   in	   RTKs,	   downstream	   of	   which	   they	  
function.	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IL-­‐6-­‐type	   cytokines	   have	   crucial	   roles	   in	   the	   development	   of	   embryonic	   cells	   (Hirai	   et	   al.,	  
2011;	  Neurath	  and	  Finotto,	  2011)	  and	  in	  cancers	  that	  are	  related	  to	  inflammatory	  processes.	  
For	   these	   reasons,	   directed	   therapies	   targeting	   gp130,	   STAT3	   and	  MAPK	   may	   be	   a	   good	  
strategy	   for	   inhibiting	   cancer	  development/progression.	   In	  order	   to	  do	   that,	   one	  needs	   to	  
understand	   in	   greater	   detail	   how	   these	  molecules	   are	   regulated	   and	   how	   they	   cross-­‐talk.	  
Accordingly,	   I	  firstly	  characterised	  signal	  transduction	  pathways	  activated	  by	  IL-­‐6	  and	  OSM,	  
as	   representatives	  of	   IL-­‐6-­‐type	   cytokines	   and	  made	  use	  of	  RNAi	   technology	   to	  manipulate	  
the	  expression	  levels	  of	  key	  molecules	  in	  these	  pathways.	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3.2.	  Results	  
3.2.1.	  Signalling	  in	  response	  to	  IL-­‐6	  type	  cytokines	  in	  A549	  and	  U2OS	  cancer	  cell	  lines	  
Before	  studying	  the	  mechanisms	  involved	  in	  the	  regulation	  of	  gp130	  and	  STAT3	  by	  ERK1	  and	  
ERK2,	  it	  was	  necessary	  to	  fully	  grasp	  IL-­‐6-­‐type	  cytokine	  responses	  in	  the	  cell	  lines	  being	  used	  
for	  this	  study.	  As	  mentioned	  in	  the	  Introduction,	  the	  main	  transcription	  factors	  activated	  by	  
IL-­‐6	  signalling	  are	  STAT3	  and,	  to	  a	  lesser	  extent,	  STAT1.	  IL-­‐6	  cytokines	  also	  lead	  to	  MAPK	  and	  
PI3K	  activation.	  
	  
Dose-­‐response	   curves	  established	   that	   the	   concentration	  at	  which	   the	   cytokines	  OSM	  and	  
LIF	  saturated	  the	  signal	  for	  STAT3	  was	  50	  ng/ml	  (Figure	  3.1	  A	  and	  B).	  This	  was	  then	  used	  in	  
subsequent	   experiments	   to	   analyse	   the	   response	   over	   time	   in	   both	  U2OS	   and	  A549	   cells,	  
two	   cancer	   cell	   lines	   with	   completely	   different	   cellular	   backgrounds	   and	   environment.	  
Neither	  cell	  line	  expresses	  the	  IL-­‐6R.	  As	  such,	  IL-­‐6	  had	  to	  be	  used	  together	  with	  sIL-­‐6R,	  and	  
the	   experiments	   established	   that	   it	   should	   be	   used	   in	   subsequent	   experiments	   at	   a	  
concentration	  of	  400	  ng/ml	  and	  500	  ng/ml,	  respectively	  (Figure	  3.1	  A	  and	  B).	  sIL-­‐6R	  together	  
with	   gp130	   form	   a	   receptor	   complex	   that	   binds	   to	   IL-­‐6	   and	   trigger	  what	   is	   referred	   to	   as	  
trans-­‐signalling	  (Heinrich	  et	  al.,	  2003).	  	  
	  
The	  responses	  of	  these	  three	  cytokines	  were	  also	  studied	  over	  time,	  from	  5	  to	  60	  minutes	  
(Figure	  3.1	  C	  and	  D).	  Proteins	  were	  extracted	  with	  Schindler	   lysis	  buffer,	  run	  on	  SDS-­‐PAGE	  
gels	   and	   analysed	   by	  Western	   blotting.	   Because	   STAT3	   and	   STAT1	   have	   similar	  molecular	  
weights	  (~91	  kDa)	  two	  parallel	  SDS-­‐PAGE	  gels	  were	  run,	  rather	  than	  stripping	  and	  re-­‐probing	  
the	   same	  Western	   blot	   membrane.	   As	   readouts	   for	   signalling,	   we	   initially	   monitored	   the	  
phosphorylation	   of	   STAT3,	   STAT1	   and	   ERK1/2	   using	   phospho-­‐specific	   antibodies	   against	  
phosphorylated	  STAT3	  (pSTAT3-­‐Y705),	  STAT1	  (pSTAT1-­‐Y701),	  ERK1/2	  (pERK1-­‐T202/Y204	  and	  
pERK2-­‐T185/Y187)	   and,	   after	   stripping,	   with	   antibodies	   against	   total	   (phosphorylated	   and	  
unphosphorylated)	  STAT3,	  STAT1	  and	  ERK1/2,	   respectively,	   to	  show	  that	  protein	   levels	  did	  
not	  change	  over	  the	  time	  of	  the	  experiment.	  Membranes	  were	  also	  probed	  for	  β-­‐actin	  as	  a	  
loading	  control.	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Figure	  3.1	  –	  STAT	  and	  ERK	  activation	  over	  time	  in	  response	  to	  varying	  concentrations	  of	  IL-­‐6,	  OSM	  
and	   LIF	   in	   U2OS	   and	   A549	   cells.	   A.	   U2OS	   and	   B.	   A549	   cells	   were	   stimulated	   with	   different	  
concentrations	   of	   IL-­‐6/IL-­‐6R,	   OSM	   or	   LIF	   for	   15	   minutes.	   Whole	   cell	   lysates	   were	   prepared	   and	  
proteins	   separated	   in	   a	   7.5%	   SDS-­‐PAGE	   gel.	   Proteins	  were	   transferred	  onto	  PVDF	  membranes	   and	  
probed	  with	  pSTAT3.	  ERK1/2	  and	  HSP90	  were	  used	  as	  loading	  controls.	  Saturating	  concentrations	  of	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Figure	  3.1	  –	  STAT	  and	  ERK	  activation	  over	  time	  in	  response	  to	  varying	  concentrations	  of	  IL-­‐6,	  OSM	  
and	   LIF	   in	  U2OS	   and	  A549	   cells	   (continued	   from	  previous	   page).	  C.	  U2OS	  and	  D.	  A549	  cells	  were	  
stimulated	  with	  IL-­‐6/sIL-­‐6R	  (400	  and	  500	  ng/ml,	  respectively),	  OSM	  (50	  ng/ml),	  or	  LIF	  (50	  ng/ml)	  for	  
the	  indicated	  times.	  Whole	  cell	  lysates	  were	  prepared	  and	  proteins	  separated	  in	  a	  7.5%	  SDS-­‐PAGE	  gel	  
as	   in	   (A.)	   and	   (B.).	   Western	   blot	   membranes	   and	   probed	   with	   pSTAT3-­‐Y705,	   pSTAT1-­‐Y701	   and	  
pERK1/2-­‐T202.Y204/T185.Y187.	  After	  stripping,	  they	  were	  re-­‐probed	  with	  STAT1,	  STAT3	  and	  ERK1/2.	  
β-­‐actin	   was	   used	   as	   loading	   control.	   The	   results	   presented	   are	   representative	   of	   3	   independent	  
experiments	  yielding	  similar	  results.	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3.2.2.	  Impact	  of	  ERK	  silencing	  on	  IL-­‐6	  and	  OSM	  signalling	  in	  A549	  and	  U2OS	  cells	  
It	   was	   previously	   observed	   that	   RNAi	   against	   ERK2	   led	   to	   reduced	   STAT3	   and	   gp130	  
expression	  in	  U2OS	  cells	  (Figure	  1.10),	  two	  molecules	  crucial	  for	  IL-­‐6-­‐type	  cytokine	  signalling.	  
We	   hypothesised	   that	   transfection	   of	   cells	  with	   siERK2	   either	   totally	   inhibited,	   or	   at	   least	  
reduced	  molecular	  responses	  downstream	  of	  the	  gp130	  receptor.	  	  
	  
Cells	  were	  transfected	  with	  siRNA	  oligonucleotides	  against	  ERK1	  (hereto	  forth	  referred	  to	  as	  
siERK1)	   and	   ERK2	   (siERK2)	   for	   48	   h	   and	   then	   stimulated	  with	   IL-­‐6/	   sIL-­‐6R,	   or	   OSM	   for	   15	  
minutes	   (Figure	   3.2).	   Proteins	   were	   extracted	   and	   analysed	   as	   described	   before.	   It	   is	  
generally	  recognised	  that	  OSM	  is	  a	  stronger	  STAT	  and	  MAPK	  activator	  than	  IL-­‐6,	  as	  judged	  by	  
their	  phosphorylation	  following	  cytokine	  stimulation.	  Here,	  this	  was	  more	  obvious	   in	  U2OS	  
than	   in	   A549	   cells.	   Interestingly,	   despite	   equally	   efficient	   knockdowns,	   the	   impact	   of	   ERK	  
silencing	   on	   signalling	   appeared	   to	   be	  more	   significant	   in	  U2OS	   than	  A549	   cells.	   In	  U2OS,	  
siERK2	   led	   to	   a	   decrease	   in	   STAT3	   total	   levels	   and	   to	   the	   total	   inhibition	   of	   the	  
phosphorylation	  of	  not	  just	  STAT3	  but	  also	  of	  STAT1	  (Figure	  3.2	  A	  and	  B,	  1st	  and	  3rd	  panels).	  
Interestingly,	   transfection	   of	   U2OS	   and	   A549	   with	   siERK2	   led	   to	   an	   increase	   in	   ERK1	  
phosphorylation	   (Figure	   3.2	   A	   and	  B,	   5th	   panel).	   This	   could	   be	   either	   due	   to	   the	   cytokine	  
treatment,	   or	   a	   compensatory	  mechanism	   for	   ERK2	   loss,	  which	  would	   be	   independent	   of	  
stimulation.	  To	  address	  this,	  cells	  were	  transfected	  with	  siERK1	  or	  siERK2	  and	  controls	  and	  
unstimulated	   cells	   analysed	   for	   the	   expression	   of	   ERK1	   and	   ERK2	   proteins.	   As	   shown	   in	  
Figure	  3.2	  C,	  ERK1	  phosphorylation	  upon	  siERK2	  was	  ligand-­‐independent.	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Figure	   3.2	   –	   Down-­‐regulation	   of	   ERK2,	   but	   not	   ERK1,	   has	   an	   impact	   on	   STAT3	   and	   STAT1	  
phosphorylation	   in	   response	   to	   IL-­‐6	   type	  cytokines	   in	  U2OS	  and	  A549	  cells.	  A.	  U2OS	  and	  B.	  A549	  
cells	  were	   transfected	   for	   48	  h	  with	  20	  nM	  of	   siNS,	   siERK1,	   siERK2	  or	  were	   left	   untransfected	   (Ø).	  
Cells	  were	  then	  treated	  with	  IL-­‐6/sIL-­‐6R	  (400	  and	  500	  ng/ml,	  respectively)	  or	  OSM	  (50	  ng/ml)	  for	  15	  
minutes.	  Whole	  cell	  lysates	  were	  prepared	  and	  proteins	  separated	  in	  a	  7.5%	  SDS-­‐PAGE	  gel.	  Proteins	  
were	   transferred	   to	  a	  PVDF	  membrane	  and	  probed	  with	  pSTAT3-­‐Y705,	  pSTAT1-­‐Y701	  and	  pERK1/2-­‐
T202.Y204/T185.Y187.	  After	  stripping,	   they	  were	  re-­‐probed	  with	  STAT1,	  STAT3	  and	  ERK1/2.	  β-­‐actin	  
was	  used	  as	  loading	  control.	  The	  results	  presented	  are	  representative	  of	  3	  independent	  experiments	  
yielding	  similar	  results.	  Unt:	  untreated;	  ø:	  untransfected	  control;	  NS:	  siNS;	  E1:	  siERK1,	  E2:	  siERK2.	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Figure	   3.2	   –	   Down-­‐regulation	   of	   ERK2,	   but	   not	   ERK1,	   has	   an	   impact	   on	   STAT3	   and	   STAT1	  
phosphorylation	   in	   response	   to	   IL-­‐6	   type	   cytokines	   in	   U2OS	   and	   A549	   cells	   (continued	   from	  
previous	  page).	  C.	  U2OS	  ERK2	  down-­‐regulation	  increases	  the	  basal	  phosphorylation	  of	  ERK1	  in	  both	  
U2OS	  and	  A549	  cells.	  Cells	  were	  transfected	  as	  before	  (siNS,	  siE1,	  siE2).	  Cells	  were	  then	  treated	  with	  
IL-­‐6/sIL-­‐6R,	  OSM	  or	  left	  untreated	  for	  15	  minutes	  and	  proteins	  analysed	  as	  previously	  described.	  The	  
PVDF	   membrane	   was	   probed	   with	   pERK1/2-­‐T202.Y204/T185.Y187	   and,	   after	   stripping,	   re-­‐probed	  
with	  ERK1/2.	  HSP90	  was	  used	  as	  loading	  control.	  
	  
	  
Though	  much	   has	   been	   learnt	   about	   RNAi,	   there	   is	   still	   much	   to	   be	   understood	   and	   it	   is	  
widely	  accepted	  that	  siRNA	  oligonucleotides	  can	  often	  have	  off-­‐target	  effects.	  Accordingly,	  it	  
was	   important	   to	   assess	   the	   specificity	  of	   each	   siRNA	  oligonucleotide	  used	   to	   target	   ERK1	  
and	  ERK2	  by	  deconvolution	  analysis.	  U2OS	  cells	  were	  transfected	  with	  each	  individual	  siERK2	  
and	  siERK1	  oligonucleotide	  that	  makes	  up	  the	  siRNA	  pools	  used	  thus	   far	   (Figure	   3.2),	  with	  
the	  pools	  themselves	  and	  siNS	  (Figure	  3.3).	  The	  expression	  level	  of	  gp130	  was	  assessed	  both	  
by	   Western	   blotting	   and	   qPCR.	   As	   per	   guidelines,	   the	   phenotype	   of	   the	   siRNA	   pool	   was	  
considered	  bona	  fide	  if	  two	  out	  of	  the	  four	  oligonucleotides	  behaved	  in	  the	  same	  way	  as	  the	  
combined	  pool.	  All	  four	  ERK1	  siRNA	  oligonucleotides	  significantly	  reduced	  ERK1	  protein	  and	  
all	   four	  siRNAs	  targeting	  ERK2	  efficiently	  downregulated	  ERK2	  expression	   levels	  (Figure	  3.3	  
A)	   without	   significantly	   affecting	   each	   other,	   indicating	   that	   they	   were	   targeting	   their	  
respective	  targets	  as	  expected.	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In	  order	  to	  quantify	  ERK1,	  ERK2	  and	  STAT3	  mRNA	  levels	  after	  RNAi	  against	  ERK1	  and	  ERK2,	  
U2OS	   and	   A549	   cells	   were	   transfected	   as	   before	   and,	   this	   time,	   cells	   transfected	   with	  
sigp130	  were	  also	  included	  in	  the	  analysis	  as	  an	  additional	  control	  (Figure	  3.3	  B-­‐D).	  RNA	  was	  
collected,	   reverse	   transcribed	   and	   analysed	   by	   qPCR.	   As	   expected,	   siERK2	   led	   the	   50%	  
reduction	  in	  the	  levels	  of	  STAT3	  but,	  unexpectedly,	  so	  did	  sigp130	  (Figure	  3.3	  D).	  This	  was	  in	  
contrast	  to	  siERK1,	  which	  actually	  led	  to	  an	  increase	  in	  the	  induction	  of	  STAT3	  (Figure	  3.3	  D).	  
Figure	  3.3	  B	  and	  3.3	  C	  demonstrated	  that	  siERK1	  and	  siERK2	  effectively	  targeted	  ERK1	  and	  
ERK2	  mRNA,	  respectively,	  and	  that	  targeting	  gp130	  actually	  led	  to	  a	  reduction	  in	  the	  levels	  of	  
ERK2	   and	   an	   increase	   of	   ERK1	  mRNA,	   suggesting	   that	   signalling	   through	   gp130	   can	   itself	  
regulate	  the	  expression	  of	  these	  two	  MAPKs.	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Figure	  3.3	  –	  ERK1	  and	  ERK2	  can	  be	  downregulated	  independently.	  A.	  U2OS	  cells	  were	  transfected	  as	  
before	  with	  each	  individual	  oligonucleotide	  that	  normally	  compose	  the	  siRNA	  pool	  against	  ERK1	  (#1,	  
#2,	  #6	  and	  #19)	  and	  ERK2	  (#1,	  #2,	  #4	  and	  #9).	  Forty-­‐eight	  h	  after	  transfections,	  cells	  were	  collected	  
and	   analysed	   by	   Western	   blot	   as	   described	   before.	   An	   ERK1/2	   antibody	   was	   used	   to	   test	   the	  
efficiency	   of	   each	   oligonucleotide	   in	   targeting	   the	   intended	   protein.	   β-­‐actin	   was	   used	   as	   loading	  
control.	  B-­‐D.	  The	   impact	  of	  each	  pool	  on	   their	   targets	  was	  measured	  by	  qPCR,	  which	  showed	   that	  
siERK1	  targeted	  ERK1	  but	  not	  ERK2	  (B.)	  and	  that	  siERK2	  targeted	  ERK2	  but	  not	  ERK1	  (C.).	  Interestingly	  
ERK1	  mRNA	  levels	  increased	  (B.)	  and	  ERK2	  mRNA	  levels	  decreased	  C.	  when	  the	  gp130	  receptor	  was	  
silenced	  by	  RNAi	  (sigp130).	  D.	  STAT3	  mRNA	  decreased	  upon	  silencing	  either	  ERK2	  or	  gp130	  in	  U2OS	  
cells.	  For	  these	  qPCR	  analyses,	  U2OS	  cells	  were	  transfected	  as	  before,	  RNA	  isolated	  and	  analysed	  as	  
previously,	   using	   GAPDH	   and	  β-­‐actin	   as	   house-­‐keeping	   genes.	   The	   data	   is	   representative	   of	   three	  
independent	  experiments	  that	  yielded	  identical	  results.	  Statistical	  analysis	  was	  done	  using	  standard	  
error	  of	  the	  mean	  (SEM)	  and	  Student’s	  t-­‐test	  (*	  -­‐	  P<0.05,	  **	  -­‐	  P<0.01,	  ***-­‐P<0.005	  versus	  siNS).	  Unt:	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3.2.3.	  Impact	  of	  ERK	  silencing	  on	  target	  genes	  induced	  by	  OSM	  
Silencing	  ERK2	  had	  a	  negative	  effect	  on	   the	   tyrosine	  phosphorylation	  of	   STAT3	  and	  STAT1	  
(Figure	   3.2	   A	   and	   B,	   1st	   and	   3rd	   panels)	   suggesting	   that	   IL-­‐6-­‐type	   cytokine	   signalling	   was	  
compromised	  in	  the	  absence	  of	  this	  kinase.	  To	  confirm	  this	  we	  analysed	  the	  induction	  of	  two	  
well-­‐characterised	  genes	  preferentially	  induced	  in	  a	  STAT3-­‐	  or	  in	  an	  ERK-­‐dependent	  manner,	  
SOCS3	  (Figure	  3.4	  A)	  and	  EGR-­‐1	  (Figure	  3.4	  B),	  respectively.	  
	  
U2OS	  cells	  were	  transfected	  for	  48	  h	  with	  siRNA	  against	  ERK1,	  ERK2,	  gp130	  or	  with	  siNS,	  as	  
described	  before.	   Then	   they	  were	  either	   treated	  with	  OSM	   for	  1	  h	  or	   left	  untreated.	  RNA	  
was	  isolated	  and	  processed	  as	  before,	  and	  SOCS3	  and	  EGR-­‐1	  genes	  were	  analysed	  by	  qPCR.	  
HPRT	  was	  the	  house-­‐keeping	  gene	  used	  for	  normalisation.	  These	  initial	  qPCR	  analyses	  were	  
done	  in	  collaboration	  with	  Dr	  Heike	  Hermanns	  and	  Mr	  Johannes	  Drechsler	  (Rudolf	  Virchow	  
Center,	   DFG	   Research	   Center	   for	   Experimental	   Biomedicine,	   Würzburg,	   Germany).	   RNAi	  
targeting	   ERK2	   inhibited	   STAT3	   and	   STAT1	   activation	   and,	   therefore,	   it	  was	   not	   surprising	  
that	  SOCS3	  mRNA	  induction	  was	  also	  markedly	  reduced	  (2.5-­‐fold;	  ~60%)	  when	  compared	  to	  
the	  induction	  seen	  in	  siNS-­‐transfected	  cells	  (Figure	  3.4	  A).	  In	  contrast,	  OSM	  treatment	  led	  to	  
1.4-­‐fold	  increase	  of	  SOCS3	  mRNA	  in	  siERK1-­‐transfected	  cells.	  Downregulation	  of	  gp130	  was	  
used	   as	   a	   positive	   control.	   Cells	   lacking	   the	   gp130	   receptor	   (or	   with	   very	   low	   levels)	   are	  
expected	  not	  to	  respond	  to	  an	  IL-­‐6-­‐type	  ligand	  and,	  as	  expected,	  there	  was	  a	  14-­‐fold	  (~90%)	  
reduction	  in	  SOCS3	  mRNA	  induction	  after	  the	  treatment	  with	  OSM.	  Whereas	  silencing	  ERK1	  
resulted	  in	  a	  1.6-­‐fold	  increase	  in	  EGR-­‐1	  mRNA	  induction	  when	  compared	  to	  the	  siNS	  control,	  
silencing	   ERK2	   led	   to	   a	   1.7-­‐fold	   reduction	   (Figure	   3.4	   B).	   The	   induction	   of	   EGR-­‐1	   mRNA	  
following	  RNAi	  against	  gp130	  was	  decreased	  by	  50%,	  suggesting	  that	  EGR-­‐1	  induction	  after	  
OSM	  also	   relied	  on	  signalling	  mediated	  by	  gp130.	  Together	   these	  data	  suggested	  a	  critical	  
role	   for	   ERK2	   in	   IL-­‐6	   type	   cytokine	   responses.	   We	   therefore	   sought	   to	   determine	   the	  
expression	  of	  molecules	  activated	  by	   IL-­‐6	  and	  OSM	  upstream	   from	  the	  STATs,	   such	  as	   the	  
JAKs	  (JAK1,	  JAK2	  and	  TYK2),	  or	  relevant	  receptor	  components	  (gp130,	  OSMR	  and	  LIFR).	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Figure	  3.4	  -­‐	  Knocking	  down	  ERK1	  or	  ERK2	  affects	  the	  activation	  of	  ERK	  (EGR-­‐1)	  and	  STAT	  (SOCS3)	  
target	   genes	   upon	   OSM	   stimulation.	   U2OS	   cells	   were	   transfected	   as	   before,	   RNA	   isolated	   and	  
analysed	   by	   qPCR.	   The	   data	   shown	   represents	   the	   fold	   induction	   of	   each	  mRNA	   upon	   stimulation	  
with	   OSM	   for	   1	   h	   for	   in	   relation	   to	   the	   corresponding	   untreated	   value.	  A.	   SOCS3.	   B.	   EGR-­‐1.	   The	  
results	  presented	  are	  representative	  of	  3	  independent	  experiments	  yielding	  similar	  results.	  Statistical	  
analysis	  was	  done	  using	  SEM	  and	  Student	  t-­‐test	  (*	  -­‐	  P<0.05,	  **	  -­‐	  P<0.01,	  ***-­‐P<0.005	  versus	  siNS).	  I	  
am	  grateful	  to	  Mr.	  Johannes	  Drechsler	  who	  kindly	  performed	  these	  experiments.	  	  
	  
	  
3.2.4.	  ERK2	  silencing	  did	  not	  affect	  JAK	  expression	  but	  it	  led	  to	  reduced	  the	  levels	  of	  gp130	  	  
The	   phenotype	   observed	   regarding	   STAT	   activation	   clearly	   pointed	   to	   a	   defect	   in	   the	  
expression	  of	  one	  or	  more	  key	  components	  of	  the	  signalling	  pathways	  activated	  in	  response	  
to	   IL-­‐6	  and	  OSM.	  Catarina	  Ramos	  dos	  Carmo’s	  work	   suggested	   that	   the	  defected	  could	   lie	  
with	   the	   expression	   of	   gp130,	   a	   possibility	   that	  we	   have	   explored	   further,	   after	   analysing	  
expression	   of	   the	   three	   JAKs	   known	   to	   associate	  with	   gp130	   receptor	   complexes,	   namely	  
JAK1,	   JAK2	   and	   TYK2	   (Figure	   3.5).	   JAKs	   are	   expressed	   at	   low	   levels	   and	   the	   antibodies	  
available	   are	   not	   the	   best.	   However,	   it	   is	   clear	   from	   the	   Western	   blots	   used	   to	   analyse	  
samples	  from	  U2OS	  cells	  transfected	  with	  siNS,	  siERK1,	  siERK2	  and	  sigp130	  that	  none	  of	  the	  
siRNA	  pools	  affected	  the	  expression	  of	   the	  JAKs	  when	  compared	  to	   JAK	  expression	   in	  cells	  
transfected	   with	   the	   non-­‐targeting	   control	   (Figure	   3.5,	   2nd	   column).	   The	   results	   from	   the	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Figure	  3.5	  -­‐	  Down-­‐regulation	  of	  ERK1	  and	  ERK2	  does	  not	  affect	  JAKs	  protein	  levels.	  U2OS	  cells	  were	  
transfected	  and	  proteins	  extracted	  and	  analysed	  as	  before.	  The	  Western	  blotting	  membranes	  were	  
probed	  for	  JAK1,	  JAK2,	  TYK2	  and	  ERK1/2.	  HSP90	  was	  used	  as	  loading	  control.	  The	  results	  presented	  
here	  are	  representative	  of	  3	   independent	  experiments	  yielding	  similar	  results.	   I	  am	  thankful	  to	  Ms.	  
Laura	  Crook	  that	  kindly	  performed	  the	  experiment.	  
	  
	  
U2OS	  cells	  were	  transfected	  as	  previously	  described.	  Permeabilised	  or	  unpermeabilised	  cells	  
were	  stained	  with	  an	  anti-­‐gp130	  antibody	  conjugated	  to	  PE	  and	  analysed	  by	  flow	  cytometry	  
(Figure	  3.6	  A	  and	  B).	  Protein	  expression	  was	  calculated	  using	  geometric	  means	  obtained	  for	  
cells	   transfected	   with	   siERK1,	   siERK2	   or	   sigp130	   compared	   to	   those	   obtained	   for	   siNS.	  
Numeric	   values	   obtained	   are	   tabulated	   underneath	   the	   flow	   cytometry	   histograms.	   The	  
results	   of	   three	   independent	   experiments	   and	   their	   statistical	   significance	   are	   shown	   in	  
Figure	   3.6	   C.	   Surprisingly,	   gp130	   expression	   levels	   were	   reduced	   by	   both	   ERK1	   and	   ERK2	  
silencing	  in	  unpermeabilised	  cells,	  albeit	  to	  different	  extents	  (Figure	  3.6	  A).	  However,	  when	  
probed	  further,	  it	  became	  apparent	  that	  cells	  transfected	  with	  siERK1	  actually	  had	  increased	  
levels	   of	   gp130	   protein	   but	   for	   some	   reason	   this	   was	   being	   retained	   in	   the	   cytoplasm,	  
whereas	  cells	  transfected	  with	  siERK2	  had	  truly	  reduced	  expression	  of	  this	  receptor	  (Figure	  
3.6	   B).	   The	   data	   suggested	   that	   ERK1	   could	   impact	   on	   the	  maturation	   of	   gp130,	  which	   is	  
known	  to	  be	  required	  for	  its	  presentation	  on	  the	  cell	  surface.	  To	  verify	  this	  hypothesis	  and	  
concomitantly	   exclude	   the	   possibility	   of	   an	   off-­‐target	   effect,	   cells	   were	   transfected	   with	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individual	   siERK1	   and	   siERK2	   oligonucleotides	   and	   the	   gp130	   protein	   expression	   analysed	  
(Figure	   3.7).	   Both	   extra-­‐	   and	   intracellular	   expression	   of	   gp130	   was	   studied	   using	   flow	  
cytometry	   (Figure	   3.7	   A	   and	  B)	   and/or	  Western	  blotting	   (Figure	   3.7	   C).	  Despite	  our	   initial	  
validation	   of	   the	   siRNA	   pools,	   this	   latter	   analysis,	   using	   a	   different	   readout,	   clearly	  
demonstrated	  that	  one	  of	  the	  siERK1	  oligonucleotides	  was	  targeting	  something	  other	  than	  
just	  ERK1	   (Figure	   3.7	  A	  and	  B),	  whereas	  all	   siERK2	  oligonucleotides	  behaved	  essentially	  as	  
the	  pool	  (Figure	  3.7	  B).	  Accordingly,	  Western	  blot	  analysis	  of	  ERK1	  deconvolution	  revealed	  
that	   oligonucleotide	   1	   totally	   blocks	   the	  maturation	   of	   gp130,	   as	   shown	   by	   its	   molecular	  
weight	   (130	   versus	   150	   kDa	   for	   the	  mature	   protein).	   This	   oligonucleotide	  was,	   therefore,	  
excluded	  from	  all	  subsequent	  analyses.	  
	  
It	   would	   have	   been	   interesting	   to	   identify	   the	  molecule	   regulating	   gp130	  maturation	   and	  
which	  was	  targeted	  by	  siERK1#1,	  potentially	  regulating	  its	  half-­‐life.	  Indeed,	  we	  analysed	  the	  
sequence	   of	   this	   siRNA	   oligonucleotide	   by	   running	   a	   BLAST	   search.	   This	   search	   led	   to	   the	  
testing	   of	   SAR1A,	   a	   GTPase	   present	   in	   COPII	   vesicles,	   previously	   described	   to	   regulate	  
membrane	   trafficking	   (Zhuang	   et	   al.,	   2010).	   Analyses	   of	   U2OS	   cells	   transfected	   with	   a	  
siSAR1A	   pool,	   SAR1A	   individual	   oligonucleotides	   or	   with	   siNS	   for	   48	   h,	   revealed	   that	  
knocking	   down	   SAR1A	   did	   not	   reduce	   gp130	   receptor	   expression	   and	   it	   did	   not	   affect	   its	  
maturation	  either,	  indicating	  that	  this	  protein	  was	  not	  the	  one	  targeted	  by	  siERK1#1	  (Figure	  
3.7	  D).	  The	  search	  for	  this	  off-­‐target	  was	  not	  pursued	  any	  further.	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Figure	  3.6	  –	  ERK2	  silencing	   leads	  to	  the	   inhibition	  of	  gp130	  expression,	  whereas	  ERK1	  appears	  to	  
lead	  to	  an	  increase.	  U2OS	  cells	  were	  transfected	  as	  previously	  with	  siNS,	  siERK1,	  siERK2,	  or	  sigp130	  
and	  analysed	  48	  h	  later.	  Single-­‐cell	  suspensions	  of	  Unpermeabilised	  (A.)	  or	  permeabilised	  (B.)	  U2OS	  
cells	   were	   stained	   with	   anti-­‐gp130-­‐PE	   labelled	   antibody	   and	   analysed	   by	   flow	   cytometry.	   The	  
numbers	   on	   the	   top	   right	   corner	   refer	   to	   the	   geometric	   mean	   (GM)	   corrected	   for	   background	  
fluorescence	   and	   the	   table	   below	   the	   histograms	   summarises	   data	   from	   a	   typical	   experiment.	   U:	  
unstained;	  S:	  stained.	  C.	  Quantification	  of	  gp130	  levels	  (GM)	  using	  the	  data	  from	  three	  independent	  
experiments	   including	  data	   shown	   in	   (A.).	  M:	   cell	   surface	   gp130;	   T:	   cell	  membrane-­‐associated	   and	  
intracellular	  gp130	  (total	  gp130).	  The	  experiments	  were	  performed	  at	   least	  3	   times	  yielding	  similar	  
results.	  SEM	  and	  Student	  t-­‐test	  applied	  to	  at	   least	  three	   independent	  experiments	  (*	  -­‐	  P<0.05,	  **	  -­‐	  
P<0.01,	  ***-­‐P<0.005	  versus	  siNS).	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Figure	  3.7	  –	  gp130	  accumulation	  inside	  the	  cells	  upon	  ERK1	  knockdown	  is	  the	  result	  of	  an	  off-­‐target	  
effect.	  U2OS	  cells	  were	   transfected	  as	  before	  with	   the	   individual	  oligonucleotides	   that	   form	  siRNA	  
pools	   against	   ERK1	   (#1,	   #2,	   #6	  and	  #19)	   and	  ERK2	   (#1,	   #2,	   #4,	   #9).	   Forty-­‐eight	  h	  after	   transfection	  
cells	   were	   collected	   and	   analysed	   by	   flow	   cytometry	   as	   described	   before,	   using	   a	   PE-­‐gp130	  
conjugated	  antibody	  was	  used	  to	  quantify	  the	  reduction	  of	  gp130	  after	  knocking	  down	  ERK1	  (A.)	  or	  
ERK2	  (B.).	  C.	  The	  impact	  that	  each	  siERK1	  oligonucleotide	  had	  on	  gp130	  expression	  was	  also	  analysed	  
by	  Western	  blot,	  as	  this	  enabled	  to	  discriminate	  between	  mature	  (150	  kDa)	  and	  immature	  (130	  kDa)	  
gp130.	  D.	  The	  putative	  off-­‐target	  target,	  SAR1A	  was	  also	  investigated	  by	  SDS-­‐PAGE/Western	  blotting	  
as	   in	   (C).	   Cells	  were	   transfected	  with	   a	   siSAR1A	  pool,	   or	  with	  each	   individual	  oligonucleotide	   from	  
that	  that	  pool	  siSAR1A	  #1,	  #2,	  #4	  and	  #17.	  All	  these	  experiments	  were	  performed	  at	  least	  3	  times	  and	  
yielded	   similar	   results.	   Student	   t-­‐test	   and	   SEM	   were	   applied	   to	   at	   least	   three	   independent	  
experiments	  (*	  -­‐	  P<0.05,	  **	  -­‐	  P<0.01,	  ***-­‐P<0.005	  versus	  siNS).	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As	  a	   result	  of	   these	  data,	  gp130	  expression	  analyses	  were	  re-­‐analysed	  using	  a	  siERK1	  pool	  
that	  did	  not	  include	  siERK1#1	  (Figure	  3.8).	  Silencing	  siERK1	  did	  not	  reduce	  the	  extracellular	  
expression	  of	   gp130,	  but	   silencing	   siERK2	  did	   (Figure	   3.8	   A	   and	  B),	   and	   this	  was	  also	   true	  
with	   regards	   to	   protein	   extracts	   that	   enabled	   analysing	   extra-­‐	   and	   intracellular	   levels	   of	  
gp130	   (Figure	   3.8	   C).	   This	  explained	  why	  STAT1	  and	  STAT3	  were	  not	  phosphorylated,	   and	  
thus	  activated,	  after	  OSM	  stimulation	  when	  cells	  were	   transfected	  with	   siERK2	   (Figure	   3.2	  
and	  3.4).	   RNAi	   against	   ERK1	   induced	   a	   decrease	  of	   5%	  on	   the	   gp130	   receptor	   expression,	  
which	  was	  not	  statistically	  significant,	  and,	  unsurprisingly,	  siRNA	  targeting	  gp130	  caused	  its	  
massive	  reduction	  (95%).	  	  
	  
qPCR	  was	   also	   used	   to	   quantity	  mRNA	   levels	   of	   gp130	   upon	   ERK	   silencing	   to	   understand	  
whether	   ERK2	   regulated	   gp130	   at	   the	   transcriptional	   level	   (Figure	   3.8	   D).	   The	   mRNA	  
expression	  data	  almost	  mirrored	  the	  protein	  expression	  data	  shown	  in	  Figure	  3.8	  A-­‐C.	  ERK2	  
knockdown	  reduced	  the	  gp130	  mRNA	  level	  by	  80%	  compared	  to	  siNS-­‐transfected	  cells.	  This	  
observation	  suggested	  that	  ERK2	  could,	  somehow,	  control	  the	  expression	  of	  the	  gp130	  gene.	  
Interestingly,	   unlike	  what	  was	   seen	   for	   the	  protein,	   ERK1	   knockdown	   led	   to	   a	  decrease	   in	  
gp130	  mRNA	  of	  about	  ~15%.	  Indeed,	  this	  reduction	  is	  unlikely	  to	  have	  biological	  relevance	  as	  
there	  was	   only	   5%	   reduction	   in	   gp130	   protein	   expression	   and	   there	  was	   no	   inhibition	   of	  
STAT3	  and	  STAT1	  activation	  (Figure	  3.2),	  and	  IL-­‐6-­‐target	  genes	  were	  induced	  (Figure	  3.4).	  	  
	  
Curiously,	   limited	   analysis	   of	   gp130	   phosphorylation	   by	   immunoprecipitation	   of	   gp130	  
followed	  by	  Western	  blotting	  with	  pan-­‐tyrosine	  antibodies	  (4G10	  and	  PY20),	  suggested	  that	  
this	   receptor	   was	   still	   phosphorylated	   upon	   transfection	   with	   siERK1.	   However,	   the	  
phosphorylation	   was	   reduced	   suggesting	   that	   ERK1	   can	   also	   modulate	   gp130	   but	   this	  
regulation	  is	  unlikely	  to	  have	  a	  significant	  impact	  at	  the	  molecular	  level,	  as	  STAT3	  and	  STAT1	  
were	  still	  active	  and	  able	  to	  induce	  the	  transcription	  of	  STAT3	  target	  genes	  when	  ERK1	  was	  
silenced	  (Figure	  3.4	  and	  3.8	  E).	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Figure	  3.8	  –	  ERK2	  silencing	  leads	  to	  a	  decrease	  in	  gp130	  protein	  levels.	  U2OS	  cells	  were	  transfected	  
as	   before	   with	   siERK1,	   siERK2,	   or	   sigp130	   for	   48	   h.	   A.	   U2OS	   cells	   were	   stained	   with	   a	   gp130-­‐PE	  
conjugated	   antibody	   and	   analysed	   by	   flow	   cytometry.	   Geometric	   means	   (GM)	   corrected	   to	   the	  
background	   fluorescence	   are	   shown	   on	   the	   right	   top	   corner	   of	   the	   histograms	   and	   are	   tabulated	  
below.	   U:	   unstained,	   S:	   stained.	  B.	  Quantification	   of	   gp130	   levels	   (GM)	   relative	   to	   siNS	  was	   done	  
using	  data	  obtained	  in	  three	  independent	  experiments,	  including	  that	  shown	  in	  (A).	  C.	  Western	  blot	  
analysis	   of	   gp130	   expression	   in	  whole	   cell	   extracts.	   SEM	  and	   Student	   t-­‐test	  were	   applied	   to	   three	  
independent	  experiments	  (*	  -­‐	  P<0.05,	  **	  -­‐	  P<0.01,	  ***-­‐P<0.005	  versus	  siNS).	  	  
Cont./ed	  




































































































































NS gp130E1 E2U siRNA
siRNA
3.	  Characterisation	  of	  signalling	  downstream	  of	  IL-­‐6	  type	  cytokines	  	  
upon	  the	  silencing	  of	  ERK1	  or	  ERK2	  
	   103	  
	  
Figure	  3.8	  –	  ERK2	  silencing	   leads	   to	  a	  decrease	   in	  gp130	  protein	   levels	   (continued	   from	  previous	  
page)	   (continued	   from	   previous	   page).	   D.	   gp130	   mRNA	   levels	   were	   measured	   by	   qPCR.	   All	  
experiments	  performed	  at	   least	  3	   times	  and	  similar	   results	  were	  obtained.	  SEM	  and	  Student	   t-­‐test	  
were	  applied	  to	  three	  independent	  experiments	  (*	  -­‐	  P<0.05,	  **	  -­‐	  P<0.01,	  ***-­‐P<0.005	  versus	  siNS).	  E.	  
U2OS	  cells	  were	   transfected	  as	  before	   for	  48	  h	  with	   siNS,	   siERK1,	  or	   siERK2.	  Cells	  were	   stimulated	  
with	   OSM	   (50	   ng/ml)	   for	   5	   or	   10	   minutes	   or	   were	   then	   left	   untreated.	   gp130	   receptor	   was	  
immunoprecipitated	   using	   RIPA	   buffer.	   Western	   blotting	   was	   done	   as	   before	   and	   proteins	   were	  
probed	  with	  pan-­‐tyrosine	  antibodies.	  The	  membrane	  was	  also	  probed	  for	  gp130,	  which	  was	  used	  to	  
control	  the	  efficiency	  of	  the	  immunoprecipitation.	  The	  results	  presented	  here	  are	  representative	  of	  2	  
independent	  experiments	  yielding	  similar	  results.	  
	  
Since	   ERK2	   silencing	   affected	   the	   expression	   of	   gp130,	   the	   expression	   of	   other	   receptor	  
molecules	  that	  are	  also	  engaged	  by	   IL-­‐6-­‐type	  cytokines,	  such	  as	  OSMR	  and	  LIFR,	  were	  also	  
looked	  at	  (Figure	  3.9).	  Two	  cell	  lines	  were	  used	  to	  distinguish	  between	  general	  observations	  
and	   cell-­‐type	   specific	   phenomena.	   U2OS	   and	   A549	   cells	   were	   transfected	   with	   siERK1	   or	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for	  the	  specificity	  of	  the	  knockdown,	  cells	  were	  transfected	  with	  siRNA	  molecules	  targeting	  
each	  receptor	  molecule	  under	  investigation	  (denoted	  by	  R	  in	  the	  figure).	  Protein	  expression	  
analysis	  suggested	  that	  OSMR	  expression	  was	  decreased	  when	  the	  levels	  of	  either	  ERK1	  or	  
ERK2	   were	   reduced	   and	   that	   the	   levels	   of	   LIFR	   were	   increased	   when	   ERK2	   was	   silenced	  
(Figure	  3.9	  A,	  2nd	  and	  3rd	  panels).	  qPCR	  analyses	  confirmed	  these	  results	  (Figure	  3.9	  B)	  and	  
also	  demonstrated	  that	  ERK2	  silencing	  also	  impacts	  on	  OSMR	  mRNA	  induction,	  a	  fact	  that	  is	  
not	   particularly	   obvious	   by	   Western	   blot	   (Figure	   3.9	   A).	   In	   any	   case,	   this	   reduction	   was	  
nowhere	  near	  as	  significant	  as	  that	  seen	  for	  gp130	  (Figure	  3.9,	  1st	  panel).	  It	  thus	  appeared	  
that	  ERK1	  and	  ERK2	  could	  both	  modulate	  expression	  of	  several	  receptors,	  a	  fact	  that	  to	  the	  
best	  of	  our	  knowledge	  had	  not	  yet	  been	  reported	  by	  anyone	  else.	  The	  question	  was:	  “but	  
how?”	  
Figure	   3.9	   –	   Silencing	   ERK2	   and	   ERK1	   also	   impacts	   on	   the	   expression	   levels	   of	   other	   receptors.	  
U2OS	   and	   A549	   cells	   were	   transfected	   as	   before	   with	   NS:	   siNS,	   E1:	   siERK1,	   siE2:	   siERK2,	   R:	  
corresponding	   receptor	   in	   analysis	   (sigp130,	   siOSMR,	   siLIFR)	   or	   Ø:	   left	   untransfected.	   Forty-­‐eight	  
hours	   later,	   cells	  were	   analysed	   by	  Western	   blot	   as	   previously	   described.	   Each	   individual	   receptor	  
analysis	   was	   run	   on	   a	   different	   membrane,	   which	   were	   then	   probed	   for	   gp130,	   OSMR,	   or	   LIFR.	  
β-­‐actin	   was	   used	   as	   loading	   control.	   B-­‐C.	   RNA	   was	   isolated	   and	   qPCR	   analysis	   was	   performed	   as	  
described	  before.	  (B)	  OSMR,	  (C)	  LIFR	  (α-­‐receptor).	  β-­‐actin	  and	  GAPDH	  were	  used	  as	  loading	  controls.	  
Data	   represent	   experiments	   performed	   at	   least	   3	   times	   yielding	   similar	   results.	   Student	   t-­‐test	   and	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3.2.5.	  ERK2	  enzymatic	  activity	  was	  not	  involved	  in	  gp130	  regulation	  
ERK2	   phosphorylates	   many	   different	   transcription	   factors	   that	   are	   responsible	   for	   the	  
expression	  of	  an	  even	  greater	  number	  of	  genes.	  Taking	  an	  individual	  protein	  from	  the	  cells	  
using	  RNAi,	  removes	  not	  only	  the	  associated	  enzymatic	  activity	  but	  also	  any	  structural	  role(s)	  
that	   the	   protein	   may	   have.	   For	   this	   reason,	   it	   was	   necessary	   to	   establish	   whether	   ERK2	  
activity	  was	  necessary	  for	  the	  ERK2	  regulation,	  or	  not.	  
	  
U2OS	   cells	   were	   treated	   with	   different,	   well-­‐established,	   MEK	   inhibitors	   and	   an	   ERK1/2	  
inhibitor	  for	  the	  times	  specified	  in	  the	  figures,	  and	  gp130	  expression	  levels	  were	  assessed	  by	  
Western	   blot	   (Figure	   3.10	   A	   and	   C)	   or	   by	   flow	   cytometry	   (Figure	   3.10	   B),	   as	   described	  
previously.	  With	  the	  aim	  of	  activating	  ERK1/2	  and	  testing	  the	  inhibitor	  efficiency,	  cells	  were	  
treated	  with	  FCS	  for	  15	  minutes	  prior	  to	  analyses.	  	  
	  
Each	   MEK	   inhibitor	   tested	   (PD0325901,	   PD98059	   and	   U0126)	   had	   no	   impact	   on	   gp130	  
expression	   levels,	   regardless	   of	   the	   incubation	   time,	   dose,	   or	   their	   mechanism	   of	   action	  
(Figure	   3.10	  A),	  nor	  did	   it	   impact	  on	  gp130	  cell	   surface	  presentation	   (Figure	   3.10	  B).	  MEK	  
inhibitors	  block	  ERK1/2	  phosphorylation	  and,	  consequently,	  their	  activation	  plus	  associated	  
translocation	   to	   the	   nucleus.	   However,	   this	   experimental	   procedure	   did	   not	   exclude	   the	  
possibility	   that	   ERK2	   might	   auto-­‐phosphorylate	   or	   be	   activated	   by	   MEK-­‐independent	  
mechanisms.	  For	  this	  reason,	  we	  also	  used	  FR180204,	  an	  ERK1/2	  inhibitor	  that	  competes	  for	  
the	   its	  ATP	  binding	  pocket.	  U2OS	   cells	  were	   incubated	  with	   the	   inhibitor	   for	   the	   specified	  
times,	   treated	  with	   FCS	   for	   15	  minutes	   prior	   to	   collection	   and	   RSK1	   phosphorylation	  was	  
used	   as	   a	   readout	   for	   ERK1/2	   activity.	   In	   the	   presence	   of	   this	   inhibitor,	   ERK2	   could	   be	  
phosphorylated	   but	   was	   unable	   to	   phosphorylate	   its	   substrates,	   as	   evidenced	   by	   the	  
decrease	  in	  RSK1	  activation	  (Figure	  3.10	  C).	  Taken	  together,	  these	  data	  suggested	  that	  ERK2	  
had	  a	  structural	  role	  in	  gp130	  regulation	  that	  was	  independent	  of	  its	  enzymatic	  activity.	  One	  
caveat	  is	  that	  in	  vitro	  kinase	  assays	  were	  not	  conducted	  and	  there	  is	  the	  possibility	  that	  there	  
was	  still	  some	  residual	  ERK1/2	  kinase	  activity.	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  In	  order	  to	  establish	  if	  these	  inhibitors	  had	  any	  impact	  on	  Il-­‐6-­‐type	  cytokine	  signalling,	  U2OS	  
cells	  were	  treated	  for	  24	  h	  with	  MEK	  (PD98059,	  PD0325901,	  U0126)	  or	  ERK	  (FR180204	  and	  
CAS294675-­‐79-­‐9)	  inhibitors.	  Fifteen	  minutes	  before	  collection,	  cells	  were	  treated	  with	  OSM	  
to	   activate	   signalling	   downstream	   of	   gp130,	   or	   they	   were	   left	   untreated.	   As	   previously	  
mentioned,	  due	  to	  STAT1	  and	  STAT3	  having	  similar	  molecular	  weights,	  samples	  were	  run	  in	  
two	  separate	  SDS-­‐PAGE	  gels.	  Western	  blotting	  revealed	  that,	  unlike	  what	  was	  seen	  by	  RNAi	  
(e.g.	  Figure	  3.2),	  none	  of	  the	   inhibitors	  used	   in	  this	  study	  affected	  the	  expression	   levels	  of	  
STAT1	   or	   STAT3.	   As	   expected,	  MEK	   inhibitors	   inhibited	   basal	   ERK1/2	   phosphorylation	   and	  
this	  was	  not	  touched	  by	  the	  ERK1/2	  inhibitors.	  Interestingly,	  PD98059	  and	  U0126,	  both	  MEK	  
inhibitors,	  led	  to	  a	  reduction	  on	  pSTAT1-­‐Y701.	  However,	  these	  data	  suggest	  that	  this	  was	  not	  
specific	   to	   ERK1/2	   enzymatic	   inhibition	   but	   rather	   to	   non-­‐specific	   inhibition	   by	   these	  












Figure	   3.10	   –	   ERK2	   enzymatic	   activity	   does	   not	  modulate	   gp130	   expression.	   A.	  U2OS	   cells	  were	  
treated	   for	   the	   indicated	   times	  with	  PD0325901,	  PD98059	  and	  U0126,	  used	  at	  0.5,	  50	  and	  10	  µM,	  
concentrations,	   respectively.	  Fifteen	  minutes	  before	  harvesting	  cells,	  FCS	  was	  added	   to	   the	  culture	  
media.	   gp130	  protein	   levels	  were	  analysed	  by	  Western	  blotting.	  Membranes	  were	  also	  probed	   for	  
pERK1/2	  as	  a	  read-­‐out	  for	  inhibitor	  activity	  and	  total	  ERK1/2.	  HSP90	  was	  used	  as	  loading	  control.	  B.	  
Cells	  were	   incubated	  with	  different	  concentrations	  of	  PD0325901	  for	  24	  h.	  They	  were	  then	  stained	  
with	   anti-­‐gp130	   (B-­‐R3)	   and	   anti-­‐mouse-­‐PE.	   Expression	   levels	   of	   gp130	   on	   the	   cell	   surface	   were	  
analysed	  by	  comparing	  the	  GM	  of	  each	  sample	  to	  NS	  value	  as	  described	  before.	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Figure	  3.10	  –	  ERK2	  enzymatic	  activity	  does	  not	  modulate	  gp130	  expression.	  C.	  Cells	  were	  treated	  
with	  FR180204	  (10	  µM)	  for	  8,	  24	  and	  48	  h.	  Before	  collection,	  cells	  were	  stimulated	  with	  FCS	  for	  15	  
minutes	  and	  phosphorylation	  of	  RSK1	  on	  Ser308	  was	  used	   to	  control	   inhibitor	  activity.	  β-­‐actin	  was	  
used	   as	   a	   loading	   control.	  D.	   Cells	   were	   incubated	   with	   PD98059	   (50	   µM),	   PD0325901	   (0.5	   µM),	  
U0126	   (10	   µM),	   FR180204	   (10	   µM)	   or	   CAS	   294675-­‐79-­‐9	   (10	   µM).	   Twenty-­‐four	   h	   later,	   cells	   were	  
treated	   with	   OSM	   (50	   ng/ml)	   for	   15	   minutes.	   The	   proteins	   were	   analysed	   by	   Western	   blot	   as	  
previously	   described.	   Proteins	   were	   probed	   for	   pSTAT3-­‐Y705,	   pSTAT1.Y701	   and	   pERK1/2-­‐
T202.Y204/T185.Y187	  and,	   after	   stripping	   the	  antibodies	  of	   the	  membrane,	   re-­‐probed	  with	   STAT1,	  
STAT3	  and	  ERK1/2	  antibodies	  that	  recognise	  phosphorylated	  and	  unphosphorylated	  proteins.	  HSP90	  
was	   used	   as	   loading	   control.	   These	   results	   are	   representative	   of	   three	   independent	   experiments	  
yielding	  similar	  results.	  I	  am	  grateful	  to	  Dr.	  Heike	  Hermanns	  who	  kindly	  performed	  and	  analysed	  the	  
experiment	  presented	  in	  (B).	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3.2.6.	  ERK2	  regulates	  gp130	  expression	  levels	  in	  different	  cancer	  and	  non-­‐cancer	  cell	  lines.	  
The	   impact	  of	   ERK2	  knockdown	  on	  gp130	  protein	   and	  mRNA	   levels	  was	  mainly	   studied	   in	  
U2OS	  osteosarcoma	  cells.	  It	  was	  important	  to	  understand	  whether	  this	  impact	  was	  specific	  
to	   this	   cell	   type,	   or	   whether	   it	   was	   a	   more	   general	   phenomenon,	   before	   addressing	   any	  
further	  the	  mechanism	  by	  which	  ERK2	  regulated	  the	  induction	  and	  expression	  of	  gp130.	  	  
	  
To	   address	   this,	   a	   number	   of	   additional	   cell	   lines	   containing	   different	   mutational	  
backgrounds	  (described	  in	  Table	  2.1)	  were	  transfected	  for	  48	  h	  as	  previously	  described	  with	  
siERK2,	  siERK1,	  sigp130	  or	  siNS	  (Figure	  3.11).	  These	  initial	  analyses	  focussed	  on	  A549	  (lung),	  
HeLa	   (cervix),	   MCF-­‐7	   (breast),	   DU145	   and	   LNCaP	   C4-­‐2	   (both	   prostate)	   cells.	   After	  
transfection	  with	  the	  siRNA	  molecules,	  cells	  were	  separated	  into	  two	  groups,	  one	  to	  quantify	  
gp130	   by	   flow	   cytometry	   and	   the	   other	   to	   confirm	   efficient	   ERK1/2	   knockdown	   and	   to	  
analyse	  STAT3	  levels	  by	  Western	  blot.	  	  
	  
It	  is	  often	  suggested	  that	  ERK1	  cannot	  compensate	  for	  ERK2	  functions	  due	  to	  its	  much	  lower	  
expression	  in	  most	  cells.	  We,	  therefore,	  included	  in	  the	  analyses	  MCF-­‐7	  cells	  that	  expressed	  
comparable	  levels	  of	  ERK1	  and	  ERK2	  (Figure	  3.11	  A).	  Irrespective	  of	  the	  ERK2/ERK1	  ratio	  and	  
cellular	  background,	  all	  these	  cancer	  cell	  lines	  showed	  a	  decrease	  in	  gp130	  levels	  when	  the	  
levels	   of	   ERK2	   were	   reduced	   by	   RNAi	   (Figure	   3.11	   A-­‐E).	   Collectively,	   these	   data	   thus	  
suggested	  that	  ERK1	  and	  ERK2	  had	  non-­‐redundant	  and	  non-­‐overlapping	  functions,	  at	  least	  in	  
what	  regards	  the	  regulation	  of	  gp130	  expression.	  In	  addition,	  each	  Western	  blot	  membrane	  
was	  probed	  with	  antibodies	  against	   STAT3	   in	  order	   to	  determine	   if	   the	  decrease	   in	  STAT3	  
mRNA	  and	  consequent	  decrease	  in	  protein	  levels	  seen	  in	  U2OS	  cells	  (Figure	  3.2	  A	  and	  Figure	  
3.2	   D)	   was	   specific	   to	   these	   cells.	  With	   the	   exception	   of	   DU145,	   all	   the	   cancer	   cell	   lines	  
tested	  showed	  a	  clear	  reduction	  in	  STAT3	  protein	  levels	  upon	  siERK2.	  	  
	  
Having	  observed	  that	  reduced	  ERK2	  levels	  led	  to	  a	  decrease	  in	  gp130	  expression	  in	  different	  
cell	   lines	   (Figure	   3.11	   A-­‐E),	   we	   hypothesised	   that	   the	   levels	   of	   these	   two	   proteins	   may	  
directly	  correlate	  in	  the	  cells.	  A549,	  DU145,	  HeLa,	  LNCaP	  C4-­‐2,	  MCF-­‐7,	  as	  well	  as	  H1299	  and	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H460	  (both	  lung)	  cells	  were	  collected	  and	  double-­‐stained	  with	  antibodies	  against	  gp130	  and	  
ERK2.	   Of	   the	   eight	   cell	   lines	   analysed,	   six	   showed	   a	   strong	   direct	   correlation	   (r2=0.73)	  
between	   ERK2	   and	   gp130	   expression,	   with	   A549	   and	   HeLa	   cells	   being	   clear	   outliers	   for	  
reasons	  that	  are	  not	  at	  present	  obvious	  (Figure	  3.11	  F).	  	  
	  
Figure	  3.11	  –	  ERK2	  controls	  gp130	  expression	  in	  different	  types	  of	  cancer	  cell	  lines	  regardless	  of	  the	  
ratio	  of	  ERK1	  to	  ERK2	  protein	  expression.	  A549	  (A),	  HeLa	  (B),	  MCF-­‐7	  (C),	  DU145	  (D)	  and	  LNCaP	  C4-­‐2	  
(E)	  cells	  were	  transfected	  as	  described	  before	   for	  48	  h	  with	  siNS	  (NS),	  sigp130	  (gp130),	  siERK1	  (E1)	  
and	  siERK2	   (E2).	  Cells	  were	  stained	   for	  cell	   surface	  gp130	  with	  a	  gp130-­‐PE	  conjugated	  antibody	  by	  
flow	  cytometry.	  The	  GMs	  obtained	  were	  analysed	  as	  described	  before.	  Statistical	  analysis	  was	  done	  
using	   Student	   t-­‐test	   applied	   and	   SEM	   to	   at	   least	   three	   independent	   experiments	   (*	   -­‐	   P<0.05,	   **	   -­‐	  
P<0.01,	   ***-­‐P<0.005	   versus	   siNS).	  Western	   blot	  was	   used	   to	   analyse	   the	   levels	   of	   STAT3	   after	   the	  
different	  transfections.	  To	  confirm	  the	  knockdown	  efficiency,	  ERK1/2	  total	  protein	  was	  also	  probed.	  
β-­‐actin	  was	  used	  as	  loading	  control.	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Figure	  3.11	  –	  ERK2	  controls	  gp130	  expression	  in	  different	  types	  of	  cancer	  cell	  lines	  regardless	  of	  the	  
ratio	   of	   ERK1	   to	   ERK2	   protein	   expression	   (continued	   from	   previous	   page).	   F.	   ERK2	   and	   gp130	  
proteins	  levels	  correlated	  in	  different	  cancer	  cell	  lines.	  The	  different	  cell	  lines	  analysed	  before	  were	  
stained	   with	   both	   ERK2-­‐APC	   and	   gp130-­‐PE	   antibodies.	   Six	   of	   the	   eight	   cells	   lines	   tested	   (the	  
exceptions	  being	  A549	  and	  HeLa	  cells)	  showed	  a	  correlation	  between	  the	  levels	  of	  ERK2	  and	  gp130.	  
The	  data	  is	  representative	  of	  3	  independent	  experiments	  yielding	  similar	  results.	  
	  
As	   all	   eight	   cell	   lines	   tested	   were	   derived	   from	   cancer	   cells,	   two	   cell	   lines	   not	   originally	  
derived	  from	  cancer	  cells	  were	  also	  tested	  whether	  this	  regulation	  was	  specific	  to	  tumour-­‐
derived	  cells	  (Figure	  3.12).	  Human	  embryonic	  kidney	  (HEK)	  293	  and	  prostate-­‐derived	  PNT1A	  
cells	   were	   transfected	   for	   48	   h	   as	   before	   with	   siERK2,	   siERK1,	   sigp130,	   siNS	   or	   left	  
untransfected.	  Protein	  and	  mRNA	  samples	  were	  prepared	  and	  the	  levels	  of	  gp130	  and	  STAT3	  
were	   determined	   as	   previously	   by	   SDS-­‐PAGE/	  Western	   blotting	   (Figure	   3.12	   C	   and	  F)	   and	  
qPCR	  (Figure	  3.12	  A,	  B,	  D	  and	  E),	  respectively.	  ERK1/2	  expression	  was	  assessed	  byWestern	  
blotting	  to	  confirm	  the	  knockdown	  efficiency	  (Figure	  3.12	  C	  and	  F).	  As	  was	  observed	  for	  the	  
eight	   cancer	   derived	   cell	   lines	   tested	   (Figure	   3.11),	   both	   the	  mRNA	   and	   protein	   levels	   of	  
gp130	  were	  reduced	  in	  cells	  transfected	  with	  siERK2,	  suggesting	  that	  the	  regulation	  of	  gp130	  
by	  ERK2	  is	  likely	  a	  general	  mechanism	  that	  occurs	  independently	  of	  the	  cell	  type	  (Figure	  3.11	  
and	  3.12	  A,	  C,	  D	  and	  F).	  In	  contrast,	  the	  levels	  of	  STAT3	  mRNA	  were	  only	  reduced	  in	  HEK293	  
but	  not	  in	  PNT1A.	  This	  is	  interesting	  as	  HEK293	  cells	  have	  been	  immortalised	  in	  the	  70s	  with	  
sheered	   adenovirus	   5	   DNA	   and	   their	   karyotype	   is	   complex	   with	  many	   abnormalities	   that	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The	  fact	  that	  silencing	  ERK2	  had	  little	  effect	  on	  STAT3	  levels	   in	  DU145	  cells	  (Figure	  3.11	  D)	  
and	   now	   in	   PNT1A	   (Figure	   3.12	   E	   and	  F),	  makes	   it	   tempting	   to	   suggest	   that	   STAT3	   is	   not	  
regulated	   by	   ERK2	   in	   prostate	   cancer	   cells.	   However,	   LNCaP	   C4-­‐2	   (Figure	   3.11	   E)	   display	  
reduced	  STAT3	  expression	  after	  RNAi	  against	  ERK2,	  so	  this	  is	  clearly	  not	  the	  case.	  It	  remains	  
a	  possibility	  that	  the	  site	  of	  metastasis	  and	  tumour	  environment	  may	  dictate	  in	  a	  great	  part	  
how	  any	  one	  protein	  is	  regulated.	  
	  
Figure	  3.12	  –	  ERK2	  also	  controls	  gp130	  expression	  in	  non-­‐cancer	  cell	  lines.	  HEK293	  (A-­‐C)	  and	  PTN1A	  
(D-­‐F)	  cells	  were	  transfected	  as	  described	  before	  with	  with	  siNS	  (NS),	  sigp130	  (gp130),	  siERK1	  (E1)	  and	  
siERK2	  (E2).	  RNA	  was	  isolated	  and	  gp130	  (A,	  D)	  or	  STAT3	  mRNA	  (B-­‐E)	  amplified	  by	  qPCR.	  β-­‐actin	  and	  
GAPDH	  were	  used	  as	  house-­‐keeping	  genes.	  Statistical	  analysis	  was	  done	  using	  Student	  t-­‐test	  applied	  
and	   SEM	   to	   at	   least	   three	   independent	   experiments	   (*	   -­‐	   P<0.05,	   **	   -­‐	   P<0.01,	   ***-­‐P<0.005	   versus	  
siNS).	  At	  the	  same	  time,	  protein	  was	  also	  extracted	  and	  analysed	  by	  Western	  blot	  (C,	  F).	  The	  proteins	  
were	  probed	  for	  gp130,	  ERK1/2.	  α-­‐tubulin	  was	  used	  as	  loading	  control.	  The	  Western	  blot	  results	  are	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In	  view	  of	   these	  correlations,	   it	  was	  hypothesised	  that	  manipulation	  of	  ERK2	   levels	   in	  cells	  
would	   influence	   the	   levels	   of	   gp130	   (Figure	   3.13).	   To	   demonstrate	   this,	   U2OS	   cells	   were	  
transfected	   with	   varying	   concentrations	   of	   siRNA	   for	   48	   h,	   after	   which	   the	   cells	   were	  
collected	  and	  stained	  concomitantly	  with	  anti-­‐gp130	  and	  anti-­‐ERK2	  antibodies	  as	  described	  
before.	  As	  expected,	  the	  higher	  the	  concentration	  of	  siERK2	  the	  greater	  the	  decrease	  in	  ERK2	  
protein	  expression	  and,	  reassuringly,	  gp130.	  It	  was	  intriguing	  that	  we	  did	  not	  observe	  a	  near	  
complete	  ablation	  of	  ERK2,	  which	  may	  explain	  why	  we	  also	  never	  eliminated	  100%	  of	  gp130.	  
In	  fact,	  the	  shape	  of	  the	  curves	  and	  our	  previous	  data	  (e.g.	  Figure	  3.11	  F)	  suggest	  that	  ERK2	  
is	  unlikely	  to	  be	  the	  sole	  determinant	  of	  gp130	  expression	  and	  that	  there	  is	  a	  level	  of	  ERK2	  
that	  is	  saturating.	  
	  
	  
Figure	   3.13	   –	   gp130	   protein	   expression	   directly	   correlates	   with	   ERK2	   levels.	   U2OS	   cells	   were	  
transfected	  as	  before	  with	  different	  concentrations	  of	  siRNA	  targeting	  ERK2,	  which	  was	  titrated	  over	  
a	  wide	   range	   of	   concentrations.	   Forty-­‐eight	   h	   later,	   cells	   were	   double-­‐stained	  with	   ERK2-­‐APC	   and	  
gp130-­‐PE	  and	  analysed	  by	   flow	  cytometry.	  GM	  of	  stained	  cells	  was	  normalized	  to	  background	  GM.	  
This	  was	  then	  compared	  to	  GM	  value	  of	  siNS	  cells.	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In	  view	  of	  these	  data,	  we	  overexpressed	  ERK2	  in	  cells	  and	  asked	  whether	  that	  reverted	  the	  
RNAi	   ‘phenotype’	   by	   increasing	   the	   expression	   of	   gp130.	   ERK2	   overexpression	   was	  
consistent	   with	   the	   hypothesis	   that	   ERK2	   is	   necessary	   only	   up	   to	   a	   certain	   point	   (Figure	  
3.14).	   U2OS	   cells	   were	   transiently	   transfected	   (24	   and	   48	   h)	   with	   a	   number	   of	   SF-­‐tagged	  
cDNA	   plasmids:	   SF-­‐ERK2,	   SF-­‐ERK1,	   two	   ERK1/ERK2	   chimeras	   and,	   as	   a	   control,	   an	   empty	  
vector	  (Figure	  2.1).	  The	  chimeras,	  SF-­‐E1>E2	  and	  SF-­‐E2>E1	  were	  a	  hybrid	  of	  ERK2	  and	  ERK1	  
proteins	   that	   had	   the	   N-­‐terminal	   sequences	   swapped.	   ERK1	   has	   an	   extra	   aminoacid	  
sequence	  on	   its	  N-­‐terminus,	  which	   is	  absent	   in	  ERK2	  and	  thus	  may	  explain	  why	   these	   two	  
proteins	  behave	  differently	  despite	  their	  very	  high	  sequence	  similarity.	  Cells	  were	  lysed	  with	  
RIPA	   buffer	   and	   the	   proteins	   run	   on	   an	   SDS-­‐PAGE	   gel,	   as	   described	   before.	  Western	   blot	  
membranes	  were	  probed	  for	  gp130,	  pERK1/2	  and,	  to	  control	  the	  transfection	  efficiency	  and	  
the	   expression	   levels,	   ERK1/2.	   β-­‐actin	   was	   used	   as	   loading	   control.	   Regardless	   of	   the	  
amounts	   of	   ERK2	   expressed	   in	   the	   cells,	   no	   upregulation	   of	   gp130	   was	   observed	   (Figure	  
3.14).	   The	  overexpression	  of	   ERK1	  or	   the	   two	   chimeras	  was	   also	  without	   effect	   on	   gp130	  
expression	   levels.	   Suggesting	   that	   the	   endogenous	   levels	   of	   ERK2	   were	   like	   present	   at	  
saturating	  concentrations	  which	  are	  sufficient	  to	  regulate	  gp130.	  Taken	  together,	  these	  data	  
suggested	  that	  ERK2	  was	  critical	  for	  the	  modulation	  of	  gp130	  expression	  irrespective	  of	  cell	  
type	  and	  its	  cellular	  and	  molecular	  backgrounds,	  and	  that	  such	  regulation	  did	  not	  require	  the	  







Figure	   3.14	   –	   Overexpression	   of	   ERK2	   does	   not	   change	   gp130	   protein	   levels.	   U2OS	   cells	   were	  
transfected	  with	  1	  µg	  of	  each	  plasmids:	  empty	  Vector	  (EV),	  SF-­‐ERK1	  (E1),	  SF-­‐ERK2	  (E2),	  SF-­‐ERK1>SF-­‐
ERK2	   (E1>E2)	  or	  SF-­‐ERK2>SF-­‐ERK1	   (E2>E1).	  Cells	  were	  collected	  after	  24h	  or	  48h	  of	   transfection	  as	  
indicated.	   Proteins	   were	   separated	   by	   Western	   blot	   and	   probed	   for	   gp130	   receptor,	   pERK1/2	  
(T202.T204/T185.Y187)	   and	   ERK1/2	   total.	   β-­‐actin	   was	   used	   as	   loading	   control.	   Presented	  
experiments	  are	  representative	  of	  three	  independent	  experiments	  that	  yielded	  identical	  results.	  I	  am	  
grateful	  to	  Ms	  Sarah	  Stöcker	  who	  kindly	  ran	  these	  Western	  blots.	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3.2.7.	  Chronic	  absence	  of	  Erk2	  in	  mouse	  cells	  did	  not	  compromise	  gp130	  expression	  	  
After	   establishing	   by	   RNAi	   that	   ERK2	   knockdown	   decreased	   the	   level	   of	   gp130	   in	   many	  
different	  human	  cell	  lines,	  it	  was	  important	  to	  determine	  what	  happened	  in	  cells	  from	  other	  
species	  as	  many	  cytokine	  receptors	  are	  regulated	  differently	  in	  disparate	  species.	  Wild-­‐type,	  
Erk1-­‐null	   and	   Erk2-­‐null	   MEFs	   were	   obtained	   from	   Prof.	   S.	   Meloche	   (Montreal,	   Canada).	  
Assuming	   that	   chronic	   and	   acute	   Erk	   depletion	   were	   functionally	   equivalent,	   then	   MEFs	  
lacking	  Erk2	  should	  either	  lack,	  or	  have	  considerable	  reduction	  in	  gp130	  protein	  levels	  when	  
compared	   to	   wild-­‐type	   or	   Erk1-­‐null	   MEFs.	   To	   examine	   this,	   total	   RNA	   was	   isolated	   from	  
these	  three	  types	  of	  MEFs	  and	  analysed	  by	  qPCR	  for	  the	  following	  genes:	  gp130,	  Erk1,	  Erk2	  
and	  Stat3.	  Gapdh	  and	  β-­‐actin	  were	  the	  house-­‐keeping	  genes	  used	  for	  normalisation	  (Figure	  
3.15	   A).	   In	   addition,	   protein	   extracts	   were	   isolated	   from	   the	   three	   MEFs,	   protein	  
concentrations	   quantified	   and	   equal	   amounts	   of	   total	   protein	   run	   in	   a	   SDS-­‐PAGE	   gel.	   The	  
Western	  blot	  membrane	  was	  probed	  for	  gp130	  and	  Erk1/2,	  with	  β-­‐actin	  serving	  as	  a	  loading	  
control	  (Figure	  3.15	  B).	  Surprisingly,	  gp130	  mRNA	  levels	  were	  2-­‐fold	  higher	  in	  Erk2-­‐/-­‐	  MEFs	  
than	  in	  wild-­‐type	  cells.	  The	  same	  was	  seen	  for	  Erk1-­‐/-­‐	  MEFs	  but	  to	  a	   lesser	  extent	  and	  this	  
was	  not	  statistically	  significant.	  The	  increase	  in	  gp130	  mRNA	  seen	  for	  the	  Erk2	  -­‐/-­‐	  MEFs	  was	  
reflected	  by	  the	  amount	  of	  gp130	  protein	  (Figure	  3.15	  B).	  Interestingly,	  Stat3	  mRNA	  was	  also	  
greater	   in	   Erk2-­‐/-­‐	   than	   in	   wild-­‐type	  MEFs.	   Either	   these	   knockout	  MEFs	   have	   developed	   a	  
mechanism	   to	   compensate	   for	   the	   chronic	   loss	   of	   Erk2,	   or	   Erk2	   is	   not	   an	   important	  
modulator	   of	   gp130	   expression	   in	   mouse	   cells	   contrary	   to	   what	   was	   observed	   in	   human	  
cells.	  	  
	  
Following	  the	  observation	  that	  ERK2	  -­‐/-­‐	  MEFs	  had	  higher	  levels	  of	  gp130	  than	  their	  wild-­‐type	  
counterparts,	   we	   postulated	   that	   perhaps	   in	   mouse	   cells	   Erk2	   did	   not	   regulate	   gp130	  
expression	  through	  the	  same	  mechanism	  used	  in	  human	  cells.	  To	  investigate	  this	  hypothesis,	  
NIH	  3T3	  mouse	  cells	  were	  transfected	  with	  siERK2,	  siERK1	  or	  siNS	  for	  48	  h.	  RNA	  and	  proteins	  
were	   isolated	   and	   analysed	   as	   before.	   Despite	   its	   specificity	   human	   siERK1	   and	   siERK2	  
oligonucleotides	  were	  able	  to	  target	  mouse	  Erk1	  and	  Erk2	  mRNA	  as	  shown	  in	  Figure	  3.15	  C	  
and	  D.	   Despite	   the	   efficient	   knockdown,	   silencing	   Erk1	   or	   Erk2	   did	   not	   alter	   gp130	   levels	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significantly.	  There	  was	  a	  hint	  of	  a	  reduction	  of	  gp130	  after	  siERK2	  transfection,	  which	  was	  
accompanied	  by	  a	  small	  reduction	  of	  STAT3,	  and	  a	  not	  significant	  increase	  in	  the	  amount	  of	  
Stat3	  after	  silencing	  Erk1,	  which	  had	  been	  observed	  previously	   in	  U2OS	  cells	   (Figure	  1.11),	  
albeit	   to	   a	   smaller	   extent.	   Taken	   at	   face	   value,	   these	   data	   seem	   to	   suggest	   that	   acute	  
depletion	  of	  ERK2	  impacts	  on	  gp130	  expression	  and	  that	  cells	  which	  have	  never	  ‘seen’	  Erk2	  















Figure	  3.15	  –	  ERK2	  does	  not	  seem	  to	  regulate	  gp130	  expression	  in	  mouse	  cells.	  ERK2-­‐/-­‐	  MEF	  s	  have	  
higher	   levels	   of	   gp130	   than	  wild-­‐type	  or	   ERK1-­‐/-­‐	  MEFs.	  A.	   RNA	  was	   isolated	   from	  MEFs	   that	  were	  
wild-­‐type,	  Erk1-­‐null	  or	  Erk2-­‐null	  as	  described	  before	  and	  qPCR	  was	  used	  to	  quantify	  mRNA	  levels	  of	  
gp130,	  ERK2,	  ERK1	  and	  STAT3.	  β-­‐actin	  and	  GAPDH	  were	  used	  as	  house	  keeping	  genes.	  B.	  Proteins	  
from	  each	  cell	  line	  were	  extracted	  using	  RIPA	  buffer,	  quantified	  and	  equal	  amounts	  were	  analysed	  by	  
Western	   blot.	   Proteins	   were	   probed	   for	   gp130.	   ERK1/2	   was	   used	   to	   confirm	   phenotypes	   and	  
α-­‐tubulin	  was	  used	  as	  a	  loading	  control.	  NIH	  3T3	  mouse	  cells	  gp130	  does	  not	  seem	  to	  be	  regulated	  
by	  ERK2.	  C.	  Cells	  were	   transfected	  as	   for	  48	  h,	   and	  RNA	  was	   collected	  and	  processed	  as	   in	   (A.)	   D.	  
Proteins	  were	  collected	  and	  analysed	  as	  in	  (B.)	  A.	  C.	  The	  number	  of	  times	  that	  each	  experiment	  was	  
independently	  done	  is	  given	  in	  the	  figure.	  .	  Statistical	  analysis	  was	  done	  using	  Student	  t-­‐test	  applied	  
and	   SEM	   to	   at	   least	   three	   independent	   experiments	   (*	   -­‐	   P<0.05,	   **	   -­‐	   P<0.01,	   ***-­‐P<0.005	   versus	  
siNS).	  
3.	  Characterisation	  of	  signalling	  downstream	  of	  IL-­‐6	  type	  cytokines	  	  
upon	  the	  silencing	  of	  ERK1	  or	  ERK2	  
	   116	  
	  
3.2.8.	  ERK2	  knockdown	  decreased	  cell	  growth	  without	  engaging	  the	  apoptotic	  pathway	  
IL-­‐6-­‐type	   cytokine	   signalling	  promotes	   cell	   differentiation	  and	  growth.	   For	   this	   reason,	   the	  
growth	   of	   U2OS	   cells	   after	   depletion	   of	   ERK2	   and,	   consequently,	   of	   gp130	  was	   analysed.	  
These	   experiments	   also	   served	   to	   inform	   as	   whether	   the	   siRNA	   pool	   against	   ERK2	   was	  
triggering	   apoptotic	   signalling	   pathways	   that	   resulted	   in	   the	   downregulation	   of	   the	   gp130	  
receptor.	  
	  
U2OS	   cells	   were	   transfected	   with	   siRNA	   against	   ERK2,	   ERK1,	   gp130,	   with	   siNS	   or	   left	  
untransfected	  for	  24,	  48,	  72	  or	  96	  h.	  Cells	  were	  then	  washed,	  fixed	  and	  stained	  with	  crystal	  
violet	   as	   described	   in	   the	  Materials	   and	   Methods	   section.	   As	   shown	   in	   Figure	   3.16	   A,	  
transfection	  of	  U2OS	  cells	  with	  siERK1,	  siERK2	  or	  sigp130	  led	  at	  later	  time	  points	  to	  reduced	  
cellular	  growth	  rate	  when	  compared	  to	  cells	  transfected	  with	  siNS	  or	  left	  untreated,	  and	  this	  
is	  more	   pronounced	   in	   the	   case	   of	   cells	   transfected	   with	   siERK2.	   At	   the	   time	   point	  most	  
experiments	   are	   carried	   out	   (48	   h	   post-­‐transfection)	   the	   differences	   in	   cellularity	   are	   not	  
significant.	  In	  order	  to	  understand	  whether	  the	  observed	  decrease	  in	  growth	  was	  due	  to	  an	  
increase	   in	   apoptosis,	   U2OS	   cells	   were	   transfected	   for	   48	   h	   as	   in	   Figure	   3.16	   A,	   and	  
subsequently	   incubated	   with	   Caspase	   Glo®	   3/7	   reagent	   to	   assess	   caspase	   activation.	   The	  
fluorescence	   values	   obtained	   for	   each	   set	   of	   conditions	   were	   normalized	   to	   the	   siNS-­‐
transfected	  control	  (Figure	  3.16	  B).	  Transfection	  of	  U2OS	  cells	  with	  siERK2	  or	  sigp130	  did	  not	  
lead	   to	   caspase	   activation,	   as	   can	   be	   seen	   by	   comparing	   these	   samples	   with	   the	  
untransfected	  control	  and	  NS-­‐transfected	  cells.	  Silencing	  ERK1	  appeared	  to	  trigger	  caspase	  
activity	   and	   it	   is	   thus	   surprising	   that	   this	   was	   not	   reflected	   in	   the	   data	   obtained	   for	   the	  
viability	  assays	  shown	  in	  Figure	  3.16	  A.	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Figure	   3.16	   –	   Transfection	   of	   siERK2	   decreases	   cell	   growth	   but	   does	   not	   activate	   apoptotic	  
signalling.	  U2OS	  cells	  were	  transfected	  with	  siRNA	  against	  ERK1,	  ERK2,	  gp130,	  with	  siNS	  or	  were	  left	  
untransfected.	   A.	   At	   the	   indicated	   times	   after	   transfection,	   cells	   were	   washed	   and	   stained	   with	  
crystal	  violet.	  Each	  condition	  was	  analysed	   in	   triplicate.	  B.	  After	  48	  h	  of	   transfection,	  Caspase-­‐Glo®	  
3/7	  reagent	  was	  added	  to	  cells,	  the	  fluorescence	  was	  quantified	  and	  the	  values	  obtained	  normalized	  
to	   the	   siNS	   condition.	   The	   data	   are	   representative	   of	   three	   independent	   experiments	   that	   yielded	  
identical	  results.	  Statistical	  analysis	  was	  done	  using	  SEM	  and	  Student’s	  t-­‐test	  (*	  -­‐	  P<0.05,	  **	  -­‐	  P<0.01,	  
***-­‐P<0.005	  versus	  siNS).	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3.2.9.	  ERK2	  knockdown	   induced	  a	  G1	  cell	   cycle	  arrest	   in	  U2OS	  cells	  but	   it	  did	  not	   trigger	  
apoptosis	  
The	  data	  sets	  presented	   in	  Figure	  3.16	   led	  us	  to	  explore	  the	   impact	  that	  reducing	  ERK1	  or	  
ERK2	   levels	   had	   on	   the	   life	   of	   cells	   by	   analysing	   their	   cell	   cycle	   profiles.	   U2OS	   cells	   were	  
transfected	  as	  before	  for	  48	  h.	  Cells	  were	  collected	  and	  fixed	  with	  methanol	  followed	  by	  PI	  
staining.	  The	  cell	  cycle	  profile	  for	  each	  sample	  was	  then	  analysed	  by	  flow	  cytometry	  (Figure	  
3.17).	   Cell	   percentages	   from	   three	   independent	   experiments	   were	   used	   to	   calculate	   and	  
compare	   the	   amount	   of	   cells	   in	   each	   phase	   of	   the	   cell	   cycle	   (Figure	   3.17	   B).	   Upon	  
transfection	  with	   siERK2	   there	  was	   a	   significant	   increase	   in	   the	   number	   of	   cells	   in	   the	  G1	  
phase	  of	   the	  cycle	  and	  a	  significant	  decrease	   in	   the	  numbers	  of	  cells	  both	   in	   the	  S	  and	  G2	  
phases	  but	  there	  was	  no	  increase	  in	  sub-­‐G1	  cells,	  suggesting	  that	  against	  all	  odds	  silencing	  
ERK2	   did	   not	   lead	   to	   apoptosis.	   In	   accordance	   to	  what	  was	   previously	   observed	   in	  Figure	  
3.16	   B,	   RNAi	   against	   ERK1	   increased	   by	   1.8-­‐fold	   the	   number	   of	   cells	   in	   the	   sub-­‐G1	   phase	  
thereby	  explaining	  the	  slight	  increase	  in	  caspase	  activity	  seen	  in	  Figure	  3.16	  B.	  	  
	  
3.2.10.	  A	  G1	  arrest	  is	  not	  sufficient	  to	  induce	  downregulation	  of	  gp130	  in	  U2OS	  cells	  	  
Following	   the	   observation	   that	   RNAi	   against	   ERK2	   altered	   the	   cell	   cycle	   by	   causing	   a	   G1	  
arrest,	  it	  was	  important	  to	  investigate	  if	  the	  reduction	  in	  gp130	  levels	  was	  related	  to	  this	  G1	  
arrest	   (Figure	  3.17).	   In	  order	  to	   induce	  a	  G1	  arrest,	  U2OS	  cells	  were	  starved	  by	   incubating	  
them	  without	  FCS	  for	  24	  h.	  As	  a	  control,	  cells	  were	  incubated	  in	  full	  medium.	  Cell	  cycle	  was	  
analysed	  as	  described	  in	  the	  previous	  section	  and,	  this	  time,	  RNA	  and	  protein	  samples	  were	  
also	  examined	  for	  gp130.	  As	  shown	  in	  Figure	  3.18	  A,	  there	  were	  less	  starved	  cells	  in	  G2	  and	  
there	  were	  more	  arrested	  in	  G1	  and/or	  undergoing	  apoptosis,	  as	  shown	  by	  an	  increased	  sub-­‐
G1	   population.	   Despite	   the	   cell	   cycle	   alterations,	   levels	   of	   gp130	   under	   these	   conditions	  
remained	  the	  same	  (Figure	  3.18	  C),	  indicating	  that	  gp130	  regulation	  by	  ERK2	  was	  unlikely	  to	  
be	  caused	  by	  a	  G2	  arrest	  caused	  by	  downregulating	  ERK2	  in	  U2OS.	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Figure	   3.17	   –	   Downregulation	   of	   ERK2	   promotes	   a	   G1	   cell	   cycle	   arrest	   in	   U2OS	   cells.	  Cells	  were	  
transfected	  as	  described	  before	  with	  siNS,	  siERK1,	  siERK2,	  sigp130	  or	  left	  untransfected.	  Forty-­‐eight	  
hours	   later,	   cells	   were	   washed	   and	   fixed	   with	   iced	   cold	   methanol,	   followed	   by	   RNase	   treatment	  
together	  with	  PI	  staining.	  PI	   incorporation	  was	  measured	  by	  flow	  cytometry.	  Each	  phase	  of	  the	  cell	  
cycle	  is	  indicated	  in	  the	  histograms:	  from	  left	  to	  right,	  sub-­‐G1,	  G1,	  S	  and	  G2	  phases	  of	  the	  cell	  cycle.	  
The	  histograms	  presented	  are	  the	  result	  of	  one	  experiment	  that	  is	  representative	  of	  three	  different	  
experiments.	   Student	   t-­‐test	   and	   SEM	  were	   applied	   to	   at	   least	   three	   independent	   experiments	   (*	   -­‐	  
P<0.05,	  **	  -­‐	  P<0.01,	  ***-­‐P<0.005	  versus	  siNS).	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Figure	  3.18	  –	  Downregulation	  of	  gp130	  by	  ERK2	  is	  not	  due	  to	  alterations	  in	  the	  cell	  cycle.	  U2OS	  cells	  
were	  starved	  or	  left	  in	  full	  media	  (10%	  FCS)	  for	  24	  h.	  A.	  Cells	  cycle	  analysis	  was	  performed	  as	  before	  
and	   it	   showed	   clear	   cell	   cycle	   arrest	   in	   starved	   cells.	  B.	   Cell	   cycle	   profiles	   representative	   of	   three	  
independent	   experiments	   are	   summarised	   graphically.	   C.	   gp130	   protein	   levels	   were	   analysed	   by	  
Western	  blot	  ,	  as	  described	  before.	  Serum	  starvation	  did	  not	  change	  gp130	  expression	  in	  these	  cells.	  	  
D.	  mRNA	   of	   gp130	   and	   ERK2	  were	   analysed	   by	   qPCR	   using	  β-­‐actin	   and	   GAPDH	   as	   house	   keeping	  
genes.	  Student	  t-­‐test	  and	  SEM	  were	  applied	  to	  at	   least	  three	  independent	  experiments	  (*	  -­‐	  P<0.05,	  




3.2.11.	   Expression	   of	   ERK1	   and	   ERK2	   also	   had	   an	   impact	   on	   the	   expression	   of	   other	  
cytokine	  and	  growth	  factor	  receptors	  
Following	  the	  observation	  that	  ERK2	  regulated	  the	  expression	  of	  gp130,	  a	  receptor	  that,	   in	  
addition	   to	   JAK/STAT,	   activates	   MAPK	   pathways,	   we	   wondered	   whether	   this	   type	   of	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activate	  MAPK	  signalling.	  Once	  again,	  both	  U2OS	  and	  A549	  cell	  lines	  were	  used	  to	  minimally	  
distinguish	  between	  general	  observations	  and	  cell-­‐type	  specific	  observations.	  Binding	  of	  FGF	  
and	  EGF	  to	  FGFR1	  and	  EGFR,	  respectively,	  leads	  to	  the	  activation	  of	  MAPK	  pathways	  and,	  as	  
such,	  were	  picked	  up	  as	  examples	  of	  growth	  factor	  receptors	  that	  could	  also	  be	  regulated	  by	  
ERK1	  and/or	  ERK2.	  The	  cytokine	  receptor	  Interferon	  (IFN)-­‐γ	  receptor	  1	  (IFNGR1)	  was	  used	  as	  
an	  example	  of	  a	  receptor	  that	  does	  not	  usually	  couple	  to	  MAPKs.	  
	  
U2OS	   and	   A549	   cells	   were	   transfected	   with	   siNS,	   siERK1,	   siERK2	   and	   with	   siRNA	  
oligonucleotides	   targeting	   the	   receptor	   being	   analysed	   (denoted	   in	   the	   figures	   by	   R).	   The	  
latter	  was	  important	  to	  determine	  whether	  the	  bands	  picked	  up	  by	  the	  antibodies	  used	  for	  
Western	  blotting	  were	   specific	   to	   the	   receptor	  under	   investigation	   (Figure	   3.20	   A).	   FGFR1	  
was	   slightly	   reduced	   upon	   siERK1	   transfection	   in	   both	   U2OS	   and	   A549	   cells	   and	   its	  
expression	   appeared	   to	   increase	   after	   ERK2	   silencing.	   In	   contrast,	   EGFR	   expression	   was	  
reduced	  upon	  ERK2	  knockdown	  in	  A549	  cells	  and,	  to	  our	  surprise,	  we	  were	  unable	  to	  detect	  
it	  in	  U2OS	  cells.	  ERK1	  silencing	  was,	  in	  this	  case,	  without	  effect.	  Despite	  the	  fact	  that	  IFNGR1	  
is	  not	  known	  to	  significantly	  activate	  MAPK	  kinase	  cascades,	  there	  was	  a	  hint	  of	  an	  inhibition	  
after	   siERK1	   knockdown	   in	   U2OS	   cells	   that	   was	   not	   obvious	   in	   A549	   cells,	   whereas	   the	  
silencing	   of	   ERK2	   was	   without	   effect	   in	   both	   cell	   lines.	   It	   was	   important	   to	   understand	  
whether	  these	  changes	  in	  receptor	   levels	  were	  a	  reflection	  of	  a	  decrease	  in	  the	  amount	  of	  
mRNA	  or	   due	   to	   direct	   regulation	   at	   the	   protein	   level.	   For	   that	   purpose,	  U2OS	   cells	  were	  
transfected	   the	   same	   way	   as	   before,	   RNA	   was	   isolated	   and	   qPCR	   analyses	   carried	   out.	  
Following	   ERK1	   or	   ERK2	   silencing,	   the	   decrease	   observed	   in	   FGFR1	   upon	   siERK1	   was	  
proportional	  to	  what	  was	  observed	  at	  the	  mRNA	  level	  and	  the	  increase	  upon	  siERK2	  was	  also	  
observed	   and	   reflected	   by	   the	   protein	   levels	   (Figure	   3.19	   A	   and	   B).	   Interestingly,	   mRNA	  
levels	  of	  FGFR2	  were	  robustly	  decreased	  upon	  siERK1	  (Figure	  3.19	  C)	  but	  unfortunately	  the	  
FGFR2	   antibodies	   available	   were	   not	   good	   enough	   to	   perform	   a	   robust	  Western	   blotting	  
analysis.	  mRNA	  analysis	  of	  EGFR	   levels	  after	  silencing	  ERK1	  or	  ERK2	  revealed	  no	  change	   in	  
mRNA	  levels	  (Figure	  3.19	  D).	  However,	  the	  regulation	  of	  EGFR	  by	  ERK2	  was	  questionable,	  as	  
in	  our	  hands	  these	  cells	  did	  not	  seem	  to	  express	  greatly	  EGFR.	  Accordingly,	  the	  latter	  analysis	  
was	  also	  carried	  out	  in	  A549	  using	  the	  siERK2	  pool	  and	  the	  four	  individual	  oligonucleotides	  in	  
that	  pool.	  The	  data	  was	  disappointing:	  the	  net	  result	  was	  that	  transfection	  with	  siERK2	  led	  to	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a	  decrease	  in	  EGFR	  that	  was	  also	  seen	  with	  siERK2	  #9,	  but	  not	  with	  siERK2	  #1,	  which	  actually	  
led	   to	   an	   increase	   in	   EGFR	  expression.	   The	  other	   two	  oligonucleotides	   (siERK2	  #2	   and	  #4)	  
were	  without	  any	  effect.	  This	  would	  suggest	   that	   initial	  observation	  reflected	  an	  off-­‐target	  
effect	   and	   was	   another	   stark	   reminder	   of	   the	   perils	   of	   working	   with	   RNAi.	   Nevertheless,	  
taken	   together,	   these	   data	   suggest	   that	   ERKs	   can	   modulate	   the	   expression	   of	   several	  
receptors	  and	  that	   it	   is	   likely	  that	  this	   is	  via	  a	  complex	   interplay	  between	  these	  molecules,	  
the	  pathways	  they	  activate	  and	  multiple	  protein-­‐chromatin	  interactions.	  
	  
Figure	  3.19	  –	  Knocking	  down	  ERK2	  and	  ERK1	  alters	  the	  expression	  levels	  of	  receptor	  chains	  other	  
than	  gp130.	  U2OS	  and	  A549	  cells	  were	  transfected	  as	  before	  with	  siNS	  (NS),	  siERK1	  (E1),	  siERK2	  (E2),	  
corresponding	  receptor	  in	  analysis	  (R=siFGFR1,	  siFGFR2	  siEGFR,	  siIFNGR1)	  or	  were	  left	  untransfected	  
(ø).	  A.	  Forty-­‐eight	  h	  later	  proteins	  were	  analysed	  by	  Western	  blot.	  Each	  individual	  receptor	  analysis	  
was	  run	  in	  a	  different	  membrane,	  which	  were	  probed	  for	  FGFR1,	  EGFR	  or	  IFNGR.	  β-­‐actin	  was	  used	  as	  
loading	  control.	  RNA	  was	  isolated	  and	  B.	  FGFR1,	  C.	  FGFR2	  or	  D.	  EGFR	  mRNA	  was	  quantified	  by	  qPCR.	  
β-­‐actin	  and	  GAPDH	  were	  used	  as	  house-­‐keeping	  genes.	  Experiments	  were	  performed	  at	  least	  3	  times	  
yielding	   similar	   results.	   Student	   t-­‐test	   and	   SEM	   were	   applied	   to	   at	   least	   three	   independent	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Figure	  3.19	  –	  Knocking	  down	  ERK2	  and	  ERK1	  altered	  the	  expression	  levels	  of	  receptor	  chains	  other	  
than	   gp130.	   E.	   A549	   cells	  were	   transfected	  with	   siNS,	   siERK2,	   or	  with	   individual	   siRNAs	   from	   that	  
pool	   (siERK2	   #1,	   #2,	   #4	   or	   #9).	   The	   RNA	   was	   subsequently	   extracted	   and	   analysed	   by	   qPCR.	  
Experiments	  were	  performed	  at	   least	  3	   times	  yielding	  similar	   results.	   Student	   t-­‐test	  and	  SEM	  were	  
applied	  to	  three	  independent	  experiments	  (*	  -­‐	  P<0.05,	  **	  -­‐	  P<0.01,	  ***-­‐P<0.005	  versus	  siNS).	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3.3.	  Discussion	  	  
Using	  RNAi	  we	  have	  genetically	  manipulated	  ERK1	  and	  ERK2	  independently	  (Figure	  3.2	  and	  
3.3)	   revealing	   at	   least	   one	   novel	   non-­‐overlapping	   role	   of	   these	   two	   isoforms.	   Silencing	   of	  
ERK2	  does	  not	  impact	  on	  the	  expression	  of	  the	  JAKs	  (Figure	  3.5)	  but	  it	  leads	  to	  a	  significant	  
reduction	  in	  gp130	  protein,	  whilst	  knocking	  down	  ERK1	  has	  no	  effect	  on	  this	  receptor	  (Figure	  
3.6,	  3.7	  and	  3.8).	  ERK1	  does	  not	  seem	  to	  be	  able	  to	  compensate	  for	  the	  ERK2	  loss.	  This	  could	  
either	  be	  because	  ERK1	  does	  not	  play	  a	  role	  on	  gp130	  regulation,	  or	  because	  the	  ERK1	  levels	  
are	  not	  enough	  to	  contribute	  to	  this	  regulation.	  It	  is	  challenging	  to	  achieve	  100%	  knockdown	  
efficiency	  using	  siRNA.	  Therefore	  it	  is	  possible	  that	  if	  ERK2	  was	  entirely	  knocked	  down	  in	  the	  
cells,	   a	   complete	   inhibition	   of	   gp130	   expression	   could	   have	   been	   achieved.	   Furthermore,	  
analysis	   of	   gp130	   mRNA	   levels	   in	   cells	   transfected	   with	   siERK2	   shows	   a	   considerable	  
reduction	   of	   the	   receptor	   indicating	   that	   ERK2	   regulates	   gp130	   by	   controlling	   its	  
transcription	  (Figure	  3.8	  D).	  
	  
IL-­‐6	  signalling	  in	  U2OS	  and	  A549	  cells	  is	  represented	  in	  Figure	  3.1	  and	  it	  follows	  the	  expected	  
trend.	   Following	   treatment	   with	   IL-­‐6,	   OSM	   or	   LIF	   STAT3,	   STAT1	   and	   ERK1/2	   are	  
phosphorylated	  (Figure	  3.1).	  Upon	  ERK2	  knockdown,	  the	  expression	  of	  the	  crucial	  receptor	  
shared	   by	   all	   IL-­‐6-­‐type	   cytokines,	   gp130,	   decreases	   leading	   to	   the	   abrogation	   of	   signalling	  
downstream	  of	  gp130	  which	  is	  mediated	  mainly	  by	  STAT3	  activation	  (Figure	  3.2).	  As	  a	  result,	  
the	  induction	  of	  an	  immediate-­‐early	  STAT3	  gene,	  SOCS3	  (Figure	  3.4	  A),	  a	  STAT3/ERK	  target,	  
EGR-­‐1	  (Figure	  3.4	  B)	  and	  the	  expression	  of	  STAT3	  itself	  (Figures	  3.2,	  3.3	  D,	  3.11	  and	  3.12)	  is	  
impaired.	   In	   contrast,	   cells	   with	   silenced	   ERK1	   treated	   with	   OSM,	   significantly	   increase	  
SOCS3	  and	  EGR-­‐1	  mRNA	  induction	  when	  compared	  to	  cells	  transfected	  with	  a	  non-­‐targeting	  
siRNA	  pool	  (siNS)	  (Figure	  3.4).	  This	  suggests	  opposing	  roles	  for	  ERK1	  and	  ERK2	  in	  response	  to	  
IL6-­‐type	   cytokine	   stimuli.	   Interestingly,	   upon	   the	   silencing	   of	   ERK2,	   ERK1	   appears	   to	   be	  
constitutively	  phosphorylated,	  independently	  of	  cytokine	  treatment,	  without	  any	  changes	  at	  
the	  protein	  level	  (Figures	  3.2).	  This	  is	  also	  observed	  in	  ERK2	  conditionally	  knocked	  out	  mice	  
cortices	   (Samuels	   et	   al.,	   2008).	   Similarly,	   ERK2	   phosphorylation	   has	   been	   observed	   in	  
different	   tissues	   of	   ERK1	   knockout	   mice,	   without	   changes	   in	   ERK2	   expression	   levels	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(Mazzucchelli	  et	  al.,	  2002;	  Pages	  et	  al.,	  1999;	  Selcher	  et	  al.,	  2001).	  In	  fact,	  this	  can	  be	  spotted	  
in	  Figure	   3.15A	   too.	   These	  data	   suggest	   that	   these	   two	  molecules	  do	  not	   compensate	   for	  
each	   other	   and	   likely	   have	   some	   biological	   functions	   that	   are	   not	   shared	   between	   them	  
[reviewed	  in	  (Lloyd,	  2006)].	  	  
	  
Intriguingly,	  deconvolution	  analysis	  of	  each	  siRNA	  pool	  used	  in	  this	  study	  suggested	  that	  one	  
of	   the	   siERK1	   oligonucleotides	   produced	   an	   off-­‐target	   effect	   that	   impacted	   on	   gp130	  
maturation.	  We	   eliminated	   this	   siRNA	   from	  our	   analysis	   but	  we	  were	   naturally	   curious	   to	  
identify	  its	  other	  target.	  BLAST	  searches	  suggested	  that	  SAR1A	  was	  a	  likely	  candidate	  and	  we	  
were	  delighted,	  as	  it	  had	  been	  implicated	  in	  cell	  trafficking.	  However,	  experiments	  suggested	  
that	  this	  was	  not	  the	  case	  and	  we	  abandoned	  pursuing	  the	  identity	  of	  such	  a	  target	  (Figure	  
3.7	  D).	  
	  
ERK2	  is	  a	  kinase	  widely	  studied	  and	  well	  characterized	  as	  regulating	  more	  than	  200	  genes	  by	  
virtue	  of	  its	  kinase	  activity	  (Wortzel	  and	  Seger,	  2011).	  We	  expected	  that	  this	  would	  also	  be	  
the	   case	   for	   gp130	   regulation.	   However,	   chemical	   inhibition	   of	   either	   MEKs,	   which	   are	  
kinases	  upstream	  from	  ERK1/2,	  or	  of	  ERK1/2,	  does	  not	  impact	  on	  gp130	  expression	  (Figure	  
3.10).	   This	   suggests	   that	   the	   kinase	   activity	   of	   ERK2	   is	   not	   required	   for	   the	   regulation	   of	  
gp130.	  We	  analysed	   the	  phosphorylation	   status	  of	   the	   residual	   gp130	   receptor	  after	  ERK2	  
RNAi.	  No	  phosphorylation	  could	  be	  detected	  after	   stimulus,	   indicating	   that	  ERK2	   regulates	  
both	  the	  gp130	  expression	  and	  its	  phosphorylation,	  possibly	  by	  two	  separate	  mechanisms	  of	  
action	  (Figure	  3.8	  E),	  neither	  of	  which	  seem	  to	  require	  ERK2	  kinase	  activity	  (Figure	  3.10).	  It	  
may	  also	  mean	  that,	  more	   likely,	  the	  phosphorylation	  of	  the	  remaining	  gp130	  molecules	   is	  
below	   the	   limit	   of	   detection	   of	   the	   assay.	   By	   screening	   a	   number	   of	   different	   cancer	   cell	  
types	   we	   concluded	   that	   ERK2	   regulates	   gp130	   expression	   in	   multiple	   cancer	   types	   from	  
different	   origins	  with	   different	  mutational	   and	   cellular	   backgrounds	   (Table	   2.1	   and	   Figure	  
3.11).	   By	   looking	   at	   the	   effect	   of	   ERK2	   RNAi	   in	   cell	   lines	   of	   non-­‐cancer	   origin,	   we	  
demonstrated	   that	   the	   regulation	  of	   gp130	  by	  ERK2	   is	  not	   limited	   to	   tumour-­‐derived	   cells	  
(Figure	   3.12	   and	   Table	   2.1),	   indicating	   that	   this	   regulation	   is	   likely	   to	   be	   a	   general	   and	  
relevant	   biological	   effect.	   Linear	   regression	   analyses	   established	   that	   ERK2	   expression	  
correlates	  with	  gp130	  protein	  expression	  with	  coefficient	  of	  determinations	  of	  0.73	  and	   in	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silico	   analyses	   suggest	   that	   this	  may	   also	   be	   true	   at	   the	  mRNA	   level	   (Figure	   3.11	   F).	   This	  
suggests	  further	  that	  ERK2	  can	  directly	  control	  the	  gp130	  expression.	  Indeed,	  manipulation	  
of	   ERK2	   protein	   levels	   by	   targeting	   ERK2	   by	   RNAi	   directly	   impacted	   on	   gp130	   protein	  
expression	  (Figure	  3.13).	   Increasing	  the	  expression	   levels	  of	  ERK2,	  however,	  can	  only	  drive	  
gp130	  expression	  up	   to	  a	   certain	  point	  after	  which	  gp130	  concentration	   can	  no	   longer	  be	  
enhanced	  even	  if	  ERK2	  is	  overexpressed	  (Figure	  3.14).	  Some	  cell	  lines	  such	  as	  A549	  and	  HeLa	  
(Figure	  3.11	  F)	  did	  not	  show	  a	  correlation	  between	  the	  levels	  of	  ERK2	  and	  gp130,	  although	  
the	  reduction	  of	  ERK2	  by	  RNAi	  also	  leads	  to	  a	  decrease	  in	  gp130	  expression.	  This	  may	  be	  due	  
to	  high	  basal	   levels	  of	  gp130	  in	  these	  cell	   lines,	  but	  formal	  demonstration	  of	  this	   is	  not	  yet	  
available.	  	  
	  
Because	   ERK1	   and	   ERK2	   isoforms	   share	   85%	   of	   sequence	   homology	   they	   were	   initially	  
described	  as	  having	  identical	  activities,	  kinetics	  and	  substrates	  (Mebratu	  and	  Tesfaigzi,	  2009;	  
Roux	   and	   Blenis,	   2004).	   The	   differences	   in	   activation	   between	   these	  molecules	   are	   often	  
linked	   to	   the	   variation	   on	   expression	   levels	   (Lefloch	   et	   al.,	   2008).	   Structural	   differences	  
between	   ERK1	   and	   ERK2	   are	   also	   thought	   to	   be	   at	   least	   partially	   responsible	   for	   their	  
recently	   recognised	   distinct	   functions	   (Chen	   et	   al.,	   2001).	   This	   was	   suggested	   for	   cell	  
transformation	   mediated	   by	   Ras	   (Vantaggiato	   et	   al.,	   2006),	   in	   epithelial	   to	   mesenchymal	  
transformation	  (EMT)	  (Shin	  et	  al.,	  2010),	  in	  controlling	  different	  genes	  during	  embryogenesis	  
(Krens	  et	  al.,	  2008)	  and	   in	  proliferation	  as	  there	   is	  a	  decrease	   in	  neuron	  generation	  during	  
neurogenic	   period	   when	   ERK2	   is	   absent	   in	   conditional	   knockout	   mice	   (Samuels,	   2008).	  
ERK1’s	  N-­‐terminal	  sequence,	  which	  is	  absent	  in	  ERK2,	  contributes	  decreased	  import	  of	  ERK1	  
into	   the	  nucleus	  when	   compared	   to	   ERK2.	   This	  may	  explain	  differences	  observed	   in	   some	  
biological	   responses	   (Marchi	   et	   al.,	   2008).	   Importantly,	   ERK1/2	   have	   numerous	   biological	  
roles	  independent	  of	  their	  enzymatic	  roles	  [reviewed	  in	  (Rodriguez	  and	  Crespo,	  2011)].	  	  
	  
Erk2-­‐deficient	  mice	  are	  not	  viable	  (Yao	  et	  al.,	  2003),	  while	  Erk1-­‐deficient	  mice	  present	  minor	  
defects	   in	  thymocyte	  maturation	  (Pages	  et	  al.,	  1999),	  adipocyte	  differentiation	  (Bost	  et	  al.,	  
2005a;	   Bost	   et	   al.,	   2005b)	   and	   striatum-­‐dependent	   synaptic	   plasticity	   (Mazzucchelli	   et	   al.,	  
2002).	  To	  further	  investigate	  the	  role	  of	  ERK2	  on	  gp130	  expression,	  we	  have	  compared	  the	  
levels	  of	  gp130	  in	  Erk2	  -­‐/-­‐,	  Erk1	  -­‐/-­‐	  and	  matched	  wild-­‐type	  MEFs	  generously	  given	  to	  us	  by	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Prof.	  S.	  Meloche	  (Voisin	  et	  al.,	  2010).	  Surprisingly,	  gp130	  levels	  are	  higher	   in	  Erk2	  -­‐/-­‐	  MEFs	  
than	  in	  wild-­‐type	  MEFs	  (Figure	  3.15	  A).	  This	  could	  be	  possibly	  due	  to	  the	  long-­‐term	  depletion	  
of	   Erk2	   leading	   to	   a	   gene	   compensatory	   mechanism	   that	   enables	   gp130	   to	   be	   fully	  
expressed.	   Indeed,	   further	   investigations	  using	  RNAi	   show	  that	   in	  another	  mouse	  cell	   line,	  
NIH3T3,	   ERK2	   appeared	   to	   have	   an	   effect	   on	   the	   expression	   of	   mouse	   gp130	   receptor	  
although	  the	  effect	  was	  very	  modest	  and	  not	  statistically	  significant	  (Figure	  3.15	  B).	  Due	  to	  
time-­‐constrains	  it	  was	  not	  possible	  to	  examine	  additional	  mouse	  cell	  lines.	  It	  thus	  remains	  to	  
be	  established	  whether	   the	   regulation	  of	  gp130	  by	  ERK2	   is	   specific	   to	  human	  cells,	  or	   can	  
also	  be	  seen	   in	  cells	   from	  other	  species.	  Cell	   type	  specific	   regulation	  of	  cytokine	  receptors	  
has	  been	  well	  described	  by	  others	  (Drechsler	  et	  al.,	  2012;	  Wu	  et	  al.,	  2000)	  possibly	  because	  
the	   immunity	   between	   different	   species	   is	   different	   (Mestas	   and	   Hughes,	   2004)	   and,	  
consequently,	  the	  regulation	  of	  the	  different	  molecules	  involved	  is	  likely	  to	  be	  also	  different.	  
Another	  possibility	   for	   the	  differences	  observed	  between	  mice	  and	  humans	   is	   that	  mouse	  
cells	  may	   potentially	   express	   an	   alternative-­‐splicing	   variant,	   which	   is	   not	   found	   in	   human	  
cells.	   Indeed,	   mice	   express	   the	   46	   kDa	   Erk1	   isoform	   Erk1b	   (Yung	   et	   al.,	   2000),	   whereas	  
humans	  express	  the	  42kDa	  ERK1c	  (Aebersold	  et	  al.,	  2004).	  	  
	  
Depletion	  of	  ERK2	  results	  in	  reduced	  cell	  growth	  and,	  therefore,	  it	  was	  legitimate	  to	  consider	  
that	   the	   gp130	   reduction	   may	   be	   a	   cell	   cycle-­‐mediated	   phenomenon	   instead	   of	   being	   a	  
direct,	   molecular	   driven,	   regulation	   (Figure	   3.16	   A).	   Silencing	   ERK2	   has	   been	   shown	   to	  
reduce	   cell	   growth	   in	   different	   cell	   types:	  HeLa	   (Liu	   et	   al.,	   2004),	   ovarian	   cancer	   cell	   lines	  
(Zeng	  et	  al.,	  2005),	  myoblasts	   (Li	  and	  Johnson,	  2006),	   fibroblasts	   (Vantaggiato	  et	  al.,	  2006)	  
and	   hepatocytes	   (Fremin	   et	   al.,	   2007).	   Interestingly,	   reduced	   levels	   of	   Erk1	   in	   NIH	   3T3	  
fibroblasts	  was	  shown	  to	  contribute	  to	  cell	  proliferation	  whereas	  Erk2	  silencing	  decreased	  it	  
(Lefloch	  et	  al.,	   2009;	  Vantaggiato	  et	  al.,	   2006).	  However,	   Lenormand	  and	  co-­‐workers	  have	  
debated	  this,	  and	  have	  convincingly	  demonstrated	  that,	  at	  least	  in	  the	  system	  they	  studied,	  
the	  expression	  levels	  of	  Erk1	  and	  Erk2	  were	  the	  factors	  responsible	  for	  such	  differences.	  We	  
observed	   that	   ERK1	   silencing	   caused	   a	   reduction	   of	   cell	   growth	   possibly	   due	   to	   a	   slight	  
increase	  in	  apoptosis,	  judging	  by	  an	  increase	  in	  caspase	  activity	  in	  cells	  where	  ERK1	  has	  been	  
knocked	  down	  (Figure	  3.16	  B).	  This	  could	  be	  either	  because	  the	  siERK1	  oligonucleotides	  used	  
are	   themselves	   toxic	   to	   the	   cells,	   or	   because	   ERK1	   absence	   increases	   apoptotic	   signalling.	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The	  former	  is	  more	  likely	  to	  be	  the	  case,	  as	  visual	  inspection	  of	  cells	  during	  the	  experiments	  
did	   not	   reveal	   any	   significant	   cell	   death	   in	   the	   cultures.	   This	   was	   further	   confirmed	   by	  
determining	  the	  cell	  cycle	  profile	  of	  these	  cells	  (Figure	  3.17).	  It	  is	  reported	  that	  ERK1/2	  have	  
a	  crucial	  roles	  in	  cell	  cycle	  progression.	  More	  specifically,	  they	  are	  essential	  for	  progression	  
of	   phases	   G1	   and	   S	   by	   inducing	   positive	  mediators	   involved	   in	   cell	   cycle	   and	   by	   having	   a	  
negative	  effect	  on	  anti-­‐proliferative	  genes	  (Chambard	  et	  al.,	  2007;	  Meloche	  and	  Pouyssegur,	  
2007).	  Furthermore,	  p53	  decreases	  cell	  proliferation	  by	  mediating	  caspase	  cleavage	  of	  ERK2	  
(Marchetti	   et	   al.,	   2004).	   Several	   cancer	   cells	   are	   p53-­‐null	   or	   have	   developed	   specific	  
mutations	   that	   reduce	   its	   activity	   (Table	   2.1).	   This,	   amongst	   other	   things,	   increases	   ERK2	  
thereby	   contributing	   to	  growth	  and	  development	  of	   tumour	   cells.	   The	   reduction	  of	   gp130	  
receptor	  following	  ERK2	  knockdown	  is	  not	  a	  consequence	  of	  the	  influence	  that	  ERK2	  has	  in	  
the	   cell	   cycle,	   as	   starving	   cells	   promotes	   G1	   arrest	   (Figure	   3.18	   A	   and	   B)	   but	   it	   does	   not	  
change	  gp130	  levels	  (Figure	  3.18	  C	  and	  D).	  
	  
In	  addition	  to	  studying	  the	  impact	  of	  ERK2	  depletion	  on	  gp130	  receptor	  expression	  we	  also	  
looked	  at	  a	  number	  of	  other	   receptors.	  We	  observed	   that	  depletion	  of	  ERK2	  also	  effected	  
EGFR	  expression	  (Figure	  3.19).	  However,	  this	  seems	  to	  be	  an	  off-­‐target	  effect	  (Figure	  3.19	  E).	  
FGFR1	  and	  FGFR2	  expression	  levels	  are	  reduced	  when	  ERK1	  is	  downregulated	  (Figure	  3.19),	  
suggesting	  that	  ERK1	  can	  also	  regulate	  expression	  of	  receptors.	  ERK2	  had	  the	  opposite	  effect	  
by	  up-­‐regulating	  FGFR1	  and	  FGFR2.	  Mutations	  on	  FGFRs	  can	  increase	  their	  function	  and	  they	  
are	  often	  amplified,	  mutated	  or	  deregulated	  in	  cancer	  [reviewed	  in	  (Kelleher	  et	  al.,	  2013)].	  
Further	   investigation	   of	   how	   ERK1	   regulate	   the	   expression	   of	   these	   receptors	   is	   thus	  
important	  as	  it	  may	  eventually	  lead	  to	  novel	  cancer	  therapies.	  	  
	  
We	  also	  analysed	   the	  expression	  of	  other	   receptors	   involved	   in	   IL-­‐6	   signalling	   in	  cells	  with	  
silenced	   ERK2.	   The	   levels	   of	   OSMR	   decrease	   while	   the	   levels	   of	   LIFR	   increase	   after	  
transfection	  with	  siERK2	  (Figure	  3.9).	  Cross-­‐regulation	  among	  receptors	  is	  well	  known.	  More	  
specifically,	  cytokines	  such	  IL-­‐1	  and	  TNF-­‐α	  decrease	  IL-­‐6	  signalling	  by	  inducing	  internalization	  
and	   degradation	   of	   gp130	   (Radtke	   et	   al.,	   2010).	   This	   suggests	   that	   interfering	   with	   one	  
receptor	   expression	   and/or	   activation	   can	   impact	   the	   expression	   of	   others.	   IL-­‐6	   receptors	  
also	  cross-­‐talk	  with	  toll-­‐like	  receptors	  in	  inflammation-­‐associated	  diseased,	  which	  includes	  a	  
3.	  Characterisation	  of	  signalling	  downstream	  of	  IL-­‐6	  type	  cytokines	  	  
upon	  the	  silencing	  of	  ERK1	  or	  ERK2	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variety	   of	   cancers	   [reviewed	   in	   (Mansell	   and	   Jenkins,	   2013)],	   IFN-­‐α,	   IFN-­‐β	   (Mitani	   et	   al.,	  
2001)	  and	  with	  IFN-­‐γ	  (Qi	  et	  al.,	  2013).	  	  
	  
In	  summary,	  we	  have	  shown	  that	  ERK2	  controls	  the	  expression	  of	  gp130	  mRNA	  and	  possibly	  
other	   molecules.	   This	   regulation	   occurs	   in	   human	   cancer	   and	   non-­‐cancer	   cells,	   and	   it	  
remains	  unclear	  whether	  is	  also	  occurs	  in	  cells	  from	  other	  species.	  This	  regulation	  does	  not	  
seem	   to	   involve	   the	  kinase	  activity	  of	   ERK2	  and	   is	  not	  dependent	  on	   the	   cell	   cycle.	   In	   the	  
next	  chapter,	  the	  impact	  of	  ERK2	  depletion	  on	  responses	  that	  occur	  at	  the	  chromatin	  level	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4.1.	  Introduction	  
In	  the	  previous	  chapter	  we	  showed	  that	  ERK2	  regulated	  the	  expression	  of	  gp130.	  Chemical	  
inhibition	  of	  ERK2	  kinase	  activity	  did	  not	  change	  the	   levels	  of	   this	   receptor,	   indicating	  that	  
ERK2	  regulated	  gp130	  by	  a	  mechanism	  that	  was	  independent	  of	  its	  enzymatic	  activity.	  	  
	  
Several	  roles	  have	  been	  described	  for	  ERK2	  that	  do	  not	  involve	  its	  kinase	  activity	  [reviewed	  
in	   (Rodriguez	  and	  Crespo,	  2011)],	  many	  of	  which	  have	  been	  discussed	   in	  the	   Introduction.	  
For	  example,	  ERK2	  can	  bind	  to	  the	  promoter	  of	  transcripts	  that	  are	  induced	  by	  the	  IFNs,	  to	  a	  
consensus	  DNA	  sequence	  defined	  as	  C/GAAAG/C,	  and	  this	  can	  result	  in	  the	  inhibition	  of	  their	  
expression	  (Hu	  et	  al.,	  2009).	  PARP	  proteins	  are	  key	  sensors	  of	  DNA	  single	  strand	  breaks	  and	  
are	   involved	   in	   repairing	   the	   DNA.	   They	   are	   also	   involved	   in	   chromatin	   remodelling	   and,	  
thus,	   in	   gene	   transcription.	   They	   catalyse	   a	   post-­‐translational	   modification	   on	   nuclear	  
proteins	   called	   poly(ADP-­‐ribosylation)	   that	   is	   important	   for	   the	   binding	   of	   these	   nuclear	  
proteins	   to	   the	  DNA.	  Phosphorylated	  ERK2	  can	  activate	  PARP1	   independently	  of	   its	  kinase	  
activity	  by	  binding	  though	  CD	  domain	  of	  ERK2	  (Rodriguez	  and	  Crespo,	  2011).	  ELK1	  controls	  
the	  expression	  of	  different	  transcription	  factors	  and,	  therefore,	  it	  has	  different	  cellular	  roles.	  
Like	  PARP1,	  ELK1	  can	  also	  interact	  with	  the	  CD	  domain	  of	  ERK2,	  which	  leads	  to	  an	  increase	  in	  
the	   expression	   of	   ELK1	   transcription	   factors	   such	   as	   c-­‐FOS	   (Cohen-­‐Armon	   et	   al.,	   2007).	  
Recently,	   it	   was	   shown	   that	   both	   ERK2	   and	   ELK1	   chromatin	   binding	   sites	   matched	   in	   a	  
genome-­‐wide	   analysis	   carried	   out	   in	   human	   embryonic	   stem	   cells	   (hESCs).	  When	   ERK2	   is	  
absent	  from	  ELK1-­‐bound	  promoters,	  the	  expression	  of	  those	  genes	  is	  repressed	  by	  polycomb	  
proteins	   that	  are	  also	  recruited	  by	  ELK1.	  When	  cells	  are	   treated	  with	  MAPK	   inhibitors,	   the	  
binding	  of	  both	  ERK2	  and	  ELK1	  to	  ELK1-­‐bound	  promoters	  decreases,	  suggesting	  that,	  in	  this	  
case,	  kinase	  activity	  contributes	  to	  such	  co-­‐occupancy	  and	  to	  the	  regulation	  of	  those	  target	  
genes,	  many	  of	  which	   are	   involved	   in	  metabolic	   regulations	   (Goke	   et	   al.,	   2013).	   ERK2	   can	  
also	  bind	  promoters	   in	  the	  absence	  of	  ELK1	  and	   in	  this	  case,	  many	  of	  the	  target	  genes	  are	  
pluripotency	  genes	  and	  genes	   involved	   in	  chromatin	  remodelling	  and	  transcription.	   In	  fact,	  
under	  stress	  conditions,	  ERK2	  can	  influence	  the	  phosphorylation	  of	  RNAP	  II	  on	  S5	  (Bonnet	  et	  
al.,	  1999).	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We	   observed	   that	  MEK	   inhibitors	   did	   not	   alter	   gp130	   expression	   levels.	   Therefore,	   either	  
ERK2	  activity/phosphorylation	  is	  not	  important	  for	  this	  regulation,	  or	  the	  inhibitors	  used	  had	  
an	  effect	  on	  both	  ERK2	  and	  on	  the	  repressors/repressor	  recruiters	  that	  co-­‐occupy	  promoters	  
with	   ERK2.	   The	   aim	  of	   this	   chapter	  was	   to	   further	   explore	   the	  mechanism	  by	  which	   ERK2	  
regulated	  gp130	  expression	  and,	  possibly,	  other	  receptor	  molecules.	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4.2.	  Results	  
4.2.1.	  ERK2	  bound	  to	  the	  GP130	  promoter	  
As	  enzymatic	   inhibition	  of	  ERKs	  did	  not	   lead	   to	  a	  decrease	   in	  gp130	  protein	  expression	  or	  
mRNA	  induction,	  we	  postulated	  that	  ERK2	  might	  instead	  bind	  to	  the	  GP130	  promoter	  and/or	  
somewhere	  else	  on	  the	  gene	  to	  influence	  its	  expression.	  In	  order	  to	  address	  this	  question	  we	  
performed	  ChIPs	   in	  U2OS	  cells	  with	  an	  anti-­‐ERK2	  antibody,	   followed	  by	  DNA	  amplification	  
using	  different	  primer	  pairs	  that	  were	  specific	  to	  the	  GP130	  gene	  (Figure	  4.1	  A	  and	  B).	  We	  
used	  six	  primer	  sets:	  three	  that	  bound	  the	  DNA	  within	  the	  promoter,	  denoted	  by	  p1,	  p2	  and	  
p3,	  and	  three	  that	  bound	  in	  other	  regions	  of	  the	  gp130	  gene,	  denoted	  by	  g1,	  g2	  and	  g3.	  As	  a	  
negative	   control	   we	   amplified	   a	   non-­‐specific	   (NS)	   region	   of	   chromosome	   5,	   which	   is	   the	  
chromosome	  where	  the	  GP130	  gene	  is	  located,	  and	  we	  used	  IgG	  as	  a	  non-­‐specific	  antibody	  
to	  give	  an	  impression	  of	  the	  background	  binding	  (represented	  by	  dashed	  lines	  in	  the	  graphs).	  
Additionally,	  as	  positive	  controls,	  we	  ChIPed	  RNAP	  II	  (Figure	  4.1	  C)	  and	  acetylated	  histone	  H3	  
(Figure	  4.1	  D).	  	  
	  
ERK2,	  RNAP	   II	   and	  acetylated	  histone	  H3	  bound	   to	   the	  GP130	  promoter	   in	  untreated	  cells	  
and	   this	   was	   detected	   using	   three	   primer	   sets	   that	   bind	   to	   different	   places	   within	   the	  
promoter.	  Under	  the	  conditions	  of	  this	  study,	  none	  of	  the	  three	  proteins	  bound	  significantly	  
outside	  the	  promoter	  or	  to	  the	  NS	  region.	  This	  suggested	  that	  ERK2	  might	  be	  necessary	  for	  
at	   least	   full	   transcription	   of	   the	   gene	   either	   by	   remodelling	   the	   chromatin,	   thereby	  
facilitating	  the	  access	  of	  transcription	  factors	  to	  the	  promoter,	  or	  by	  preventing	  transcription	  
repressors	   to	   bind.	   It	   was	   also	   possible	   that	   ERK2	   interacted	   with	   the	   transcription	  
machinery	  itself,	  or	  interfered	  with	  the	  RNA	  maturation	  process.	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Figure	   4.1	   –	   ERK2	  binds	   to	  GP130	  promoter.	  A.	  Representation	  of	   the	  GP130	  promoter	  and	  gene,	  
and	   approximate	   position	   of	   six	   primer	   pairs	   used	   for	   ChIP:	   p1-­‐3,	   in	   or	   near	   the	   promoter;	   g1-­‐3,	  
places	   along	   the	   GP130	   gene;	   TSS,	   transcription	   starting	   site;	   NS,	   non-­‐specific	   location	   within	  
chromosome	  5.	  B-­‐D.	  Untreated	  U2OS	  cells	  were	  fixed	  and	  washed.	  Cell	  nuclei	  were	  isolated	  and	  the	  
DNA	  sonicated.	  Fragmented	  chromatin	  was	  then	  probed	  for	  the	  binding	  of	  (B.)	  ERK2,	  (C.)	  RNAP	  II	  and	  
(D.)	   acetylated	   histone	  H3.	   IgG	   antibodies	   (dashed	   lines)	  were	   used	   to	   assed	   background	   binding.	  
qPCR	   analysis	   was	   performed	   using	   the	   indicated	   primer	   set.	   Data	   are	   representative	   of	   three	  
biological	  repeats	  each	  using	  duplicate	  samples.	  Statistical	  analysis	  was	  done	  using	  SEM	  and	  Student	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Figure	  4.1	  –	  ERK2	  binds	  to	  GP130	  promoter	  (continued	  from	  previous	  page).	  E.	  Representation	  of	  
the	  areas	  amplified	  by	  primers	  in	  the	  ChIP	  experiment	  [Taken	  from	  (Bonito	  et	  al.,	  2013)].	  
	  
	  







CTTTGCATCACACCTGTTATCTCAGCACTTTGGGAGGCCACTAAGGCCGG AGGATCGTTTGTTGCCAGCAGTTCAAGACCAGCCGGGTCAGCATACCAAA -1501 
ATCTTGTCTCTCCAAAAATTTTAAAAATTGGCCAGGTATTGTAGGGGCAC CTGTAGTCTGAGATACTTGGGAGGTTGAGGTGGGAGGATCGCTAGAGCCC 
AGGAATTTGAACGTGCGGTGAGCATGATCCAGCCACTGCACTCCAGCCTG GGTGACAGAGTGAGACTGTGAACAACAACAAAAAAATCAAGTTTCCTGGA 
TCTATACAAAATTTTCAATTTAACAAATTTTTATAAAAATTTGTTTTAAA ATAAACACCCCTCTAAATGGCAAAGCTAGAACAGAATCTGGTCACAATCT  
                                                                       
ATAGGTTAGATATAGGATGACAGGGAGGAGCAAGAGCTGAACACATCAGC TGCAGCACCATCTACTTTGCCTGCGACTCCGTTAGCAGGCCCACTTTGCC 
CTTTTATAAATTATCTGATCAACAACTAAGAGATTAAAATTCGATCTATG TTTTACTCTATCTGAATCCTCAATATAATGAAGAACTTTATAATTGTTAA -1001 
TTTATGGATATAATTTAAGTTCATTAAACCATTATTTCCTTCCTATATCC TCTCATTCTTCCACAAAAACCTCTACCTTTGGGTGTTTACTTTTACAGAC 
ACCCACGCACACACCCCACACGCACGCACGCACATGCCTTATCTTTTAAC TCAAGATTCTCATCTTCCTTTGGGGAGAAACAAACATCATGAGCCTTGAG 
                                                                               
GTCCATTTTCTGAGGGAAAGGGGGGGGCGGAGGCGGGATGAATAGGTTTT TACCCGGTATTTTTTATCATAAACGGGGAGGTACAAACCGCAAAGAAACA  
                                                                                             
CTAGTCGCTTGGTGGGCCACCACCTCTGGGGCTCACTGATCAATCGCACC CAAACTCATTTACTAATTTAAAAAAGTACTGTGGCAAGGCTCGTTTACGT 
                                                                                  β        β 
AAGTCTTGGAGAGAAGCCGCCGCCACAATCTGCCGCAGTCTCGTGCGGAG TCACGGCCACCGAGCTCTTCACTTTCCCCAAGAGGCTCCCACGCCTTCCC -501  
 
CATCCCCAAGGGAGCTAGGCGGTCCCTCGCGGCTCTGAGTCCCTCGGGGA AGGCCGCGAAGAGAGGCCGCAGGCGCCCTGGCGAGAAGGGAGGGCGGGGG  
                                                                                              
CAGCGGGCGGCGGGCAGCACCCGGGCTCCAGTTCATGACCCCGTTATTCC ACAGAAAAATGGAACATTCCGCTCTTTCCGCCCACAGAGGGGAGGTGGGG  
     
GGAACCCTTCGATCTAGTCTGGGAGAGGCGACGCGGACGCAGCCACCGGA ATCCGGGACGCGAAGAGCCGCGTTACGGGAATCGCTACCCCTCGGAGTCC 
                   
CGCCCCCTCGTCGACAGGCGGCCACTGGACCAATGCCTGGGCGCAAAGGG TCTCTCAGGGGCCAATCAGCGCCTAGGTCCCGGTAGGGGGCGGGGCGCAG 
   
CGTTGGCCGGCCGGGGGCGCAGCTGGGCGGGATTGGGGAGCGCCCCGCCC CGCCGCGGGACTGGGGTGGCGCGCTACCTCTGCGGAGAAGGATCTGACAG -1  





CCAGGCGCACGCACGCACCCCTCTTAACGCCCGCCCCGCAGAACGCCCTT CAAGAACAAACCCCCCTTTTTGTTACCAGATCCCACGTTTTTCCCAATCC +500 
CCTTTTCATCTCCCCTGAAATTCTATTCGCTCCGCACTTGTCTTCATTCT CGAGGTGGATTTCCCTTCCCCAAAGCCGTTTTTTCATCTTGAAATCGTAA 
CGTTTCAGCTTTGTTGAAAGTTCACAATGCTTATAAACACTATTAACGTT TCTTTCCTTCTTTTGATCTTTTCTATTAATAATTATCATTCCTAACGAAT 
TCCACATCTCACTGTATCCCAAGGAGAACAAATCAGTTTTTAAAATTTTA CCTCCTCCGACCTAAACTTTTGAAGATAGTGCAGGAAGCAAGGGTCTGTT  
… [2kb] 
CACTGACAGCAAAGATGTTTGAAGTGGGGGGAAATTCCATATAAGAGATG ATACTTCAAAAGCAGTTTGTAGTGCACAGCAGAGTCAGGAAAGACATTGG 
















TATAGAGTATAGAGAAATATAAGAGTCCAACCTTTGCTGCTGATTAGTTA TATGTTCTCTGTACCTCATCCTTCACATGAGAAAATAGTTTCCTAGAGCA +40500 
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4.2.2.	  ERK2	  was	  not	  required	  for	  the	  binding	  of	  RNAP	  II	  binding	  to	  the	  GP130	  promoter	  	  
Having	   observed	   that	   endogenous	   ERK2	   bound	   to	   the	   GP130	   promoter,	   we	   next	   asked	  
whether	   ERK2	   was	   necessary	   to	   mediate	   maximal	   binding	   of	   RNAP	   II	   to	   the	   promoter,	  
thereby	  enabling	  the	  activation	  of	  GP130	  gene	  expression.	  	  
	  
U2OS	   cells	  were	   transfected	  with	   siRNA	   against	   ERK2,	   ERK1	   and	  with	   the	  NS	   transfection	  
control.	   After	   48	  h,	   ChIP	  was	  performed	   for	  RNAP	   II,	   as	   previously	   described.	  As	   controls,	  
ERK2	   and	   acetylated	   histone	   H3	   were	   also	   immunoprecipitated	   and	   amplified.	   For	   this	  
purpose,	  three	  qPCR	  primer	  pair	  sets	  were	  used:	  one	  that	  bound	  within	  the	  GP130	  promoter	  
near	  the	  TSS	  (p3),	  another	  that	  bound	  within	  the	  GP130	  gene	  but	  outside	  the	  promoter	  (g2)	  
and	  one	  designed	  to	  an	  unrelated	  region	  within	  chromosome	  5	  (NS)	  (Figure	  4.2	  A).	  
	  
The	  binding	  of	  ERK2	  to	  the	  GP130	  promoter	  was	  much	  reduced	  in	  cells	  with	  silenced	  ERK2,	  
confirming	  the	  specificity	  of	  this	  antibody	  (Figure	  4.2	  B).	  To	  our	  surprise,	  ERK2	  binding	  was	  
also	  affected	  by	  downregulating	  ERK1	  and,	  although	  this	  was	  statistically	  significant,	  we	  are	  
unsure	  of	  the	  biological	  relevance	  of	  it,	  as	  ERK1	  knockdown	  did	  not	  impair	  gp130	  expression	  
(Figure	  3.8	  A-­‐C).	   It	  may,	  however,	  explain	  why	  the	   induction	  of	  gp130	  mRNA	  was	  reduced	  
after	   ERK1	   silencing	   (Figure	   3.8	   D).	   Surprisingly,	   RNAP	   II	  was	   equally	  well	   recruited	   to	   the	  
GP130	  promoter	  regardless	  of	  ERK2	  expression	  levels	  (Figure	  4.2	  C).	  This	  would	  suggest	  that	  
lack	  of	  ERK2	  did	  not	   interfere	  with	  chromatin	  remodelling	  processes	  necessary	   for	  RNAP	   II	  
binding	   to	   the	   DNA.	   This	   was	   odd	   as	   there	   seemed	   to	   be	   a	   reduction	   in	   the	   level	   of	  
acetylated	  histone	  H3	  at	  the	  GP130	  promoter,	  suggesting	  that	  the	  promoter	  was	  less	  active	  
(Figure	  4.2	  D).	  Accordingly,	  we	  explored	  the	  possibility	  that	  despite	  binding	  normally	  to	  the	  
promoter,	   RNAP	   II	   was	   somehow	   not	   fully	   activated,	   thereby	   impairing	   transcription	   of	  
GP130.	  For	   that	  purpose,	  we	  next	   investigated	  the	  phosphorylation	  of	  RNAP	   II	  on	   two	  key	  
serine	  residues,	  namely	  S5	  and	  S2	  (Figure	  4.3).	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Figure	   4.2	   –	   ERK2	   knockdown	   does	   not	   have	   an	   impact	   on	   RNAP	   II	   binding	   to	   the	   promoter.	   A.	  
Representation	  of	  the	  GP130	  promoter	  and	  gene	  illustrating	  the	  approximate	  position	  of	  two	  primer	  
pairs	   used	   for	   immunoprecipitating	   the	   chromatin.	   B-­‐D.	  U2OS	   cells	  were	   transfected	   as	   described	  
before	  with	  siNS,	  siERK1	  and	  siERK2	  for	  48	  h.	  ChIP	  was	  performed	  as	  before	  and	  the	  chromatin	  was	  
probed	  for	  (B.)	  ERK2,	  (C.)	  RNAP	  II	  and	  (D.)	  acetylated	  histone	  H3.	  Immunoprecipitations	  with	  IgG	  are	  
represented	   by	   the	   dashed	   lines.	   Data	   are	   representative	   of	   three	   biological	   repeats,	   each	   with	  
duplicate	  samples,	  and	  which	  have	  yielded	  identical	  results.	  Statistical	  analysis	  was	  done	  using	  SEM	  
and	  Student	  t-­‐test	  (*	  -­‐	  P<0.05,	  **	  -­‐	  P<0.01	  and	  ***	  -­‐	  P<0.005	  versus	  NS	  primer	  pair).	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4.2.3.	  Binding	  of	  RNAP	  II	  did	  not	  require	  ERK2	  but	  its	  activation	  did	  
Although	  it	  would	  appear	  that	  the	  GP130	  gene	  is	  less	  active	  in	  the	  absence	  of	  ERK2	  judging	  
by	  the	  decrease	  of	  histone	  H3	  acetylation	  at	  the	  promoter,	  RNAP	  II	  was	  still	  recruited	  to	  the	  
promoter	   to	   the	   same	   extent	   as	   it	   was	   in	   cells	   that	   express	   ‘normal’	   ERK2	   levels.	   It	   was	  
possible,	   however,	   that	   RNAP	   II	  was	   fully	   activated	   or	   that,	   for	   some	   reason,	   it	   stalled	   at	  
some	  stage	  during	  transcription.	  
	  
U2OS	   cells	  were	   transfected	  with	   siRNA	   against	   ERK2,	   ERK1	   and	  with	   a	  NS	   siRNA	   control.	  
After	   48	   h,	   RNA	   samples	   were	   subjected	   to	   ChIP.	   Anti-­‐pRNAP	   II-­‐S5	   and	   anti-­‐pRNAP	   II-­‐S2	  
antibodies	   were	   used	   to	   immunoprecipitate	   RNAP	   II.	   The	   DNA	   bound	   to	   it	   was	   amplified	  
using	  primers	  to	  a	  region	  near	  the	  TSS	  within	  the	  GP130	  promoter	  (p3),	   to	  a	  region	  of	  the	  
gene	  that	  did	  not	   localise	   to	   the	  promoter	   (g2)	  and	  using	  a	   third	  set	   that	  hybridised	  to	  an	  
unrelated	  region	  in	  chromosome	  5	  (Figure	  4.3).	  
	  
The	   cartoon	   in	   Figure	   4.3	   A	   depicts	   the	   primer	   pairs	   used	   and	   their	   location	   within	   the	  
GP130	  and	  Figure	  4.3	  B	  the	  typical	  behaviour	  of	  pRNAP	  II-­‐S5	  and	  pRNAP	  II-­‐S2	  along	  genes:	  
phosphorylation	  on	  S5	  is	  mainly	  present	  on	  RNAP	  II	  molecules	  bound	  to	  the	  gene	  promoter,	  
while	  S2	  phosphorylation	   increases	  after	   the	  TSS	  and	   this	   is	  maintained	  as	  RNAP	   II	   ‘walks’	  
along	   the	   gene.	   Indeed,	   cells	   transfected	   with	   siNS,	   or	   siERK1,	   showed	   greatly	   increased	  
pRNAP	  II-­‐S5	  only	  at	  the	  promoter	  (Figure	  4.3	  C)	  and	  increased	  pRNAP	  II-­‐S2	  only	  within	  the	  
gene,	  outside	  the	  promoter	  region	  (Figure	  4.3	  D).	   In	  contrast,	  cells	  transfected	  with	  siERK2	  
had	  greatly	  reduced	  phosphorylation	  of	  RNAP	  II	  on	  S5	  and,	  predictably,	  on	  S2.	  Reducing	  the	  
expression	   of	   ERK2	   led	   to	   a	   decrease	   in	   histone	   H3	   acetylation	   (Figure	   4.2	   D)	   and	   in	  
phosphorylation	  of	  RNAP	  II	  on	  serine	  residues	  5	  and	  2	  	  (Figure	  4.3	  C	  and	  D).	  The	  data	  were	  
consistent	  with	  there	  being	  defective	  activation	  of	  RNAP	  II	  and	  it	  was	  a	  likely	  explanation	  as	  
to	   why	   GP130	   gene	   expression	   decreased,	   even	   though	   RNAP	   II	   bound	   to	   the	   GP130	  
promoter	  to	  the	  same	  extent	  as	  it	  did	  in	  cells	  transfected	  with	  a	  NS	  control,	  or	  with	  siERK1	  
(Figure	  4.2	  C).	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Figure	  4.3	  –	  ERK2	  knockdown	  decreases	  the	  phosphorylation	  of	  RNAP	  II	  on	  both	  S5	  and	  S2	  sites.	  A.	  
Representation	  of	  the	  GP130	  gene,	  illustrating	  the	  approximate	  position	  of	  two	  primer	  pairs	  used	  in	  
ChIP	   experiments	   B.	  RNAP	   II	   phosphorylation	   status	   during	   the	   transcription	   cycle.	   [Adapted	   from	  
(Brookes,	  et	  al.	  2009)].	   C-­‐D.	  U2OS	  cells	  were	  transfected	  as	  described	  before	  with	  siNS,	  siERK1	  and	  
siERK2	  for	  48	  h.	  After	  ChIP,	  the	  chromatin	  was	  probed	  for	  (C.)	  pRNAP	  II-­‐S5,	  or	  (D.)	  pRNAP	  II-­‐S2.	  Either	  
IgG	  or	  IGM	  (dashed	  lines)	  were	  used	  to	  assess	  background	  binding.	  Data	  are	  representative	  of	  three	  
biological	  repeats	  each	  using	  duplicates	  samples.	  Statistical	  analysis	  was	  done	  using	  SEM	  and	  Student	  
t-­‐test	  (*	  -­‐	  P<0.05,	  **	  -­‐	  P<0.01	  and	  ***	  -­‐	  P<0.005	  versus	  NS	  primer	  pair).	  	  
	  













































































4.	  ERK2	  controls	  GP130	  expression	  
	  
	   140	  
	  
4.2.4.	   ERK2	   regulated	  GP130	   transcription	  but	  not	  by	  binding	   to	  GATE	   sequences	  within	  
the	  GP130	  promoter	  	  
ERK2	   knockdown	   did	   not	   influence	   RNAP	   II	   binding	   to	   GP130	   promoter.	   However,	   the	  
reduction	  in	  ERK2	  levels	  decreased	  the	  activation	  of	  RNAP	  II.	  This	  was	  manifested	  by	  the	  fact	  
that	   RNAP	   II	  was	   less	   phosphorylated	   on	   S5	   and	   S2.	  We	   sought	   to	   analyse	  whether	   ERK2	  
bound	  directly	   to	   the	  DNA	   through	   its	  DNA	  binding	  domain,	  or	  whether	   it	   interacted	  with	  
the	  transcriptional	  machinery,	  perhaps	  indirectly	  affecting	  transcription	  of	  GP130.	  ERK2	  can	  
associate	   with	   to	   the	   DNA	   by	   binding	   to	   the	   sequence	   G/CAAAG/C,	   named	   GATE.	   GATE	  
elements	   are	   usually	   located	   around	   100	   bp	   from	   the	   TSS	   (Hu	   et	   al	   2009).	   Figure	   4.4	  
represents	   schematically	   the	   GP130	   promoter	   where	   GATE	   and	   GATE-­‐like	   sequences	   are	  
highlighted	   in	   pink.	   To	   understand	   whether	   ERK	   bound	   to	   any	   of	   these	   sequences,	   we	  
obtained	   a	   full-­‐length	   wild-­‐type	   GP130	   promoter	   luciferase	   construct	   (p2433)	   from	   Dr	  
Charles	  A.	  O’Brien	  (University	  of	  Arkansas	  for	  Medical	  Sciences,	  Little	  Rock,	  USA),	  which	  we	  
subsequently	   mutated.	   These	   mutations	   included	   single	   and	   combined	   mutations	   from	  
CAAAG	   to	   CACAG	   and	  were	   denoted	   by	   GATE	   (mutation	   of	   the	   GATE	   element	  within	   the	  
promoter)	   and	  mutations	   of	   each	   GATE-­‐like	   element	   denoted	   by	   control	   (crt)	   1,	   crt2	   and	  
crt3.	  If	  any	  of	  these	  sequences	  was	  crucial	  to	  the	  binding	  of	  ERK2	  to	  the	  promoter,	  then	  we	  
would	  expect	   the	  mutated	  plasmids	  to	  have	  a	  reduced	  expression	  rate	  when	  compared	  to	  
the	  wild-­‐type	  construct,	  and	  that	  this	  could	  not	  be	  further	  reduced	  upon	  ERK2	  knockdown.	  	  
	  
U2OS	  cells	  transfected	  with	  siERK2,	  siNS	  or	  left	  untransfected	  for	  24	  h	  were	  subsequently	  re-­‐
transfected	  with	  different	  gp130	  DNA	  plasmids	  for	  another	  24	  h	  and	  then	  the	  extracts	  used	  
for	  Dual	  Glo®	  luciferase	  assays,	  according	  to	  the	  manufacturer’s	  instructions	  (Figure	  4.5).	  
	  
GP130	  promoter	  luciferase	  assay	  using	  the	  full-­‐length	  construct	  (p2433)	  showed	  that	  gp130	  
expression	  is	  highly	  impaired	  upon	  ERK2	  knockdown	  (Figure	  4.5	  A),	  which	  corroborates	  the	  
ChIP	  data	  shown	  in	  Figure	  4.2	  B.	  Mutations	  of	  the	  GATE	  sequence	  did	  not	  influence	  how	  the	  
GP130	  promoter	  was	  driven	  and	  siERK2	  impaired	  its	  transcription	  the	  same	  way	  as	  it	  did	  for	  
wild-­‐type	   gp130	   (Figure	   4.5	   A).	   This	   indicated	   that	   this	   sequence	   was	   not	   necessary	   for	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ERK2-­‐mediated	   regulation	  of	  GP130.	  Mutation	  of	  other	  GATE-­‐like	   sequences,	  namely	   crt1,	  
ctr2	  and	  ctr3,	  which	  are	   indicated	   in	  Figure	  4.4,	   reduced	  the	  transcription	  of	  gp130.	  Single	  
(Figure	   4.5	   B),	   or	   combined	   (Figure	   4.5	   C)	   mutations	   were	   tested	   in	   cells	   previously	  
transfected	  with	   either	   siNS,	   siERK2	   or	   in	   cells	   that	  were	   left	   untransfected.	   All	   the	   three	  
single	  mutations	   (crt1,	  ctr2,	  ctr3)	  decreased	  the	  expression	  of	   the	  promoter	  by	  about	  50%	  
(Figure	   4.5	   B).	   One	   possibility	   was	   that	   ERK2	   was	   binding	   to	   all	   of	   the	   three	   GATE-­‐like	  
sequences	   and,	   consequently,	   a	   single	   mutation	   caused	   only	   a	   partial	   decrease	   in	  
transcription.	   In	  this	  case,	  ERK2	  could	  still	  bind	  to	  the	  other	  two	  sites	  and,	  therefore,	  RNAi	  
against	   ERK2	   would	   still	   lead	   to	   a	   further	   decrease	   in	   the	   promoter	   expression	   rate.	  
Alternatively,	   the	   decrease	   in	   expression	   that	   was	   observed	   might	   have	   been	   totally	  
unrelated	   to	   ERK2	   binding.	   To	   test	   this,	   we	   performed	   combined	   mutations	   (crt1/ctr2,	  
crt2/ctr3,	   crt1/ctr3	  and	  crt1/ctr2/ctr3)	   and	   followed	   the	   same	  experimental	  protocol	   as	   in	  
Figure	   4.5	   B.	   As	   shown	   in	   Figure	   4.5	   C	   combined	  mutations	   of	   two	   GATE-­‐like	   sequences	  
(ctr1/ctr2;	   ctr2/ctr3;	   ctr1/ctr3)	   did	   not	   have	   a	   significant	   impact	   on	   the	   expression	   rate,	  
indicating	   that	   ERK2	   was	   either	   not	   dependent	   on	   those	   sites	   in	   order	   to	   regulate	   the	  
expression,	  or	   that	   it	  only	  needed	  one	  site.	  This	  was	  not	   the	  case	  as	  mutation	  of	  all	   three	  
GATE-­‐like	  sequences	  (ctr1/ctr2/ctr3)	  actually	  led	  to	  an	  increase	  on	  the	  transcription	  of	  gp130	  
and	  RNAi	  against	  ERK2	  was	  capable	  of	  inhibiting	  GP130	  promoter’s	  full	  expression.	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Figure	  4.4	  –	  Representation	  of	   the	  GP130	  promoter	   sequence	  and	  GP130	  gene.	  Several	  potential	  
binding	   sites	   are	  highlighted	   in	   the	  GP130	  promoter,	   including	   a	  GATE	   sequence	   (pink),	  which	   is	   a	  
potential	  binding	  site	  for	  ERK2,	  CAT	  (green),	  an	  ELK-­‐ERK	  binding	  region	  (turquoise),	  specific	  protein	  
(SP)	   1	   (grey)	   motif,	   STAT	   binding	   element	   (SBE)	   sequence	   (orange)	   and	   acute	   phase	   response	  
element	   (APRE)	  motif	   (yellow).	  Other	  GATE-­‐like	   sequences	   (crt1,	   crt2	   and	   crt3)	   and	   the	  mutations	  
















































































TCGCGCTGGGCCGCCCCGGC GCAGCTGAACCGGGGGCCGC  
ELK-ERK
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Figure	   4.5	   –	   ERK2	   regulates	   GP130	   transcription	   independently	   of	   GATEs.	   U2OS	   cells	   were	  
transfected	   with	   siNS,	   siERK2	   or	   left	   untransfected	   for	   24	   h,	   prior	   to	   co-­‐transfection	   with	   GP130	  
promoter-­‐Firefly	   luciferase,	  or	  with	  CMV	  promoter-­‐Renilla	   luciferase	  constructs.	  The	  data	  obtained	  
for	   Firefly	   luciferase	   activity	   was	   normalized	   to	   that	   of	   Renilla	   luciferase.	   Normalised	   luciferase	  
activity	  for	  each	  sample	  was	  then	  normalized	  to	  cells	  transfected	  with	  the	  siNS	  control	  and	  wild-­‐type	  
GP130	  construct.	  Mutant	  constructs	  are	  represented	  in	  Figure	  4.4.	  The	  mutation	  of	  GATE	  within	  the	  
GP130	  promoter	  does	  not	   inhibit	  the	  transcription	  of	  GP130	  (A.)	  but	   individual	  mutations	  of	  GATE-­‐
like	  elements	  (crt1;	  crt2;	  crt3)	  (B.),	  or	  combined	  mutations	  (crt1/2;	  crt2/3;	  crt1/3	  and	  crt1/2/3)	  (C.)	  
do.	  Data	   are	   representative	   of	   three	   experiments	   yielding	   identical	   results.	   Statistical	   analysis	  was	  
done	   using	   SEM	   and	   Student	   t-­‐test	   (*	   -­‐	   P<0.05,	   **	   -­‐	   P<0.01	   and	   ***	   -­‐	   P<0.005	   versus	   siNS	   WT	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4.2.5.	  ERK2	  decreased	  the	  stability	  of	  gp130	  mRNA	  	  
Our	   data	   clearly	   suggested	   that	   ERK2	   was	   crucial	   for	   maximal	   gp130	   expression	   and	   we	  
wondered	  whether	  this	  was	  only	  due	  to	  a	  decrease	  in	  GP130	  transcription	  or,	  whether	  ERK2	  
was	  also	  necessary	  to	  regulate	  and	  maintain	  gp130	  mRNA	  stability.	  
	  
U2OS	   cells	  were	   transfected	  as	  before	   for	  48	  h	  and	   then	   incubated	  with	   the	   transcription	  
inhibitor	  actinomycin	  D	  (5	  µg/ml)	  for	  the	  times	  indicated	  in	  Figure	  4.6.	  Cells	  were	  collected,	  
RNA	  was	  extracted	  and	  analysed	  by	  qPCR	  as	  described	  before	  (Figure	  4.6	  A).	   Interestingly,	  
reduced	  levels	  of	  ERK2	  led	  to	  a	  reduction	  in	  gp130’s	  mRNA	  half-­‐life.	  Indeed,	  in	  untransfected	  
cells	  or	  cells	  transfected	  with	  the	  siNS	  control,	  the	  half-­‐life	  of	  the	  receptor	  was	  12.5	  h,	  but	  in	  
cells	  transfected	  with	  siERK2	  it	  was	  3	  h.	  There	  are	  three	  mRNA	  maturation	  processes	  that	  are	  
controlled	  by	  the	  transcription	  machinery	  namely	  capping,	  splicing	  and	  polyadenylation,	  all	  
of	  which	  are	  represented	   in	  Figure	  4.6	  B.	  We,	  therefore,	   tested	  the	  hypothesis	  that	   it	  was	  
the	  binding	  of	  ERK2	  to	  the	  promoter	  that	  controlled	  gp130	  mRNA	  maturation.	  	  
	  
	  
4.2.5.1.	  Capping	  	  
The	  phosphorylation	  of	  RNAP	  II	  on	  S5	  triggers	  the	  signal	  that	  leads	  to	  the	  recruitment	  of	  the	  
capping	  machinery.	  As	  this	  phosphorylation	  was	  reduced	  in	  cells	  with	  silenced	  ERK2	  (Figure	  
4.3	  C),	  the	  prediction	  was	  that,	  if	  that	  was	  the	  reason	  why	  gp130	  mRNA	  was	  less	  stable,	  then	  
there	  would	  be	  a	   reduction	   in	   the	   capping	  process	   in	   the	   little	   gp130	  mRNA	   that	  was	   still	  
being	   produced.	  Newly	   synthesised	   RNAP	   II	   transcripts	   get	   a	  m7G	   cap	   added,	  which	   then	  
dictates	   pre-­‐mRNA	   synthesis	   and	   splicing,	   cytoplasmic	   transport	   of	   RNA	   and	   mRNA	  
translation	  and	  stability.	  Antibodies	  against	  this	  modification	  exist	  and	  can	  be	  used	  to	  study	  
capping	  of	  the	  mRNA	  at	  the	  5’	  end	  (http://www.sysy.com/products/cap/index.php)	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Figure	   4.6	   –	   ERK2	   expression	   levels	   have	   an	   impact	   on	   gp130	  mRNA	   stability.	   Forty-­‐eight	  h	  after	  
RNAi	  against	  ERK1	  (E1),	  ERK2	  (E2)	  cells	  were	  treated	  with	  actinomycin	  D	  (5	  µg/ml)	  for	  the	  indicated	  
times.	   Untransfected	   cells	   and	   cells	   transfected	   with	   a	   siNS	   control	   were	   also	   included	   in	   the	  
analyses.	  RNA	  was	  isolated	  and	  analysed	  by	  qPCR	  as	  before.	  Data	  shown	  are	  the	  mean	  gp130	  mRNA	  
for	   each	   time	   point	   relative	   to	   the	   initial	   gp130	  mRNA	   amount	   which	   was	   defined	   as	   100%.	   This	  
experiment	  was	  done	  three	  times	  and	  it	  yielded	  identical	  results.	  Statistical	  analysis	  was	  carried	  using	  
SEM	  and	  Student	  t-­‐test	  (*	  -­‐	  P<0.05,	  **	  -­‐	  P<0.01	  and	  ***	  -­‐	  P<0.005	  versus	  siNS-­‐transfected	  cells).	  B.	  
Co-­‐transcriptional	  RNA	  processing.	  At	  promoters	  of	  active	  genes	  pRNAP	   II-­‐S5	   is	   responsible	   for	   the	  
recruitment	  of	  the	  capping	  machinery	  that	  adds	  m7G	  to	  the	  DNA.	  During	  elongation,	  pRNAP	  II-­‐S2	  is	  
involved	   in	   recruiting	   the	   splicing	   machinery	   and	   polyadenylation	   [Adapted	   from	   (Brookes,	   et	   al	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U2OS	  cells	  were	  transfected	  with	  RNAi	  against	  ERK2,	  ERK1	  and	  with	  a	  NS	  control	   for	  48	  h,	  
after	  which	  time	  RNA	  was	  quantified.	  Two	  µg	  of	  total	  RNA	  were	  used	  per	  condition	  to	  carry	  
out	  immunoprecipitations	  with	  an	  anti-­‐m7G	  antibody	  and	  a	  specific	  RNA	  buffer	  (Figure	  4.7).	  
After	   the	   immunoprecipitations,	   the	   RNA	   was	   isolated	   using	   phenol/chloroform	   and	   the	  
samples	  analysed	  by	  qPCR	  using	  gp130	  primer	  pairs.	  The	  ratios	  between	  gp130	  mRNA	  in	  the	  
input	   and	   m7G-­‐immunoprecipitated	   samples	   remained	   the	   same	   when	   siERK2-­‐trasfected	  
cells	  were	  compared	  to	  untransfected	  or	  siNS-­‐transfected	  cells.	  The	  results	  show	  that	  there	  
was	  no	  difference	   in	  capping	  of	  gp130	  mRNA	   in	  cells	  with	  decreased	  ERK2	  suggesting	   that	  





Figure	  4.7	  –	  ERK2	  knockdown	  does	  not	  affect	  capping	  of	  gp130	  mRNA.	  U2OS	  cells	  were	  transfected	  
as	   before	   with	   siNS,	   siERK1,	   siERK2	   for	   48	   h.	   RNA	   was	   isolated	   as	   before	   and	   2	   µg	   of	   RNA	   were	  
incubated	   in	  a	   specific	  RNA	   immunoprecipitation	  buffer	  with	  an	  antibody	   that	   recognises	   the	  m7G	  
modification.	  The	  immunoprecipitated	  RNA	  was	  then	  washed	  and	  extracted	  using	  phenol-­‐chloroform	  
and	  the	  samples	  were	  analysed	  by	  qPCR	  for	  gp130	  mRNA.	  β-­‐actin	  and	  GAPDH	  were	  used	  as	  house	  
keeping	   genes.	   The	   experiment	   was	   performed	   three	   times,	   yielding	   identical	   results	   each	   time.	  
Statistical	  analysis	  was	  done	  using	  SEM	  and	  Student	  t-­‐test	  (*	  -­‐	  P<0.05,	  **	  -­‐	  P<0.01	  and	  ***	  -­‐	  P<0.005	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4.2.5.2.	  Splicing	  and	  polyadenylation	  	  
The	  phosphorylation	  of	   RNAP	   II	   on	   S2	   is	   responsible	   for	   recruiting	   the	   splicing	  machinery.	  
This	  phosphorylation	  was	  also	  reduced	  upon	  siERK2	  (Figure	  4.3	  C)	  and	  this,	  together	  with	  the	  
data	   in	   the	  previous	  section,	  predict	   that	  gp130	  mRNA	  splicing	  and	  polyadenylation	  would	  
also	  be	  compromised	  in	  ERK2-­‐depleted	  cells.	  
	  
U2OS	   cells	   were	   transfected	   with	   siRNA	   against	   ERK2,	   ERK1	   or	   gp130.	   They	   were	   also	  
transfected	  with	  a	  NS	  control	  siRNA	  or	  left	  untransfected	  for	  48	  h.	  Cells	  were	  lysed	  and	  RNA	  
isolated	  as	  before.	  Two	  splicing	  variants	  of	  gp130	  mRNA	  have	  been	  described	  (Figure	  4.8	  A).	  
In	  order	  to	  determine	  if	  splicing	  was	  affected,	  qPCR	  was	  used	  to	  quantify	  the	  different	  sites	  
represented	  in	  Figure	  4.8	  A,	  some	  of	  which	  correspond	  to	  both	  mature	  and	  immature	  RNA	  
(c.	   d.	   e.)	   and	   one	   that	   corresponds	   exclusively	   to	  mature	   RNA	   (denoted	   in	   the	   picture	   by	  
cDNA)	  and	  which	  is	  the	  region	  that	  was	  used	  to	  quantify	  gp130	  mRNA	  throughout	  this	  study	  
(Figure	   4.8	   B).	   Independently	   of	   which	   primer	   pair	   was	   used,	   the	   proportions	   between	  
immature	  and	  mature	  gp130	  mRNA	  did	  not	  change	  upon	  RNAi,	  suggesting	  that	  splicing	  was	  
unaffected	  by	  ERK2	  silencing	  (Figure	  4.8).	  
	  
To	   assess	   polyadenylation,	   RNA	  was	   converted	   into	   cDNA	  either	   using	   random	  primers	   to	  
amplify	   total	   RNA,	   or	   oligo	   dT	   anchoring	   primers	   to	   select	   for	   mRNA,	   followed	   by	   qPCR	  
analysis	   for	   gp130	   mRNA	   (Figure	   4.9).	   The	   proportions	   between	   the	   control	   siNS-­‐
transfection	  and	  the	  sample	  tested	  were	  analysed	  and,	  as	   for	  the	  splicing,	  polyadenylation	  
did	  not	  seem	  to	  be	  affected	  by	  drastically	  reducing	  the	  expression	   levels	  of	  ERK2,	  as	  there	  
was	  no	  difference	  between	  total	  RNA	  and	  mRNA	  levels	  across	  the	  samples	  (Figure	  4.9).	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Figure	  4.8	  –	  ERK2	  knockdown	  does	  not	  have	  an	  impact	  on	  gp130	  mRNA	  splicing.	  A.	  Representation	  
of	   the	   two	   gene	   transcripts	   that	   can	   be	   generated	   by	   the	   GP130	   gene,	   which	   encode	   two	  mRNA	  
splicing	  variants.	  The	  primer	  sets	  targeting	  different	  places	  on	  these	  transcripts	  are	  denoted	  by	  a.and	  
b.	  (intron);	  c.,	  d.	  or	  e.	  (exon);	  cDNA	  can	  only	  be	  amplified	  in	  cDNA	  sequences	  because,	  as	  depicted,	  it	  
amplifies	  between	  exon	  7	  and	  exon	  8.	  B-­‐D	  U2OS	  cells	  were	  transfected	  with	  siNS,	  siERK1,	  siERK2,	  or	  
sigp130	  for	  48	  h	  and	  RNA	  was	  isolated	  as	  before.	  qPCR	  was	  done	  using	  different	  primer	  sets	  to	  study	  
the	  RNA	  frequency	  at	  specific	  places	  under	  different	  transfected	  conditions.	  Data	  was	  normalized	  to	  
the	  house	  keeping	  genes	  β-­‐actin	  and	  GAPDH.	  The	  experiments	  were	  performed	  three	  times,	  yielding	  
identical	  results.	  Statistical	  analysis	  was	  done	  using	  SEM	  and	  Student	  t-­‐test	  (*	  -­‐	  P<0.05,	  **	  -­‐	  P<0.01	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Figure	  4.9	  –	  Polyadenylation	  of	  gp130	  occurs	  regardless	  of	  ERK2	  expression	  levels.	  U2OS	  cells	  were	  
transfected	   as	   before	   with	   siNS,	   siERK1,	   or	   siERK2	   for	   48	   h	   and	   RNA	   was	   isolated.	   The	   cDNA	  
conversion	  was	  done	  using	  either	  random	  primers	  (total	  RNA)	  or	  dT	  oligonucleotides	  (mRNA	  only)	  as	  
primers.	   The	   results	   were	   then	   analysed	   by	   qPCR	   as	   described	   before.	   The	   experiments	   were	  
performed	  three	  times,	  yielding	  identical	  results.	  Statistical	  analysis	  was	  done	  using	  SEM	  and	  Student	  
t-­‐test	  (*	  -­‐	  P<0.05,	  **	  -­‐	  P<0.01	  and	  ***	  -­‐	  P<0.005	  versus	  the	  same	  transfection	  conditions).	  
	  
	  
4.2.6.	  ELK1	  knockdown	  did	  not	  change	  gp130	  expression	  levels	  
ELK1	  has	  the	  ability	  to	  bind	  to	  certain	  promoters	  repressing	  their	  activity.	  This	  repression	  can	  
be	   reduced	   by	   ERK2	   binding	   to	   the	   complex	   (Goke	   et	   al.,	   2013).	   We	   showed	   that	   ERK2,	  
directly	  or	  indirectly,	  bound	  to	  the	  GP130	  promoter	  (Figure	  4.1)	  and	  that	  in	  its	  absence	  the	  
GP130	  promoter	  activity	  was	  reduced	  (Figure	  4.2	  D,	  Figure	  4.3	  C	  and	  4.3	  D).	  This	  suggested	  
that	  GP130	  promoter	  might	  share	  the	  mechanism	  suggested	  by	  Goke	  et	  al.	  2013.	  The	  levels	  
of	  gp130	  were	  therefore	  analysed	  after	  ELK1	  knockdown.	  We	  have	  also	  analysed	  the	  levels	  
of	   this	   receptor	   after	   silencing	   PARP1	   and	   the	   activator	   protein	   (AP)-­‐1	   complex	   (JUN	   and	  
FOS).	  This	  was	  done	  because	  PARP1	  is	  known	  to	  interact	  with	  ERK2	  and	  the	  AP-­‐1	  complex	  is	  
activated	  by	  IL-­‐6	  type	  cytokines.	  
	  
U2OS	  cells	  were	  transfected	  with	  siERK1,	  siERK2,	  sigp130,	  siELK1,	  siFOS,	  siJUN,	  siPARP	  and	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analysed	  by	  qPCR	  (Figure	  4.10).	  If	  ELK1	  recruited	  repressors	  of	  gene	  expression	  to	  the	  GP130	  
promoter,	   then	   ELK1	   down-­‐regulation	   would	   either	   not	   change	   the	   levels	   of	   gp130	   or	   it	  
would	  increase	  them.	  Accordingly,	  RNAi	  against	  ELK1	  did	  not	  reduce	  gp130	  levels	  and	  when	  
combined	  with	  siERK2	  the	  mRNA	  levels	  of	  gp130	  were	  identical	  to	  those	  in	  cells	  transfected	  
with	   ERK2	   siRNA	   alone	   (Figure	   4.10	   A).	   Figures	   4.10	   B	   and	   C	   confirmed	   the	   effective	  
knockdown	   of	   ERK2	   and	   ELK1.	   Interestingly,	   gp130	   mRNA	   induction	   was	   impaired	   by	  
silencing	   FOS	   or	   PARP1	   (Figure	   4.10	   A)	   and	   ELK1	  was	   significantly	   reduced	   after	   silencing	  
ERK2	  (Figure	  4.10	  B).	  
	  
	  
Figure	   4.10	   –	   ELK1	   does	   not	  modulate	   gp130	  mRNA	   levels.	  U2OS	   cells	  were	   transfected	   as	  
before	  with	  siERK1	   (E1),	   siERK2	   (E2),	   sigp130,	  siERK2	  combined	  with	  ELK1,	  siELK1,	   siFOS,	   siJUN	  and	  
siPARP1	  for	  48	  h.	  RNA	  was	  isolated	  and	  analysed	  by	  qPCR	  as	  previously	  described:	  A.	  gp130.	  B.	  ERK2.	  
C.	   ELK1.	   The	  data	   shows	   the	   fold	   change	  normalized	   to	   the	   corresponding	  NS-­‐transfected	   sample.	  
The	  experiments	  were	  performed	   three	   times	  and	   yielded	   identical	   results.	   Statistical	   analysis	  was	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4.2.7.	  Silencing	  ELK1,	  FOS	  and	  JUN	  decreased	  cell	  growth	  
Similarly	   to	   what	   was	   observed	   for	   ERK1	   and	   ERK2	   in	   the	   previous	   chapter,	   we	   checked	  
whether	  knockdown	  of	  ELK1,	  FOS,	  JUN	  or	  PARP1	  influenced	  cell	  growth	  and	  apoptosis.	  For	  
this	  purpose,	  U2OS	  cells	  were	  transfected	  with	  siRNA	  against	  ELK,	  FOS,	  JUN	  or	  PARP1,	  with	  a	  
NS	  control	  or	  left	  untransfected	  for	  the	  indicated	  times.	  They	  were	  then	  either	  washed	  with	  
PBS	  followed	  by	  fixation	  and	  staining	  with	  crystal	  violet	  in	  0.5%	  (v/v)	  methanol	  (Figure	  4.11	  
A),	  or	  incubated	  with	  Caspase	  Glo®	  3/7	  (Figure	  4.11	  B),	  as	  previously	  described.	  
	  
As	  shown	  in	  Figure	  4.11	  A,	  silencing	  ELK1,	  FOS	  and	  JUN	  reduced	  cell	  growth	  and	  in	  the	  case	  
of	  JUN	  and	  FOS	  this	  was	  accompanied	  by	  an	  increase	  in	  caspase	  activity	  (Figure	  4.11	  B).	  ELK1	  
knockdown,	  however,	  increased	  caspase	  activity	  by	  less	  than	  10%,	  which	  is	  unlikely	  to	  justify	  




Figure	   4.11	   –	   Transfection	   of	   siRNA	   FOS	   JUN	   and	   ELK	   decreases	   cell	   growth.	   U2OS	   cells	   were	  
transfected	  with	  siRNA	  against	  FOS,	  JUN,	  ELK,	  PARP,	  with	  a	  NS	  control	  or	   left	  untransfected.	  A.	  Cell	  
viability	   was	   assessed	   using	   crystal	   violet	   staining	   after	   48	   h	   after	   transfection.	   B.	   Apoptosis	   was	  
measured	   using	   Caspase	  Glo®	   3/7	   reagent	   after	   48h	   of	   transfection,.	   Fluorescence	  was	   quantified	  
and	  values	  obtained	  were	  normalized	  to	  the	  NS	  sample.	  Experiments	  were	  repeated	  three	  times	  and	  
each	  condition	  was	  analysed	  in	  duplicates.	  Statistical	  analysis	  was	  done	  using	  SEM	  and	  Student	  t-­‐test	  
(*	  -­‐	  P<0.05,	  **	  -­‐	  P<0.01,	  ***-­‐P<0.005	  versus	  siNS).	  




























































4.	  ERK2	  controls	  GP130	  expression	  
	  
	   152	  
	  
4.3.	  Discussion	  
ERK2	  can	  have	  a	  role	   in	  transcriptional	  regulation	  and	  in	  chromatin	  remodelling	  by	  directly	  
associating	  with	  the	  DNA	  (Hu	  et	  al.,	  2009),	  or	  by	  binding	  to	  proteins	  such	  as	  PARP1	  (Cohen-­‐
Armon	  et	  al.,	  2007)	  and	  topoisomerase	  II	  (Shapiro	  et	  al.,	  1999).	  Under	  these	  circumstances,	  
ERK2	   must	   be	   phosphorylated,	   even	   though	   its	   kinase	   activity	   is	   not	   necessary	   (Cohen-­‐
Armon	  et	  al.,	  2007;	  Shapiro	  et	  al.,	  1999).	  RNAi	  against	  ERK2	  has	  an	  impact	  on	  gp130	  protein	  
expression	   (Figure	   3.8	   B	   and	  C)	   and	  mRNA	   induction	   (Figure	   3.8	   D),	   indicating	   that	   ERK2	  
regulates	  gp130	  expression,	  perhaps	  by	  binding	   to	   its	  promoter	   (Figure	   4.1	  A	  and	  B).	  This	  
binding	   can	   be	   the	   result	   of	   an	   interaction	   of	   ERK2	   with	   other	   transcription	   factors,	   co-­‐
activators,	  and	  it	  may	  lead	  to	  chromatin	  remodelling	  thus	  facilitating	  transcription	  or	  more	  
directly	  impact	  on	  gp130	  transcription.	  	  
	  
Depletion	  of	  ERK2	  does	  not	  change	  the	  recruitment	  of	  RNAP	  II	  (Figure	  4.2	  C),	  but	  it	  has	  an	  
impact	  on	  RNAP	  II	  activation,	  as	  phosphorylation	  of	  both	  RNAP	  II	  on	  S5	  (Figure	  4.3	  C)	  and	  S2	  
is	  impaired	  (Figure	  4.3	  D).	  The	  acetylation	  of	  histone	  H3,	  an	  indicator	  of	  actively	  expressed	  
genes,	  is	  also	  decrease	  under	  the	  same	  conditions	  (Figure	  4.2	  D).	  	  
	  
In	   unstimulated	   cells,	   the	   presence	   of	   ERK2	   in	   the	   GP130	   promoter	   is	   necessary	   for	   its	  
expression.	   The	   GP130	   promoter	   is	   represented	   in	   Figure	   4.4,	   together	   with	   several	  
predicted	   binding	   sites	   described	   before	   (Goke	   et	   al.,	   2013;	   Hu	   et	   al.,	   2009;	   O'Brien	   and	  
Manolagas,	  1997;	  Odrowaz	  and	  Sharrocks,	  2012).	  	  
	  
Hu	  et	  al	  2009,	  have	  shown	  that	  ERK2	  can	  bind	  to	  promoters	  of	   ISGs,	  genes	   involved	  in	  IFN	  
signalling,	   inhibiting	   the	   promoter	   activity.	   In	   contrast,	   ERK2	   binding	   to	   GP130	   promoter	  
increases	  promoter	  activity	   thus	   increasing	   the	  gp130	  expression.	  These	  authors	  have	  also	  
identified	  a	  DNA	  binding	  site	  sequence	  for	  ERK,	  G/CAAAG/C,	  which	  is	  found	  ~90	  bp	  upstream	  
of	   the	  TSS	   (Hu	  et	  al.,	   2009).	  The	  non-­‐dependence	  on	  MEKK1/ERK	  activity	   is,	  however,	   still	  
questionable,	   as	   other	   authors	   have	   shown	   the	   requirement	   for	   this	   activation	   for	   the	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transcription	  of	  γ-­‐ISGs	  by	  C/EBP-­‐β	  via	  GATE	  elements	  (Roy	  et	  al.,	  2002).	  Nevertheless,	  in	  the	  
sequence	  of	   the	  GP130	  promoter,	   there	   is	   an	  ERK	  binding	   site	  at	  153	  bp	  upstream	  of	  TSS	  
surrounded	  by	  two	  CAT	  boxes	  and	  two	  SP1	  consensus	  sites	  equidistantly	   located	   from	  the	  
ERK	  binding	  site,	  all	  of	  which	  are	  downstream	  SBE	  and	  APRE	  sequences	  (Figure	  4.4).	  Initially,	  
we	  hypothesised	   that	  ERK2	  bound	  to	  a	  GATE	  element,	  which	   is	  an	  ERK2	  DNA	  binding	  site.	  
However,	  we	  mutated	  that	  sequence,	  as	  well	  as	  several	  GATE-­‐like	  sequences	   in	  the	  GP130	  
promoter	  but	  none	  of	  these	  mutations	  affects	  the	  impact	  that	  ERK2	  has	  on	  GP130	  promoter	  
activity	   (Figure	   4.5).	   GP130	   is	   a	   STAT3	   target	   gene	   (Heinrich	   et	   al.,	   2003;	   O'Brien	   and	  
Manolagas,	  1997)	  and	  STAT	  binding	  sites	  are	  often	  located	  in	  close	  proximity	  to	  where	  other	  
transcription	   factors	   bind.	   It	   is,	   therefore,	   possible	   that	   ERK2	   influenced	   interactions	  
between	   different	   transcription	   factors	   involved	   such	   as	   STAT3,	   SP-­‐1,	   AP-­‐1,	   NF-­‐κB	   and/or	  
C/EBP-­‐β.	  The	  concept	  that	  kinases	  can	  associate	  to	  both	  regulatory	  and	  transcription	  regions	  
of	   their	   target	   genes	   is	   increasingly	   accepted	   (Pokholok	   et	   al.,	   2006).	   The	   interaction	  
between	  STAT3	  and	  ERK2	  has	  been	  shown	  in	  the	  cytoplasm	  (Jain	  et	  al.,	  1998)	  suggesting	  that	  
it	  may	   also	   happen	   on	   the	   chromatin.	   However,	   knocking	   down	   STAT3	   does	   not	   have	   an	  
impact	   on	   gp130	   levels	   (Figure	   1.12).	   ERK2	   was	   also	   described	   to	   phosphorylate	   SP-­‐1,	  
thereby	  increasing	  its	  binding	  to	  DNA	  and	  to	  phosphorylate	  AP-­‐1	  proteins	  when	  they	  are	  not	  
bound	  to	  DNA	  (Merchant	  et	  al.,	  1999).	  AP-­‐1	  proteins	  are	  not	  phosphorylated	  when	  bound	  to	  
the	  DNA	  and	  the	  interaction	  with	  ERK2	  under	  these	  conditions	  was	  not	  observed	  (Kumar	  and	  
Bernstein,	  2001).	   In	  addition,	   IFN-­‐γ	   leads	  ERK2	  to	  activate	  C/EBP-­‐β	  at	   the	  DAPK1	  promoter	  
(Gade	  et	  al.,	  2008).	  ERK2	  can	  interact	  and	  phosphorylate	  these	  different	  transcription	  factors	  
involved	   in	   GP130	   regulation.	   Importantly,	   this	   molecule	   has	   also	   been	   shown	   to	  
phosphorylate	  RNAP	  II	  S5	  in	  vitro	  (Bonnet	  et	  al.,	  1999).	  	  
	  
The	   regulation	   of	   GP130	   by	   ERK2	   appears	   to	   be	   independent	   of	   its	   phosphorylation	   and	  
kinase	  activity	   (Figure	   3.10).	   It	   is	   conceivable	   that	  when	  one	  or	  more	   transcription	   factors	  
are	   bound	   to	   the	   DNA	   together	   with	   ERK2	   at	   the	   GP130	   promoter,	   somehow,	   ERK2	  
influences	   the	   interaction	   of	   those	   transcription	   factors	  with	   the	   transcription	  machinery,	  
thereby	  altering	  gene	  expression.	  It	  is	  also	  possible	  that	  one	  or	  more	  downstream	  effectors	  
of	  ERK2	  inhibit	  GP130	  gene	  expression	  in	  the	  absence	  of	  ERK2	  and	  its	  presence	  may	  release	  
that	  repression.	  In	  fact,	  in	  hESC,	  in	  the	  absence	  of	  ERK2,	  ELK1	  is	  recruits	  polycomb	  proteins	  
that	  can	  repress	  gene	  expression	  but	  this	  can	  be	  release	  by	  ERK2	  binding	  (Goke	  et	  al.,	  2013).	  
4.	  ERK2	  controls	  GP130	  expression	  
	  
	   154	  
In	  these	  cells,	  ERK2	  and	  ELK1	  bind	  to	  the	  GP130	  promoter	  suggesting	  that	  the	  regulation	  of	  
GP130	  promoter	  activity	  follows	  the	  same	  pattern	  as	  described	  by	  Goke	  and	  his	  co-­‐workers.	  
The	   inhibition	   of	   this	   pathway	   using	   a	   MEK	   inhibitor	   decreases	   the	   binding	   to	   gene	  
promoters	  of	  both	  ERK2	  and	  ELK1	  (Goke	  et	  al.,	  2013).	  As	  a	  result,	  ELK1	  can	  no	  longer	  recruit	  
repressors,	  which	  explains	  why	  U2OS	  treatment	  with	  MEK	  or	  ERK	  inhibitors	  has	  no	  effect	  on	  
gp130	   expression	   (Figure	   3.10).	   Surprisingly,	   in	  MCF10A	   cells,	   ELK1	   knockdown	   lead	   to	   a	  
reduction	  in	  gp130	  expression	  (Odrowaz	  and	  Sharrocks,	  2012)	  suggesting	  that	  ELK1	  does	  not	  
contribute	   to	  GP130	  promoter	   repression.	   In	  U2OS	   cells,	   reducing	   the	   levels	   of	   ELK1	  does	  
not	  change	  gp130	  levels	  (Figure	  4.10).	  Combined	  knockdown	  of	  ERK2	  and	  ELK1	  phenocopied	  
the	  reduction	   in	  gp130	   levels	   induced	  by	  silencing	  ERK2	   (Figure	   4.10),	  which	  suggests	   that	  
ELK1	  is	  not	  repressing	  GP130	  promoter.	  	  
	  
However,	  contrary	  to	  what	  was	  observed	  by	  Goke	  and	  colleagues	  in	  hESC	  (Goke	  et	  al.,	  2013),	  
ChIP-­‐sequencing	  using	  an	  ELK1	  antibody	  in	  MCF10A	  cells	  showed	  no	  binding	  of	  ELK1	  to	  the	  
GP130	   promoter	   (Odrowaz	   and	   Sharrocks,	   2012).	   Under	   these	   conditions,	   treatment	  with	  
EGF	  for	  30	  minutes	   increases	  gp130	  expression	  slightly,	   indicating	  that	  treatment	  with	  this	  
growth	   factor	   increases	   the	  expression	  of	  gp130	   receptor	  possibly	  by	  activating	   the	  MAPK	  
pathway	  (Odrowaz	  and	  Sharrocks,	  2012).	  
	  
RNAi	   against	   ERK2	   reduces	   the	   stability	  of	   gp130	  mRNA	  when	   compared	   to	  untransfected	  
cells	   and	   cells	   transfected	   with	   a	   non-­‐specific	   control	   (Figure	   4.6).	   For	   this	   reason,	   we	  
considered	  the	  possibility	  that	  ERK2	  not	  only	   influences	  the	  expression	  of	  gp130	  but	   it	  can	  
also	  affect	  the	  stability	  of	  gp130	  mRNA	  molecule.	  Since	  ERK2	  binds	  to	  the	  GP130	  promoter,	  
the	   RNA	  might	   be	   controlled	   at	   the	   promoter	   level	   while	   GP130	   is	   being	   transcribed.	   As	  
mentioned	  before,	   there	   are	   three	  main	   processes	   involved,	   namely	   capping,	   splicing	   and	  
polyadenylation.	  Upon	  ERK2	  knockdown,	  none	  of	  these	  processes	  seemed	  to	  be	  affected	  by	  
reduced	  levels	  of	  ERK2	  (Figure	  4.7,	  4.8	  and	  4.9).	  Activated	  MAP	  kinase-­‐interacting	  kinase	  1	  
(MNK1)	   phosphorylates	   eukaryotic	   initiation	   factor-­‐4E	   (eIF-­‐4E)	   increasing	   it	   affinity	   to	   7-­‐
methyl-­‐guanosine	  cap	  and,	  consequently,	  stimulating	  translation.	  Unphosphorylated	  ERK1/2	  
can	  form	  a	  complex	  with	  MNK1,	  dissociating	  upon	  phorbol	  ester	  (TPA)	  stimulus	  (Waskiewicz	  
et	   al.,	   1997).	   In	   fact,	   ERK2	   phosphorylates	   the	  mRNA	   splicing	   factor	   45	   (SPF45),	   which	   is	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often	  increased	  in	  cancer	  (Al-­‐Ayoubi	  et	  al.,	  2012).	  MAPK	  signalling	  has	  also	  been	  described	  to	  
control	  the	  splicing	  of	  MITF,	  a	  protein	  involved	  in	  the	  regulation	  of	  cell	  survival,	  proliferation,	  
differentiation	  and	  migration	  (Primot	  et	  al.,	  2010).	  In	  addition,	  activated	  ERK	  phosphorylates	  
poly(A)-­‐polymerase	   (PAP),	   the	  polymerase	   responsible	   for	  RNA	  polyadenylation	  at	   S537.	   If	  
the	   activation	   of	   MEK-­‐ERK2	   were	   necessary	   for	   the	   maturation	   of	   gp130	   mRNA	   then	  
treatment	  with	  ERK2	  inhibitors	  would	  have	  decreased	  gp130	  levels	  (Figure	  3.8).	  Interactions	  
between	   designed	   ankyrin	   repeat	   proteins	   (DARPins)	   and	   ERK2	   unphosphorylated	   or	  
phosphorylated	  protein	  reveal	  that	  these	  two	  isoforms	  have	  different	  affinities	  for	  different	  
proteins	  suggesting	  different	  conformation	  and	  consequently	  different	  targets	  regulated	  by	  
these	  two	  forms	  (Kummer	  et	  al.,	  2012).	  	  
	  
Here,	  we	  have	  shown	  that	  ERK2	  regulates	  the	  expression	  of	  gp130	  receptor	  by	  binding	  to	  its	  
promoter	   and	   consequently	   controlling	   its	   activity.	   More	   importantly,	   ERK2	   does	   not	  
interfere	  with	  the	  binding	  of	  RNAP	  II	  to	  the	  promoter	  but	  it	  is	  necessary	  for	  its	  activation.	  In	  
fact,	  at	  this	  promoter,	  the	  absence	  of	  ERK2	  compromises	  the	  phosphorylation	  of	  RNAP	  II-­‐S5	  
and	  RNAP	   II-­‐S2	  and,	  consequently,	   its	  activity.	  We	  have	  also	  shown	  that	  ERK2	   is	  necessary	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5.1.	  Introduction	  
Crosstalk	  between	  ERK	  and	  AKT	  pathways	  has	  been	  reported	  [reviewed	  in	  (Mendoza	  et	  al.,	  
2011)].	   These	   pathways	   are	   involved	   in	   cell	   survival,	   growth	   and	   motility	   and	   have	   been	  
implicated	  in	  carcinogenesis.	  They	  share	  a	  large	  number	  of	  downstream	  effectors	  and	  both	  
the	  phosphorylation	  of	  AKT	  and	  ERK	  are	  involved	  in	  proliferation.	  It	  is	  believed	  that	  the	  cross	  
talk	  between	  these	  pathways	  occurs	  by	  cross-­‐activation	  or	  by	  cross-­‐inhibition	   (Figure	   5.1).	  
Cross-­‐activation	  is	  observed	  when	  RAS-­‐GTP,	  an	  upstream	  molecule	  that	  belongs	  to	  the	  ERK	  
pathway,	  can	  interact	  and	  activate	  PI3K	  protein	  (Kodaki	  et	  al.,	  1994;	  Rodriguez-­‐Viciana	  et	  al.,	  
1994;	  Suire	  et	  al.,	  2002).	  Also,	  the	  activated	  ERK	  pathway	  can	  increase	  mTORC1	  activity	  by	  
the	   interaction	   between	   TSC2	   complex	   and	   ERK/RSK	   proteins	   (Sengupta	   et	   al.,	   2010).	  
RAPTOR	  can	  also	  be	  phosphorylated	  by	  ERK	  and	  RSK,	  increasing	  mTORC1	  activity	  (Carriere	  et	  
al.,	  2011;	  Foster	  et	  al.,	  2010).	  Cross-­‐inhibition,	   the	  opposite	  process	   is	  observed	  when	  one	  
pathway	   represses	   another.	   Consequently,	   when	   that	   pathway	   is	   chemically	   inhibited	   an	  
activation	   of	   the	   other	   pathway	   is	   observed	   (Mendoza	   et	   al.,	   2011).	   EGF-­‐induced	   ERK	  
activation	   phosphorylates	   the	   GAB1	   protein	   on	   four	   different	   residues,	   inhibiting	   the	  
recruitment	   of	   PI3K	   to	   the	   EGFR	   and,	   consequently,	   inhibiting	   the	   activation	   of	   the	   PI3K	  
pathway	   (Hoeflich	   et	   al.,	   2009;	   Lehr	   et	   al.,	   2004;	   Yu	   et	   al.,	   2002).	   Strong	   IGF1	   stimulation	  
induces	  AKT	   activation	   that	   phosphorylates	   RAF	   in	   an	   inhibitory	   site	   (Cheung	   et	   al.,	   2008;	  
Dhillon	   et	   al.,	   2002;	   Guan	   et	   al.,	   2000;	  Moelling	   et	   al.,	   2002;	   Zimmermann	   and	  Moelling,	  
1999).	  This	  leads	  to	  ERK	  signalling	  inhibition.	  	  
	  
Cross-­‐talk	  between	  ERK	  and	  PI3K	  pathways	  may	  be	  significant	  in	  the	  regulation	  of	  gp130.	  We	  
have	  thus	  far	  shown	  that	  ERK2	  regulated	  gp130	  expression	  (Chapter	  3)	  by	  controlling	  GP130	  
promoter	   activation	   (Chapter	   4).	   As	   mentioned	   before,	   IL-­‐6-­‐type	   cytokines	   lead	   to	   the	  
phosphorylation	   of	   gp130	   and,	   consequently,	   to	   the	   activation	   of	   JAK/STAT,	   MAPK	   and	  
PI3K/AKT	  pathways.	  All	  of	  these	  pathways	  contribute	  to	  the	  responses	  seen	  upon	  IL-­‐6-­‐type	  
cytokine	   stimulation	   and	   all	   have	   important	   roles	   in	   cancer	   and	   inflammation.	   We	   have	  
previously	  shown	  that	  even	  though	  STAT3	   is	  a	   transcription	  factor	   for	  gp130	  (Bromberg	  et	  
al.,	   1999;	   Heinrich	   et	   al.,	   2003;	   Santos	   and	   Costa-­‐Pereira,	   2011;	   Yu	   et	   al.,	   2009),	   the	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knockdown	  of	  STAT3	  has	  no	  impact	  on	  gp130	  expression	  (Figure	  1.11).	  This	  is	  in	  contrast	  to	  
what	  was	  seen	  for	  ERK2	  and	  we	  considered,	  therefore,	  that	  it	  was	  important	  to	  understand	  
whether	  AKTs	   also	   contributed	   to	   the	   regulation	  of	   the	   gp130	   receptor.	   Indeed,	  both	  ERK	  
and	  AKT	  pathways	  are	  interconnected	  and	  both	  are	  activated	  by	  gp130	  receptor.	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Figure	  5.1	  -­‐	  Cross-­‐talk	  between	  ERK	  and	  AKT	  pathways.	  Cross-­‐talk	  nodes	  between	  ERK	  and	  AKT	  are	  
depicted,	  with	  cross-­‐inhibition	  represented	   in	   red	  and	  cross-­‐activation	   in	  green.	  Examples	  of	  cross-­‐
inhibition	   include:	   1.	  Phosphorylation	   of	   GAB	   by	   ERK,	   which	   leads	   to	   AKT	   inhibition	   and	  
2.	  Phosphorylation	  of	  RAF	  on	  an	  inhibitory	  amino	  acid	  by	  AKT,	  which	  leads	  to	  ERK	  signaling	  inhibition.	  
In	  contrast,	  examples	  of	  positive	  feedback	  include:	  3.	  Interaction	  of	  RAS	  with	  PI3K,	  which	  culminates	  
in	  PI3K;	  4.	  mTORC1	  activation	  by	  ERK	  and	  RSK	  and	  5.	   Interaction	  of	  ERK	  and	  TSC,	  which	  inhibits	  TSC	  
and	  promotes	  mTORC1	  activation	  [Adapted	  from	  (Mendoza	  et	  al.,	  2011)].	  
	  
	  





























5.	  AKT	  also	  regulates	  gp130	  expression	  
	   160	  
5.2.	  Results	  
5.2.1.	  LY29004	  treatment	  decreased	  gp130	  levels.	  
As	  described	  previously	  (Section	  1.2.4),	  the	  PI3K/AKT	  pathway	  can	  also	  be	  activated	  by	  IL-­‐6-­‐
type	  cytokines.	  For	  this	  reason,	  we	  considered	  it	  important	  to	  investigate	  whether	  inhibition	  
of	  this	  pathway	  would	  affect	  the	  expression	  of	  gp130	  and	  consequently	  its	  signalling.	  	  
	  
U2OS	  cells	  were	  treated	  with	  LY29004,	  a	  PI3K	  inhibitor,	  for	  24	  h.	  They	  were	  then	  collected,	  
stained	   for	   gp130	   and	   analysed	  by	   flow	   cytometry	   (Figure	   5.2	   A).	   A	   time	   course	  was	   also	  
performed	  with	  this	  inhibitor	  at	  10	  µM.	  The	  cells	  were	  collected	  periodically	  and	  separated	  
by	  Western	   blot.	  Membranes	  were	   probed	   for	   gp130	   and	   pERK1/2.	  HSP90	  was	   used	   as	   a	  
control	  (Figure	  5.2	  B).	  As	  can	  be	  seen	  in	  Figure	  5.2,	  treatment	  with	  LY294002	  decreased	  the	  
levels	  of	  gp130	  at	  5	  µM	  reaching	  a	  “plateau”	  of	  inhibition	  at	  20	  µM.	  Eight-­‐hours	  of	  treatment	  
with	  this	  inhibitor	  was	  enough	  to	  reduce	  the	  gp130	  levels.	  Regardless	  of	  the	  treatment	  time,	  
gp130	  levels	  were	  reduced	  to	  about	  40%	  compared	  to	  untreated	  samples.	  	  
	  
Figure	   5.2	   –	   A	   PI3K	   inhibitor,	   LY294002,	  
decreases	   gp130	   levels.	   A.	   U2OS	   cells	   were	  
treated	   with	   LY294002	   with	   the	   indicated	  
concentrations	   for	   24	   h.	   The	   levels	   of	   gp130	  
receptor	   were	   analysed	   by	   flow	   cytometry.	  
Quantification	   of	   gp130	   levels	   (GM)	   relative	  
to	  siNS	  were	  done	  using	  data	  obtained	  in	  two	  
independent	   experiments.	   Statistical	   analysis	  
was	  done	  using	  Student’s	  t-­‐test	  (*	  -­‐	  P<0.05,	  **	  
-­‐	  P<0.01,	  ***	  -­‐	  P<0.005	  versus	  siNS).	  B.	  U2OS	  
cells	  were	  incubated	  with	  10	  µM	  of	  LY294002	  
for	  the	  indicated	  time	  points.	  Fifteen	  minutes	  
before	   collection,	   cells	   were	   stimulated	   with	  
OSM	   (50	   ng/ml).	   Whole	   cell	   lysates	   were	  
prepared	   and	   proteins	   separated	   in	   a	   7.5%	  
SDS-­‐PAGE	  gel.	  Proteins	  were	  transferred	  onto	  
PVDF	  membranes	  and	  probed	  with	  antibodies	  
against	  gp130	  and	  pERK1/2.	  HSP90	  was	  used	  
as	   a	   loading	   control.	   The	   data	   is	  
representative	   of	   three	   independent	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5.2.2.	  AKT2	  and	  AKT3	  silencing	  reduced	  gp130	  expression	  levels.	  
Following	  the	  observation	  that	  PI3K	  inhibitor	  reduced	  gp130	  protein	  levels,	  we	  investigated	  
which	  of	  the	  three	  AKTs,	  if	  any,	  influenced	  the	  gp130	  levels	  and	  consequently	  its	  signalling.	  	  
	  
For	  that	  purpose,	  U2OS	  cells	  were	  transfected	  with	  siAKT1,	  siAKT2,	  siAKT3	  or	  a	  NS	  control	  for	  
48	  h,	  after	  which	  they	  were	  either	  left	  untreated	  or	  they	  were	  treated	  for	  15	  minutes	  with	  
50	   ng/ml	   of	   OSM.	   Cells	   were	   then	   collected	   and	   run	   in	   a	   Western	   blot,	   as	   previously	  
described.	  Membranes	  were	  probed	   for	  gp130,	  OSMR,	  pSTAT3,	  pSTAT1,	  pERK1/2,	  ERK1/2,	  
pAKT-­‐S473	   and	   α-­‐tubulin	   (for	   normalization	   purposes).	   As	   can	   be	   seen	   in	   Figure	   5.3,	  
knocking	  down	  AKT2	  and	  AKT3	  had	  an	  affect	  on	  gp130	  protein	  levels	  and	  consequently,	  on	  
OSM	  signalling	  read-­‐outs,	  pSTAT3-­‐Y705	  and	  pSTAT1-­‐Y701.	  Surprisingly,	  even	  though	  siAKT1	  
did	   not	   affect	   the	   level	   of	   gp130,	   signalling	   was	   also	   reduced	   in	   cells	   with	   reduced	   AKT1	  
(pSTAT3-­‐Y705,	   pSTAT1-­‐Y701	   and	   pERK1/2-­‐T202.Y204/T185.Y187.)	   The	   membrane	   was,	  
therefore,	   also	   probed	   for	   OSMR,	   which	   is	   the	   other	   component	   of	   the	   OSMR	   receptor	  






Figure	   5.3	   –	   Knockdown	   of	   AKT	   affects	   gp130	  
signalling.	   U2OS	   cells	   were	   transfected	   with	  
siRNA	   against	   AKT1,	   AKT2,	   AKT3,	   a	   NS	   siRNA	   or	  
left	  untransfected	  for	  48h.	  Before	  collection,	  cells	  
were	  either	  treated	  with	  50	  ng/ml	  of	  OSM	  or	  left	  
untreated	  for	  15	  minutes	  and	  proteins	  levels	  were	  
analysed	  by	  Western	  blot.	  PVDF	  membranes	  were	  
probed	   for	   gp130,	   OSMR,	   pSTAT3-­‐Y705,	   pSTAT1-­‐
Y701,	   pERK1/2-­‐T202.Y204/T185.Y187,	   pAKT-­‐S473	  
and	   ERK1/2.	   α-­‐tubulin	   was	   used	   as	   loading	  
control.	   Due	   to	   time	   constrains	   this	   experiment	  
was	  repeated	  only	  one	  time.	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To	  explore	  whether	  gp130	  was	  truly	  regulated	  by	  AKT2	  and	  AKT3,	  deconvolution	  analysis	  of	  
the	  siRNA	  oligonucleotides	  present	   in	  each	  AKT	  pool	  was	  carried	  out.	  Each	  oligonucleotide	  
siRNA	  and	  pools	  were	  transfected	  into	  U2OS	  cells	  for	  48	  h,	  as	  described	  before.	  Cells	  were	  
stained	   for	   gp130	   and	   analysed	   by	   flow	   cytometry.	   As	   expected,	   none	   of	   the	   AKT1	  
oligonucleotides	  affected	  gp130	   levels.	  Although	  this	  experiment	  was	  only	   repeated	  twice,	  
the	  combined	  results	  indicate	  that	  siAKT2	  and	  siAKT3	  specifically	  decrease	  gp130	  levels,	  as	  2	  
out	   of	   the	   4	   oligonucleotides	   used	   in	   the	   siRNA	   pool	   had	   an	   impact	   on	   gp130	   levels,	  
validating	  the	  pool	  (Figure	  5.4).	  AKT2	  and	  AKT3	  thus	  appeared	  to	  play	  roles	  in	  the	  regulation	  
of	  gp130	  receptor	  and,	  consequently,	  in	  IL-­‐6	  signalling.	  
	  
Figure	   5.4	   –	   Silencing	   AKT2	   and	   AKT3	   decreases	   gp130	   levels.	  U2OS	   cells	   were	   transfected	  with	  
different	  siRNA	  oligonucleotides	  targeting	  AKT1,	  AKT2	  and	  AKT3	  for	  48	  h.	  Cells	  were	  then	  collected	  
and	  stained	  with	  an	  anti-­‐gp130-­‐PE	  labelled	  antibody.	  The	  levels	  of	  gp130	  were	  then	  analysed	  by	  flow	  
cytometry.	  gp130	  levels	  were	  measured	  using	  GM	  values	  and	  these	  were	  compared	  to	  those	  of	  siNS	  
samples.	  Statistical	  analysis	  of	   two	   independent	  experiments	  was	  done	  using	  SEM	  and	  Student’s	   t-­‐
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Further	   investigation	   was	   needed	   in	   order	   to	   understand	   how	   gp130	   and	   OSMR	   were	  
regulated	   by	   the	   AKTs.	   AKT2	   and	   AKT3	   could	   either	   regulate	   gp130	   transcription	   or	   by	  
interfering	  with	   its	  proper	   translation/maturation	  processes.	  The	   latter	  would	  not	  have	  an	  
impact	   on	   the	   levels	   of	   gp130	   mRNA	   molecule	   but	   rather	   on	   how	   it	   was	   processed	   to	  
generate	  the	  mature	  protein	  presented	  at	  the	  cell	  surface.	  
	  
To	   discriminate	   between	   these	   options,	   U2OS	   cells	   were	   transfected	   with	   siRNA	   against	  
AKT1,	  AKT2	  and	  AKT3	  and	  a	  NS	  control	   for	  48	  h.	  After	   this	  period,	  RNA	  was	  extracted	  and	  
processed	  as	  described	  before.	  As	  shown	   in	  Figure	  5.5	  A,	  gp130	  mRNA	  was	  reduced	  upon	  
siAKT2	   and	   siAKT3,	   indicating	   that	   these	   molecules	   regulated	   the	   receptor	   protein	  
expression	   by	   controlling	   its	   transcription	   or	   gp130	  mRNA	   stability.	   Interestingly,	   silencing	  
AKT1	   led	   to	   a	   reduction	   in	   OSMR	  mRNA,	  whereas	   silencing	   AKT2	   to	   a	  massive	   induction.	  
However,	  this	  was	  only	  done	  once	  and	  this	  result	  is	  thus	  preliminary	  (Figure	  5.5	  B).	  	  
	  
Figures	  5.5	  C	  and	  5	  D	  document	  the	  effect	  that	  silencing	  one	  AKT	  molecule	  has	  on	  another	  
AKT	  and	  the	  high	  efficiency	  of	  the	  AKT2	  and	  AKT3	  knockdown.	  The	  levels	  of	  AKT2	  mRNA	  in	  
U2OS	  cells	  were	  slightly	  lower	  upon	  transfection	  with	  siAKT1	  and	  slightly	  higher	  upon	  RNAi	  
against	  AKT3	   (Figure	   5.5.	   C).	  Although	   it	   is	  difficult	   to	  understand	   the	  biological	   impact	  of	  
these	  changes,	  the	  latter	  may	  explain	  why	  AKT2	  was	  less	  efficient	  at	  downregulating	  gp130	  
(Figure	   5.5	   A).	   On	   the	   other	   hand,	   as	   shown	   in	   Figure	   5.5	   D,	   AKT3	   mRNA	   considerably	  
decreased	  upon	  siAKT1	   (~30%)	  and	  upon	  siAKT2	   (~50%).	  This	  decrease	   in	  AKT3	  when	  cells	  
were	  transfected	  with	  siAKT2	  suggested	  that	  the	  decrease	  observed	  in	  gp130	  mRNA	  (Figure	  
5.5	  A)	  could	  possibly	  be	  due	  to	  this	  decrease	  in	  AKT3	  and	  may	  not	  have	  been	  directly	  related	  
to	   decreased	   levels	   of	   AKT2.	   It	   remains	   unclear,	   however,	   as	   to	  whether	   this	   decrease	   in	  
AKT3	  mRNA	  was	  related	  to	  the	  decrease	  of	  AKT2	  in	  cells	  or	  due	  to	  the	  fact	  that	  siAKT2	  also	  
targeted	  AKT3.	  Indeed,	  these	  data	  make	  it	  more	  difficult	  to	  assign	  particular	  functions	  in	  the	  
regulation	  of	  gp130	  expression	  strictly	  to	  AKT3	  (Figure	  5.5	  D).	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Figure	  5.5	  –	  AKT1,	  AKT2	  or	  AKT3	  knockdown	  reduces	  the	  expression	  of	  gp130	  and/or	  OSMR.	  U2OS	  
cells	  were	   transfected	  with	   siRNA	  oligonucleotides	   targeting	  AKT1,	  AKT2,	  AKT3,	  or	   gp130	   for	  48	  h.	  
NS-­‐transfected	  and	  untransfected	  cells	  were	  also	  analysed.	  RNA	  was	  isolated	  and	  qPCR	  analysis	  was	  
performed	   as	   described	   before.	  A.	   gp130.	  B.	   OSMR.	  C.	   AKT2.	  D.	   AKT3.	  mRNA	  was	   quantified	   and	  
represented	  relative	  to	  siNS.	  β−actin	  and	  GAPDH	  were	  used	  as	  house	  keeping	  genes.	  The	  number	  of	  
independent	  experiments	   is	   shown	  on	   the	   top	   right	  hand	  corner	  of	  each	  graph.	  Statistical	   analysis	  
was	  done	  using	  SEM	  and	  Student’s	  t-­‐test	  (*	  -­‐	  P<0.05,	  **	  -­‐	  P<0.01,	  ***-­‐P<0.005	  versus	  siNS).	  
	  
5.2.3.	  siAKT3	  increased	  ERK2	  binding	  to	  GP130	  promoter	  
We	  wondered	  whether,	  like	  ERK2,	  AKT2	  or	  AKT3	  bound	  to	  the	  gp130	  promoter.	  Perhaps	  AKT	  
regulated	  the	  expression	  of	  gp130	  by	  contributing	  to	  ERK2	  phosphorylation	  independently	  of	  
MEKs,	  or	  by	  interfering	  with	  the	  transcriptional	  machinery.	  
	  
To	   investigate	  whether	   this	  was	   the	   case,	  U2OS	   cells	  were	   transfected	  with	   siRNA	  against	  
AKT1,	  AKT2,	  AKT3	  or	  with	  a	  NS	  control	  for	  48	  h,	  after	  which	  ChIP	  was	  performed	  using	  ERK2	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site	  near	  the	  TSS	  and	  another	  one	  on	  the	  gene,	  outside	  the	  promoter,	  were	  amplified.	  
	  
Interestingly,	   and	   against	   what	   was	   seen	   for	   ERK2,	   silencing	   AKT3	   actually	   significantly	  
increased	   ERK2	  binding	   to	   the	  GP130	  promoter	   (Figure	   5.6	   B).	   This	  was	   coincidental	  with	  
increased	  binding	  of	  phosphorylated	  RNAP	  II	   (pRNAP	  II-­‐S5)	  to	  the	  promoter	   (Figure	  5.6	  C).	  
This	   indicated	   that	   siAKT3	   was	   unlikely	   to	   alter	   the	   expression	   of	   GP130	   by	   the	   same	  
mechanism	  as	  ERK2.	  It	  may	  be	  possible	  that	  the	  slightly	  increased	  ERK2	  binding	  was	  part	  of	  a	  
compensatory	  mechanism.	  Neither	  AKT1	  nor	  AKT2	  changed	  ERK2,	  or	  pRNAP	  II-­‐S5	  binding	  to	  
the	   GP130	   promoter	   significantly,	   even	   though	   AKT2	   also	   led	   to	   a	   decrease	   in	   gp130	  
expression.	   Interestingly,	   the	   fact	   that	   both	   ERK2	   and	   pRNAP	   II-­‐S5	   increased	   after	   RNAi	  
against	  AKT3	  further	  suggested	  a	  positive	  correlation	  between	  ERK2	  and	  pRNAP	  II-­‐S5	  in	  the	  
regulation	  of	  gp130	  expression.	  
Figure	   5.6	   –	   ERK2	   binding	   to	   the	   GP130	   promoter	   increases	   upon	   downregulation	   of	   AKT3.	   A.	  
Representation	   of	   the	   GP130	   promoter	   and	   gene	   illustrating	   the	   approximate	   position	   of	   the	   2	  
primer	  pairs	  used	  For	  ChIP.	  B-­‐C	  U2OS	  cells	  were	  transfected	  as	  described	  before	  with	  siNS,	  siAKT1,	  
siAKT2	  and	  siAKT3	   for	  48	  h.	  After	   the	   immunoprecipitation	  chromatin	  was	  probed	   for	   (B.)	   ERK2	  or	  
(C.)	   pRNAP	   II-­‐S5.	   The	   dashed	   lines	   represent	   the	   signal	   obtained	   with	   the	   IgG	   control.	   Data	   are	  
representative	   of	   three	   biological	   repeats,	   each	   using	   duplicate	   samples,	   and	   yielding	   identical	  
results.	  Statistical	  analysis	  was	  carried	  out	  using	  Student’s	   t-­‐test	   (*	   -­‐	  P<0.05,	  **	   -­‐	  P<0.01	  and	  ***	   -­‐	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5.2.4.	  Inhibition	  of	  AKT2	  decreased	  the	  stability	  of	  gp130	  mRNA	  molecule	  	  
Having	   observed	   that	   AKT2	   and	   AKT3	   affected	   gp130	   expression,	   and	   that	   there	   was	   no	  
inhibition	  of	  ERK2	  or	  pRNAP	  II-­‐S5	  binding	  to	  the	  promoter,	  we	  investigated	  whether	  this	  was	  
due	   to	   a	   decrease	   in	   GP130	   transcription	   rate,	   or	   whether	   AKT2	   and/or	   AKT3	   were	   also	  
necessary	  to	  maintain	  gp130	  mRNA	  stability.	  
	  
U2OS	   cells	  were	   transfected	   as	   before	   and	   subsequently	   incubated	  with	   actinomycin	  D	   (5	  
µg/ml)	   for	   the	   times	   and	   concentration	   indicated	   in	  Figure	   5.7.	   Cells	  were	   collected,	   RNA	  
was	  extracted	  and	  gp130	  levels	  analysed	  by	  qPCR	  (Figure	  5.7).	  Surprisingly,	  the	  gp130	  mRNA	  
in	  siAKT2	  transfected	  cells,	  had	  a	  shorter	  half-­‐life	  than	  that	   in	  untreated	  cells	   (4.5	  h	  versus	  
~14h	  h).	  RNA	  isolated	  from	  siAKT3-­‐transfected	  cells	  had	  a	  similar	  half-­‐life	  to	  that	  within	  the	  
controls.	   As	   mentioned	   previously,	   there	   are	   three	   mRNA	  maturation	   processes	   that	   are	  
controlled	  by	  the	  transcriptional	  machinery	  namely	  capping,	  splicing	  and	  polyadenylation,	  all	  
of	  which	  are	  represented	  in	  Figure	  4.6	  B.	  As	  AKT2	  did	  not	  have	  an	  impact	  on	  pRNAP	  II-­‐S5	  but	  
appeared	   to	   lead	   to	   a	   decrease	   in	   the	   stability	   of	   gp130	  mRNA,	  we	   investigated	  whether	  
splicing	   and/or	   polyadenylation	   were	   affected.	   This	   was	   effectively	   done	   as	   described	   in	  
Chapter	  4	  (Section	  4.2.5.2).	  
	  
Figure	   5.7	   –	  AKT2	   contributes	   to	  
the	   stability	   of	   gp130	   mRNA.	   A.	  
RNAi	  was	  induced	  as	  before.	  After	  
48	   h,	   cells	   were	   incubated	   with	  
actinomycin	   D	   (5	   µg/ml),	   a	  
transcription	   inhibitor,	   for	   the	  
time	   periods	   shown.	   RNA	   was	  
extracted	   and	   analysed	   by	   qPCR	  
as	   before.	   The	   initial	   measure	   of	  
gp130	  mRNA	   level	   is	   set	  as	  100%	  
and	   the	   data	   is	   presented	   as	   a	  
mean	   of	   gp130	   mRNA.	   I	   am	  
grateful	   to	   Ms	   Sarah	   Söcker	   for	  
performing	  this	  experiment.	  .	  The	  
data	   presented	   here	   is	   from	   two	  
independent	  experiments.	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U2OS	  cells	  were	  transfected	  with	  siAKT1,	  siAKT2,	  or	  siAKT3,	  with	  a	  NS	  control	  siRNA	  or	  left	  
untransfected	  for	  48	  h.	  RNA	  was	  purified	  and	  analysed	  by	  qPCR	  to	  establish	  if	  splicing	  of	  the	  
mRNA	  was	  affected.	  Different	  sites,	  represented	  in	  Figure	  5.8	  A,	  one	  corresponding	  to	  both	  
mature	  and	  immature	  RNA	  (denoted	  in	  picture	  by	  d.)	  and	  one	  corresponding	  exclusively	  to	  
mature	  RNA	   (denoted	   in	   the	  picture	  by	   cDNA),	  were	  quantified.	  The	  proportions	  between	  
immature	  and	  mature	  gp130	  mRNA	  did	  not	  change	  with	  the	  transfections,	  suggesting	  that	  
AKTs	  played	  no	  role	  in	  gp130	  splicing	  (Figure	  5.8	  B).	  
	  
To	   assess	   polyadenylation	   (Figure	   5.8	   C),	   RNA	   was	   converted	   into	   cDNA	   using	   random	  
primers,	  or	  oligo	  dT	  anchoring	  primers	  and	  then	  analysed	  by	  qPCR	  analysis	  for	  gp130	  mRNA.	  
The	  proportions	  between	  the	  control	  NS	  and	  each	  sample	  tested	  did	  not	  seem	  to	  be	  affected	  
by	  AKT1,	  AKT2	  or	  AKT3	  silencing	  as	  there	  was	  no	  difference	  between	  total	  and	  mRNA	  levels	  
across	  the	  samples,	  suggesting	  that	  polyadenylation	  was	  identical	  between	  the	  samples	  and	  
excluding	  a	  role	  for	  AKTs	  in	  the	  regulation	  of	  this	  process,	  at	  least	  for	  gp130	  (Figure	  5.8	  C).	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Figure	   5.8	   –	   AKTs	   knockdown	   does	   not	   have	   an	   impact	   on	   gp130	   mRNA	   splicing,	   gp130	   mRNA	  
polyadenylation.	   A.	  Representation	  of	   the	   two	  genetic	   transcripts	  obtained	   from	   the	  GP130	  gene.	  
The	  primer	  sets	  targeting	  different	  places	  on	  these	  transcripts	  are	  sign	  posted,	  namely	  d.	  and	  cDNA	  
B.	  U2OS	  cells	  were	  transfected	  with	  siNS,	  siAKT1,	  siAKT2,	  siAKT3	  or	  left	  untransfected	  for	  48	  h.	  RNA	  
was	  isolated	  as	  before.	  qPCR	  was	  done	  using	  different	  primer	  sets	  to	  study	  RNA	  frequency	  of	  those	  
two	  specific	  places	  under	  different	  transfection	  conditions.	  C.	  The	  cDNA	  conversion	  was	  performed	  
using	   either	   random	   primers	   (total	   RNA)	   or	   dT	   oligonucleotides	   (mRNA).	   The	   results	   were	   then	  
analysed	  by	  qPCR	  as	  before.	  The	  experiments	  were	  performed	  three	  times,	  yielding	  identical	  results.	  
Data	  was	   normalized	   to	   the	   house	   keeping	   genes	   -­‐	  β-­‐actin	   and	   GAPDH.	   SEM	   and	   Student’s	   t-­‐test	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5.2.5	  AKT	  knockdown	  decreased	  cell	  growth	  
Similarly	   to	   what	   was	   observed	   for	   ERK1	   and	   ERK2	   in	   Chapter	   3,	   we	   investigated	   if	   the	  
knockdown	  of	  AKT1,	  AKT2	  or	  AKT3	  influenced	  cell	  growth	  and/or	  apoptosis	  of	  U2OS	  cells,	  as	  
this	  might	  have	  an	  impact	  on	  gp130	  expression.	  	  
	  
For	  this	  purpose,	  U2OS	  cells	  were	  transfected	  with	  siRNA	  against	  AKT1,	  AKT2	  AKT3,	  with	  a	  
NS	  control	  or	  left	  untransfected	  for	  the	  indicated	  times.	  They	  were	  then	  either	  washed	  with	  
PBS,	  followed	  by	  fixation	  and	  staining	  with	  crystal	  violet	  in	  0.5%	  (v/v)	  methanol	  (Figure	  5.9	  
A),	  or	  incubated	  with	  Caspase	  Glo®	  3/7	  (Figure	  5.9	  B).	  
	  
As	   shown	   in	   Figure	   5.9	   A,	   silencing	   any	   of	   the	   AKT	  molecules	   significantly	   decreased	   cell	  
growth.	   In	   addition,	   AKT1,	   AKT2	   and	  
AKT3	   knockdown	   increased	   caspase	  
activity	   (Figure	   5.9	   B).	   Since	   this	  
increase	   in	   AKT1	   activity	  was	   less	   than	  
10%,	  it	  is	  unclear	  why	  there	  was	  such	  a	  
great	   impact	   in	   cell	   growth	   seen	   in	  
Figure	  5.9	  A.	  	  
	  
	  
Figure	  5.9	  –	  Reducing	  the	  expression	  levels	  
of	   AKT1	   AKT2	   and	   AKT3	   decreases	   cell	  
growth.	   U2OS	   cells	   were	   transfected	   with	  
siRNA	  against	  AKTs	  or	  left	  untransfected.	  A.	  
At	   the	   indicated	   times	   after	   transfection,	  
cells	  were	  washed	  and	  stained	  with	  Crystal	  
Violet.	   B.	   After	   48	   h	   of	   transfection,	  
Caspase	   Glo®	   3/7	   reagent	   was	   added	   to	  
cells	   and	   corresponding	   media.	   The	  
fluorescence	  was	  quantified	  and	  the	  values	  
obtained	   normalized	   to	   NS	   condition.	   The	  
experiments	   were	   repeated	   three	   times	  
and	   each	   condition	   was	   analysed	   in	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5.3.	  Discussion	  
Inhibition	  of	  PI3K	  using	  LY294002	  decreases	  the	  level	  of	  gp130	  on	  the	  cell	  surface	  (Figure	  5.2	  
A).	  This	  does	  not	  reflect	  a	  defect	  on	  cell	  surface	  presentation	  as	  it	  is	  also	  observed	  on	  whole	  
cell	   lysates	   (Figure	   5.2	   B).	   A	   role	   for	   the	   PI3K/AKT	   pathway	   in	   the	   regulation	   of	   gp130	  
expression	   is	   further	   suggested	   by	   carrying	   out	   RNAi	   against	   three	   members	   of	   the	   AKT	  
family,	  namely	  AKT1,	  AKT2	  and	  AKT3	  (Figure	  5.3).	  The	  caveat	  is	  that,	  due	  to	  time	  constraints,	  
this	   experiments	   was	   only	   carried	   out	   once	   and	   caution	   must	   be	   exerted	   in	   the	  
interpretation	   of	   these	   data.	   Taking	   the	   data	   at	   face	   value	   suggests,	   however,	   that,	  
knockdown	   of	   AKT2	   and,	   particularly,	   AKT3	   greatly	   decreases	   the	   levels	   of	   gp130	   protein	  
(Figure	   5.3).	  When	  compared	   to	   the	  NS	  control,	   the	  knockdown	  of	   seems	   to	  decrease	   the	  
levels	   of	   OSMR	   irrespective	   of	   treatment.	   This	   explains	   why	   in	   siAKT1-­‐transfected	   cells	  
pSTAT3,	   pSTAT1	   and	   pERK1/2	   are	   reduced	   in	   response	   to	   OSM.	   Although	  we	   need	   to	   be	  
careful	   interpreting	   the	  data	   in	  Figure	   5.3,	   further	  experiments	  where	  deconvoluted	  siAKT	  
oligonucleotides,	  or	  siAKT	  pools,	  were	  used	  to	  measure	  the	  cell	  surface	  expression	  of	  gp130	  
suggest	   that	   indeed	   reducing	   the	   levels	   of	   AKT2	   and	   AKT3	   lead	   to	   a	   decrease	   in	   protein	  
expression	  (Figure	  5.4	  and	  5.5	  A).	  The	  latter	  also	  confirm	  that	  inhibition	  of	  AKT1	  leads	  to	  a	  
decrease	   in	  OSMR	   levels	   (Figure	   5.5	   B).	  AKT2	  and	  AKT3	  molecules	   are	   very	   similar	   to	  one	  
another.	   For	   this	   reason	   we	   have	   investigated	   whether	   the	   knockdown	   of	   one	   of	   these	  
molecules	  would	  change	  the	  mRNA	  levels	  of	  the	  other.	  We	  have	  shown	  that	  AKT3	  is,	  in	  fact,	  
reduced	   after	   knocking	   down	   either	   AKT1	   or	   AKT2,	   whereas	   AKT2	   induction	   is	   slightly	  
increased	  by	  AKT2	  or	  AKT3	  silencing	  (Figure	  5.5	  C	  and	  D).	  	  
	  
AKTs	  were	  previously	  described	  to	  regulate	  other	  receptors.	  However	  differently	  to	  what	  is	  
observed	  with	  respect	  to	  gp130	  and	  OSMR	  levels,	   inhibition	  of	  AKT	  releases	  the	  repression	  
induced	  by	  forkhead	  box	  O	  (FOXO)	   in	  RTK	  genes	  such	  as	  HER3,	   insulin-­‐like	  growth	  factor-­‐1	  
receptor	  (IGF-­‐1R)	  and	  insulin	  receptor	  (Chandarlapaty	  et	  al.,	  2011).	  
	  
Signalling	   through	   gp130	   can	   activate	   the	   PI3K	   pathway,	   which	   has	   been	   described	   to	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crosstalk	   with	   the	   MAPK	   pathway	   (Figure	   5.1)	   [Reviewed	   in	   (Castellano	   and	   Downward,	  
2011)].	  We	   have	   shown	   that	   treatment	  with	   LY294002,	   a	   PI3K	   inhibitor,	   decreases	   gp130	  
expression	   (Figure	   5.2).	   In	   fact,	   LY294002	   treatment	   can	   also	   affect	   ERK	   phosphorylation	  
following	  stimulation	  capsaicin	  and	  NGF	  (Zhuang	  et	  al.,	  2004).	  Consequently,	  it	  was	  possible	  
that	   both	   ERK2	   and	   AKT	   regulated	   the	   expression	   of	   gp130	   via	   the	   same	   molecular	  
mechanism.	  However,	  when	  either	  AKT2	  or	  AKT3	  are	  knocked	  down,	  we	  do	  not	  observe	  a	  
decrease	   in	  RNAP	  II	  activation	  at	  the	  GP130	  promoter,	  as	  manifest	  by	  the	  phosphorylation	  
on	   S5	   (Figure	   5.6	   C),	  which	   is	   seen	   in	   cells	   transfected	  with	   siERK2	   (Figure	   4.3).	  We	  have	  
therefore	   concluded	   that	   ERK2	   and	   AKTs	   regulate	   the	   gp130	   receptor	   chain	   in	   different	  
ways.	   In	   contrast	   to	   what	   was	   seen	   with	   MEK/ERK	   inhibitors	   (Figure	   3.10),	   the	   levels	   of	  
gp130	   decreased	   after	   pharmacological	   inhibition	   of	   PI3K/AKT	   signalling	   (Figure	   5.2).	   This	  
further	   indicates	   that	   the	   PI3K	   and	   ERK	   pathways	   control	   gp130	   expression	   by	   distinct	  
mechanisms.	  Interestingly,	  an	  interaction	  between	  PI3K	  and	  STAT3	  has	  been	  reported	  [(Hart	  
et	   al.,	   2011);	   reviewed	   in	   (Vogt	   and	  Hart,	   2011)]	   suggesting	   that	   PI3K	  may	   act	   by	   directly	  
altering	  STAT3	  activation.	  	  
	  
RNAi	  against	  AKT2	  decreases	  the	  half-­‐life	  of	  gp130	  mRNA,	  and	  this	  effect	  is	  not	  seen	  when	  
either	  AKT1	  or	  AKT3	  are	  knocked	  down	  (Figure	  5.7).	  However,	   it	  does	  not	  seem	  that	  AKT2	  
alters	  gp130	  splicing	  (Figure	  5.8	  A	  and	  B),	  or	  its	  polyadenylation	  (Figure	  5.8	  C).	  	  
	  
AKT2	  is	  known	  to	  have	  a	  role	  in	  alternative	  splicing	  through	  the	  activation	  of	  serine/arginine-­‐
rich	   (SR)	  p40	   (Jiang	  et	   al.,	   2009;	  Patel	   et	   al.,	   2004;	  Patel	   et	   al.,	   2005).	  AKT2	  has	  also	  been	  
shown	   to	   play	   a	   role	   in	   the	   stability	   of	   β-­‐catenin	   mRNA	   by	   phosphorylating	   RNA-­‐binding	  
proteins,	  such	  as	  KH-­‐type	  splicing	  regulatory	  protein	  (KSRP),	  thus	  promoting	  the	  interaction	  
with	   14-­‐3-­‐3	   proteins.	   Consequently,	   KSRP	   impairs	   the	   RNA	   decay	   (Gherzi	   et	   al.,	   2006).	   It	  
remains	  to	  be	  seen	  if	  a	  similar	  mechanism	  is	  at	  play	  here.	  
	  
Furthermore,	  adenylate-­‐	  and	  uridylate-­‐rich	  element	  (ARE)	  motifs	  are	  commonly	  present	  in	  3’	  
untranslated	  region	  of	  mRNA	  (3’UTR)	  of	  certain	  genes	  involved	  in	  inflammatory	  and	  cancer	  
processes	   (Sanduja	   et	   al.,	   2011),	   including	   gp130,	   which	   is	   represented	   in	   Figure	   5.10	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(http://rna.tbi.univie.ac.at/AREsite).	   RNA-­‐binding	   proteins,	   including	   tristetraprolin	   (TTP)	  
and	  butyrate	  response	  factors	  (BRF-­‐1	  and	  -­‐2),	  contribute	  to	  the	  regulation	  of	  ARE-­‐containing	  
mRNA	   [reviewed	   in	   (Sanduja	  et	   al.,	   2011;	  Wilusz	   and	  Wilusz,	   2004)].	   It	   has	  been	   reported	  
that	  the	  PI3K/AKT	  pathway	  controls	  the	  turnover	  of	  mRNAs	  by	  turning	  off	  the	  destabilization	  
role	   of	   BRF1	   and	   TTP	   of	   selected	   mRNAs	   (Marderosian	   et	   al.,	   2006;	   Ming	   et	   al.,	   2001;	  
Schmidlin	  et	  al.,	  2004).	  AKT2,	  but	  not	  AKT1,	  is	  also	  reported	  to	  contribute	  to	  the	  expression	  
and	  stabilization	  of	  palladin,	  an	  actin-­‐binding	  protein	  (Chin	  and	  Toker,	  2010).	  In	  contrast,	  in	  
developing	   muscle	   cell	   differentiation,	   active	   AKT2	   decreases	   Ccnd1	   mRNA	   by	  
phosphorylating	  Pitx2.	  This	  is	  believed	  to	  reduce	  its	  interaction	  with	  HuR,	  a	  mRNA	  stabilizer,	  
and	  to	  contribute	  to	  the	  subsequent	  instability	  of	  this	  mRNA	  (Gherzi	  et	  al.,	  2010).	  	  
	  
Figure	  5.10	  –	  ARE	  sites	  on	  gp130	  mRNA	  molecule.	  Schematic	  representation	  of	  ARE	  sites	  identified	  
on	   the	   3’	   UTR	   of	   the	   gp130	   mRNA	   transcript.	   The	   arrows	   point	   the	   location	   of	   the	   identified	  
sequences.	  Five	  protein	  coding	  transcripts	  are	  represented.	  The	  highlighted	  one	  has	  26	  ATTTA	  motifs	  
and	  5	  WWATTTTAWW.	  [Taken	  from	  http://rna.tbi.univie.ac.at/AREsite].	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In	  mice,	  Akt1	  and	  Akt2	  double	  knockout	  cells	  are	  associated	  with	  a	  considerable	  reduction	  in	  
IFN-­‐induced	  antiviral	  activity	  (Kaur	  et	  al.,	  2008).	  Loss	  of	  either	  AKT1	  or	  AKT2	  decreases	  the	  
tendency	   to	   tumour	   formation	   (Watson	   and	   Moorehead,	   2013)	   and	   AKT2	   and	   AKT3	   are	  
believed	   to	  be	  essential	   in	   the	   carcinogenesis	  of	  malignant	  gliomas	   (Mure	  et	   al.,	   2010).	   In	  
addition,	   suppression	  of	  AKT2	   in	  metastatic	   liver	   cells	   reduces	   the	   ability	   of	   these	   cells	   to	  
metastasize.	   This	   cannot	   be	   recovered	   by	   AKT1	   overexpression	   (Rychahou	   et	   al.,	   2008),	  
suggesting	   that	   these	  proteins	  are	  not	   functionally	  equivalent.	   Likewise,	   signalling	   through	  
gastrin-­‐releasing	   peptide	   (GRP)/GRP-­‐R/AKT2	   is	   important	   to	   the	   metastatic	   potential	   of	  
neuroblastoma	  cells	  (Qiao	  et	  al.,	  2013).	  Together	  with	  the	  data	  presented	  in	  this	  chapter,	  the	  
data	  not	  only	  confirm	  the	  non-­‐redundant	  roles	  of	  AKT1,	  AKT2	  and	  AKT3	  molecules,	  but	  also	  
suggest	  the	  possibility	  of	  the	  existence	  of	  a	  new	  role	  for	  these	  kinases	   in	  the	  regulation	  of	  
gp130	  expression.	  Importantly,	  gp130	  is	  often	  mentioned	  in	  relation	  to	  cancer	  development	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6.1.	  General	  Discussion	  
Cytokines	  belonging	  to	  the	  IL-­‐6	  superfamily	  share	  a	  common	  receptor	  subunit	  named	  gp130,	  
which	  is	  vital	  to	  their	  action	  (Heinrich	  et	  al.,	  2003).	  These	  cytokines	  reveal	  some	  redundancy	  
among	  them,	  and	  are	  mostly	  involved	  in	  biological	  processes	  such	  as	  inflammation,	  immune	  
responses,	  cell	  survival	  and	  the	  acute	  phase	  response.	  Sadly,	  gp130	  -­‐/-­‐	  mice	  die	  at	  birth	  or	  
soon	  after	  and,	  for	  this	  reason,	  most	  knockout	  studies	  are	  done	  in	  conditional	  knockout	  mice	  
[reviewed	   in	   (Fasnacht	   and	   Muller,	   2008)].	   The	   role	   of	   the	   gp130	   receptor	   in	   cancer	  
development	   is	  well-­‐established	   [reviewed	   in	   (Silver	  and	  Hunter,	  2010)],	  which	   is	  why	   it	   is	  
important	   to	   understand	   mechanisms	   that	   regulate	   the	   expression	   of	   this	   particular	  
molecule.	  The	  main	  aim	  of	  my	  PhD	  studies	  was	  to	  understand	  how	  gp130	  was	  regulated	  by	  
ERK2,	  as	  it	  was	  previously	  shown	  in	  our	  lab	  that	  reducing	  the	  levels	  of	  ERK2	  had	  an	  impact	  
on	  gp130	  levels	  (Figure	  1.12).	  	  
	  
In	  Chapter	   3	  we	  have	  confirmed	  this	   initial	  observation	  and	  expanded	  upon	  the	   impact	  of	  
this	   reduction	   on	   IL-­‐6-­‐type	   cytokine	   signalling	   (Figure	   3.2	   and	  3.4).	  With	   the	   exception	   of	  
STAT3,	  ERK2	  knockdown	  does	  not	  affect	  the	  levels	  of	  other	  molecules	  typically	  activated	  by	  
gp130	   (Figure	   3.2,	   3.3	   and	   3.5).	   Analysis	   of	   the	   mRNA	   expression	   of	   gp130	   after	   ERK2	  
knockdown	  has	   revealed	   that	   ERK2	   controls	   the	  expression	  of	   gp130	   (Figure	   3.6	   and	  3.8).	  
Surprisingly,	  the	  kinase	  activity	  does	  not	  seem	  to	  be	  important	  for	  this	  regulation	  as	  treating	  
cells	  with	  either	  MEK	  or	  ERK	   inhibitors	  has	  no	  effect	  on	   the	   levels	  of	   this	   receptor	   (Figure	  
3.10).	   More	   importantly,	   the	   regulation	   of	   gp130	   by	   ERK2	   seems	   to	   be	   a	   general	   effect	  
rather	  than	  specific	  to	  certain	  cancer	  cells,	  as	  it	  occurs	  in	  different	  cancer	  cells	  with	  different	  
backgrounds	  (Table	  2.1),	  as	  well	  as	  in	  cells	  with	  no	  cancer	  background	  (Figure	  3.11	  and	  3.12,	  
respectively).	  A,	  somewhat	  limited,	  set	  of	  experiments	  suggest	  that	  this	  regulation	  does	  not	  
occur	  in	  mouse	  cells.	  Indeed,	  in	  ERK2	  -­‐/-­‐	  knockout	  MEFs	  (Figure	  3.15	  A)	  and	  in	  NIH3T3	  cells	  
transfected	  with	  siERK2	  (Figure	  3.15	  B)	  the	  levels	  of	  gp130	  are	  comparable,	  or	  even	  higher,	  
that	   in	   matching	   controls.	   This	   could	   be	   either	   because	   in	   mice	   another	   molecule	  
compensates	   for	   the	   loss	   of	   ERK2	   or	   because	   their	   immune	   system	   differs	   from	   that	   in	  
human	  cells.	   In	  humans,	  ERK2	  is	  only	  necessary	  for	  the	  regulation	  of	  gp130	  up	  to	  a	  certain	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point,	   as	   the	   complete	   restoration	  of	   ERK2	   levels	   is	   not	   necessary	   for	   the	   cells	   to	   express	  
‘normal’,	  endogenous	  levels	  of	  gp130	  (Figure	  3.13)	  and	  overexpression	  of	  this	  molecule	  does	  
not	  increase	  the	  levels	  of	  gp130	  further	  (Figure	  3.14).	  	  
	  
ERK2	  knockdown	  has	  an	  impact	  on	  cell	  growth	  (Figure	  3.16)	  not	  just	  because	  gp130	  is	  absent	  
from	  these	  cells	  but	  probably	  because	  the	  lack	  of	  ERK2	  promotes	  a	  G1	  arrest	  (Figure	  3.17).	  
This	   observation	   suggested	   that	   gp130	  may	   be	   downregulated	   in	   cells	   due	   to	   the	   G1	   cell	  
cycle	  arrest	   induced	  by	  the	  knockdown	  of	  ERK2,	   rather	   than	  as	  a	  direct	  effect	  of	   the	  ERK2	  
molecule.	  This,	  however,	  is	  not	  the	  case	  as	  one	  can	  mimic	  the	  above	  phenotype	  by	  depriving	  
cells	  of	  FCS.	  Indeed,	  serum	  deprivation	  leads	  to	  a	  G1	  arrest	  without	  causing	  any	  changes	  in	  
gp130	  expression	  levels	  (Figure	  3.18).	  
	  
The	   impact	  of	  ERK1	  and	  ERK2	  knockdown	  on	  other	   receptors	  was	  also	  studied.	  Both	  ERK2	  
and	   ERK1	   appear	   to	   positively	   control	   OSMR.	   ERK1	   appears	   to	   negatively	   regulate	   the	  
expression	   of	   LIFR	   and	   to	   be	   necessary	   to	   the	   maximal	   expression	   of	   FGFR1	   and	   FGFR2.	  
While	   it	   looked	   as	   if	   ERK2	   was	   necessary	   for	   EGFR	   full	   expression	   (Figure	   3.19	   D),	  
deconvolution	   analysis	   revealed	   that	   it	   reflected	   an	   unfortunate	   RNAi	   off-­‐target	   effect	  
(Figure	   3.19	   E).	   The	   regulation	   of	   FGFR1	   and	   FGFR2	   by	   ERK1	   needs	   to	   be	   further	  
investigated.	  	  
	  
The	  mechanism	   by	  which	   ERK2	   regulates	   the	   expression	   of	   gp130	  was,	   therefore,	   further	  
investigated	   in	  Chapter	   4.	  We	   found	   that	  ERK2	  binds	   to	   the	  GP130	  promoter	   (Figure	   4.1).	  
ERK2	   knockdown	   does	   not	   interfere	   with	   the	   binding	   of	   RNAP	   II	   to	   the	   GP130	   promoter	  
(Figure	  4.2)	  and	  this	  results	  in	  defective	  RNAP	  II	  activation	  (Figure	  4.3).	  We	  have	  highlighted	  
several	  transcription	  factors	  binding	  sites,	   including	  the	  GATE	  sequence	  that	  was	  described	  
before	   as	   an	   ERK2	  DNA	  binding	   site	   in	  Figure	   4.4.	   However,	   ERK2	  does	   not	   bind	   to	   these	  
sequences	  (Figure	  4.5).	  Further	  analysis	  indicates	  that	  ERK2	  not	  only	  controls	  the	  expression	  
of	   gp130	  by	  binding	   to	   its	  promoter	   region	  but	   it	   also	  decreases	   the	   stability	  of	   its	  mRNA	  
(Figure	  4.6	  A).	  The	  stability	  of	  mRNA	  molecules	  can	  be	  regulated	  by	  several	  processes,	  such	  
as	  capping,	  splicing	  and	  polyadenylation	  (Figure	  4.6	  B).	  As	  these	  they	  can	  be	  controlled	  by	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the	   promoter	   region	   we	   next	   investigated	   each	   one	   of	   these	   processes.	   However,	   our	  
analyses	   do	   not	   obviously	   implicate	   ERK2	   in	   the	   regulation	   of	   capping,	   splicing	   or	  
polyadenylation	   (Figure	   4.7,	   4.8,	   4.9).	   It	   remains	   possible,	   nevertheless,	   that	   the	   capping	  
may	   be	   slightly	   affected,	   if	   our	   experimental	   conditions	   led	   to	   the	   degradation	   of	   the	  
uncapped	   RNA	   (Figure	   4.7).	   More	   rigorous	   analyses	   of	   these	   processes	   will	   need	   to	   be	  
carried	  out	  in	  the	  future.	  
	  
Recently,	   it	   was	   suggested	   that	   ERK2	   regulates	   the	   expression	   of	   a	   subset	   of	   genes	   by	  
relieving	   the	   repression	   induced	   by	   ELK1	   at	   the	   promoter	   level.	   For	   this	   reason	   we	   have	  
investigated	   the	   induction	   and	   expression	   of	   gp130	   receptor	   upon	   ELK1	   knockdown,	   or	  
combined	  knockdown	  of	  ERK2	  and	  ELK1.	  Silencing	  of	  ELK1	  has	  no	  impact	  on	  gp130	  and	  the	  
combined	   knockdown	  decreases	   the	   levels	   of	   gp130	   to	   the	   same	  extent	   as	   that	   observed	  
following	   ERK2	   knockdown	   on	   its	   own	   (Figure	   4.10),	   which	   indicates	   that	   ELK1	   does	   not	  
repress	  the	  GP130	  promoter.	  Furthermore,	  RNAi	  against	  ERK2	  decreases	  the	  levels	  of	  ELK1	  
(Figure	  4.10),	  something	  that	  adds	  further	  support	  to	  the	  theory	  that	  ELK1	  does	  not	  repress	  
the	  GP130	  promoter	  in	  the	  absence	  of	  ERK2.	  
	  
The	   common	   receptor	   for	   IL-­‐6	   type	   cytokines,	   gp130,	  mediates,	   directly	   or	   indirectly,	   the	  
activation	   of	   three	  main	   pathways	   as	   described	   in	   the	   Introduction:	   JAK/STAT,	  MAPK	   and	  
PI3K.	  We	  have	  shown	  that	  silencing	  STAT3,	  the	  main	  transcription	  factor	  activated	  by	   IL-­‐6-­‐
type	  cytokines	  via	  JAK/STAT	  signalling,	  does	  not	  affect	  gp130	  expression	  levels	  (Figure	  1.11).	  
However,	   ERK2	   does	   regulate	   gp130	   as	   described	   in	   Chapter	   3	   and	   4.	   We,	   therefore,	  
examined	   whether	   this	   was	   the	   case	   too	   for	   PI3K	   (Chapter	   5).	   This	   was	   an	   important	  
question,	  not	  only	  because	   the	  PI3K/AKT	  pathway	   is	  activated	  by	  gp130,	  but	  also	  because	  
the	   MAPK	   pathway	   can	   cross-­‐activate	   or	   -­‐inhibit	   the	   PI3K/AKT	   pathway	   and	   both	   these	  
pathways	  are	  believed	  to	  be	  involved	  in	  the	  vast	  majority	  of	  cancers	  (Figure	  5.1).	  As	  shown	  
in	   Figure	   5.2,	   chemical	   inhibition	   of	   PI3K	   decreases	   the	   levels	   of	   gp130	   and	   RNAi	   against	  
AKT1,	  AKT2	  and	  AKT3	  decreases	  OSM	  signalling	  (Figure	  5.3).	  Either	  AKT2	  or	  AKT3	  knockdown	  
decreases	  the	   levels	  of	  gp130	  mRNA	  while	  AKT1	  knockdown	  decreases	  the	   levels	  of	  OSMR	  
mRNA	  (Figure	  5.5).	  In	  contrast	  to	  what	  was	  observed	  for	  ERK2,	  reducing	  the	  expression	  level	  
of	  AKT2	  nor	  AKT3	  does	  not	  decrease	  the	  phosphorylation	  of	  RNAP	  II-­‐S5,	  nor	  the	  binding	  of	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ERK2	   to	   the	   GP130	   promoter.	   These	   observations	   indicate	   that	   AKT2	   and	   AKT3	   regulate	  
gp130	  through	  an	  ERK2-­‐independent	  mechanism.	  With	  the	  exception	  of	  AKT2,	  none	  of	  the	  
other	  AKTs	  affect	  gp130	  mRNA	  stability	  (Figure	  5.7).	  This	  is	  possibly	  because	  gp130	  mRNA	  is	  
an	  ARE-­‐regulated	  mRNA	  (Figure	  5.10)	  and	  AKT2	  is	  reported	  to	  play	  a	  role	  in	  the	  regulation	  of	  
ARE	  mRNA.	  AKTs	  do	  not	  change	  gp130	  mRNA	  splicing	  nor	  polyadenylation	  (Figure	  5.8).	  	  
	  
The	  mechanisms	  that	  govern	  gp130	  expression	  are	  extremely	  important	  to	  the	  homeostasis	  
and	  health	  of	  cells.	  Cells	  have	  different	  ways	  to	  respond	  to	  change	  and	  to	  restore	  stability	  
after	  any	  perturbation,	  often	  by	  compensation	  mechanisms.	  Disease	  states	  occur	  when	  the	  
body	   fails	   to	   restore	   equilibrium	   after	   perturbation	   of	   normal	   physiology.	   Often	   in	   this	  
situation,	  cells	  do	  not	  die	  but	  instead	  divide	  regardless	  of	  restraining	  cues,	  becoming	  rogue	  
characters	   of	   a	   society	   that,	   up	   to	   that	   point,	   functioned	   in	   harmony.	   For	   this	   reason,	  
division/differentiation	  processes	  and	  the	  molecules	  involved	  in	  these	  are	  tightly	  regulated.	  
The	   IL-­‐6	   type	  cytokines	   receptor,	   gp130,	  activates	   three	  main	  pathways,	   two	  of	  which	  are	  
involved	   in	   the	   regulation	   of	   the	   receptor	   itself.	   Furthermore,	   JAK/STAT,	   ERK	   and	   AKT	  
pathways	   interact	   with	   each	   other,	   thus	   cross-­‐regulating	   their	   activities.	   Surprisingly,	  
whereas	  the	  regulation	  of	  gp130	  does	  not	  to	  require	  enzymatic	  activity	  that	  exerted	  by	  AKT2	  
or	   AKT3	   does.	   Interestingly,	   it	   seems	   that	   ERK2	   also	   regulates	   other	   receptor	   molecules	  
through	  this	  mechanism.	  To	  the	  best	  of	  our	  knowledge,	  this	  has	  not	  been	  reported	  before.	  
Overall,	   our	   data	   unravels	   levels	   of	   regulation	   of	   the	   gp130	   receptor	   that	   had	   not	   been	  
identified	   before,	   opening	   the	   possibility	   of	   developing	   new	   strategies	   for	   clinical	  
intervention.	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6.2	  Limitations	  of	  the	  work	  
6.2.1.	  In	  vitro	  studies,	  not	  physiological	  enough?	  
Perhaps	  the	  most	  concerning	  limitation	  in	  any,	  work	  performed	  on	  cell	   lines	   in	  vitro	   is	  that	  
sometimes	   results	   are	   not	   confirmed	   in	   vivo	   due	   to	   the	   effects	   of	   the	   immortalization	  
process	  or	  of	   the	  artificial	  environment	  used.	  Unfortunately,	  we	  were	  not	  able	   to	   test	  our	  
hypothesis	   in	   primary	   cells,	   which	   would	   have	   established	   if	   the	   results	   were	   ‘true’	   and	  
would	  have	  enabled	  us	  to	   immediately	  exclude	  manipulation	  of	  cells	  as	  the	  reason	  for	  the	  
current	  phenotypes.	  	  
	  
Mouse	  primary	  cells	  are	  also	  unlikely	  to	  be	  an	  option	  in	  this	  respect,	  as	  we	  tested	  MEF	  Erk2	  -­‐
/-­‐	  and	  RNAi	  against	  Erk2	  in	  NIH3T3	  cells	  and	  found	  that	  the	  absence	  of	  Erk2	  had	  no	  impact	  
on	  gp130	   levels	   (Figure	  3.15).	  This,	  at	   least	   in	  part,	   indicates	  that	   the	  results	  observed	  are	  
not	  a	  consequence	  of	  on	  immortalization	  process,	  as	  NIH3T3	  are	  immortal.	  
	  
6.2.2.	  Transient	  transfection	  for	  48	  h,	  not	  ideal?	  
Another	  possible	   criticism	  of	  our	  work	   is	  possibly	   that	   the	  molecular	  mechanism	   involving	  
ERK2	  and	  gp130	  was	  only	  studied	  using	  transient	  transfections.	  Indeed,	  the	  mouse	  data	  raise	  
the	   possibility	   that	   acute	   and	   chronic	   (i.e.	   prolonged)	   absence	   of	   ERK2	   may	   have	  
fundamentally	  different	  biological	  outcomes.	   It	   is	  arguable	   that	  cells	  could,	   somehow,	   find	  
an	  alternative	  way	  to	  express	  gp130	  in	  the	  absence	  of	  ERK2	  protein.	  Having	  said	  that,	  acute	  
depletion	  of	  ERK2	  is	  likely	  closer	  to	  human	  pathology	  than	  chronic	  depletion	  and	  our	  results	  
can,	  therefore,	  have	  far	  reaching	  implications.	  To	  analyse	  the	  expression	  of	  gp130	  in	  human	  
cells	  during	  prolonged	  absence	  of	  ERK2,	  one	  could	  stably	   transfect	  cells	  with	  short	  hairpin	  
(sh)	  RNAs.	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6.2.3.	  Chemical	  inhibition	  of	  ERK2,	  not	  conclusive?	  
We	  have	  shown	  that	   inhibition	  of	  ERK1/2	  with	  different	  MEK/ERK	  chemical	   inhibitors	  does	  
not	  change	  gp130	  expression	  levels.	  To	  further	  confirm	  this,	  we	  would	  have	  had	  to	  carry	  our	  
in	   vitro	   kinase	   assays	   to	   categorically	   show	   that	   the	   enzymatic	   activity	   of	   ERK	  was	   totally	  
abolished	   by	   the	   inhibitors.	  We	   attempted	   to	   probe	   further	   into	   this	   issue	   by	   doing	   ChIP	  
assays	   with	   different	   pERK1/2	   antibodies	   but	   we	   were	   never	   able	   to	   immunoprecipitate	  
phosphorylated	   ERK.	  Whether	   this	   reflects	   the	   fact	   that	   only	   non-­‐phosphorylated	   ERK1/2	  
binds	   to	   the	   promoter	   or	   the	   unsuitability	   of	   the	   antibodies	   for	   immunoprecipitation	  
remains	  to	  be	  established.	  
	  
Perhaps	  ERK2	  kinase	  activity	  controls	  a	  repressor	  that	  co-­‐localizes	  at	  the	  GP130	  promoter.	  If	  
this	  is	  the	  case,	  then	  when	  cells	  are	  treated	  with	  a	  MEK/ERK	  inhibitor	  both	  ERK2	  and	  such	  a	  
repressor	  will	  be	  removed	  from	  the	  promoter	  and	  the	  repression	  relieved.	  
	  
One	  important	  experiment	  that	  was	  not	  done	  was	  to	  check	  the	  binding	  of	  ERK2	  to	  the	  GP130	  
promoter	  after	  chemical	  inhibition	  of	  ERK2.	  If	  the	  levels	  of	  ERK2	  at	  the	  promoter	  decrease,	  
then	  this	  will	  indicate	  that	  ERK	  enzymatic	  activity	  is	  likely	  involved	  in	  the	  regulation	  of	  gp130	  
expression.	  On	  the	  other	  hand,	  if	  MEK/ERK	  inhibitors	  do	  not	  reduce	  the	  binding	  of	  ERK2	  to	  
the	  gp130	  promoter,	   then	  MAPK	  activity	  and/or	   is	  not	   involved	   in	   the	  regulation	  of	  gp130	  
induction	  and	  expression.	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6.3.	  Future	  Perspectives	  
The	  work	  reported	   in	  this	  thesis	  defines	  a	  new	  role	  for	  ERK2,	  not	  shared	  with	  ERK1,	   in	  the	  
regulation	   of	   gp130	   expression.	   Surprisingly,	   it	   seems	   that	   ERK2	   kinase	   activity	   is	   not	  
involved	   in	   this	   regulation	   and	   that	   ERK2	   does	   not	   bind	   directly	   to	   the	   DNA	  molecule	   as	  
initially	   suspected.	   Instead,	   it	   likely	   binds	   to	   other	   molecules	   present	   on	   the	   GP130	  
promoter.	   However,	   whenever	   a	   scientific	   question	   is	   answered	   several	   others	   arise,	   and	  
this	   research	   is	  no	  exception.	   In	   this	   final	   section,	  possible	   future	  work	  arising	   from	   these	  
discoveries	  is	  presented.	  
	  
6.3.1.	  Which	  part	  of	  ERK2	   is	   required	  for	   the	  regulation	  of	   the	  GP130	  promoter?	   Is	  ERK2	  
kinase	  activity	  important?	  
To	  address	  this	  question,	  ERK2	  could	  be	  stably	  silenced	  using	  a	  short	  hairpin	  (sh)	  ERK2,	  and	  
the	  extent	  of	  the	  knockdown	  of	  ERK2	  and	  gp130	  confirmed	  by	  qPCR	  and	  western	  blotting.	  
Subsequently,	  it	  would	  be	  possible	  to	  use	  shERK2-­‐tranfected	  cells	  could	  be	  transfected	  with	  
various	   SF-­‐ERK2	   tagged	   constructs,	   which	   would	   include	   wild-­‐type,	   kinase-­‐dead	   and	  
constitutively	  active	  ERK2.	  Cells	  would	  also	  be	  transfected	  with	  constructs	  corresponding	  to	  
different	  parts	  of	  the	  molecule	  in	  order	  to	  identify	  which	  part,	  or	  parts,	  of	  the	  molecule	  are	  
important	  for	  the	  regulation	  of	  ERK2.	  	  
	  
6.3.2.	  Which	  molecules	  are	  involved	  in	  the	  regulation	  GP130	  promoter?	  
We	   have	   shown	   that	   in	   ‘resting	   cells’,	   ERK2	   binds	   to	   GP130	   promoter,	   facilitating	  
transcription	   of	   GP130.	   Downregulation	   of	   ERK2	   expression	   by	   RNAi	   does	   not	   change	   the	  
amount	   of	   RNAP	   II	   that	   binds	   to	   the	   GP130	   promoter	   but	   it	   compromises	   the	   way	   it	   is	  
activated.	   Indeed,	   the	   phosphorylation	   of	   both	   S5	   and	   S2	   are	   reduced,	   as	   is	   histone	   H3	  
polyacetylation.	  This	   indicates	  that	   the	  GP130	  promoter	   is	   less	  active	   in	  cells	  with	  silenced	  
ERK2	  than	   it	   is	   in	  wild-­‐type	  and	   in	  cells	   transfected	  with	  a	  NS	  RNAi	  control.	  This	   is	  a	  novel	  
observation	   and	   others	   in	   the	   laboratory	   are	   in	   the	   process	   of	   identifying	   which	   other	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molecules	  are	  involved	  in	  this	  regulation.	  We	  suspect	  that	  ERK2	  does	  not	  bind	  directly	  to	  the	  
DNA,	  as	   the	  mutation	  of	  known	  putative	  ERK2	  DNA	  binding	  sites	  on	   the	  promoter	  did	  not	  
completely	  revert	  the	  phenotype.	  Therefore,	  these	  interactions	  likely	  require	  other	  proteins	  
as	  yet	  unidentified.	  Goke	  and	  co-­‐workers	   (Goke	  et	  al.,	  2013)	  have	   recently	   suggested	   that	  
ELK-­‐1	  recruits	  polycomb	  proteins	  to	  the	  DNA	  and	  ERK2	  may	   interfere	  with	  this	   interaction.	  
We	  analysed	  Goke’s	  data	  set	  and	  noted	  with	  great	   interest	   that	  ELK1	  bound	  to	  the	  GP130	  
promoter.	  We	  were,	   thus,	   disappointed	   to	   learn	   that	   silencing	   ELK1	   does	   not	   reduce	   the	  
induction	  of	   gp130	  mRNA.	   Indeed,	  RNAi	   against	   ELK1	   individually,	   or	   in	   combination,	  with	  
ERK2	  does	  not	  have	  an	  impact	  on	  the	  levels	  of	  gp130	  mRNA.	  This	  indicates	  that	  GP130	  does	  
not	  follow	  the	  same	  pattern	  described	  by	  Goke	  and	  co-­‐workers.	  To	  identify	  proteins	  involved	  
in	   this	   regulatory	   complex	   and,	   subsequently,	   their	   precise	   roles,	   one	   could	   perform	  
immunoprecipitation	   with	   the	   ERK2	   antibody	   used	   for	   ChIP	   and	   the	   same	   experimental	  
conditions,	   followed	  by	  mass	   spectrometry.	   Any	   proteins	   identified	   by	   this	  method	  would	  
then	   be	   verified	   by	   ChIP	   using	   specific	   antibodies.	   This	   could	   then	   be	   followed	   by	   RNAi	  
against	  each	  one	  of	  these	  targets,	  and	  against	  them	  and	  ERK2	  concomitantly,	  using	  gp130	  as	  
a	   read-­‐out.	   We	   have	   tried	   to	   co-­‐immunoprecipate	   ERK2	   with	   RNAP	   II	   without	   success.	  
However,	   it	   is	  possible	  that	  such	  failure	  was	  due	  to	  the	  experimental	  conditions	  used.	  This	  
too	  will	  need	  to	  be	  re-­‐assessed	  and	  investigated	  in	  greater	  detail.	  
	  
6.3.3.	   Can	   ERK2	   influence	   the	   binding	   of	   transcription	   factors	   and/or	   repressors	   to	   the	  
GP130	  promoter?	  
One	  hypothesis	  that	  was	  not	  tested	  was	  the	  possibility	  that	  ERK2	  might,	  somehow,	  influence	  
the	   binding	   of	   transcription	   factors	   to	   the	  GP130	   promoter.	   If	   that	  was,	   indeed	   the	   case,	  
then	  knocking	  down	  ERK2	  in	  cells	  would	  influence	  the	  binding	  of	  transcription	  factors	  such	  
as	  SP1,	  STAT3,	  AP-­‐1	  or	  C/EBP-­‐β.	  As	  shown	  in	  Figure	  4.4	  several	  binding	  sites	  were	  identified	  
for	  SP1	  protein.	  Similarly,	  ERK2	  could	  contribute	  to	  reducing	  the	  binding	  of	  GP130	  promoter	  
repressors.	  This	  question	  can	  be	  addressed	  by	  analysing	  by	  ChIP	  binding	  of	  the	  transcription	  
factors	   in	   the	   presence	   or	   absence	   of	   ERK2.	   If	   the	   binding	   of	   some	   of	   these	   molecules	  
changed,	   then	   it	   is	   possible	   that	   ERK2	   influences	   their	   binding	   to	  GP130	   promoter.	   Those	  
molecules	   are	   probably	   involved	   in	   the	   mechanism	   through	   which	   ERK2	   regulates	   gp130	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expression.	  	  
In	   addition,	   It	   is	   still	   possible	   that	   proteins	   belonging	   to	   the	   ELK1	   family	   could	   recruit	  
repressors	   as	   it	   was	   previously	   described	   to	   ELK1	   (Goke	   et	   al.,	   2013).	   The	   analysis	   of	   the	  
binding	   of	   such	   proteins	   to	   GP130	   promoter	   and	   their	   knockdown	   individually	   or	   in	  
combination	  with	  ERK2	  protein	  would	  define	  their	  role	  in	  the	  regulation	  of	  GP130	  promoter.	  
	  
6.3.4.	  Can	  ERK2	  activation	  and/or	  activity	  influence	  ERK2	  binding	  to	  the	  GP130	  promoter?	  
In	   order	   to	   determine	   whether	   ERK2	   activity	   is	   important	   for	   its	   binding	   to	   the	   GP130	  
promoter,	  one	  could	  treat	  cells	  with	  MEK/ERK	  chemical	  inhibitors	  and	  analyse	  ERK2	  binding	  
to	  this	  promoter	  by	  ChIP.	   If	  similar	  binding	  was	  observed	  before	  and	  after	  treatment,	  then	  
that	  would	  indicate	  that	  ERK	  kinase	  activity	  is	  not	  relevant	  for	  this	  binding	  and,	  therefore,	  for	  
the	   regulation	  of	  gp130.	  On	   the	  other	  hand,	   If	  ERK2	  did	  not	  bind	  when	  cells	  were	   treated	  
with	  the	  inhibitor,	  then	  that	  would	  suggest	  that,	  in	  the	  context	  of	  gp130	  regulation,	  both	  the	  
functions	  of	  ERK2	  and,	  perhaps,	  a	  repressor	  are	  dependent	  on	  activated	  ERK.	  
	  
We	   have	   tested	   specific	   pERK2	   antibodies	   in	   ChIP	   assays	   but	   none	   of	   them	  have	  worked.	  
However,	  without	  a	  good	  positive	  control,	   it	   is	  not	  possible	  to	  distinguish	  whether	   it	   is	  the	  
antibodies	   that	   are	   not	   working,	   or	   whether	   this	   reflects	   a	   bona	   fide	   negative	   result	   and	  
phosphorylated	  ERK2	  does	  not	  bind	  to	  a	  specific	  sequence	  within	  GP130.	  	  
	  
6.3.5.	  Which	  part	  of	  GP130	  promoter	   is	   important	   for	   the	  direct,	  or	   indirect,	   interaction	  
with	  ERK2?	  
The	   full-­‐length	  gp130	   luciferase	  plasmid	   (p2433)	  could	  be	  cut	  using	   restriction	  enzymes	  as	  
described	   previously	   (O'Brien	   and	   Manolagas,	   1997).	   This	   would	   create	   smaller	   DNA	  
fragments	   with	   the	   following	   length	   from	   TSS:	   1151,	   539,	   38	   and	   191	   nucleotides.	   By	  
analysing	  each	  reporters’	  activity	  before	  and	  after	  ERK2	  knockdown,	  it	  would	  be	  possible	  to	  
discover	  which	  part	  of	  the	  GP130	  promoter	  is	  necessary	  for	  this	  regulation.	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6.3.6.	   Is	   human	  GP130	   luciferase	  promoter	   activity	   decreased	   in	  MEF	   ERK2	   -­‐/-­‐	   knockout	  
cell	  when	  compared	  to	  WT	  or	  ERK1	  -­‐/-­‐?	  
The	  human	  and	  mouse	  ERK2	  proteins	  are	  very	  similar.	  This	  would	  suggest	  that	  ERK2	  can	  play	  
similar	  roles	  in	  both	  human	  and	  mouse	  systems.	  However,	  the	  absence	  of	  Erk2	  in	  MEFs	  did	  
not	  affect	   the	  expression	  of	  gp130.	   Indeed,	   the	  question	  of	  whether	  mouse	  Erk2	  can	  even	  
regulate	  promoter	  activity	  of	  genes	  is	  still	  unclear.	  	  
	  
To	  approach	  this,	  one	  could	  compare	  the	  luciferase	  activity	  of	  the	  human	  GP130	  promoter	  
construct	   in	  the	  wild-­‐type	  and	  Erk2-­‐/-­‐	  MEFs.	  This	  experiment	  would	  establish	   if	   the	  reason	  
why	   Erk2	   does	   not	   regulate	  mouse	   gp130	   expression	   is	   because	   its	   promoter	   is	   different	  
from	  the	  human	  promoter.	  
	  
6.3.7.	  Can	  ERK2	  also	  regulate	  the	  expression	  of	  other	  receptor	  molecules	  using	  the	  same	  
mechanism?	  
The	  mechanism	  through	  which	  ERK2	  regulates	  gp130	  expression	  is	  probably	  not	  exclusive	  to	  
gp130.	  After	  understanding	   this	  mechanism	   fully,	   it	  would	  be	   interesting	   to	   identify	  other	  
receptors	  whose	  expression	  is	  controlled	  by	  ERK2.	  Such	  molecules	  could	  be	  identified	  using	  
ChIP-­‐seq	  for	  ERK2	  and	  one	  or	  more	  molecules	  identified	  in	  Section	  6.3.1.	  	  
	  
6.3.8.	  Is	  IL-­‐31	  Receptor	  α 	  regulated	  by	  ERK2?	  
Unlike	   other	   family	   members,	   IL-­‐31	   does	   not	   signal	   though	   gp130	   but	   instead	   it	   uses	   IL-­‐
31Rα,	  either	  as	  a	  monomer,	  or	  as	  a	  complex	  with	  OSMR.	  Interestingly,	  the	  genomic	  position	  
of	   IL31RA	   (5q11.2)	   is	   only	   24	   Kb	   downstream	   of	   the	   GP130	   gene	   having	   opposite	  
transcriptional	   orientations	   [Reviewed	   in	   (Zhang	   et	   al.,	   2008)].	   This	   receptor	   activates	   the	  
same	  main	  pathways	  described	  for	  the	  other	  IL6-­‐type	  cytokines,	  so,	  it	  would	  be	  interesting	  
to	  understand	  whether	   these	   receptors	   are	   regulated	  by	   the	   same	  mechanisms	  described	  
for	  gp130.	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6.3.9.	  How	  does	  ERK1	  regulate	  receptors	  such	  as	  FGFR1	  and	  FGFR2?	  
Before	   studying	   this	   further,	   it	   will	   be	   necessary	   to	   understand	   whether	   the	   initial	  
observation	  that	  suggests	   that	  FGFR1	  and	  FGFR2	  expression	   is	  at	   least	  partially	  dependent	  
on	  ERK1	  is	  a	  RNAi	  specific	  effect,	  or	  an	  off-­‐target	  effect.	  If	   it	  proves	  to	  be	  the	  former,	  then	  
similar	   analyses	   like	   the	   ones	   performed	   during	   this	   study	   would	   give	   us	   valuable	  
information	  about	  the	  nature	  of	  the	  regulation.	  	  
	  
An	  understanding	  of	  whether	  ERK1	  kinase	  activity	   is	  necessary	   for	   this	   could	  be	  gained	  by	  
using	  chemical	  inhibition.	  Overexpression	  of	  ERK1	  and	  ERK1/ERK2	  chimeras,	  as	  described	  in	  
Chapter	  3	  might	  identify	  which	  part	  of	  the	  ERK1	  molecule	  is	  important	  to	  the	  regulation	  of	  
FGFRs	  and	  probably	  explain	  why	  ERK1,	  but	  not	  ERK2,	  has	  an	   impact	  on	  FGFR1	  and	  FGFR2	  
expression.	   This	   would	   further	   demonstrate	   that	   ERK1	   and	   ERK2	   have	   distinct	   roles.	   and	  
define	   a	   new	   role	   for	   ERK1.	   This	   could	   be	   an	   important	   advance	   in	   our	   knowledge	   of	  
carcinogenesis	  as	  FGFRs	  are	  often	  mutated,	  or	  de-­‐regulated,	  in	  cancer	  malignancy	  [reviewed	  
in	  (Ahmad	  et	  al.,	  2012)].	  
	  	  
6.2.10.	  How	  do	  AKT2	  and	  AKT3	  control	  gp130	  expression?	  
Some	  of	   the	  experiments	  performed	  using	   siERK2	   in	  Chapter	   3	   and	  Chapter	   4	  need	   to	  be	  
repeated	   using	   siAKT2	   and	   siAKT3	   in	   order	   to	   characterize	   the	   regulation	   of	   gp130	  
expression	   by	   these	   molecules.	   Questions	   that	   need	   to	   be	   addressed	   include	   whether	  
overexpression	   of	   AKT2	   and/or	   AKT3	   would	   change	   gp130	   levels,	   and	   whether	  
knockdown/overexpression	  of	  either	  would	   influence	  GP130	  promoter	   induction.	  We	  have	  
tested	  the	  suitability	  of	  different	  AKTs	  antibodies	  for	  ChIP	  but	  none	  yielded	  a	  positive	  result	  
under	  the	  experimental	  conditions	  used.	  It	  remains	  the	  possible	  that	  the	  antibodies	  used	  or	  
indeed	  the	  experimental	  conditions	  were	  not	   ideal	   for	  detecting	  this	  association	  and	  more	  
work	  has	  to	  be	  done	  to	  establish	  this.	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6.3.11.	   Does	   AKT2	   regulate	   gp130	   expression	   through	   the	   regulation	   of	   ARE-­‐containing	  
mRNA	  or	  through	  another	  mRNA	  degradation	  pathway?	  
AKT2	   has	   been	   reported	   to	   regulate	   the	   levels	   of	  mRNA	   containing	   ARE	   elements.	   GP130	  
mRNA	  contains	  several	  such	  motifs	  as	  discussed	  in	  Section	  5.3.	  Further	  investigation	  will	  be	  
necessary	  to	  understand	  whether	  this	  is	  indeed	  the	  case.	  This	  seems	  likely	  because	  knocking	  
down	  AKT2	   led	   to	   a	   decrease	   in	   the	   stability	   of	   gp130	  mRNA.	   To	   address	   this,	   one	  would	  
need	   to	   analyse	  molecules	   involved	   in	   the	   regulation	  of	  ARE-­‐containing	  mRNA	  upon	  AKT2	  
knockdown.	   If	   AKT2	   was	   involved	   in	   this	   regulation,	   then	   one	   would	   expect	   that	   in	   cells	  
transfected	   with	   siRNA	   targeting	   AKT2,	   or	   cells	   overexpressing	   AKT2,	   the	   affinity	   of	   the	  
proteins	   involved	   in	  the	  regulation	  of	  ARE-­‐containing	  elements	  within	  gp130	  mRNA	  will	  be	  
altered.	  In	  case	  of	  these	  pathway	  is	  not	  affected	  we	  would	  need	  to	  test	  the	  other	  regulatory	  
regulated	  pathways.	  
	  
6.3.12.	  Does	  AKT1	  modulate	  the	  expression	  of	  OSMR?	  
The	  control	  of	  expression	  of	  OSMR	  needs	  further	  investigation.	  As	  described	  in	  Section	  6.3.6	  
for	   the	   regulation	  of	  FGFR	  by	  ERK1,	   first	  of	  all,	   the	  possibility	   that	   this	   is	  a	  RNAi	  off-­‐target	  
effect	  must	  be	  excluded	  by	  deconvolution	  analysis.	   If	   it	   is	  not,	   then	   it	  will	  be	   important	   to	  
establish	  whether	   PI3K	   chemical	   inhibitors	   decrease	   the	   expression	   levels	   of	   OSMR.	   AKT1	  
overexpression	  would	   also	   help	   characterize	   the	   nature	   of	   this	   regulation.	   Following	   this,	  
further	   research	   probing	   molecular	   pathways	   in	   greater	   detail	   would	   be	   necessary	   to	  
understand	  the	  mechanism	  involved.	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6.4.	  Final	  conclusions	  
The	  present	  thesis	  describes	  an	  important	  new	  role	  for	  ERK2,	  not	  shared	  with	  ERK1,	   in	  the	  
regulation	   of	   gp130	   receptor.	   ERK2	   does	   not	   behave	   in	   the	   ‘classical’	   manner,	   as	   its	   full	  
kinase	  activity	   is	  dispensable.	  Alternatively,	  ERK2	  binds,	  directly	  or	   indirectly,	  to	  the	  GP130	  
promoter	  and	  regulates	  the	  expression	  of	  gp130.	  Indeed,	  the	  presence	  of	  ERK2	  at	  the	  GP130	  
promoter	   is	   crucial	   for	   its	  expression.	  This	  new	  mechanism	  of	   regulation	  of	  gp130	  has	  not	  
been	  described	  before	  and	  it	  is	  likely	  that	  it	  can	  be	  extended	  to	  molecules	  other	  than	  gp130.	  
	  
Both	  ERK2	  and	  gp130	  are	  frequently	  implicated	  in	  carcinogenesis,	  be	  it	  by	  helping	  cancers	  to	  
develop	  or	  to	  spread.	  Understanding	  these	  mechanisms	  may	  highlight	  alternative	  therapies	  






















Control of gp130 expression by the mitogen-activated protein
kinase ERK2
NA Bonito1, J Drechsler2,4, S Stoecker1,4, CR Carmo1,3,4, MJ Seckl1, HM Hermanns2 and AP Costa-Pereira1
Interleukin (IL)-6-type cytokines such as IL-6, oncostatin M (OSM) and leukaemia inhibitory factor (LIF) signal through receptor
complexes that are critically dependent on gp130. The latter is the common signal-transducing molecule that couples these
cytokines to their downstream effectors, Janus kinases (JAKs) and signal transducers and activators of transcription (STATs).
IL-6-type cytokine signalling additionally involves the recruitment and activation of extracellular signal-regulated kinase (ERK) 1 and
ERK2. Both STATs and ERKs regulate responses mediated by members of the IL-6 family. Here, we show that ERK2, but not ERK1,
also controls the expression and function of gp130 per se, as silencing ERK2 in human osteosarcoma U2OS cells inhibits the
expression of gp130. This does not simply reﬂect quantitative differences between ERK1 and ERK2, and the effects are not restricted
to osteosarcoma cells, as they can be extended to several other cancer cell types analysed to date (such as breast, prostate, lung
and cervical cancer cells). Importantly, ERK2 binds to the GP130 promoter, where it perhaps interacts with the transcriptional
machinery. Indeed, its role in the transcriptional regulation of the GP130 gene was corroborated using luciferase reporter assays and
messenger RNA stability experiments. Considering the pivotal role that gp130 has in cancer and inﬂammation these data thus
identify novel non-overlapping functions for ERK1 and ERK2 that are biologically relevant.
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INTRODUCTION
One ﬁfth of all cancers are thought to be associated with chronic
inﬂammation.1 Inﬂammatory cytokines such as interleukin (IL)-6 are
frequently elevated in cancer patients and this correlates with
adverse prognosis.1–3 Karin and co-workers have demonstrated
that IL-6 can be a tumour promoting cytokine by virtue of causing
inﬂammation and STAT3 activation.4 STAT3 is recognised as a bona
ﬁde oncogene5 and constitutive tyrosine phosphorylation of STAT3
on position 705 (Y705), which is indicative of activation, is observed
in a surprisingly large number of tumours.6,7 Though abnormally
activated in so many cancer cells, STAT3 mutations are not very
common, with perhaps the exception of large granular
lymphocytic leukaemia,8 arguing that deregulated signalling
upstream of STAT3 is an important component of carcinogenesis.
Interestingly, IL-6-type cytokine signalling can trans-activate the
epidermal growth factor receptor (EGFR), thereby enhancing
tumour growth,9 and STAT3 without classical activation can
transform cells through novel/non-canonical mechanisms.10–12
STAT3 is the main transcription factor activated by IL-6-type
cytokines.13–16 These cytokines (for example, IL-6, oncostatin M
(OSM), leukaemia inhibitory factor (LIF)) not only activate Janus
kinase (JAK)/signal transducers and activators of transcription
(STAT) signalling but also trigger phosphorylation of extracellular-
regulated kinase (ERK) 1 and ERK2. Both arms of the response
have an impact on biological responses triggered by IL-6-type
cytokines.14,17–19 These cytokines signal through diverse receptor
complexes that have in common a subunit called gp130 and a
variable subunit (IL-6R, OSMR, LIFR). The gp130 has several
intracellular tyrosine residues that become phosphorylated by
three distinct JAKs upon ligand binding, thus creating docking
sites for the STATs. STATs can also be recruited via OSMR and LIFR.
Additional tyrosine residues on gp130, LIFR or OSMR recruit SRC
homology (SH) 2 domain-containing tyrosine phosphatase 2
(SHP2/PTPN11) or SH2 domain containing (SHC) transforming
protein, and the suppressor of cytokine signalling (SOCS) 3.14,18
SHP2 and SHC can trigger mitogen-activated protein kinase
(MAPK) signalling downstream of IL-6/LIF and OSM,
respectively.20–22
Increased secretion of IL-6-type cytokines can lead to deregu-
lated activation of IL-6 signalling,23 and gain-of-function mutations
within the GP130 gene can lead to an increase of its cellular
functions and constitutive STAT3 activation.24 IL-6 induces many
antiapoptotic genes through activation of STAT3 and MAPKs,
thereby contributing to cancer cell survival and cancer
progression.25,26 In addition, IL-6-type cytokines have critical
roles in embryonic cell development.3,26 These properties, and
more recently recognised roles in inﬂammation-associated
cancers, explain why a considerable amount of effort is going
into developing therapies that target gp130, STAT3 and MAPK
signalling in the clinic. Much is known about JAK/STAT and MAPK
signalling downstream of IL-6-type cytokines, but how all the
molecules involved in these signalling pathways interact and are
potentially regulated by each other remains to be fully
understood, and was the main aim of our study.
The MAPKs ERK1 and ERK2 are highly homologous serine/
threonine kinases, ubiquitously expressed and can be activated by
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the same upstream effectors. They also share many substrates and
are often assumed to have identical cellular roles, which depend
on their relative expression.27 Indeed, Lenormand and co-workers
provided striking evidence for the indiscriminate activation of the
two kinases by the same effectors and a direct correlation
between the activation and expression levels of ERK1 and ERK2.
The fact that Erk2 / mice are embryonic lethal28 and Erk1 /
viable29 has also been attributed to generally lower Erk1 levels
seen in most cells. More recent work, however, has provided
evidence for the existence of additional, distinct, cellular functions.
For example, keratinocytes from Erk1 / mice proliferated less in
response to mitogenic factors, displayed impairment in c-Fos
expression and were more resistant to the development of skin
papillomas than the wild-type cells.30 It is also clear that ERKs have
additional functions that do not depend on their kinase activity
and that they can bind to speciﬁc DNA sequences.31
Despite reports that ERK1 opposed some of ERK2 mitogenic
functions, a recent study by Meloche and co-workers, employing
both mouse embryonic ﬁbroblasts (MEFs) and RNAi, strongly
argues against this.32 A similar study has not been conducted in
the context of IL-6-type cytokine signalling. We therefore
investigated the impact of genetic inhibition of ERK1 or ERK2 on
molecular events triggered by IL-6-type cytokines in human U2OS
osteosarcoma cells. Here, we show that genetic ablation, but not
chemical inhibition, of ERK2 leads to a nearly complete abrogation
of gp130 expression, a receptor essential to transduce IL-6-type
cytokine signals. ERK2 has an impact on GP130 transcription. It
binds to the GP130 promoter and may thus regulate this protein’s
expression by interacting with the mediator complex or by
remodelling the chromatin. Luciferase-based reporter assays and
experiments involving the transcription inhibitor actinomycin D,
however, argue for the former. These selective ERK2 effects are
likely to have far-reaching implications, as they were observed in
several other types of cancer cells, and ERK2 and gp130 protein
expression were almost directly proportional.
RESULTS
Downregulation of ERK2, but not ERK1, abrogates STAT1 and
STAT3 phosphorylation in response to IL-6-type cytokines
U2OS cells are highly transfectable and amenable to RNAi, which
was important to study the impact that reducing the levels of
ERK1 or ERK2 had on events triggered by IL-6-type cytokines.
U2OS cells were treated with IL-6/sIL-6R, OSM or LIF, and time- and
dose-responses carried out using STAT and ERK phosphorylation
as readouts (Figure 1a and data not shown). STAT3 phosphoryla-
tion on Y705 was stronger than STAT1 phosphorylation on Y701,
with OSM being the strongest activator of these transcription
factors. ERK1 and ERK2 phosphorylation was also more pro-
nounced downstream of OSM signalling. The predominant
activation of ERK2 correlated with the higher expression level of
this isoform in these cells. ERK2 phosphorylation was barely
triggered by IL-6/sIL-6R and not detectable following LIF stimu-
lation under these experimental conditions.
U2OS cells were transfected with siRNA pools targeting ERK2
(hereinafter referred to as siERK2), ERK1 (siERK1) or with non-
targeting siRNA (siNS) (Supplementary Table SI). Forty-eight hours
later whole-cell extracts were analysed by western blotting for the
activation of relevant signalling components (Figure 1b). In all
experiments, untransfected cells were included in the analyses.
Surprisingly, the knockdown of ERK2 completely blunted STAT3
and STAT1 tyrosine phosphorylation on critical residues upon IL-6
or OSM treatment (Figure 1b). This was surprising, as both proteins
were still highly expressed in these cells. Cells transfected with
siNS oligonucleotides behaved essentially as the untransfected
controls. ERK1 knockdown did not affect the expression levels of
STAT3 or STAT1 nor their phosphorylation status, which was in
contrast to what was seen after silencing ERK2 (Figure 1b).
Silencing ERK2 led to an increase in ERK1 phosphorylation,
which was particularly obvious after IL-6 treatment. This was
intriguing, as IL-6 is a much weaker activator of the ERKs than OSM
(Figures 1a and b). However, this phosphorylation event was not
ligand-dependent, as it could also be observed in U2OS cells that
were transfected with siERK2 but were not challenged with any
IL-6-type cytokine (Supplementary Figure S1), and it was not cell
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Figure 1. Downregulation of ERK2 but not ERK1 abrogates STAT3
and STAT1 phosphorylation in response to IL-6-type cytokines.
(a) Kinetics of phosphorylation/activation of STAT1, STAT3, ERK1 and
ERK2 in response to IL-6/sIL-6R (400 ng/ml; 500 ng/ml), OSM (50 ng/
ml) and LIF (50 ng/ml) in human osteosarcoma U2OS cells. Western
blot membranes were probed with pSTAT3Y705, pSTAT1Y701 and
pERK1/2T202Y204/T185Y187, and after stripping, re-probed with
antibodies against STAT1, STAT3 and ERK1/2, respectively. b-actin
was used as a loading control. (b) Cells were transfected for 48 h
with 20 nM siNS, siERK1, siERK2 or left untransfected (Supplementary
Table I). Cells were then treated with IL-6/sIL-6R, or OSM for 15min
and 30 mg total protein extract analysed as above. (c) Silencing ERK2,
but not ERK1, led to STAT3 mRNA downregulation. Cells were
transfected as before, RNA isolated and analysed by qPCR, using
HPRT as a house-keeping gene. Data shown are representative of
three independent experiments that yielded identical results.
Statistical analysis was done using Student’s t-test (*Po0.05,
**Po0.01, ***Po0.005 versus siNS-transfected control). Unt:
untreated; ø: untransfected control; NS: siNS; E1: siERK1, E2: siERK2.
Dotted line indicates a discontinuous gel.
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The transfection of U2OS cells with siERK2 also led to a decrease
in the total amounts of STAT3 (Figure 1b). In order to establish at
what level this occurred, cells were transfected as described
above, RNA extracted, reverse transcribed and analysed by real-
time PCR (qPCR) (Supplementary Table SII). The decrease observed
at the protein level (Figure 1b) was also observed at the
messenger RNA (mRNA) level (Figure 1c) and appeared to be
B33%.
Impact of ERK2 silencing on OSM target gene induction
The inhibition of STAT3 and STAT1 tyrosine phosphorylation
(Figure 1b) suggested that ERK2 silencing affected OSM-mediated
STAT3 and STAT1 activation. To determine to what extent the ERKs
participated in STAT-target gene induction, we analysed
well-described target genes of these transcription factors. RNAi
against ERK1, ERK2 and, as a control, gp130 was performed as
previously, and RNA extracted from untreated and OSM-treated cells
was analysed by qPCR for levels of suppressor of cytokine signalling
(SOCS)-3 and early growth response protein (EGR)-1, which are
downstream transcriptional targets of predominantly STAT3 and
ERKs, respectively (Figure 2 and Supplementary Table SII).
Downregulation of ERK2 greatly affected JAK/STAT signalling
downstream of the gp130/OSMR complex, as SOCS3 mRNA
induction was reduced more than 2.5-fold (B60%) when
compared with the levels measured in siNS-transfected cells
(Figure 2a). Silencing ERK1 actually increased 1.4-fold the
induction of SOCS3 by OSM when compared with the siNS-
transfected cells. In control cells, direct downregulation of gp130
reduced the mRNA induction by 14-fold (B93%).
Interestingly, silencing ERK1 or ERK2 modulated EGR-1 mRNA in
opposite ways: silencing ERK1 led to a 1.6-fold increased induction
of EGR-1, whereas silencing ERK2 led to 1.7-fold decrease. This
reﬂected perhaps an antagonistic role of these kinases in the
regulation of this particular gene. EGR-1 mRNA levels were also
reduced following RNAi against gp130 (B50% versus siNS),
presumably due to the downregulation of STAT/ERK signalling in
these cells, as OSM relies on gp130 (together with OSMR or LIFR)
for signal transduction. Collectively, these data suggested that
ERK2 downregulation had a negative effect on a critical signalling
component upstream of phosphorylation/activation of STAT3 and
STAT1. We hypothesised that such a component was likely to be
gp130 or the JAKs. Expression levels of JAK1, JAK2 and TYK2, all
engaged upon IL-6-type cytokine signalling, remained unaltered
after silencing ERK1 or ERK2 (data not shown). We, therefore,
investigated the expression of gp130, which is the most upstream
signalling component of all IL-6-type cytokine receptor complexes.
Downregulation of ERK2 leads to the absence of gp130, the
essential signal-transducing component of IL-6-type cytokine
receptor complexes, independently of MAPK activity
U2OS cells were transfected as previously described, stained with
an anti-gp130 antibody and analysed by ﬂow cytometry
(Figure 3a). The quantitative expression of gp130 and correspond-
ing statistical signiﬁcance is shown in Figure 3b, using data from
three independent experiments. Strikingly, silencing ERK2 had a
major impact on gp130 protein expression on the cells’ surface
(B80% reduction versus siNS-transfected cells). As this is the
molecule to which STAT1 and STAT3 dock in order to become
phosphorylated by the JAKs, it explained why these molecules
were not phosphorylated by IL-6 and OSM stimulation when ERK2
was silenced (Figure 1b), and why transcription of OSM target
genes was only marginally induced (Figure 2). There was a very
small decrease in the levels of gp130 protein upon siERK1 (B5%),
but this was not statistically signiﬁcant and, naturally, there was a
massive reduction (B95%) when gp130 was targeted by RNAi.
qPCR was used to measure the mRNA levels of gp130 following
silencing of ERK1 or ERK2 (Figure 3c). The mRNA levels reﬂected
protein expression data shown in Figures 3a and b. Silencing ERK2
decreased the mRNA levels of gp130 down toB35% of the amount
of gp130 in siNS-transfected cells, indicating that, somehow, ERK2
controlled the transcription of the GP130 gene. Interestingly, despite
the fact that silencing ERK1 was without effect on the activation of
STAT3 and STAT1, gp130 mRNA levels were B12.5% lower than
those measured in untransfected cells (data not shown) or cells
transfected with siNS, and this reduction was statistically signiﬁcant
(Figure 3c). Regardless, the reduction of gp130 mRNA and protein
elicited by siERK1 was not sufﬁcient to have an impact on the
phosphorylation of STAT1 and STAT3 (Figure 1b), nor did it appear
to have a negative impact on signalling downstream OSM
(Figure 2). Analyses of gp130 phosphorylation per se suggested
that the gp130 receptor could not be phosphorylated upon
transfection with siERK2 but was still phosphorylated when ERK1
was downregulated (data not shown), further suggesting a speciﬁc
role for ERK2 in the regulation of gp130.
ERKs phosphorylate many transcription factors, thus promoting
transcription of many different genes. RNAi permitted efﬁcient
manipulation of protein levels and enzymatic activity of ERK2
concomitantly. For this reason, and in order to establish if it was
the lack of enzymatic activity of ERK2 that affected the expression
of gp130, U2OS cells were treated with different well-established
MAPK kinase (MEK) inhibitors and gp130 expression assessed
(Figures 3d–f). In order to activate ERK1/2 and test the efﬁcacy of
the inhibitors, cells were incubated with fetal calf serum (FCS) for
15min only. Regardless of the incubation time or dose, and
despite being functional as judged by the inhibition of ERK1/2
phosphorylation, PD0325901, PD98059 and U0126 did not
inﬂuence the total amount of gp130 (Figure 3d) or the cell
surface localisation of the protein as determined by a highly
quantitative ﬂow cytometry-based method (Figure 3e). These
inhibitors block both the phosphorylation and subsequent
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Figure 2. ERK2 and ERK1 knockdown affects ERK (EGR-1) and STAT-
(SOCS3) target gene induction following OSM signalling. U2OS cells
were transfected with siRNAs as before, RNA was isolated and
analysed by qPCR. The data represent, for each set of siRNA
transfection, the average values of gene induction in treated
samples (n¼ 3) over the induction in untreated cells and, for
statistical purposes, all comparisons have used siNS as the reference
sample. (a) SOCS3. (b) EGR-1. The results shown represent the
statistical analysis using Student’s t-test (*Po0.05, **Po0.01,
***Po0.005 versus siNS-transfected control).
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ERK1/2 auto-phosphorylation or phosphorylation independent of
MEKs. We therefore also used FR180204, an ERK1/2 ATP-
competitive inhibitor. Cells were incubated with this inhibitor
and stimulated with FCS. This inhibitor did not affect phosphory-
lation of ERK1/2 per se, but it blocked the phosphorylation of an
ERK1/2 downstream target, RSK1, used here as a readout for
inhibitor efﬁcacy (Figure 3f). Despite the clear inhibition of RSK1
phosphorylation, no alteration in gp130 expression was detected
at any time-point. These data suggested that ERK2 might provide
a structural role in the regulation of gp130, which is independent
of enzymatic activity. This was intriguing, as the knockdown of
ERK2 affected gp130 mRNA levels, implying a role in its
transcriptional regulation (Figure 3c).
ERK2 binds to the promoter of GP130 and regulates GP130
transcription
Having shown that the enzymatic activity of ERK2 was not critical
for full expression of gp130 but that downregulation of ERK2
protein affected both its protein expression and mRNA induction,
we next asked whether ERK2 acted at the level of the GP130
promoter. For that purpose, chromatin immunoprecipitation
(ChIP) experiments were done using an anti-ERK2 antibody and
primer pairs that hybridised to different locations of the GP130
gene (Figure 4a and Supplementary Table SIII). As additional
controls, a non-related region of chromosome 5 was also
ampliﬁed and RNA polymerase II was also immunoprecipitated.
In all experiments immunoprecipitations using IgG were carried
out in order to calculate background binding. ERK2 and RNA
polymerase II were shown to bind to the GP130 promoter using
three distinct primer pairs (Supplementary Table SIII). Neither ERK2
nor RNA polymerase II signiﬁcantly bound outside the promoter or
to another chromatin region in chromosome 5 (Figures 4b and c).
This suggested that ERK2 could facilitate the transcription of the
constitutively active gene GP130, most likely by virtue of
interacting with the transcriptional machinery.
We also analysed transcriptional regulation of gp130 using



























































on GM (S) - GM (U)
siNS [GM (S) - GM (U)]














































0 8 4 24 
U0126
























































Figure 3. ERK2 silencing leads to the inhibition of gp130 expression independently of MAPK enzymatic activity. U2OS cells were transfected as
previously with siNS, siERK1, siERK2, or sigp130 and analysed 48 h later. (a) Single-cell suspensions were stained with anti-gp130-PE labelled
antibody and analysed by flow cytometry. The numbers on the top right corner refer to the geometric mean (GM) corrected for background
fluorescence and the table below the histograms summarises data from a typical experiment. U: unstained; S: stained. (b) Quantification of
gp130 levels (GM) using the data from three independent experiments including data shown in (a). (c) gp130 mRNA levels were analysed by
qPCR (n¼ 3). Statistical analysis was done as in Figure 2. (d) Cells were treated with three different MEK inhibitors for 4, 8 and 24 h, stimulated
with FCS for 15min and gp130 expression analysed by western blotting. PD0325901, PD98059 and U0126 were used at 0.5, 50 and 10 mM,
respectively. (e) Cells were incubated with the indicated concentrations of PD0325901 for 24 h followed by staining with anti-gp130 (B-R3) and
anti-mouse-PE. gp130 cell surface localisation was analysed by flow cytometry as described in (a). (f ) U2OS cells were treated with 10 mM
FR180204 for 8, 24 and 48h, stimulated with FCS for 15min and phosphorylation of RSK1 on S308 used as a read-out. HSP90 and b-actin were
used as loading controls. Data are representative of three independent experiments yielding identical results.
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luciferase assays and showed that gp130 transcription is highly
impaired in cells that had ERK2 silenced (Figure 5), thus
corroborating the ChIP data shown in Figure 4. In addition, the
GP130 promoter has a number of g-interferon activated transcrip-
tional element (GATE) sequences, including one  157 to  153
upstream of the TSS, and ERK2 is known to be capable of binding
to these sequences (Supplementary Figure S2). In order to
establish if ERK2 regulated gp130 expression by directly binding
to this particular GATE, we modiﬁed the original wild-type GP130
reporter construct by site-directed mutagenesis (CAAAG4CACAG)
but the mutation did not have an impact on the expression of
gp130 (Figure 5). In addition, experiments using the transcription
inhibitor actinomycin D to block on-going transcription demon-
strated that the presence of ERK2 had an impact on the stability of
gp130 mRNA. Indeed, in cells that were transfected with siERK2,
gp130 mRNA had a half-life of 3 h as opposed to 12.5 h, which was
measured for cells transfected with the siNS (Figure 6).
The impact that siERK2 has on gp130 mRNA and protein is a
speciﬁc effect observed on several types of cancer cells
Importantly, the inhibition of gp130 upon ERK2 silencing was not
particular to U2OS cells. It was observed in additional cancer cell
lines of different origins, with different known mutations
(Supplementary Table SIV) (Figure 7a). A549 (lung), MCF-7 (breast),
HeLa (cervix), DU145 and LNCaP C4-2 (both prostate) were
transfected as described previously, and samples divided into two
experimental groups: one group was analysed by ﬂow cytometry
for gp130 cell surface expression and another was analysed by
western blotting for ERK1/ERK2 levels. In every cell type analysed,
a reduction in ERK2 expression led to a decrease in the amounts of
gp130 on the cells’ surface. While most cells have more ERK2 than
ERK1, MCF-7 expresses comparable levels of these proteins
(Figure 7a). This argues against the siERK2 phenotype being
purely due to quantitative differences between ERK1 and ERK2
expression. The data thus far further suggest that ERK1 and ERK2
have important non-redundant, non-overlapping functions,
including the regulation of gp130 expression, a key component
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Figure 4. ERK2 binds to the GP130 promoter. (a) Representation of
the GP130 gene, depicting the approximate location of the primer
pairs used for the ChIP experiments: p1-3, within or near the
promoter; g1-3, within the gene outside the promoter; NS, non-
related region within chromosome 5. ERK2 (b), RNA polymerase II
(c) and IgG (dashed line) antibodies were used for ChIP of GP130,
which was amplified using different primer pairs (Supplementary
Table SIII). Data are representative of three independent experi-
ments each using duplicate samples that yielded identical results.
Statistical analysis was carried out using Student’s t-test (*Po0.05,

























Figure 5. GP130 is transcriptionally regulated by ERK2. RNAi was
initiated 24 h prior to co-transfection of U2OS cells with gp130
promoter-Firefly luciferase constructs that were either wild-type or
mutant at the GATE, with a CMV promoter/Renilla-luciferase plasmid
construct. Twenty four hours later, both Firefly- and Renilla-luciferase
activities were quantified. For data analysis, the obtained lumines-
cence for the Firefly luciferase activity was normalised to the
luminescence obtained for the Renilla luciferase activity. The
experiments were done three times and yielded identical results,
and the data represent the means of luciferase activity±s.e.m.
Statistical analysis was carried out using Student’s t-test (*Po0.05,
**Po0.01, ***Po0.005 versus wild-type siNS-transfected control).
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Figure 6. ERK2 contributes to the stability of gp130 mRNA. RNAi was
induced as before and 48h later cells were incubated with the
transcription inhibitor, actinomycin D (5 mg/ml) for varying periods
of time as indicated in the figure. RNA was extracted and analysed
by qPCR as before. The data are presented as the mean gp130
mRNA±s.e.m. and, for each sample, the initial amount of gp130 was
considered to represent 100%. The experiments were done three
times and yielded identical results. Statistical analysis was carried
out using Student’s t-test (*Po0.05, **Po0.01, ***Po0.005 versus
siNS-transfected cells).
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The amount of ERK2 protein in cells correlates with the expression
of gp130
Eight different cell lines were analysed for the endogenous
expression of ERK2 and gp130 (Figure 7b). Despite the highly
disparate cellular backgrounds and growth properties of these
cells, 75% of the cell lines analysed (6/8) showed striking
correlation between ERK2 and gp130 expression (r2¼ 0.73). The
two outliers were A549 and HeLa cells. Conversely, if ERK2 directly
regulated the expression of gp130, then it would be expected that
modulating the intracellular concentration of ERK2 would have a
direct impact on gp130 expression levels (Figure 7c). For that
purpose, U2OS cells were transfected with different amounts of
siERK2, stained dually with anti-ERK2 and anti-gp130, and
analysed by ﬂow cytometry (Figure 7c). Untransfected cells and
cells transfected with non-targeting siRNA were used as controls
and behaved essentially in an identical manner. The higher the
ERK2 knockdown, the greater the reduction in gp130 levels. Taken
together, the data are consistent with ERK2 being critical for the
control of gp130 expression and, importantly, with the fact that
this effect is not cell type-speciﬁc and is independent of cellular
background.
DISCUSSION
Using RNAi we have successfully genetically manipulated ERK1
and ERK2 independently (Figure 1b). This has unravelled
undescribed distinct, non-overlapping, roles for these two iso-
forms. Indeed, ERK2 downregulation leads to a highly signiﬁcant
decrease in gp130 protein expression, whereas silencing ERK1 has
no effect (Figures 3a and b). Knockdowns obtained using siRNA or
transgene expression by transient transfections are seldom
achieved with 100% efﬁciency, and it remains a possibility that
if ERK2 was totally absent from the cells, a full inhibition of gp130
expression would have been achieved. Downregulation of ERK1
leads to a small decrease in the levels of gp130 mRNA but siERK2
causes a major reduction, suggesting that ERK2 may regulate
gp130 transcriptionally (Figure 3c). If this was the case and ERK2
worked in the ‘classical manner’, then one would expect the
kinase activity to be required. Yet, this does not seem to be the
case, as inhibition of phosphorylation/activation of ERK1/ERK2
with speciﬁc chemical inhibitors has no impact on gp130
expression (Figures 3d–f). Instead, ERK2 likely regulates gp130
expression by binding to the GP130 promoter (Figure 4). ERK2 may
interact with other transcription factors, co-activators or alter the
chromatin structure, thereby facilitating the transcription of
GP130. Our data suggest that ERK2 is more likely to interact with
the transcriptional machinery than causing chromatin
remodelling.
Importantly, ERK2 regulates the expression of gp130 in many
cancer cell types, characterised by different mutations and cellular
backgrounds (Supplementary Table SIV and Figure 7), suggesting
that this is a general and relevant biological effect. Concomitant
analysis for the endogenous expression of ERK2 and gp130
resulted reproducibly in a line-up with a coefﬁcient of determina-
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Figure 7. Levels of ERK2 correlate with the expression of gp130 in
many different types of cancer cells. (a) Downregulation of ERK2
significantly reduced cell surface gp130 expression in several types
of cancer cells (A549, MCF-7, DU145, LNCaP C4-2 and HeLa)
regardless of the ratio of ERK1 to ERK2 protein expression. The
results shown represent the statistical analysis (Student’s t-test) of
three independent flow cytometric experiments (*Po0.05,
**Po0.01, ***Po0.005 versus siNS-transfected control). Western
blot panels assessing ERK1/2 knockdown are shown underneath the
plots and are typical examples of the data obtained across
independent experiments. b-Actin was used as a loading control.
NS: siNS; gp130: sigp130; E1: siERK1; E2: siERK2. (b) Different tumour
cell lines were stained dually with ERK2-APC and gp130-PE
antibodies. With the exception of two outliers (A549 and HeLa),
the other six cell- lines showed a striking correlation between the
levels of ERK2 and gp130. (c) Titration of ERK2 siRNA showed a direct
correlation between ERK2 and gp130 expression. Cells were
transfected as before with different amounts of siERK2 and analysed
by flow cytometry. The experiments are representative of three
independent experiments that yielded identical results.
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strongly suggests that ERK2 can directly modulate the expression
of gp130. Indeed, a reduction in gp130 expression can be easily
achieved by transfecting cells with increased amounts of siERK2
(Figure 7c). This suggests that there is a straight correlation
between the amount of ERK2 and gp130 that cells express. Clearly,
ERK2 is not the sole determinant of gp130 protein synthesis, as
A549 and HeLa cells deviated from all other cell lines analysed,
thus far for reasons that are yet to be understood.
The absence of gp130 upon RNAi against ERK2 explained why
STAT1 and STAT3 could not be phosphorylated upon IL-6 or OSM
treatment (Figures 1a and b), as gp130 is required for the
activation of the JAKs, which are, in turn, responsible for
phosphorylating STAT docking sites on the receptor. It also
explains why the mRNA induction of an immediate-early-STAT3
gene such as SOCS3 was so severely impaired when the levels of
ERK2 were reduced (Figure 2a), as was the induction of EGR-1, a
STAT3/ERK target (Figure 2b), and the expression of STAT3 itself
(Figures 1b and c). Intriguingly, silencing ERK1 led to a statistically
signiﬁcant increase in the relative induction of SOCS3 and EGR-1
mRNA after OSM treatment (Figure 2). This suggests that ERK1 and
ERK2 have opposite roles in the induction of particular sets of
genes and that ERK2 can perhaps negatively regulate ERK1. In fact,
silencing ERK2 led to an increase in ERK1 phosphorylation, which
was seen regardless of cytokine treatment (Figure 1b and
Supplementary Figure S1), further supporting this hypothesis.
ERK1 and ERK2 are generally described as homologous
molecules with parallel activities, kinetics and substrates.33 The
proteins are 44 and 42 kDa, respectively, and share B85%
sequence homology.34 These kinases are phosphorylated on
threonine and tyrosine residues and are spatio-temporally
regulated.34,35 Their differing biological roles have been
attributed mostly to the higher expression level of ERK2
compared with ERK1.27 The fact that these proteins have
structural differences, however, raises the possibility that they
may have different functions as well.36 There is, in fact, an ever-
growing body of evidence suggesting that this is indeed the case.
For example, ERK1 and ERK2 are thought to have different roles in
Ras-mediated transformation,37 in proliferation,38 in epithelial-to-
mesenchymal transformation39 and in cell migration during the
embryonic development.40 Interestingly, ERK1 has an additional
domain that has recently been suggested to slow down its nuclear
import when compared with ERK2, which may lead to different
biological responses.41
ERK1/2 also have a multitude of biologically important non-
enzymatic roles.31 Particularly relevant to this work is the
realisation that ERK2 can act as a transcriptional regulator and in
chromatin remodelling by associating with the DNA,42 or by
directly binding to proteins such as poly[ADP-ribose]-polymerase
(PARP)-143 and topoisomerase II.44 Although the latter does not
require ERK enzymatic activity, it does require ERK to be
phosphorylated.43,44 The regulation of gp130 by ERK2 thus
appears to be unique in the sense that neither phosphorylation
of ERK2 by MEKs nor its kinase activity is essential for the
expression of gp130. In addition, the association of ERK2 with the
GP130 promoter can be seen in ‘resting’ cells, in the absence of
OSM. ERK2 was shown to repress interferon-stimulated genes
(ISGs) by binding to a DNA consensus sequence embedded in
GATEs independently of kinase activity, and such sequences were
shown to be located B90 bp upstream the TSS.42 However, other
researchers have provided evidence that the activity of MEKK1/
ERK was required for the transcription of a subset of g-ISGs by
C/EBP-b via these elements.45 Irrespective, the GP130 promoter
has several GATEs and one such ERK-binding sequence
(G/CAAAG/C), which is 157 bp upstream from the TSS
(Supplementary Figure S2), is located equidistantly from two
CAT boxes and two SP1 consensus sequences, downstream of a
SBE and an APRE sequences. We initially hypothesised that ERK2
bound to this putative ERK binding sequence and promoted,
directly or indirectly, the transcription of GP130, which is a STAT3-
target gene.14,46 We have, however, mutated this sequence
(Figure 5) and also the other more upstream GATEs (data not
shown), and shown that gp130 expression is similar in siNS- and
siERK2-transfected cells, thus ruling out the hypothesis that ERK2
is acting in a transcription factor-like fashion upon the GP130
promoter via GATEs. STAT binding sites are often located in close
proximity to those of other transcription factors, and it is thus
possible that ERK2 inﬂuences, somehow, the interactions between
STAT3, SP-1, AP-1, NF-kB and/or C/EBP-b. STAT3 and ERK2 have
certainly been shown to interact in the cytoplasm47 and it is thus
possible that they may also do so on the chromatin. The
increasing realisation that kinases can associate both with the
regulatory regions and with the entire transcribed region of target
genes48 strongly suggests that they have more prominent roles at
the chromatin level than initially envisaged. We are therefore
scrutinising, among other possibilities, if ERK2 regulates the
expression of gp130 by recruiting RNA polymerase II, by
changing histone methylation patterns, or by directly interacting
with transcription activators, co-activators or other transcription
factors on the promoter. Interestingly, gp130 mRNA in cells with
silenced ERK2 is much less stable than that in untransfected cells,
or cells transfected with a non-targeting siRNA or siERK1 (Figure 6).
The common cytokine receptor subunit, gp130, is pivotal for
controlling the action of all cytokines that belong to the IL-6
superfamily.14 These cytokines display some redundancy and they
are mainly involved in various cellular processes such as the acute
phase response, inﬂammation, immune responses and cell
survival. Unsurprisingly, gp130 / mice die at birth, or shortly
after, and most knockout studies have had to resort to conditional
mice mutants (reviewed in Fasnacht et al.49) Such studies
conﬁrmed that gp130 has vital pleiotropic roles in many types
of cells and its role in cancer cannot be understated.
Overall, our results identify a new function for ERK2 that is not
shared by ERK1. As MAPKs are critical mitogenic kinases that
participate in many tumorigenic pathways, and as IL-6-type
cytokines are critically involved in inﬂammatory and oncogenic
processes, the regulation of gp130 expression by ERK2 likely
contributes to cancer cell survival and cancer progression. Indeed,
it has recently been shown that pro-inﬂammatory cytokines such
as IL-1 or tumour necrosis factor (TNF) dampen excessive IL-6-
mediated signalling by accelerating gp130 internalisation and
degradation. This mechanism is thus thought to prevent over-
shooting inﬂammation promoting activities of IL-6.50 Furthermore,
it has recently been shown that ERK2 can be cleaved through p53-
dependent activation of caspases in a process that can affect both
its kinase activity and the protein amount.51 As many cancer cells
have lost p53 expression, this might explain the enhanced gp130
expression often seen in cancer cells. Taken together, our study
highlights an important novel regulatory mechanism of gp130
expression, thereby opening up the possibility of additional
targeting strategies in the clinic.
MATERIALS AND METHODS
Cell culture
Cells were grown in DMEM supplemented with 10% (v/v) FCS, 2mM
L-glutamine, 50 units/ml penicillin and 50mg/ml streptomycin in a humi-
diﬁed atmosphere of 10% CO2 at 37 1C. Prostate cancer cells were cultured
in RPMI medium in 5% CO2.
Antibodies
STAT3, ERK1/2, RNA polymerase II (Santa Cruz Biotechnology, Heidelberg,
Germany); ERK2-APC and gp130-PE (BD Transduction Laboratories, Oxford,
UK), gp130 (B-R3, Diaclone, Besanc¸on, France); STAT1, pSTAT1Y701,
pSTAT3Y705, pERK1/2T202Y204/T185Y187, pRSK1S380 (Cell Signaling, Hertford-
shire, UK); ChIP anti-ERK2 (clone 1B3B9) (Millipore, Oxford, UK), mouse IgG
(Millipore); rabbit IgG (Abcam, Cambridge, UK); anti-mouse-PE (Dianova,
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Hamburg, Germany); b-actin (Sigma-Aldrich, Dorset, UK); HSP90 (Epitomics,
Burlingame, CA, USA).
Cytokines and drugs
IL-6, sIL-6R, OSM (Peprotech, London, UK); LIF (R&D, Minneapolis, MN, USA);
PD0325901 (Pﬁzer, Dorset, UK); PD98059, U0126, FR180204 (Calbiochem,
Nottingham, UK); Actinomycin D (Sigma-Aldrich, Dorset, UK). siRNA
oligonucleotides were from Dharmacon (Lafayette, CO, USA) and were
transfected using Lipofectamine RNAiMax.
RNA interference (RNAi)
This was done essentially as previously described,52 using Lipofectamine
RNAiMAX (Invitrogen, Paisley, UK) according to the manufacturer’s
instructions.
Protein analysis
Receptors were isolated using a lysis buffer containing: 93.2mM di-sodium
hydrogen phosphate, 6.8mM sodium di-hydrogen phosphate, 0.5% (v/v)
Triton X-100, 0.5mM EDTA pH8, 1mM sodium orthovanadate, 100U/ml
aprotinin, 10mg/ml leupeptin and 1mM phenylmethylsulphonyl ﬂuoride.
Unless gp130 was being analysed at the same time, STATs and ERKs were
isolated using Schindler’s buffer.52 Western blots were stripped with 2 M
glycine, pH 2.5/0.5% SDS (shaking overnight, room temperature), washed
with water, equilibrated with TBST and incubated with subsequent
antibodies.
Flow cytometry
Cells were incubated with anti-gp130-PE and/or ERK2-APC for 1 h at 4 1C,
washed ﬁve times with cold PBS and ﬁxed with 1% (w/v) p-formaldehyde.
For indirect staining, cells were incubated ﬁrst with anti-gp130 (B-R3) or
isotype control followed by anti-mouse-PE each for 30min at 4 1C. Cells
were analysed using a FACS Canto or FACS Calibur (BD Biosciences, San
Jose, CA, USA) and data mining was done with FlowJo (Tree Star, Inc,
Ashland, OR, USA). Geometric means were used for the analyses.
Real-time PCR
Gene expression analysis was done by quantitative two-step reverse
transcription PCR. Reverse transcription was performed using total RNA
and the Transcriptor First Strand cDNA Synthesis kit (Roche). A
combination of anchored-oligo(dT)18 and random hexamer priming was
used to increase sensitivity of the reaction. qPCR was done using the
FastStart Universal SYBR Green Master (Rox) with speciﬁc primer pairs
designed using the Universal ProbeLibrary Software (Roche)
(Supplementary Table SII). For each target mRNA analysed, 5 ml of FastStart
Universal SYBR Green master mix, 400 nM of each primer pair, 2.2 ml
deionised water and 2 ml of cDNA were mixed in 384-well plates in
duplicates using a robot, and qPCR carried out on an ABI PRISM 7900HT
(Applied Biosystems): initial activation—10min at 95 1C, denaturation—40
cycles, 15 s 95 1C, hybridization—20 s 60 1C, elongation—20 s 60 1C; ﬁnal
elongation—15 s 65 1C; ﬁnal melting curve—15 s 95 1C, 15 s 60 1C.
Quantiﬁcation of target messages was performed as described by Pfafﬂ53
using HPRT as an internal control.
Chromatin immunoprecipitation
This was done as described by Nelson et al., using protein G Dynabeads
blocked overnight with 3% (w/v) bovine serum albumin (BSA) diluted in
immunoprecipitation buffer without inhibitors (50mM Tris–HCl, pH 7.5;
0.5% (v/v) NP-40; 1% (v/v) Triton X-100; 150mM NaCl; 5mM EDTA; 2mg/ml
salmon sperm DNA; 0.1% (w/v) sodium azide). ChIP was done using 150mg
of chromatin and 10mg of anti-ERK2, or 2 mg of anti-RNA polymerase II.
Mouse and rabbit IgGs were also used as controls. Primer sequences used
are shown in Supplementary Table SIII. DNA quantiﬁcation (samples and
input) was done using a standard curve made from the input. Samples
were normalised to their corresponding input and presented as a
percentage of input.
Luciferase assays
Cells were transfected with siRNA oligonucleotides as described above.
Twenty-four hours later, cells were co-transfected with 100 ng of full-length
gp130 promoter (p2433)/Fireﬂy-luciferase and 10 ng of CMV promoter/
Renilla-luciferase plasmid constructs using attractene transfection reagent
(Qiagen). The day after, both Fireﬂy- and Renilla-luciferase activities were
quantiﬁed using the Dual-Glo Luciferase Assay System (Promega)
according to the manufacturer’s instructions. Luminescence was detected
using a PHERAstar Plus plate reader. The measured luminescence for Fireﬂy
luciferase activity was normalised to that of Renilla luciferase.
mRNA stability
Cells were transfected with siRNA oligonucleotides as before. Forty-eight
hours after transfection, cells were treated with 5 mg/ml Actinomycin D for
0, 0.5, 1, 2 or 3 h. Subsequently, RNA was isolated using an RNeasy Mini Kit
(Qiagen) following the manufacturer’s instructions. Gene expression
analysis was performed by qPCR as described before, using b-actin and
GAPDH as housekeeping genes.
Statistical analysis
Mean±standard error (s.e.m.) of three independent experiments was
calculated. Student’s t-test was used to determine the statistical signiﬁcance
of the differences observed between conditions. A two-tailed P-value below
0.05 was considered signiﬁcant. *Po0.05, **Po0.01, ***Po0.005.
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Janus kinase (JAK)/ signal transducer and acti-
vator of transcription (STAT) signalling 
 
Janus kinases (JAKs) and signal transducers 
and activators of transcription (STATs) are es-
sential molecules in cytokine signal transduc-
tion pathways, as shown by studies using mu-
tant cell lines, knockout mice and humans with 
somatic mutations in these genes (reviewed in 
[1, 2]). The JAKs are commonly found associ-
ated with the intracellular domains of cytokine 
receptors providing the enzymatic activity that 
they do not possess intrinsically. Following the 
binding of a given cytokine to their cognate re-
ceptor JAKs auto- and/or trans-phosphorylate. 
These activating events lead to the phosphoryla-
tion of the receptor per se and thereby the gen-
eration of STAT docking sites. STATs get re-
cruited to the receptor, undergo phosphoryla-
tion, dimerise and translocate into the nucleus 
where they initiate the transcription of target 
genes (Figure 1) (reviewed in [3]). They can also 
be phosphorylated, and presumably activated, 
downstream of several growth factors and onco-
proteins [4].  
 
JAKs and STATs in normal homeostasis 
 
Mammalian cells can express four different 
JAKs (JAK1, JAK2, JAK3 and TYK2) and seven 
STATs (STAT1-STAT6, including STAT5A and 
STAT5B). Some STATs have different splicing 
variants (STAT1, STAT3 and STAT4). These are 
found in three chromosomal clusters and can 
also arise post-translationally after, for example, 
proteolytic processing (STAT5A and STAT5B) 
(reviewed in [5]). STATs are 750-850 amino 
acids long and are ubiquitously expressed ex-
cept for STAT4, which is restricted to myeloid 
cells, thymus and testis [6]. Their activity is 
regulated not only through tyrosine but also ser-
ine phosphorylation [7-9]. The structure of these 
molecules is depicted in Figure 2. Of note: the 
well-conserved SH2 domains are responsible for 
the association of STAT with tyrosine-
phosphorylated motifs in the receptor [10] and 
for dimerisation with other tyrosine phosphory-
lated STATs [11, 12]. STAT1 and STAT3 are able 
to form homo- and heterodimers, as well as 
tetramers. Near the C-terminus is the transacti-
vation domain (TAD). This domain has a serine 
residue (amino acids 727 in STAT1 and STAT3) 
that is necessary for maximal transcriptional 
activation of some genes [8, 11, 13-15]. Un-
treated cells have STAT1 and STAT3 randomly 
distributed in cytoplasm and nucleus [16]. After 
a few minutes of cytokine treatment, however, 
they become tyrosine phosphorylated in the 
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cytoplasm and translocate to 
the nucleus [17]. In reality, it is 
not such a black and white 
picture and we now know that 
unphosphorylated STATs can 
also move into the nucleus 
and have biological impact 
(e.g. [18, 19] and reviewed in 
[3, 19]). When in the nucleus 
STATs can bind to specific se-
quences in the DNA and in-
duce the transcription of many 
genes, globally termed as In-
terferon (IFN)-stimulated 
genes (ISGs) [2, 20]. Such 
genes are involved in diverse 
biological processes such as 
cell differentiation, prolifera-
tion and cell death. 
Figure 1. Representation of JAK/STAT signal transduction pathways using IL-6 signalling as a paradigm. Ligand (IL-6) 
binding to the ligand binding unit (IL-6R) induces auto- and trans-phosphorylation of receptor pre-associated JAKs 
(JAK1, JAK2 and TYK2), phosphorylation of tyrosine motifs in the receptor signalling subunit (gp130), recruitment and 
re-arrangement of associated STATs (STAT1, STAT3 and, potentially, STAT5) which, upon tyrosine phosphorylation by 
the JAKs, are released, migrate to the nucleus and activate transcription. MAPKs are also activated via recruitment of 
SHP2/PTPN11 to tyrosine (Y) at position 759 on gp130, which leads to the transcription of additional target genes. 
Figure 2. Structure of JAKs and STATs. JAKs have 7 JAK-homology domains, 
named JH1-JH7. These form four main regions: the four-point-one, ezrin, 
radixin and moesin (FERM) domain (blue), the potential SRC homology 2 
(SH2) domain (green), and the pseudokinase (purple) and tyrosine kinase 
domains (magenta). STATs have 6 domains, named N-terminal domain 
(orange), coil-coiled domain (yellow), DNA binding domain (turquoise), linker 
domain (navy), SH2 domain (pink) and transcriptional activation domain 
(red). Key phosphorylation tyrosine (Y) and serine (S) C-terminus residues 
are also depicted. (Not drawn to scale). 
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Different cytokines activate distinct sets of JAKs 
and STATs and, consequently, have the poten-
tial to induce different gene expression pro-
grammes. Typically, type I IFNs activate JAK1 
and TYK2 and induce transcription via a protein 
complex that is composed of STAT1, STAT2 and 
IFN-regulatory factor (IRF)-9 (also known as 
p48). Type II IFN (IFN-γ) leads to the activation 
of JAK1 and JAK2 and to the formation of STAT1 
dimers. These different STAT complexes bind to 
different DNA consensus sequences and induce 
distinct sets of genes (with some overlap) [3, 
17]. Other cytokines, such as those belonging to 
the interleukin (IL)-6 family, trigger the phos-
phorylation of JAK1, JAK2 and TYK2, the accu-
mulation of STAT3 dimers and thus the tran-
scription of STAT3 target genes (Figure 1). 
STAT1 and STAT5 can also be phosphorylated 
downstream of IL-6 but the significance of such 
“activation” is as yet unclear [21, 22]. STAT5 is 
usually triggered by ligands such as erythropoi-
etin and prolactin and is thus involved in 
erythropoiesis, breast development and lacta-
tion [23]. STAT4 and STAT6 are activated by IL-
12 and IL-4, respectively, and are therefore key 
molecules in regulating T helper cell (TH) 1 and 
2 responses [24]. 
 
Studies using knockout mice and observations 
made in patients have largely confirmed initial 
work in cell lines generated by the Kerr and 
Stark groups, which were deficient in JAK/ STAT 
signalling components [25]. STAT1-deficient 
humans and mice are more susceptible to both 
viral and bacterial infections [26, 27]. STAT2-
deficient mice are also more susceptible to vi-
ruses and, unsurprisingly, have defects in type I 
IFN responses [28]. STAT3 knockout mice are 
embryonic lethal but conditional knockouts 
have revealed essential roles for the acute-
phase response in the liver and the control of IL-
6 and IL-10 cytokine responses [22, 29, 30]. 
Mice that lack STAT4 have most IL-12-mediated 
responses severely impaired, including the in-
duction of IFN-γ which is important to determine 
a TH1 response [31, 32]. IL-4, a TH2 cytokine, 
and IL-13 trigger STAT6 activation and, accord-
ingly, STAT6-deficient animals lack a TH2 re-
sponse [33, 34] and have defective IL-13 re-
sponses [35], respectively. Many cytokines and 
growth factors can lead to activation of STAT5A 
and STAT5B. Amongst these are erythropoietin, 
growth hormone, thrombopoietin, IL-2, IL-3, IL-5, 
IL-7, IL-9, IL-15 and GM-CSF (reviewed in [36]). 
STAT5A-deficient animals have pinpointed im-
portant roles in mammary gland development 
and lactation, whereas STAT5B-null animals 
suggest an important role in growth hormone 
biology. 
 
Regulation of JAK/ STAT signalling and the con-
sequences of dysregulated activation 
 
Under normal conditions, STATs are active for 
minutes up to a few hours as these molecules 
are rapidly down-regulated. STAT activity can be 
inhibited by phosphatases [37-39], suppressors 
of cytokine signalling (SOCS, also named JAK-
binding proteins and STAT-induced STAT inhibi-
tors) ([40-43] and reviewed in [44]) and protein 
inhibitors of activated STATs (PIAS) ([45-48] and 
reviewed in [49]). The SOCS family has 8 mem-
bers: SOCS1-7 and CIS. These molecules are 
characterized by an SH2 central domain and by 
a SOCS box. SOCS can act by distinct mecha-
nisms: they can bind phosphorylated tyrosine 
residues on receptor chain and JAKs, or bind to 
STATs and block their recruitment to the ligand. 
In addition, the SOCS box can target STATs to 
degradation as it has E3 ubiquitin ligase activity 
[50]. STATs can also be inactivated directly by 
protein inhibitors of activated STAT proteins 
(PIAS) [45, 46]. PIAS can act on different levels: 
they can bind directly to STATs, thereby blocking 
protein-DNA interactions; induce degradation of 
the STATs, or alter STATs localisation [49]. The 
negative regulatory mechanisms controlling 
JAK/ STAT signalling thus ensure that STAT acti-
vation is cyclic and transient (further reviewed 
in [3]).  
 
JAK deficiency can have severe consequences 
for an organism, as demonstrated by syn-
dromes such as severe combined immunodefi-
ciency (SCID) and autosomal recessive hyperim-
munoglobulin E [51]. On the other hand, JAKs 
are often found mutated in myeloproliferative 
disorders (MPDs) and in many leukaemias. The 
most common mutation occurs on JAK2 on a 
valine residue on position 617, which is located 
on the regulatory pseudokinase domain (Figure 
2). This mutation leads to constitutive activation 
of the kinase and thus constitutive phosphoryla-
tion (and, presumably, activation) of STAT3 and 
STAT5 [52-54]. These observations raise the 
possibility that JAK kinase inhibitors might prove 
useful in the management of MPDs and leukae-
mias bearing activating JAK mutations and sev-
eral such inhibitors are currently being evalu-
ated in clinical trials.  
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Interestingly, we have unravelled an additional 
role(s) for JAKs in drug resistance induced by 
signalling in response to fibroblast growth factor 
(FGF)-2 [55]. Many cancer patients have ele-
vated levels of FGF-2 in their blood, which indi-
cates a poor prognosis on univariate and multi-
variate analyses [56-58]. In fact, FGF-2 is a po-
tent mitogen and one of the many molecules 
capable of inducing drug resistance in cancer 
cells challenged with chemotherapeutic drugs 
[59-61]. Signalling through the FGF receptor 
triggers mitogen activated protein kinases 
(MAPKs) and leads to the assembly of a multi-
protein complex, which contains protein kinase 
C (PKC) , v-raf murine sarcoma viral oncogene 
homologue (B-RAF) and p70 S6 kinase b 
(S6K2). As a consequence, the translation of a 
variety of anti-apoptotic genes is upregulated 
[60, 62, 63]. Such anti-apoptotic molecules 
thus arm the cell against the noxious effects of 
chemotherapeutic agents. As several growth 
factors including FGF-2 can activate JAK/ STAT 
signalling we asked if JAKs and/or STATs might 
contribute to this novel chemoresistance 
mechanism. We have discovered that FGF-2 
induced phosphorylation of JAKs and their asso-
ciation with the multi-protein complex. Interest-
ingly, downregulation of JAK1, JAK2 or TYK2 
expression was sufficient to block FGF-2 sur-
vival signals thus leading to cell death of os-
teosarcoma cells in response to cisplatin [55]. 
However, to our surprise, silencing of STAT1, 
STAT3 or STAT5A/B did not impair FGF-2-
mediated drug resistance. These observations 
provide an example of JAK signalling that is in-
dependent of STATs. A key question though is 
whether the effects seen are dependent on JAK 
kinase activity and/or structure. On-going work 
with selective JAK kinase inhibitors suggests 
that the kinase domain is important for trans-
mitting FGF-2-induced drug resistance effects. It 
is therefore conceivable that JAK inhibitors 
could also be used to help reverse this form of 
multi-drug resistance which we have now found 
to be present in several common cancer types 
([55, 61] and our unpublished data).  
 
Unlike the JAKs, STATs are not found mutated in 
cancer cells but are inappropriately activated, 
presumably as a consequence of dysregulated 
cytokine/ growth factor signalling [4]. In particu-
lar, STAT3 and STAT5 are constitutively phos-
phorylated not just in multiple cancer cell lines 
but also in many tumour specimens [64-68] As 
these molecules regulate the transcription of 
many genes that positively control cell prolifera-
tion and cell migration, as well as genes that 
negatively regulate apoptosis and immune rec-
ognition, they may participate directly in tu-
mourigenesis [69]. Indeed, genes such as vas-
cular endothelial growth factor (VEGF), c-MYC, 
BCL-xL, MCL-1, cyclin D1, JUNB, chemokines, 
proteases such as uPA and uPAR and, paradoxi-
cally, p21WAF1/CIP1, are known transcriptional 
targets of STAT3 ([70, 71] and reviewed in [72]). 
This transcriptional profile then explains why 
STATs have such a wide biological impact, with 
far-reaching consequences. Importantly, 
whereas STAT3 is a well-documented oncogene 
[73], STAT1 has long been seen as a tumour 
suppressor gene, capable of modulating the 
immune system and, under certain circum-
stances, directing it against tumour cells [74]. 
More recent reports, however, suggest that 
STAT1 is a double-edged sword and that it can 
also promote tumourigenesis [75].  
 
Constitutive activation of STATs can be seen 
downstream of many receptor tyrosine kinases 
(RTKs), such as epidermal growth factor (EGF), 
hepatocyte growth factor (HGF) and platelet-
derived growth factor (PDGF) receptors [72] and 
downstream of non-RTKs such as ABL [76] and 
SRC [77]. Interestingly, v-SRC transformation 
requires STAT3 tyrosine phosphorylation [77]. 
However, this is not true for all downstream on-
cogenes. Indeed, RAS requires the presence of 
unphosphorylated STAT3 in mitochondria [18], 
which shifts the cell metabolism towards fer-
mentation in a manner that favours tumour cell 
growth. This raises interesting questions regard-
ing the successful use of STAT3 inhibitors in the 
clinic [78, 79]. Indeed, it may be insufficient to 
simply interfere with phosphorylated, mainly 
nuclear-localised, STAT3 as this will not impair 
the effects of unphosphorylated STAT3 in mito-
chondria. Nevertheless, inhibiting molecules 
such as STAT3 remain worthwhile approaches 
in cancer treatment and the increasing under-
standing of how these molecules operate and 
are regulated will hopefully enable this soon. 
 
JAK/ STAT signalling in lung cancer 
 
Lung cancer, one of our research interests, 
causes more deaths per year than any other 
type of cancer in men [80, 81] and it is the sec-
ond cause of death in women after breast can-
cer [82]. The classification of human lung can-
cer includes two major types: small cell lung 
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cancer (SCLC) and non-small cell lung cancer 
(NSCLC). NSCLC includes several sub-types of 
which adenocarcinoma is the most common 
[83]. Smoking is responsible for 80-85% of all 
lung cancer [83]. In 2008 about 1.52 million 
people around the world were diagnosed with 
lung cancer and approximately 1.31 million peo-
ple died from the disease [81]. Lung cancer 
symptoms are detected in most patients too 
late [80, 81], which together with lack of effec-
tive treatments contribute to a poor prognosis 
for most patients. Indeed, regional or distant 
overt metastases are found in more than two-
thirds of patients [81] and most of the remain-
ing individuals will have occult metastatic dis-
ease. Consequently, most patients are ineligible 
for curative surgery and, as the remaining radio-
therapy, chemotherapy and newer targeted 
treatment options are non-curative, novel thera-
peutic approaches and early disease markers 
are needed [81].  
 
Cytokine responses are highly regulated and 
often transient. In cancer cells, however, cyto-
kines responses can be dysregulated. For exam-
ple, IL-6 secretion is often increased in cancer 
patients and in many cancer cell lines [84]. This 
can trigger dysregulation of several signalling 
components and like EGF it can lead to constitu-
tively activated STAT3. STAT3 phosphorylation 
is, in fact, observed in around 50% primary 
NSCLC tumours and cancer cells lines derived 
from them [84-87]. This likely reflects mutations 
in EGF receptor, increased circulating IL-6, or 
activation of non-RTKs as discussed earlier. 
 
The main transcription factor induced by IL-6-
type cytokines, such as IL-6, oncostatin M 
(OSM) and leukaemia inhibitory factor (LIF), is 
STAT3. IL-6 is a pleiotropic cytokine that plays 
important roles in cell proliferation, differentia-
tion, survival and apoptosis. IL-6 also takes part 
in immune responses, haematopoiesis and in-
flammation (reviewed in [21, 88]). In addition, IL
-6 can control a variety of responses in many 
cell types and is a crucial regulator of the nerv-
ous system, endocrine system, bone metabo-
lism, amongst others [89]. IL-6 induces tran-
scription of the IL-6 gene via JAK2 and STAT3. 
This is thought to lead to increased autocrine 
production of this cytokine observed in different 
cancer cell lines. Thus, regulating JAK2 and/ or 
STAT3 could reduce IL-6 production, thereby 
impairing cell growth and enhancing their sus-
ceptiblity to other treatments [90]. Indeed, 
blockade of IL-6 signalling in lung cancer-
derived cell lines was shown to be enough to 
inhibit cell growth [84, 91]. It was also shown 
that some tumours in mice are induced by ras, 
which can also stimulate secretion of IL-6 in 
different cell types. Ras-induced transformation 
in a variety of mouse models appears to require 
IL-6 and, consistent with that, IL-6 knockout 
animals were more resistant to ras-induced car-
cinogenesis ([92] and reviewed in [93]). Accord-
ingly, knockdown, genetic ablation or antibody 
neutralization of IL-6 can limit tumour growth 
induced by ras [94]. Interestingly, some human 
lung adenocarcinomas also have RAS mutated 
[95]. Paradoxically, IL-6 can under certain cir-
cumstances decrease cell growth in some types 
of lung cancer cells [96]. For example, the 
growth of Lewis lung cancer carcinoma cells 
decreased after being transfected with IL-6 
[97]. When these cells were treated with an anti
-IL-6 antibody they did not proliferate, indicating 
that growth inhibition was not related to a direct 
autocrine effect of IL-6 [97]. In contrast, in other 
NSCLC cell lines, IL-6 caused an increase in 
growth (A549, Calu3, Calu6, and H23). In the 
presence of IL-6 antisense phosphorothioated 
oligonucleotides, cell proliferation was notably 
reduced. However, neither the presence of 
monoclonal neutralizing anti-IL-6 antibodies, nor 
exogenous IL-6, interfered with cell proliferation, 
or IL-6 synthesis. This probably reflects the now 
widely recognized importance of cellular back-
ground in determining cellular responses and 
biological outcome [22, 98]. Certainly in lung 
cancer patients, IL-6 appears to promote and 
sustain malignancy [71, 99-101]. For example, 
IL-6 has been found elevated in lung cancer 
patients and the autocrine production of IL-6 
has been shown to lead to constitutive activa-
tion of STAT3 and promote lung adenocarci-
noma and malignant pleural infusion. Increased 
levels of circulating IL-6 thus appear to be an 
adverse prognostic factor for lung cancer pa-
tients [100, 101]. 
 
In addition to JAKs and STATs, IL-6 signalling 
also involves activation of MAPKs (Figure 1). 
Hirano and colleagues [102] described several 
experiments carried out with gp130 receptor 
mutants in order to understand its regulation 
and the impact of the different pathways acti-
vated upon IL-6 signalling. They noted that there 
appeared to be a compensatory balance be-
tween the JAK/ STAT and MAPK pathways when 
either pathway was disturbed. In fact, some-
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times gp130 can activate opposite signalling 
cues. This may explain why/ how IL-6 can have 
multiple functions in different types of cells 
[102].  
 
PTPN11 (also known as SHP2) has a role not 
only as an enzyme but also as a protein adapter 
[103]. Receptor-bound PTPN11 (Y759 on 
gp130 for IL-6 and Y794 on LIF receptor) can 
bind GRB2 via two tyrosine residues in the C-
terminal (tyrosine 542 and tyrosine 580) that 
are believed to establish interactions with the 
GRB2-son-of-sevenless (SOS) complex [10, 104-
106], reviewed [21]) This complex, which forms 
a GDP/ GTP exchanger for RAS, results in MAPK 
cascade activation in response to IL-6 and LIF. 
In response to OSM, SH2- and collagen-
homology-domain-containing protein (SHC) is 
recruited instead (Y861 on OSM receptor) and 
serves as the bridge that links gp130 signalling 
to MAPK cascades [107]. This also couples to 
MAPK cascades using GRB2. 
 
Activation of MAPK signalling also involves 
GRB2-associated binding protein 1 (GAB1), an-
other scaffold protein. This further increases the 
complexity of the response by allowing the re-
cruitment of additional signalling pathways, 
such as phospholipase Cγ, phosphatidylinositol 
3’-kinase (PI3K)/AKT and c-MET (reviewed in 
[21]). Furthermore, stress-activated kinases 
(additional MAPK family members) can also be 
activated by IL-6-type cytokines [108-110]. 
These molecules have also been implicated in 
cancer including lung cancer and thus exacer-
bated production of molecules such as IL-6 not 
only favour tumourigenesis via STAT activation 
but potentially also by virtue of inducing these 
well-known pro-survival and/ or mitogenic sig-
nals. This, in turn, suggests that successful 
therapies will likely involve targeting multiple 
molecules, which may be cross-activated but 
which elicit different arms of a mitogenic or anti-




JAKs and STATs have been identified 20 years 
ago. Since then, our understanding of their mo-
lecular structures and biological functions, both 
in cellular homeostasis and pathogenesis, has 
greatly increased. With this knowledge comes 
the promise of being able to use them as useful 
and effective targets for the management of 
several diseases, including a variety of cancers. 
For this purpose, our efforts to fully understand 
their cellular roles must continue as this will 
help to minimise off-targets effects in the clinic 
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